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Summary
Familial adenomatous polyposis (FAP), MUTYH-assoc\ated polyposis (MAP) 
and Hereditary non-polyposis colorectal cancer (HNPCC) are rare inherited 
colorectal cancer (CRC) predisposition syndromes resulting from mutations in 
APC, MUTYH and mismatch repair (MMR) genes, respectively.
Mutational analysis of APC and MUTYH in 92 colorectal polyposis families living 
in Wales identified a genetic defect in 85 families (92%). Seventy unrelated 
cases (70/92, 76%) harboured pathogenic mutations in APC and biallelic 
MUTYH mutations were identified in 15 families. No pathogenic mutations 
could be detected in seven index patients without a dominant family history who 
had tens to hundreds of colorectal polyps with or without CRC.
A European collaborative project established a cohort of 237 MAP patients. 
Analysis of MUTYH mutations in 182 unrelated MAP index cases highlighted 
the need for ORF sequencing as 17% (31/182) did not carry either of the 
common non-Asian mutations (Y176C and G393D). Fifty-eight percent of the 
MAP patient cohort (138/237) developed CRC and 36% (49/138) had more than 
one CRC. Retrospective assessment of medical records indicated that MAP 
patients are not at increased risk of cancers outside the Gl tract. The mean age 
at presentation and CRC diagnosis were found to be inversely correlated with 
the number of Y176C alleles (p=0.003 & p<0.001, respectively, linear 
regression).
Analysis of mortality and cancer risk in 350 obligate MUTYH mutation 
heterozygote parents of European MAP patients revealed they were at a two­
fold increased risk of CRC compared with the general population.
To investigate whether germline mutations in other base excision repair or DNA 
damage protection genes predispose to colorectal adenomas, the ORFs of 
TOG, MPG, SMUG1, MBD4, APE1, POLL and NUDT5 were sequenced in a 
cohort of 58 unrelated patients with multiple (>10) colorectal adenomas in 
whom APC or biallelic MUTYH mutations had not been demonstrated. No 
clearly pathogenic mutations were identified, suggesting that defects in these 
glycosylases are not frequently associated with colorectal polyposis.
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Chapter One
General Introduction 
1.1 Colorectal cancer
Colorectal cancer (CRC) is one of the most common cancers worldwide. It is 
the second most prevalent form of the disease in developed countries (Weitz, J. 
et al, 2005) and in the UK alone, 35 006 new cases were diagnosed in 2003 
(Cancer Research UK). Although mortality rates are now decreasing due to 
improved screening and treatment, it is still estimated that 492 000 CRC deaths 
occur globally each year (Weitz, J. et al, 2005).
Both environmental and genetic factors are important in the development of 
CRC and either can be the predominant cause of this disease. They also 
interact with each other, for example a genetic predisposition resulting in an 
increased susceptibility to particular carcinogens in the diet may induce cancer 
(Menko, F.H., 1993). The significance of environmental influences on colorectal 
cancer risk has been shown by studying individuals who have migrated from 
one country to another. The colorectal cancer risk of Japanese immigrants to 
Hawaii, for example, was found to change from that of their native country to 
that of the host country due to environmental differences (Kolonel, L.N. et al,
2004). A diet rich in meat and fat and deficient in fibre, folate and calcium can 
increase the risk of colorectal cancer. Other risk factors include; obesity, an 
inactive lifestyle, smoking and a high intake of alcohol (Weitz, J. et al, 2005). 
Twin studies have shown that genetic factors also play an important role in 
causing colorectal cancer. By comparing concordance for colorectal cancer in 
monozygotic twins with that in dizygotic twins, it has been estimated that 
genetic factors could account for up to 35% of CRC (Lichtenstein, P. et al,
2000). A small proportion of this (approximately 2-6% of all CRC) is the result 
of known genetic predisposition syndromes (Kemp, Z. et al, 2004).
1.2 Colorectal tumourigenesis
Regardless of the causative factor of CRC, the development of malignancy 
requires multiple mutations. The stages of tumourigenesis have been relatively
1
well-defined and often occur over several years (Figure 1.1) (Kinzler, K.W. & 
Vogelstein, B., 1996). Each stage results from mutations in genes involved in 
cell cycle control and signalling pathways. Different genes involved in the same 
pathway can be mutated in different colorectal cancers but these mutations are 
generally mutually exclusive i.e. only one gene in a particular pathway is 
mutated in any one CRC (Vogelstein, B. & Kinzler, K.W., 2004). An example of 
this is the transforming growth factor-p (TGF-P) pathway, where mutations in 
TGF-fiRII and SMAD4 are found separately in CRC, but not usually together in 
the same tumour (Woodford-Richens, K.L etal, 2001). The gene mutated in a 
particular pathway is influenced by the type of genomic instability present in the 
adenoma or carcinoma.
1.2.1 Genomic instability
Genomic instability plays a key role in tumourigenesis, contributing to the 
accumulation of mutations in genes involved in colorectal cancer (Grady, W.M.
& Markowitz, S.D., 2002). This loss of genomic stability can be in the form of 
chromosomal instability (CIN) or microsatellite instability (MSI). CIN results in 
genetic alterations through chromosomal losses and gains whereas MSI causes 
genetic alterations through defective DNA mismatch repair (MMR) proteins 
(Soreide, K. et al, 2006).
MSI affects short repetitive sequences called microsatellites that are prone to 
misalignment errors during replication. In normal cells such errors are repaired 
by the MMR proteins. Defects in these proteins result in a germline 
microsatellite allele undergoing a somatic change in length by gaining or losing 
repeated units. MSI influences which genes are mutated in colorectal tumours 
with this form of genomic instability. Genes containing coding microsatellites 
are susceptible to such errors, resulting in frameshift mutations that can 
contribute to tumourigenesis (Sbreide, K et al, 2006). The TGF-pRII gene is 
mutated in colorectal tumours with MSI and frameshift mutations occur at a 
polyadenine (A)io and a (GT)3 tract within the coding region of this gene 
(Markowitz, S. etal, 1995).
CIN induces larger changes in DNA than MSI by increasing the rate of
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Figure 1.1 Colorectal tumourigenesis. The stages of tumour development in the colon and genes which, when mutated, drive this process. 
Tumour suppressors and oncogenes are attached to green and red lines respectively. Genes shown in bold are generally mutated in tumours 
with CIN and those not in bold are generally mutated in MSI tumours. The pairs of genes shown which act at the same point in the process are 
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accumulation of mutations in genes involved in colorectal cancer. Adapted from Kinzler, K.W. & Vogelstein, B., 1996.
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chromosomal gains or losses (Rajagopalan, H. et al, 2003). Such alterations 
result from mitotic recombination or aberrant segregation of chromosomes at 
mitosis and lead to the aneuploidy seen in cancers with CIN (Kinzler, K.W. & 
Vogelstein, B., 1996). The chromosomal changes are not random but are 
driven by natural selection and chromosomal arms that are frequently lost in 
tumours with CIN are the loci of genes important in tumourigenesis. Allelic loss 
(loss of heterozygosity, LOH) at 17p, 18q and 5q often occurs and these are the 
loci of p53, SMAD4 and APC respectively (Terdiman, J.P., 2000). Deletion at 
1p and 8p is also common although the genes important for tumourigenesis at 
these loci have not yet been proven. The molecular mechanism responsible for 
CIN is not fully understood but this instability is thought to occur at an early 
stage of colorectal tumourigenesis (Shih, l-M. et al, 2001). Mutations in genes 
involved in the accurate mitotic segregation of chromosomes, including hBUB1 
(Cahill, D.P. etal, 1998), APC (Fodde, R. etal, 2001a) and hCDC4 
(Rajagopalan, H. etal, 2004), has been suggested as a possible cause of CIN.
The majority of CRCs (approximately 85%) show CIN and have gross 
chromosomal alterations rather than the subtle changes found in tumours with 
MSI (Kinzler, K.W. & Vogelstein, B., 1996). In a small proportion of cases 
however, neither CIN nor MSI is evident (Goel, A., et al, 2003). Epigenetic 
instability in the form of CpG island methylator phenotype (CIMP) has been 
identified in CRC. CIMP results in the aberrant hypermethylation of CpG 
islands which are often found in the promoter regions of genes. This instability 
promotes tumourigenesis by transcriptionally silencing genes that prevent 
tumour formation (Toyota, M. etal, 1999) such as CDKN2A which encodes p16, 
a protein involved in cell cycle control (Herman, J.G. etal, 1995). Genetic and 
epigenetic instability are not mutually exclusive; colorectal tumours with CIMP 
and CIN or (more frequently) MSI have been identified (Samowitz, W.S. et al, 
2005). MSI in some CRC is in fact the result of epigenetic instability as 
promoter hypermethylation of hMLH1 (which encodes a MMR protein) silences 
this gene leading to defective MMR (Herman, J.G. etal, 1998). Genomic 
instability in some rare CRC is a result of defective base excision repair (BER) 
due to mutations in the MUTYH gene. Following DNA replication, unrepaired
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mismatches become G:C—>T:A transversions and are found in genes including 
APC and k-ras (Sampson, J.R. et al, 2005).
1.2.2 Cancer genes
Genes that are mutated in CRC and directly contribute to the adenoma to 
carcinoma sequence fall into two classes; oncogenes and tumour suppressor 
genes. Mutations in oncogenes cause them to become constitutively active or 
active when the wild-type gene would not be. Such activation can be caused by 
chromosomal translocations, gene amplifications or subtle mutations within the 
gene that affect residues important for the activity of the protein (Vogelstein, B.
& Kinzler, K.W., 2004). An oncogene often mutated in colorectal cancer is the 
K-RAS gene. The K-ras protein is involved in signal transduction and couples 
growth factors to the mitogen-activated protein kinase (MAPK) cascade which 
results in expression of genes involved in cell proliferation. K-ras is a 
monomeric GTPase which is inactive when bound to GDP but when GTP is 
bound, K-ras is activated and the MAPK cascade is stimulated. Normally, the 
GTPase activity of K-ras would then hydrolyse the bound GTP thus inactivating 
itself. The most common mutations in the K-RAS gene affect codons 12,13 
and 61 all of which result in disrupted GTPase activity, allowing K-ras to remain 
activated and stimulate cell proliferation (Grady, W.M. & Markowitz, S.D., 2002). 
Only one allele of an oncogene needs to be somatically mutated for it to have a 
tumourigenic effect. Other oncogenes involved in CRC tumourigenesis include 
CTNNB1 (Morin, P.J. etal, 1997), BRAF(Davies, H. etal, 2002) and PIK3CA 
(Samuels, Y. et al, 2005)
Mutations in tumour suppressor genes cause inactivation of the gene product. 
This loss of function can result from mutations that cause a truncated protein or 
lead to nonsense mediated decay (NMD), missense mutations at functionally 
important residues, insertions, deletions or gene silencing by promoter 
hypermethylation (Vogelstein, B. & Kinzler, K.W., 2004). A tumour suppressor 
gene mutated in the majority of colorectal cancers is the APC gene. The APC 
protein has multiple cellular functions including an inhibitory role preventing 
over-activation of the Wnt signalling pathway. This pathway stimulates cell 
growth when activated. APC mutations are often protein-truncating mutations
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and chromosomal deletions. These inactivate the APC protein so it can no 
longer regulate the Wnt signalling pathway leading genes involved in cell 
proliferation to be expressed (Grady, W.M. & Markowitz, S.D., 2002). Other 
tumour suppressor genes involved in CRC tumourigenesis include TP53 
(Hollstein, M. etal, 1991), SMAD4 (Woodford-Richens, K.L etal, 2001), 
TGFpRII (Markowitz, S. et al, 1995), PTEN (Nassif, N.T. et al, 2004) and BAX 
(Rampino, N. et al, 1997). In general, both alleles of a tumour suppressor gene 
need to be mutated to have a tumourigenic effect. The two inactivating 
mutations occur somatically in sporadic CRC but in dominantly inherited CRC 
predisposition syndromes one mutation is found in the germline and the second 
mutation occurs somatically. An example of this is found in the APC gene 
which is mutated somatically in sporadic CRC while germline mutations cause 
Familial Adenomatous Polyposis (FAP). This disease predisposes to CRC 
since a second somatic mutation in the APC gene can initiate adenoma 
development (Fearnhead, N.S. et al, 2001). This is in accordance with 
Knudson’s two-hit hypothesis that inherited and sporadic forms of the same 
type of cancer require two mutations in the same tumour suppressor gene; both 
are somatic in sporadic cancer but in dominantly inherited cancer predisposition 
syndromes the first is germline and the second is somatic (Knudson, A.G., 
1996).
The majority of CRC cases are sporadic but inherited factors can contribute to 
up to 35% of CRC (Lichtenstein, P. et al, 2000), a small proportion of which 
(approximately 2-6% of all CRC) are accounted for by known genetic 
predisposition syndromes (Kemp, Z. et al, 2004). The study of inherited CRC 
syndromes can help elucidate mechanisms of colorectal tumourigenesis in both 
sporadic and familial CRC as many of the genetic changes required for tumour 
formation are common to both.
1.3 Inherited CRC Syndromes
1.3.1 Familial Adenomatous Polyposis (FAP)
1.3.1.1 Clinical presentation
FAP is characterized by the appearance of hundreds to thousands of colorectal 
adenomas, usually by the second or third decade of life. If left untreated, one or
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more of these polyps inevitably progresses to cancer, usually by early to mid 
adult life and with CRC risk related to polyp number (Fearnhead, N.S. etal, 
2001; Strate, L.L. & Syngal, S., 2005). FAP is a rare disease, affecting 
approximately 1 in 10 000 of the population. Less than 1% of all colorectal 
cancers are due to FAP and this disease affects both men and women equally 
(Strate, L.L. & Syngal, S., 2005).
Extracolonic features are also associated with FAP. Congenital hypertrophy of 
the retinal pigment epithelium (CHRPE) affects about 60% of FAP families. It 
has no detrimental effect on sight but can be used to identify family members 
who are at risk long before polyps appear. FAP patients frequently develop 
upper gastrointestinal tumours and for those patients who have undergone 
prophylactic colectomies, periampullary carcinoma in the duodenum is an 
increasingly common cause of death (Fearnhead, N.S. etal, 2001). Desmoid 
tumours are also a major cause of morbidity in FAP patients and often occur 
after surgery. The presence of multiple desmoid tumours without colonic 
polyposis is attributed to the FAP variant hereditary desmoid disease 
(Galiatsatos, P. & Foulkes, W.D., 2006). Gardner’s syndrome is a largely 
redundant term describing a variant of FAP in which colonic polyps are 
associated with extracolonic manifestations that include epidermoid skin cysts 
and benign osteoid tumours of the mandible and long bones (Fearnhead, N.S. 
et a/, 2001). Colorectal polyposis and a primary central nervous system tumour 
(most commonly medulloblastoma) are characteristics of the variant Turcot 
syndrome (Galiatsatos, P. & Foulkes, W.D., 2006). Other infrequent 
extracolonic malignancies that have been associated with FAP include thyroid 
cancer, adrenocortical tumours and hepatoblastoma (Fearnhead, N.S. etal,
2001).
Attenuated familial adenomatous polyposis (AFAP) is a phenotypically distinct, 
milder variant of FAP traditionally characterized by the presence of fewer than 
100 colorectal adenomas. The mean age of CRC onset is delayed by -15  
years and CRC does not inevitably develop in AFAP patients although the risk 
of CRC remains high (69% by the age of 80 years) (Galiatsatos, P. & Foulkes, 
W.D., 2006). As in classical FAP, gastric fundic gland polyps and duodenal
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adenomas are frequently present, but other extracolonic manifestations are rare 
(Knudsen, A.L. etal, 2003).
1.3.1.2 Genetics
FAP is an autosomal dominant disorder caused by specific classes of germline 
mutations in the adenomatous polyposis coli (APC) gene. These mutations 
attain virtually 100% penetrance (Fearnhead, N.S. etal, 2001). At least 10% of 
FAP cases appear to result from new APC mutations so the incidence of this 
disease is maintained despite its significant selective disadvantage.
1.3.1.3 The APC gene
Groden e ta l(1991) and Kinzler e ta l(1991) identified and characterized the 
APC gene found on chromosome 5q21. The 8.5kb transcript is encoded by 21 
exons, the largest of which (exon 15) makes up more than three-quarters of the 
APC coding sequence (Fearnhead, N.S. et al, 2001). Many of the exons are 
subject to alternative splicing, giving rise to different mRNA transcripts (Figure 
1.2). Exons 0.3, 0.1, 0.2 and BS are located upstream of the initiation codon in 
exon 1 (Horii, A. etal, 1993; Thliveris, A. etal, 1994). Despite exons 0.2, 0.3 
and BS containing in-frame initiation codons, these open reading frames 
(ORFs) are not translated when found in transcripts that contain exon 1 
because of a stop codon found 6bp upstream of the exon 1 initiation codon 
(Santoro, I.M. & Groden, J., 1997). In some alternative splice forms however, 
exon 1 is excluded and exons 0.3 or BS are included resulting in transcripts that 
are translated into the APC isoforms 0.3 APC and BS APC, respectively 
(Santoro, I.M. & Groden, J., 1997; Carson, D.J. etal, 2004). Transcripts 
excluding exon 1 but containing one or more of the upstream exons are 
expressed at higher levels in terminally differentiated tissues such as brain and 
heart than other tissues, suggesting these transcripts are associated with 
differentiation (Santoro, I.M. & Groden, J., 1997). No transcripts have been 
identified containing exon 0.3 in combination with either exon 0.1 or 0.2, 
indicating the presence of two independent promoters (Thliveris, A. et al, 1994). 
Promoter 1A is most commonly active (Fearnhead, N.S. etal, 2001) and lies 
upstream of exon 0.3 (Thliveris, A. etal, 1994), while promoter 1B lies upstream 
of exon 0.1 (Horii, A. etal, 1993).
8
Figure 1.2 Alternative splicing of the APC gene. A schematic diagram of the APC gene showing its 22 exons and which of 
these undergo alternative splicing (not to scale). ■, alternatively spliced exon 5’ to exon 1; ■, alternatively spliced exon; ■, 
constitutively expressed exon. Exon 1 encodes a translational start site (|) and 5’ exons 0.3, BS and 0.2 also contain initiation 
codons ( ) in-frame with exon 2. The 5’ exons are only translated in transcripts lacking exon 1 due to a stop codon (*) in exon 1. 
Promoters 1A and 1B are located upstream of exons 0.3 and 0.1 respectively. Alternative splicing can alter the APC reading frame 
resulting in stop codons (*) but exon 5 encodes an alternative translational start site (t).
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Several exons downstream of exon 1 also undergo alternative splicing including 
exons 1-4 (Samowitz, W.S. etal, 1995; De Rosa, M. etal, 2007), 7 (Oshima, M. 
etal, 1993), 9 (Groden, J. etal, 1991; De Rosa, M. etal, 2007), 9A (De Rosa,
M. etal, 2007), 10A (Xia, L. etal, 1995) and 11-15 (Sulekova, Z. etal, 1995; 
Horii, A etal, 1993) (Figure 1.2). Alternatively spliced transcripts which are 
translated from exon 1 result in a stop codon before codon 184 and could still 
result in a protein with an intact C-terminus through the use of an alternative 
translation start site at codon 184 in exon 5 (Heppner Goss, K. et al, 2002). 
Alternative splicing of some exons results in transcripts with an in-frame 
insertion (exon 10A, Xia, L. etal, 1995) or deletion (exons 7 or 9, Oshima, M. et 
al, 1993; Groden, J. etal, 1991) but several alternatively spliced transcripts 
contain premature termination codons (Sulekova, Z. etal, 1995) and may be 
subject to NMD (De Rosa, M. et al, 2007). APC can also be spliced to an 
adjacent gene, SRP19, which encodes a signal recognition particle (Horii, A. et 
al, 1993). The most common and ubiquitously expressed APC transcript 
includes exons 1, 2-8, 9, 9A, 10,11-15 and encodes a 2843 amino acid protein.
1.3.1.4 The APC protein
APC is a large protein (312kDa) with several functional domains which allow it 
to interact with various other proteins (Figure 1.3) (Fodde, R. et al, 2001b). The 
oligomerisation domain of APC is found at the N-terminus and contains heptad 
repeats that can facilitate homodimerization (Su, L-K. et al, 1993a). The N- 
terminal and C-terminal regions of APC have recently been found to interact, 
suggesting intramolecular interactions may also occur (Li, Z. & Nathke, I.S.,
2005). A set of seven armadillo repeats are found in the N-terminal portion of 
APC and this highly conserved region can bind to protein phosphatase 2A 
(PP2A), APC-stimulated guanine nucleotide exchange factor (Asef) and KAP3 
(Nathke, I.S., 2004). The central region of APC contains three 15-amino acid 
(aa) repeats followed by seven 20-aa repeats, both of which can bind to p- 
catenin (Rubinfeld, B. etal, 1993; Su, L-K. etal, 1993b). The 15-aa repeats can 
also bind to a-catenin (Su, L-K. etal, 1993b) and C-terminal binding protein 
(CtBP) (Hamada, F. & Bienz, M., 2004). The 20-aa repeats contain a 
TPXXFSXXXSL motif (Groden, J. et al, 1991) and can bind glycogen synthase 
kinase 3p (GSK33) (Rubinfeld, B. etal, 1996). Interspersed between the 20-aa
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repeats are 3 stretches of 31-32 amino acids, each of which contains the 
sequence SAMP. These SAMP repeats can bind to axin and its homologue 
conductin (also known as axin2) (Behrens, J. etal, 1998; Hart, M.J. etal, 1998). 
The C-terminal region of APC contains a basic domain (Groden, J. etal, 1991) 
rich in arginine and lysine which can bind microtubules (Hanson, C.A. & Miller, 
J.R., 2005). The EB/RP family members EB1 and RP1 also bind to APC 
through a C-terminal domain (Juwana, J-P. etal, 1999). A PDZ binding motif 
(S/TXV) at the C-terminus allows binding of hDLG and PTP-BL to APC 
(Fearnhead, N.S et al, 2001). APC has five nuclear export signals (NESs) two 
of which are found in the N-terminal region and contain the motif LXXXLXXLXL. 
The other three signals are found in the third, fourth and seventh 20-aa repeats 
in the C-terminal portion of APC and contain the motif LXXLXL/I/MA/ 
(Fearnhead, N.S etal, 2001). The two APC nuclear localization signals (NLSs) 
are found between the fourth and fifth 20-aa repeats and within the third SAMP 
repeat (Fearnhead, N.S et al, 2001). APC can bind to DNA through sites 
containing 3-5 repeats of the sequence S/TPXX. These can be found 
overlapping the second 20-aa repeat, within the basic domain and close to the 
C-terminus (Deka, J. etal, 1999).
1.3.1.5 Functions of APC
APC is a multifunctional protein involved in a variety of cellular processes 
including Wnt signalling, cell adhesion, cell migration, mitotic spindle formation, 
chromosomal segregation and apoptosis (Fodde, R. etal, 2001b).
1.3.1.5.1 The canonical Wnt signal transduction pathway 
The role APC plays in Wnt signalling is its most important function in terms of 
tumourigenesis as loss of control of this pathway is critical to CRC development 
(Fodde, R. & Brabletz, T., 2007). A schematic illustration of the pathway is 
shown in Figure 1.4. In the absence of a Wnt signal, a multiprotein complex 
forms which is known as the destruction complex and includes APC, Axinl or 
Axin2 (conductin), GSK3p, casein kinase 1 (CK1) and PP2A (Fodde, R. & 
Brabletz, T., 2007; Nathke, I.S., 2004). Free cytoplasmic p-catenin is recruited 
and bound by APC and axin, then primed by CK1 for GSK3p serine/threonine 
phosphorylation (Reya, T. & Clevers, H., 2005; Polakis, P., 2002). Within the
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Figure 1.4 The canonical Wnt signalling pathway. In the absence of a Wnt signal, cytoplasmic p-catenin is bound by the destruction 
complex and phosphorylated by GSK3p. It is then recognised and targeted for proteasomal degradation. In the presence of a Wnt signal, p- 
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complex, GSK3P phosphorylates APC, Axin and P-catenin (Rubinfeld, B. et al, 
1996; Ikeda, S. etal, 1998a). The interactions between these proteins are 
affected by, and can affect, their phosphorylation. For example, phosphorylated 
APC binds to p-catenin (Rubinfeld, B. etal, 1996) and p-catenin enhances the 
phosphorylation of APC in the destruction complex (Ikeda, S. etal, 2000). 
Phosphorylation of APC within the complex can also be regulated by PP2A 
(Ikeda, S. etal, 2000) and CK1 (Rubinfeld, B. etal, 2001) which can bind to 
axin and dephosphorylate or phosphorylate APC respectively. Once p-catenin 
is phosphorylated by GSK3P it is recognised and ubiquitinated by a p-TrCP- 
containing E3 ubiquitin ligase. This targets P-catenin for proteasomal 
degradation (Fodde, R. etal, 2001b). Although both the 15-aa and 20-aa 
repeats of APC can bind p-catenin, it is the 20-aa repeats which are necessary 
for the downregulation of p-catenin (Rubinfeld, B. etal, 1997).
In the presence of a Wnt signal, the Frizzled and low-density lipoprotein 
receptor-related proteins (LRP) receptors cooperate to bind the Wnt ligand.
This leads to inhibition of GSK3P activity in the destruction complex through the 
Dishevelled (Dsh) protein and/or the interaction between axin and LRP5/6 
(Reya, T. & Clevers, H., 2005). The action of Dsh may be due to its 
phosphorylation by CK1 which promotes GBP (GSK3P binding protein) binding. 
Dsh activates GBP which can then inhibit GSK3p activity (Polakis, P., 2002; 
Fodde, R. et al, 2001b). Axin and APC are dephosphorylated as a result of 
their interaction with Dsh and PP2A, respectively. APC is dephosphorylated at 
GSK3p-phosphorylated sites and axin is less able to complex with APC and P- 
catenin (Fearnhead, N.S. etal, 2001). p-catenin cannot be phosphorylated by 
GSK3P, resulting in its stabilization and cytoplasmic accumulation, p-catenin 
then translocates to the nucleus where it binds to TCF/LEF transcription factors 
leading to the expression of target genes. In the absence of a Wnt signal, the 
TCF/LEF family of proteins are complexed with co-repressors so transcription of 
target genes is inhibited (Fodde, R. et al, 2001b). The main TCF family 
member expressed in intestinal epithelium is TCF-4 which upregulates genes 
including those involved in proliferation such as c-myc (Fearnhead, N.S. etal,
2001). Other Wnt target genes have roles in differentiation (e.g. ephrins) and 
adhesion (e.g matrilysin) (Schneikert, J. & Behrens, J., 2007). APC can also
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sequester P-catenin in the nucleus by cooperating with CtBP therefore 
regulating the amount of nuclear P-catenin which is free to bind TCF and 
activate transcription (Hamada, F. & Bienz, M., 2004).
If APC is mutated, p-catenin is inappropriately stabilized in the absence of a 
Wnt signal, p-catenin can then translocate to the nucleus and constitutively 
activate transcription of the Wnt target genes (Fodde, R. & Brabletz, T., 2007). 
The sequestration of nuclear P-catenin by APC could also be reduced if APC is 
mutated, which would allow more of the nuclear p-catenin to bind TCF and 
activate transcription (Bienz, M. & Hamada, F., 2004).
1.3.1.5.2 Cell adhesion
In addition to its role in Wnt signalling, p-catenin is a component of adherens 
junctions which mediate epithelial cell adhesion. Newly synthesized p-catenin 
binds to E-cadherin and a-catenin, which is bound to the actin cytoskeleton. 
These interactions can be disrupted by tyrosine phosphorylation of p-catenin 
which also promotes transcription of Wnt target genes (Schneikert, J. & 
Behrens, J., 2007). APC promotes E-cadherin mediated cell adhesion but it is 
not clear exactly how this occurs at present (Hanson, C.A. & Miller, J.R., 2005). 
The interaction between APC and protein tyrosine phosphatase PTP-BL could 
promote adhesion through tyrosine dephosphorylation of P-catenin thus 
increasing the amount of p-catenin able to bind to E-cadherin (Erdmann, K.S. et 
al, 2000). It has been suggested that APC could have a role in the regulation of 
catenin-cadherin exchange at the plasma membrane by facilitating the 
exchange of newly synthesized p-catenin between its free and E-cadherin 
bound states (Bienz, M. & Hamada, F., 2004; Hanson, C.A. & Miller, J.R.,
2005). APC also has a role in the regulation of cell adhesion through its 
interaction with Asef, a Rac-specific guanine nucleotide exchange factor (GEF). 
Mutant, but not wild-type, APC activates Asef which decreases E-cadherin 
mediated cell adhesion (Kawasaki,Y. et al, 2003).
1.3.5.1.3 Cell migration
APC is needed at the leading edge of cells for directed cell migration. 
Overexpression of APC in the intestine results in aberrant cell migration and
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mutant APC causes decreased cell migration (Schneikert, J. & Behrens, J., 
2007; Mahmoud, N.N. et al, 1997). APC is found at the plus ends of 
microtubules and regulates their stability by binding to unassembled tubulin and 
promoting microtubule assembly. APC is targeted to the microtubule tips by 
EB1 binding and the interaction between these proteins and mDia promotes cell 
migration by mediating microtubule stabilization and capture at the cell 
membrane (Hanson, C.A. & Miller, J.R., 2005). The movement of APC along 
microtubules to their plus ends is thought to involve interaction between APC 
and kinesin superfamily-associated protein 3 (KAP3) (Jimbo, T. et al, 2002).
APC also interacts with IQ motif containing GTPase activating protein 1 
(IQGAPT) at the leading edge and this is thought to stabilize captured 
microtubules. IQGAP1 may link APC to the actin cytoskeleton as it can bind F- 
actin to promote actin polymerization (Hanson, C.A. & Miller, J.R., 2005).
As discussed above, APC interacts with Asef which is also involved in 
reorganisation of the actin cytoskeleton during lamellipodia formation and 
membrane ruffling (Hanson, C.A. & Miller, J.R., 2005). Mutant APC activates 
Asef and promotes cell migration (Kawasaki,Y. et al, 2003).
1.3.5.1.4 Mitotic spindle formation and chromosome segregation 
Consistent with its localization at the plus ends of microtubules, APC is found at 
kinetochores during mitosis (Fodde, R et al, 2001a). Its interaction with EB1 at 
the plus ends of microtubules may regulate the association of microtubule tips 
with kinetochores and the cell cortex. Mutant APC acts in a dominant manner 
to interfere with the attachment of microtubule plus ends to kinetochores and 
the cell cortex, resulting in increased chromosome segregation defects (Green, 
R.A. & Kaplan, K.B., 2003). APC is also found at centrosomes and on the 
mitotic spindle (Nathke, I.S., 2004) which is anchored to the cell cortex at 
adherens junctions (Schneikert, J. & Behrens, J., 2007).
1.3.5.1.5 Apoptosis and cell cycle regulation
Mutant APC expression is associated with a decrease in apoptosis (Venesio, T. 
et al, 2003a) and inducible expression of wild type APC in cells containing only
16
mutant APC increases apoptosis (Morin, P.J. et al, 1996). This suggests a role 
for APC in the regulation of apoptosis. APC expression can upregulate the pro- 
apoptotic protein Clusterin and downregulate the anti-apoptotic factor Survivin.
It is not clear how APC regulates apoptosis, but it may be through the canonical 
Wnt signalling pathway, as appears to be the case for Survivin regulation 
(Hanson, C.A. & Miller, J.R., 2005). There is also evidence, however, that APC 
can regulate apoptosis independently of the transcriptional activation of Wnt 
target genes (Venesio, T. et al, 2003a).
APC can also downregulate cell growth through its interaction with hDLG.
These proteins form a complex that can regulate the Gi/S phase transition 
independently of the effect of p-catenin on the cell cycle. Mutant APC results in 
a weaker cell cycle blocking activity (Fearnhead, N.S. etal, 2001; Hanson, C.A. 
& Miller, J.R., 2005).
Changes in a number of processes involved in normal gut maintenance have to 
occur for tumours to develop and APC has roles in several of these processes 
(Nathke, I., 2004). The many functions of this tumour suppressor support its 
role as a gatekeeper of colonic epithelial cell proliferation (Kinzler, K.W. & 
Vogelstein, B., 1996).
1.3.1.6 Molecular genetics
1.3.1.6.1 Germline mutations
FAP is the result of germline mutations in the APC gene, most of which (>95%) 
are nonsense or frameshift mutations that result in a truncated protein. As 
shown in Figure 1.5, the vast majority of mutations are located in the 5’ half of 
the gene, with two notable hotspots at codons 1061 and 1309 (Thierry Soussi 
database, personal communication). These commonly mutated codons are part 
of short repeat sequences which may increase their mutability (Segditsas, S. & 
Tomlinson, I., 2006). Large deletions encompassing the whole APC gene or 
exons have also been identified and are estimated to contribute to 
approximately 5% of FAP cases (Sieber, O. et al, 2002; Michils, G. et al, 2005). 
There still remain, however, 20% of FAP patients in whom no germline APC 
mutation can be identified by conventional screening methods such as the
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Figure 1.5 Distribution of germline APC mutations in FAP patients. Germline mutations cluster in the 5’ half of the gene with hotspots at 
codons 1061 and 1309. Thierry Soussi database, personal communication.
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protein truncation test (PTT) or direct DNA sequencing of the coding region (de 
la Chapelle, A., 2004).
1.3.1.6.2 Somatic mutations
Tumour formation in FAP patients (and in the majority of sporadic CRC cases) 
requires somatic mutation of the wild-type APC allele either through loss of 
heterozygosity (LOH) or more frequently, protein truncating mutations. Most 
nonsense and frameshift mutations found in FAP tumours lie within the mutation 
cluster region (MCR; codons 1281-1556; Cheadle, J.P. etal, 2002), with 
hotspots at codons 1309 and 1450 (Figure 1.6, Thierry Soussi database, 
personal communication). Promoter hypermethylation of the wild-type APC 
allele that silences its expression is very rarely found in tumours from FAP 
patients (Schneikert, J. & Behrens, J., 2007). Tumourigenesis in FAP occurs 
through the chromosomal instability pathway (Kinzler, K.W. & Vogelstein, B., 
1996)
Germline and somatic mutations of APC in tumours are not independent; the 
position of the germline mutation appears to determine the type and location of 
somatic mutation. Analysis of APC mutations in tumours from classical FAP 
patients revealed relationships between germline and somatic mutations and a 
general pattern emerged (Figure 1.7) (Lamlum, H. etal, 1999; Albuquerque, C. 
etal, 2002; Crabtree, M. etal, 2003). If the germline mutation results in a 
protein lacking all its 20-aa repeats, the somatic mutation is usually a truncating 
mutation that leads to a protein with one or two 20-aa repeats. If the germline 
mutation lies between the first and second 20-aa repeats, the somatic mutation 
is usually loss of heterozygosity as a result of mitotic recombination. If the 
germline mutation lies between the second and third, or third and fourth 20-aa 
repeats, the somatic mutation is usually a truncating mutation before the first 
20-aa repeat (Albuquerque, C. etal, 2002; Crabtree, M. etal, 2003). It is 
thought that the reason for this selection lies in the ability of APC to regulate the 
canonical Wnt signalling pathway. If both APC alleles encoded proteins that 
lacked all 20-aa repeats, neither of these proteins would be able to bind and 
downregulate P-catenin in response to a Wnt signal, p-catenin would be free to 
accumulate to high levels in the nucleus and although this may seem
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advantageous for tumour formation, overexpression of p-catenin triggers 
apoptosis. Clearly there has to be some impairment of APC’s ability to 
downregulate p-catenin in order to confer a selective growth advantage on the 
cell and truncated APC containing one, two or three 20-aa repeats have some 
residual P-catenin regulating activity. This ‘just-right signalling’ model suggests 
that some, but not too much, p-catenin signalling gives the greatest advantage 
for tumour formation and is why particular APC genotypes are selected 
(Albuquerque, C. et al, 2002; Crabtree, M. et al, 2003).
This model also explains why somatic truncating mutations cluster within the 
MCR. Patients with germline mutations between the first and second 20-aa 
repeats do not contribute much to the MCR data as they tend to have LOH as 
their somatic mutation. Classical FAP patients rarely have germline mutation 
after the second 20-aa repeat due to the relatively small size of this region 
(codons 1399-1580) so patients with germline mutations before the first 20-aa 
repeat contribute most of the MCR data. The somatic mutations found in these 
patients generally encode proteins with one or two 20-aa repeats and thus lie 
between codons 1285 and 1494, within the MCR (Crabtree, M. etal, 2003).
Unlike tumours from classical FAP patients, some AFAP tumours contain two 
somatic mutations, one of which affects the germline mutant APC allele (Spirio, 
L.N. etal, 1998; Su, L-K. etal, 2000; Sieber, O. etal, 2006). The highest 
frequency of these ‘third hits’ is found in tumours from patients with a germline 
mutation in the alternatively spliced region of exon 9. The third hit often leaves 
three 20-aa repeats intact on the germline mutant allele, in combination with 
either LOH or proximal somatic mutation of the wild type allele (Sieber, O. et al,
2006). Bearing in mind the alternative splicing of exon 9, these combinations of 
mutations may be selected to give an optimal level of p-catenin signalling for 
tumour formation. Somatic mutations in tumours from AFAP patients with a 
germline mutation at the 5’ or 3’ end of APC can follow the pattern expected in 
tumours from classical FAP patients with a germline mutation before the first 
20-aa repeat; truncating mutations on the wild type allele resulting in a protein 
with one or two 20-aa repeats (Sieber, O. et al, 2006). AFAP mutations at the 
5’ or 3’ end may produce a small quantity of functionally impaired or unstable
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protein and such somatic mutations could be selected to give an optimal level of 
p-catenin signalling for tumour formation. Not all AFAP tumours require three 
hits in APC which could be a result of modifier alleles affecting levels of 
functional APC protein and its splicing efficiency, or the presence of a third hit at 
another locus (Sieber, O. et al, 2006).
1.3.1.6.3 Genotype-phenotype correlations
FAP patients do not all develop the same phenotype and this variation is 
partially accounted for by differences in the position of the germline APC 
mutation. Patients with severe polyposis tend to have germline mutations 
between codons 1250 and 1464 (Laurent-Puig, P. etal, 1998), with early onset 
severe polyposis linked to mutations at, or around codon 1309 (Friedl, W. etal,
2001). The reason for the association of a particularly severe form of FAP with 
germline mutations around codon 1309 is related to the type of somatic 
mutation selected for in these tumours, LOH. It is thought that germline 
mutations around 1309, in combination with somatic LOH of the wild type allele, 
result in a protein that gives an optimal level of p-catenin signalling, conferring a 
strong selective advantage on the cell for tumourigenesis. LOH occurs 
spontaneously at a higher frequency than truncating mutations close to codon 
1300 so the frequency of pathogenic mutations in these patients is effectively 
higher, leading to severe polyposis (Lamlum, H. etal, 1999; Crabtree, M. etal,
2003).
AFAP generally results from germline mutations at the 5’ or 3’ ends of APC 
(codons <163 and 1596-2644) or between codons 329 and 338 in the 
alternatively spliced region of exon 9 (Galiatsatos, P. & Foulkes, W.D., 2006). 
AFAP patients with germline mutations at the 5’ end tend to have a more severe 
phenotype than those AFAP patients with mutations in exon 9 or at the 3’ end 
(Soravia, C. etal, 1998; Sieber, O. etal, 2006). Translation of 5’ mutant alleles 
can start downstream of the mutation, at codon 184, producing a nearly full- 
length protein. Initiation at this site is probably inefficient so a limited amount of 
partially functional protein is predicted to be produced (Heppner Goss, K. et al,
2002). An alternatively spliced minor transcript of APC lacks exons 1-4 
(Samowitz, W.S. etal, 1995) so a germline mutation within this region would not
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affect this transcript and a small amount of protein with residual activity is 
predicted to be produced. Similarly, part of exon 9 is alternatively spliced in a 
minor APC transcript (Groden, J. et al, 1991) which would be unaffected by a 
mutation in this region so a limited amount of functional protein would also be 
predicted to be produced. Mutations at the 3’ end may result in an unstable 
mutant APC protein (Knudsen, A.L. etal, 2003) but some partially functional 
protein is likely to be present since such mutations result in AFAP rather than 
classical FAP. AFAP mutations often seem to result in production of an APC 
protein with sufficient function that not only does the wild type allele need to be 
mutated, but a second mutation in the mutant allele is often also necessary for 
tumour initiation. AFAP patients may therefore have a milder phenotype than 
classical FAP patients because of the requirement for ‘three mutational hits’ 
rather than two (Sieber, O. et al, 2006).
Extracolonic manifestations are also associated with particular germline APC 
mutations, CHRPE is found in patients with germline mutations between codons 
457 and 1444 (Fearnhead, N.S. etal, 2001) and desmoid tumours are 
associated with mutations at codons 1445-1580 (Friedl, W. et al, 2001). If the 
germline mutation lies between codons 976 and 1067, the patient appears to be 
at a higher risk of developing severe duodenal disease (Galiatsatos, P. & 
Foulkes, W.D., 2006). Papillary thyroid cancer has been found in patients with 
germline mutations ranging from codon 140 to 1309, an increased risk of 
osteomas is associated with mutations after codon 1444 (Galiatsatos, P. & 
Foulkes, W.D., 2006)
1.3.1.6.4 Phenotypic variability
Phenotypic variation also exists between FAP patients with the same APC 
germline mutation. Differences in the density of colorectal polyps have been 
found between and within FAP families with the same mutation at codon 1309, 
one of the recurrently mutated codons (Giardiello, F.M. etal, 1994). Similarly, 
variation in the number of colorectal polyps exists between families with the 
same, recurrent, codon 1061 mutation (Paul, P. etal, 1993). Extracolonic 
manifestations including; duodenal or gastric adenomas, desmoids, epidermoid 
cysts, osteomas, occult jaw lesions and extracolonic cancer also show inter-
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and intrafamilial variability in families with the same mutation, either at codon 
1309 or 1061. CHRPE, however, appears to be quite a consistent feature 
within and between these FAP families (Giardiello, F.M. etal, 1994; Paul, P. et 
al, 1993). Similar extracolonic variation was also seen within a family of 12 
affected members, all with the same mutation affecting codon 1068 (Paul, P. et 
al, 1993).
Phenotypic differences are not limited to families with mutations predicted to 
result in classical FAP. Inter- and intrafamilial variation is also seen in families 
with a 3’ mutation affecting codon 1979 which, on the basis of position, would 
be expected to result in AFAP. Most patients with this mutation do appear to 
have a phenotype characteristic of AFAP, with fewer than 100 colorectal polyps 
and a later age of onset than classical FAP. However, some patients with the 
same mutation had more than 100 colorectal polyps, traditionally classed as 
classical FAP. Extracolonic features were also variable within and between 
families with this mutation although lack of CHRPE was consistent (Brensinger, 
J.D. et al, 1998). A similar variation in phenotype was observed between 
members of the same family with a mutation affecting the alternatively spliced 
region of exon 9. The colonic features of these patients ranged from those 
typical of classical FAP to no clinical manifestation at all (Rozen, P. et al, 1999).
The inter- and intrafamilial variation in phenotype seen in FAP patients with the 
same germline mutation suggests that other genetic or environmental factors 
are contributing to the expression of germline APC mutations. Environmental 
factors such as diet are more likely to vary between families rather than within 
them, and although a high-fat low fibre diet can increase polyp number in a FAP 
mouse model (Hioki, K. et al, 1997), it is unlikely to have a profound effect on 
the phenotype of classical FAP patients due to the early age at onset of this 
disease (Crabtree, M.D. et al, 2002). First degree relatives have a more similar 
FAP phenotype than second degree relatives, which provides evidence for the 
role of unlinked genetic factors in phenotypic variation (Crabtree, M.D. et al,
2002). Consistent with this, the ApcM/n mouse model of FAP shows variation in 
polyp number dependent on the genetic background (Dietrich, W.F. et al, 1993) 
and a major modifier locus of this model, Mom1 (modifier of Min 1), was
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identified as the gene encoding secretary phospholipase A2, Pla2g2a (Dietrich, 
W.F. etal, 1993; Cormier, R.T. etal, 1997). Three other Mom loci have been 
identified (Cormier, R.T. etal, 2000; Silverman, K.A. etal, 2002; Haines, J. etal,
2005) and a variant in an ATP synthase gene (Atp5a1) has recently been found 
at the Mom2 locus (Baran, A.A. et al, 2007). The human orthologue of Pla2g2a 
does not appear to be a modifier of FAP phenotype in humans (Dobbie, Z. et al, 
1996a) but variations at the NAT1 and NAT2 loci (which encode N-acetyl 
transferases) appear to influence the disease severity of FAP patients 
(Crabtree, M.D. etal, 2004).
1.3.2 MUTYH-Associated Polyposis (MAP)
1.3.2.1 Clinical presentation
MAP is a recently described colorectal adenoma and carcinoma predisposition 
syndrome (Al-Tassan, N. etal, 2002) typically characterized by the presence of 
tens to hundreds of colorectal adenomas by the fifth or sixth decade. 
Approximately half of MAP patients have already developed CRC by 
presentation (Sampson, J.R. etal, 2003; Sieber, O.M etal, 2003; Nielsen, M. et 
al, 2005; Aretz, S. et al, 2006) and CRC can develop in the apparent absence of 
colorectal polyposis (Croitoru, M.E. etal, 2004; Wang, L., etal, 2004). MAP 
and FAP (particularly AFAP) are difficult to differentiate clinically because of 
similarities in their colorectal phenotypes. In addition, duodenal adenomas that 
are frequently present in FAP also appear to be the most common extracolonic 
feature of MAP (Nielsen, M. et al, 2005; Aretz, S. et al, 2006). Other 
extracolonic manifestations have been reported in MAP patients, but not at 
significant frequencies. Like FAP, MAP is a rare disease thought to be 
responsible for only about 1% of all colorectal cancers (Fleischmann, C. etal, 
2004).
1.3.2.2 Genetics
MAP is an autosomal recessive disorder caused by biallelic germline mutations 
in the MUTYH (also commonly, but incorrectly, referred to as MYH) gene 
(Jones, S. et al, 2002). The penetrance of this disease appears to be high as 
no unaffected older carriers of biallelic MUTYH mutations have been identified 
to date.
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1.3.2.3 The MUTYH gene
Slupska et al (1996) cloned and sequenced the human MUTYH gene found on 
the short arm of chromosome 1, between p32.1 and p34.3. This 7.1 kb gene is 
made up of 16 exons (Slupska, M.M. et al, 1996) and can produce three major 
mRNA transcripts (a, (3 and y) which differ in their 5’ sequence, indicating that 
MUTYH has three independent transcription initiation sites (Ohtsubo, T. et al, 
2000). Each transcript can be alternatively spliced to result in at least ten 
different mature transcripts, as shown in Figure 1.8.
The a transcript encodes a mitochondrial targeting signal (MTS) within its 5’ 
sequence and subtypes a1, a2 and a3 code for proteins which can localise to 
the mitochondria (Ohtsubo, T. et al, 2000). Consistent with this, the protein 
encoded by transcript a3 localises to mitochondria (Takao, M. et al, 1999) and a 
mitochondrial MUTYH polypeptide was identified by Ohtsubo et al (2000) and 
Boldogh et al (2001). By contrast, a MUTYH polypeptide corresponding to the 
predicted size of the a3-encoded protein (59kDa) was identified in nuclear 
extracts by Tsai-Wu et al (2000). This inconsistency may be the result of 
MUTYH shuttling between the nucleus and the mitochondria (Tsai-Wu, J-J. et 
al, 2000). Translation of subtype a4 from the same initiation codon as the other 
a transcripts would result in a stop codon so translation may start at a 
downstream initiation site in exon 4 resulting in a protein lacking the MTS 
(Ohtsubo, T. et al, 2000). The p and y transcripts also skip exon 1 (which 
encodes the MTS) and translation is thought to start at a downstream initiation 
codon in exon 2 resulting in a protein that lacks the first 14 amino acids 
(Ohtsubo, T. et al, 2000; Takao, M. et al, 1999). The exception to this is y4, 
whose translation is thought to start at the same initiation site as a4, in exon 4 
(Ohtsubo, T. et al, 2000). A putative nuclear localisation signal (NLS) is found 
within exon 2 and is thought to be non-functional in the context of the MTS (i.e. 
in proteins encoded by a1,2 and 3) but may function in those proteins lacking 
the first 14 amino acids (Takao, M. etal, 1999). Another NLS is located within 
exon 16 and is common to all transcripts (Tsai-Wu, J-J. etal, 2000).
MUTYH mRNA is expressed in a wide range of human tissues including the 
small intestine, lung, spleen and mammary gland but differences in the level of
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expression between various tissues are unclear (Takao, M. etal, 1999;Ohtsubo, 
T. et al, 2000). Post-mitotic tissues such as brain, heart and skeletal muscle 
have been reported to have low MUTYH expression levels compared to other 
tissues (Takao, M. etal, 1999), but adult brain tissue has also been reported to 
have higher expression levels than other tissues (Ohtsubo, T. et al, 2000).
Brain tissues appeared to be richer in the y4 transcript and expressed more a4 
than a1 transcript, in contrast to other tissues examined (Ohtsubo, T. et al,
2000). High levels of expression have been reported in the thymus, testis, 
kidney and liver although high MUTYH expression levels in the liver have been 
disputed (Ohtsubo, T. etal, 2000; Takao, M. etal, 1999). These discrepancies 
may be explained by technical difficulties as Ohtsubo et al (2000) were able to 
perform Northern blot analysis whereas Takao etal (1999) were not, citing very 
low expression levels of MUTYH. Type a is a major MUTYH transcript and its 
longest subtype (a1) includes exons 1-16 which encode a 546 amino acid 
protein.
1.3.2.4 The MUTYH protein
MUTYH is a 59kDa protein when encoded by transcript a3 (Slupska, M.M. etal, 
1999; Tsai-Wu, J-J. etal, 2000) which has 41% identity to its Escherichia coli 
(E.coli) homologue, MutY (Slupska, M.M. etal, 1996). MUTYH has several 
functional domains which allow it to interact with other proteins and DNA (Figure 
1.9). A region at the N-terminus facilitates replication protein A (RPA) binding 
through a conserved motif which includes the sequence K/RXK/R (Parker, A. et 
al, 2001). The study of MutY functional domains and their homology to the 
MUTYH protein has allowed the identification of several highly conserved motifs 
in the N-terminal domain of MUTYH; the DNA minor groove reading motif, helix- 
hairpin-helix motif (HhH), pseudo HhH motif, iron-sulphur cluster and adenine 
recognition motif (Guan, Y. et al, 1998). MutS homologue 6 (MSH6) can 
interact with MUTYH through a 23 amino acid region of the protein (Gu, Y. et al,
2002). The apurinic/apyrimidinic endonuclease 1 (APE1) binding site contains 
the motif SGXXDV (Parker, A. et al, 2001) and partially overlaps with the 
recently identified Hus1 binding site (Shi, G. et al, 2006). MUTYH also interacts 
with proliferating cell nuclear antigen (PCNA) through a C-terminal binding site 
which contains a QXXLXXFF motif (Parker, A. et al, 2001). The N-terminus of
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MUTYH contains a MTS, and a functional NLS is found at the C-terminus 
(Takao, M. etal, 1999). Six putative MUTYH serine phosphorylation sites have 
been identified, three in the N-terminal region (codons 9, 49 and 85) and three 
within the C-terminal half of the protein at codons 349, 494 and 504 (Parker,
A.R. etal, 2003).
1.3.2.5 Function of MUTYH
MUTYH is DNA repair protein which helps to maintain genomic stability through 
its role in the base excision repair (BER) of oxidative DNA damage.
1.3.2.5.1 Oxidative DNA damage
In humans, an estimated 104 oxidative DNA damage lesions occur in each cell 
per day (Ames, B.N. & Gold, L.S., 1991). The main cause of this damage is 
reactive oxygen species (ROS) which include hydroxyl radicals and hydrogen 
peroxide. ROS are generated endogenously in the cell by normal metabolic 
pathways such as the mitochondrial electron transport chain and are also 
produced as a result of lipid peroxidation or upon exposure to ionizing radiation 
(King, R.J.B., 2000; Lu, A-L. etal, 2001). Commensal bacteria and dietary 
carcinogens may also contribute to high levels of oxidative stress in the colon 
(Huycke, M.M. & Gaskins, H.R, 2004; Ames, B.N. & Gold, L.S., 1991). The 
DNA damage produced by ROS can take the form of strand breaks or several 
types of individual base lesions. If the damage is extensive, this is sensed and 
can lead to cell death. If only limited damage results, it can be repaired and 
does not have a deleterious effect on the cell. However, if modified bases are 
not repaired before DNA replication, they can be misread and result in 
mutations (King, R.J.B., 2000; Lu, A-L. etal, 2001). Oxidative DNA damage is 
thought to contribute to aging, degenerative diseases and cancer (Ames, B.N. & 
Gold, L.S., 1991).
1.3.2.5.2 Base excision repair
BER is the main mechanism that protects against oxidative DNA damage 
(Hazra, T.K, etal, 2007). Lesions resulting from methylation, deamination and 
hydroxylation can also be repaired through this pathway (Hoeijmakers, J.H.J,
2001). As shown in Figure 1.10, the damaged base is recognised by a DNA
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glycosylase which cleaves it from the sugar-phosphate backbone, resulting in 
an apurinic/apyrimidinic (AP) site. AP sites produced as a result of 
spontaneous hydrolysis can also be repaired through BER. Some glycosylases 
have an AP lyase activity and cleave the sugar-phosphate backbone 3’ to the 
AP site. The APE1 endonuclease then processes the DNA in preparation for 
DNA synthesis. In the absence of a glycosylase lyase activity, APE1 prepares 
the DNA for synthesis by cleaving the sugar-phosphate backbone 5’ to the AP 
site (Wilson III, D.M. & Bohr, V.A., 2007). Recently an APE 1-independent BER 
pathway has been described (Wiederhold, L. etal, 2004) in which the NEIL1 or 
NEIL2 DNA glycosylase cleaves DNA at the AP site, leaving a 3’ phosphate 
group. This is then removed by polynucleotide kinase (PNK) so DNA synthesis 
can occur (Wiederhold, L. et al, 2004). The repair pathway involving 
monofunctional glycosylases now diverges into either short-patch or long-patch 
BER (Wilson III, D.M. & Bohr, V.A., 2007). If long-patch repair is carried out, 
DNA polymerase p incorporates the first nucleotide but elongation is carried out 
by DNA polymerases 6/e. A two or more nucleotide repair patch is synthesized 
from the damaged site, facilitated by PCNA and replication factor C (RFC).
Flap endonuclease 1 (FEN1) then removes the displaced DNA flap and the nick 
is sealed by DNA ligase I. In short-patch repair, DNA polymerase p cleaves the 
sugar-phosphate backbone 3’ to the AP site through its phosphodiesterase 
activity and fills the one-nucleotide gap. The remaining nick is sealed by the 
DNA ligase III/XRCC1 (X-ray repair cross complementing 1) heterodimer. DNA 
synthesis in repair pathways initiated by glycosylases with AP lyase activity or 
the NEILs is also short-patch and carried out by DNA polymerase p, with the 
nick sealed by the DNA ligase III/XRCC1 complex. The choice of short patch or 
long-patch repair is dependent on the DNA glycosylase recruited, type of DNA 
damage present and cell cycle phase. Direct single strand breaks (e.g those 
induced by ROS) can also be repaired by either short-patch or long-patch BER 
once their termini have been processed to contain a 3’ hydroxyl group and a 5’ 
phosphate group i.e. prepared for DNA synthesis (Fortini, P. & Dogliotti, E.,
2007).
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1.3.2.5.3 Repair of 7,8-dihydro-8-oxoguanine
One of the most stable products of oxidative damage is 7,8-dihydro-8- 
oxoguanine (8-oxoG) (Ames, B.N. & Gold, L.S., 1991) which can readily mispair 
with adenine during DNA replication (Shibutani, S. etal, 1991) and if left 
unrepaired, results in a G:C —► T:A transversion following the next round of 
replication (Michaels, M.L. & Miller, J.H., 1992). The repair system which 
protects against 8-oxoG damage was first characterised in E.coli and the key 
enzymes involved were identified as MutT, MutM and MutY (Michaels, M.L. & 
Miller, J.H., 1992) (Figure 1.11). MutT is a nucleoside triphosphatase which 
hydrolyzes 8-oxodGTP in the nucleotide pool, preventing its incorporation into 
nascent DNA (Maki, H. & Sekiguchi, M., 1992). The MutM DNA glycosylase 
recognises and excises 8-oxoG paired opposite cytosine (Boiteux, S. et al,
1992) and MutY is a DNA glycosylase responsible for removing adenine 
residues misincorporated into the daughter strand opposite 8-oxoG following 
replication (Michaels, M.L. etal, 1992). Cytosine is then inserted in place of the 
excised adenine, resulting in a 8-oxoG:C pair which can be repaired by MutM. 
The MutS DNA glycosylase is part of the mismatch repair (MMR) system and 
can perform the same function as MutY (Zhao, J. & Winkler, M.E., 2000). 
Another DNA glycosylase, endonuclease VIII (or Nei protein) provides a backup 
pathway for repair of 8-oxoG as it can excise this damaged base from 8-oxoG:C 
pairs (Blaisdell, J.O. etal, 1999) and the nascent strand when misincorporated 
opposite adenine during replication (Hazra, T.K. etal, 2001). Human 
homologues of mutT, mutM, mutY, mutS and nei have been identified as 
NUDT1 (Sakumi, K. etal, 1993), OGG1 (Roldan-Arjona, T. etal, 1997), MUTYH 
(Slupska, M.M. etal, 1996), the MSHs (Fishel, R. etal, 1993; Acharya, S. etal, 
1996) and the NEILs (Bandaru, V. etal, 2002), respectively.
1.3.2.5.4 MutY catalytic mechanism
The bacterial MutY protein has been studied more extensively than its human 
homologue, MUTYH, and has provided the majority of the structural and 
biochemical data on this enzyme. MutY is a member of the helix-hairpin-helix 
(HhH) superfamily of proteins which all have a conserved catalytic domain 
containing an HhH motif followed by a glycine/proline-rich loop and a catalytic 
aspartate residue (HhH-GPD motif) (Fromme, J.C. etal, 2004). The N-terminal
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catalytic domain of MutY is made up of two modules; a six-helix barrel 
containing the HhH motif and an iron-sulphur cluster (Guan, Y etal, 1998). The 
C-terminal domain of MutY is unique among HhH proteins, but similar to MutT 
and is necessary for substrate specificity (Noll, D.M. et al, 1999).
The mechanism by which MutY searches for mismatches within the vast excess 
of normal DNA is not known, but models have been proposed. Boon et al 
(2003) suggested a model of long-range scanning for mismatches through 
DNA-mediated charge transport chemistry. Non-specific binding of MutY to 
DNA results in oxidation of its iron-sulphur cluster and loss of an electron. This 
electron is then transported along the DNA to another MutY molecule already 
bound and its iron-sulphur cluster is reduced, promoting dissociation of the 
protein from the DNA. If a mismatch is encountered between the two MutY 
molecules, the DNA-mediated charge transport cannot occur and the protein 
remains bound to the DNA and processively diffuses to the mismatch. The 
charge transport process is continuous in the absence of a mismatch and 
therefore a few MutY molecules can rapidly scan the genome (Boon, E.M. etal,
2003). The model proposed by Lee et al (2004) also requires more than one 
MutY molecule. A MutY monomer binds to DNA non-specifically then a second 
MutY molecule cooperatively binds the same DNA and a dimer is formed. The 
MutY dimer slides along the DNA until one of the molecules binds specifically to 
the mismatch then conformational changes occur in the active monomer and 
DNA (Lee, C-Y et al, 2004). This is consistent with a report that upon DNA 
binding, MutY assembles into a dimer and this is the functionally active state 
(Wong, I. et al, 2003). However in Lee’s model the dimer searches for a 
mismatch but only the active MutY molecule remains bound for catalysis (Lee, 
C-Y etal, 2004).
The N-terminal domain six-helix barrel and iron-sulphur cluster modules form a 
positively-charged groove through which the DNA strand containing the 
mispaired adenine is bound (Guan, Y etal, 1998; Fromme, J.C. etal, 2004).
The six-helix barrel also interacts with the backbone of the DNA strand 
containing the complementary 8-oxoG residue (Fromme, J.C. etal, 2004). The 
C-terminal domain of MutY confers specificity for 8-oxo-G:A mispairs by
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recognising the 8-oxoG base (Noll, D.M. etal, 1999; Li, X. etal, 2000). It 
makes extensive contacts with the 8-oxo-G-strand of DNA and the oxidized 
base itself. 8-oxoG is hydrogen-bonded to both the C-terminal and catalytic 
domains, ensuring that adenines correctly paired opposite thymines are not 
excised (Fromme, J.C. et al, 2004). MutY mainly contacts the G-strand and 
interacts with DNA via at least five phosphates and purine bases on either side 
of the mismatch (Lu, A-L. et al, 1995). A double base flipping mechanism was 
proposed to facilitate recognition of the 8-oxo-G:A mispair and aid adenine 
extrusion into the active site (Bernards, A.S. et al, 2002) but crystal structures of 
MutY bound to DNA showed that although the DNA is bent and the mispaired 
adenine is extruded, 8-oxoG remains within the helix (Fromme, J.C. etal,
2004). The HhH and pseudo HhH motifs at either end of the DNA binding 
groove compress the DNA intrastrand phosphate distance either side of the 
mispaired adenine causing the DNA to bend and the target base to flip out of 
the DNA helix, into the active site pocket (Guan, Y et al, 1998). When MutY 
binds to an 8-oxoG:A mispair, the 8-oxoG nucleoside changes its glycosydic 
bond conformation from a syn to an anti orientation. The anti conformation of 8- 
oxoG would sterically clash with an adenine base opposite and so may also 
promote flipping of adenine into the active site (Fromme, J.C. et al, 2004). 8- 
oxoG binding to the C-terminal domain facilitates base-flipping and thus 
accelerates the glycosylase reaction (Noll, D.M. etal, 1999). The active site 
pocket is complementary to the extrahelical adenine residue, which is deeply 
sequestered and hydrogen-bonded by the MutY protein. The catalytic and C- 
terminal domains interact to allow the enzyme to surround the DNA duplex 
(Fromme, J.C. etal, 2004). The flipped-out adenine leaves a gap in the DNA 
base stack which may be stabilized by the minor groove reading motif. MutY 
then cleaves the N-glycosylic bond through a hydrolytic mechanism (Guan, Y et 
al, 1998). The adenine base is released quickly from the enzyme and the rate- 
limiting step is release of DNA containing an AP site as it is tightly bound by 
MutY (McCann, J.A.B. & Berti, P.J., 2003).
The DNA glycosylase endonuclease III also has AP lyase activity which is 
attributed to a lysine residue within its HhH motif. MutY lacks a lysine residue 
within the HhH motif and primarily functions as a pure DNA glycosylase, but
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does have weak AP lyase activity (Guan, Y et al, 1998). Unlike endonuclease 
III, this additional activity is uncoupled to its glycosylase activity and is 
alternatively regulated by two lysine residues positioned near the active site 
(Manuel, R.C. et al, 2004).
1.3.2.5.5 Role of MUTYH in DNA repair
The human MutY homologue, MUTYH, demonstrates glycosylase activity with 
DNA substrates containing the following mispairs; A:G, 2-hydroxyadenine (2- 
OH-A):8-oxo-G, A:8-oxo-G, 2-OH-A:G and 2-OH-A:A but exhibits little AP lyase 
activity (Ohtsubo, T. et al, 2000). 2-OH-A is another product of oxidative DNA 
damage (Lu, A-L. etal, 2001). Under physiological salt conditions, MUTYH 
specifically catalyzes the glycosylase reaction on A:8-oxoG not A:G mispairs 
(Shinmura, K. et al, 2000). Mutant MUTYH is defective in binding and repair of 
A:8-oxoG and 8-oxoadenine (8-oxoA):G mispairs (Parker, A.R. etal, 2005). 
Phosphorylation of serine residues enhances MUTYH repair of A:8-oxoG 
mispairs and may regulate protein-protein interactions (Parker, A.R. etal,
2003). MUTYH interacts with APE1, PCNA and RPA1 suggesting that repair of 
DNA lesions by MUTYH occurs via the long-patch pathway of BER (Parker, A. 
et al, 2001). Indeed, short-patch BER initiated by murine MUTYH is futile and 
the repair has to proceed to the long-patch pathway (Hashimoto, K. et al, 2004). 
MUTYH can interact with Hus1 (part of the 9-1-1 DNA damage sensor complex) 
and may act as an adaptor for sensor checkpoint proteins following oxidative 
DNA damage (Shi, G. et al, 2006). Nuclear MUTYH co-localizes with PCNA at 
replication foci and levels of MUTYH are maximal during S phase indicating that 
MUTYH repair may be coupled to replication (Boldogh, I. etal, 2001).
Consistent with this, DNA replication enhances murine MUTYH repair through 
its interaction with PCNA (Hayashi, H. etal, 2002). The coupling of replication 
and MUTYH repair allows MUTYH to be directed to the daughter strand, 
thereby preventing the A:T to C:G transversions that would arise from adenine 
glycosylase activity on the template strand. MUTYH also interacts with the 
MMR protein MSH6 which forms a heterodimer with MSH2. The mammalian 
MSH2/MSH6 complex can repair 8-oxoG incorporated into the daughter strand 
during replication (Colussi, C. et al, 2002) and A:8-oxoG mismatches where the 
adenine is on the template strand are mainly recognised by this complex (Gu,
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Y. et al, 2002). However, it has been reported that MSH2/MSH6 repair of 8- 
oxoG incorporated during replication opposite adenine or cytosine is inefficient 
(Larson, E.D. et al, 2003). Recently, Macpherson et al (2005) have shown 
MSH2/MSH6 can efficiently recognise 8-oxoG opposite adenine or cytosine 
when these mispairs lie within repetitive sequences that have undergone a 
slippage event (Macpherson, P. et al, 2005). The MSH2/MSH6 complex binds 
8-oxoG:G and 8-oxoG:T mispairs efficiently and although such mispairs are rare 
in vivo, when the oxidised base is on the template strand MMR can result in 8- 
oxoG:A mispairs which are recognised by MUTYH (Larson, E.D. etal, 2003). 
The MSH2/MSH6 dimer can enhance binding of MUTYH to A:8-oxoG 
mismatches and interactions between these repair proteins may help target 
MUTYH to the daughter strands (Gu, Y. et al, 2002). Wong et al (2003) 
proposed a mechanism by which dimeric MutY could determine the level of 
oxidative damage present and remove adenines only present on the nascent 
strand. A:8-oxoG mispairs resulting from incorporation of adenine into the 
nascent strand opposite 8-oxoG are found in isolation and repaired by MutY. 
However, A:8-oxoG mispairs formed as a result of incorporation of 8-oxo-GTP 
into the nascent strand opposite adenine would arise as patches of damage. 
Wong et al (2003) suggested that concurrent binding of two of these mispairs by 
dimeric MutY would inhibit its glycosylase activity, thereby preventing A:T to 
C:G transversions and allow recruitment of more appropriate repair enzymes 
such as those involved in MMR (Wong, I. etal, 2003). Mammalian MUTYH 
protects its DNA product from OGG1 as this DNA glycosylase could excise 8- 
oxoG opposite the AP site, resulting in a loss of informative bases on both 
strands and a double strand break. MUTYH may encircle and tightly bind the 
DNA duplex (like its bacterial homologue) thus physically preventing OGG1 
from accessing the DNA (Tominaga, Y. etal, 2004)
1.3.2.6 Genetic pathway to CRC
The identification of MAP arose from investigating a family in which several 
siblings had an AFAP-like phenotype, but in whom a germline truncating 
mutation in APC was not identified. Analysis of somatic APC mutations in 
colorectal tumours from the affected siblings revealed that most of them were 
G:C to T:A transversions which almost exclusively occurred at GAA sequences,
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resulting in stop codons. The pattern of APC somatic mutations was then linked 
to functionally compromising biallelic germline MUTYH mutations in the affected 
cases (Al-Tassan, N. etal, 2002) and this association was rapidly confirmed in 
further unrelated MAP cases (Jones, S. et al, 2002). A mouse model has also 
shown that homozygous Mutyh deficiency increases intestinal tumourigenesis in 
ApcMm,+ mice and some polyps from these mice harboured G:C to T:A 
transversions resulting in termination codons (Sieber, O.M. etal, 2004). A 
specific somatic K-RAS mutation has been identified in some MAP adenomas 
and is associated with increased dysplasia. The G12C activating mutation is 
the result of a G:C to T:A transversion (Lipton, L. et al, 2003; Jones, S. et al,
2004). Although MAP tumours have somatic mutations in genes often mutated 
in the CIN pathway of tumourigenesis, they appear to be near-diploid yet they 
do not harbour somatic mutations in genes frequently mutated in MSI tumours 
such as BRAF, SMAD4 and TGFpllR (Lipton, L. etal, 2003).
Unlike other genes involved in inherited CRC predisposition, somatic mutations 
in MUTYH do not appear to be involved in sporadic colorectal tumourigenesis. 
No somatic MUTYH mutations were found in 75 sporadic CRCs and mRNA and 
protein were expressed in all of the 35 CRC cell lines examined, indicating that 
epigenetic silencing was not occurring (Halford, S.E.R. etal, 2003).
1.3.3 Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
1.3.3.1 Clinical presentation
HNPCC is the most common Mendelian CRC syndrome, contributing to 2-5% of 
all new CRC cases (Lynch, H.T. etal, 2006). The population incidence of 
HNPCC is estimated to be between 1 in 2000 and 1 in 660 (de la Chapelle, A.,
2005). The average age at CRC onset is 45 years and patients are at 
increased risk of synchronous and metachronous CRCs (Lynch, H.T. etal,
2006). A small number of colorectal adenomas (only exceptionally more than 
ten) may be present, but florid polyposis is not observed (Lucci-Cordisco, E. et 
al, 2003). Unlike FAP, where tumour initiation is accelerated but the 
progression rate is probably normal, HNPCC has accelerated tumour 
progression but probably a normal tumour initiation rate (Kinzler, K.W. & 
Vogelstein, B., 1996). HNPCC is also known as Lynch syndrome, in order to
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reflect the extracolonic malignancies associated with this disease including 
endometrial cancer and cancers of the small bowel, urinary tract, stomach, 
hepatobiliary tract, ovaries and brain (Vasen, H.F.A, 2005; Watson, P. & Riley,
B., 2005). Sebaceous skin tumours and internal malignancies are associated 
with the Muir-Torre variant (Ponti, G. & Ponz de Leon, M., 2005) and gliomas in 
addition to colorectal tumours are characteristics of Turcot syndrome (Lucci- 
Cordisco, E. et al, 2003).
1.3.3.2 Genetics
HNPCC is an autosomal dominant disorder caused by germline mutations in the 
MSH2 (Fishel, R. etal, 1993), MLH1 (Lindblom, A. etal, 1993), MSH6 (Miyaki, 
M. et al, 1997) or PMS2 (Nicolaides, N.C. et al, 1994) genes. Penetrance for 
CRC in males is approximately 80% (but is lower in females), up to 60% for 
endometrial cancer and less than 20% for other cancers (de la Chapelle, A.,
2004).
1.3.3.3 Mismatch repair (MMR)
MSH2, MLH1, MSH6 and PMS2 all encode proteins which are involved in 
MMR. This pathway repairs a wide range of single base mismatches as well as 
insertion/deletion loops arising from DNA polymerase slippage during 
replication, often within repetitive sequences (Jascur, T. & Boland, C.R., 2006). 
MMR is specific to the daughter DNA strand and in E. coli the MutH protein 
recognises a particular sequence which is methylated in the template strand but 
transiently unmethylated in the daughter strand, thus targeting repair to the 
daughter strand (Kunkel, T.A. & Erie, D.A., 2005). No such methylation 
patterns occur in humans and no human MutH homologue has been identified. 
Communication between MMR proteins and enzymes at the replication fork 
through interactions with PCNA may allow strand discrimination to occur (Plotz, 
G. et al, 2006). As shown in Figure 1.12, the DNA damage is recognised by a 
MSH2 heterodimer, formed with either MSH6 or MSH3 depending on the type 
of DNA error. MSH2/MSH6 heterodimers recognise single base mismatches or 
small insertion/deletion loops whereas MSH2/MSH3 heterodimers recognise 
insertion/deletion loops. A MLH1/PMS2 heterodimer is then recruited and 
docks to the MSH2 heterodimer (Jascur, T. & Boland, C.R., 2006; Plotz, G. et
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al, 2006). The MLH1/MLH3 heterodimer may function in repair of MSH2/MSH6 
substrates, but is not thought to play a major role in MMR in vivo (Cannavo, E. 
et al, 2005). Exonuclease I, aided by RPA and HMGB1, digests the daughter 
DNA strand in either the 5’ or 3’ direction from the point of strand recognition to 
shortly after the mismatched site. DNA synthesis is carried out by DNA 
polymerase 6 , with PCNA and RFC also required. The nick is then sealed by a 
DNA ligase (Plotz, G. et al, 2006).
1.3.3.4 Molecular genetics
1.3.3.4.1 Germline mutations
Approximately 90% of HNPCC-associated germline mutations are found in 
either MSH2 or MLH1 (Peltomaki, P., 2005) and are spread throughout these 
genes with no mutational hotspots (de la Chapelle, A. 2004). The intragenic 
location of the mutation does not affect the phenotype (de la Chapelle, A.,
2004), but MSH2 is more frequently mutated than MLH1 in patients with 
extracolonic tumours and MLH1 mutations have a higher expression of CRC 
than MSH2 mutations (Lynch, H.T. et al, 2006). MSH6 accounts for 
approximately 10% of HNPCC-associated germline mutations and may result in 
a later age of CRC onset compared with MSH2 or MLH1 mutations (Peltomaki, 
P., 2005). Women with a MSH6 mutation have a high risk of endometrial 
cancer (Wijnen, J. etal, 1999). Truncating, splicing and missense mutations 
have been identified in the MSH2, MLH1 and MSH6 genes (de la Chapelle, A.,
2004). Mutations in PMS2 are less frequent and were thought to result in 
severe, early onset HNPCC often associated with brain tumours (Turcot 
syndrome) (de la Chapelle, A., 2004). Recently however, Hendriks et al (2006) 
reported that patients with a germline PMS2 mutation show a milder phenotype 
than those with mutations in either MLH1 or MSH2 (Hendriks, Y.M. et al, 2006). 
Mutations in MLH3 have been reported (Wu, Y. et al, 2001) but their 
contribution to HNPCC is unclear (Cannavo, E. et al, 2005). Germline 
mutations in MSH2, or less frequently in MLH1 (Ponti, G. & Ponz de Leon, M.,
2005) and MSH6 (Arnold, A. etal, 2007), can cause Muir-Torre syndrome and 
mutations in MSH2, MLH1 or PMS2 are associated with Turcot syndrome 
(Lucci-Cordisco, E. et al, 2003).
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Homozygotes for either MSH2 (Whiteside, D. et al, 2002), MLH1 (Wang, Q. et 
al, 1999) or PMS2 (De Vos, M. et al, 2004) point mutations are rare and have a 
severe phenotype with haematological malignancies and some skin 
characteristics of neurofibromatosis type 1 (NF1). Compound heterozygotes for 
PMS2 point mutations have a phenotype consistent with Turcot syndrome (De 
Rosa, M. et al, 2000). Recently, Will et al (2007) described a large (400kb) 
homozygous PMS2 deletion in a patient with 10 CRCs, 35 colorectal adenomas 
and duodenal cancer in his twenties. The patient had no brain tumour but had 
mental retardation and cafe-au-lait spots. This case shows that gross 
homozygous mutations in a MMR gene can result in a severe phenotype 
uncharacteristic of HNPCC (Will, O. et al, 2007).
1.3.3.4.2 Somatic mutations
A somatic inactivating mutation in the inherited wild-type allele of the MMR gene 
results in defective MMR (Yuen, S.T. et al, 2002). Errors normally corrected by 
this pathway are left unrepaired, leading to a mutator phenotype which 
increases the chance of mutations occurring in growth regulatory genes (Ionov, 
Y. etal, 1993; Fishel, R. etal, 1993). Microsatellite instability (MSI) is a 
consequence of defective MMR (Thibodeau, S.N. etal, 1993) and colorectal 
tumourigenesis in HNPCC occurs via the MSI pathway, with genes such as 
TGF-pRII or BAX often somatically mutated (Soreide, K et al, 2006). Tumours 
deficient in MLH1, MSH2 or PMS2 show MSI at no less than 40% of loci and 
are termed MSI-high (Peltomaki, P., 2005; Umar, A. etal, 2004), whereas 
tumours from patients with MSH6 mutations can have lower levels of instability 
(Peltomaki, P., 2005). Some sporadic tumours also display MSI but unlike 
HNPCC tumours, their mismatch repair deficiency is most often the result of 
hypermethylation of the MLH1 promoter (Kuismanen, S.A. etal, 2000).
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1.4 Hypotheses and aims
1.4.1 FAP and MAP as causes of adenomatous colorectal polyposis
Previous studies of unrelated colorectal polyposis patients have indicated that a 
large proportion (274/660, 42% (Aretz, S. et al, 2006); 37/60, 62% (Aceto, G. et 
al, 2005)) are not accounted for by germline APC or MUTYH mutations.
Families recorded on the Wales Polyposis Register were screened for APC and 
MUTYH mutations in order to identify those in which novel polyposis genes 
could be sought. Novel candidate genes were assessed for the presence or 
absence of high penetrance polyposis alleles in APC and MUTYH mutation- 
negative cases from the Wales Polyposis Register and collaborating registers in 
the UK.
1.4.2 Characterization of MAP and the MUTYH mutational spectrum
MUTYH mutations in MAP cases from three European countries were 
characterized to better define the mutation spectrum and identify population- 
specific changes. Germline biallelic MUTYH mutations result in a BER defect 
which could lead to an increased risk of extracolonic manifestations in MAP. 
Genotypes and clinical features of MAP patients from three European centres 
were assessed to define the MAP phenotype and establish genotype-phenotype 
correlation.
1.4.3 Cancer risk in MUTYH heterozygotes
Previous studies have provided evidence for an increased CRC risk in 
monoallelic MUTYH mutation carriers (Farrington, S.M. etal, 2005; Peterlongo, 
P. et al, 2006) but other reports have contested this (Webb, E.M. et al, 2006; 
Balaguer, F. et al, 2007). To clarify whether MUTYH heterozygosity has 
implications for health, 350 monoallelic MUTYH mutation carriers identified 
through three European polyposis registers were included in a retrospective 
study of CRC, other cancer and mortality.
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Chapter Two
Materials and Methods 
2.1 Suppliers
Materials and equipment were purchased from the following companies: AB 
gene (Surrey, UK), Ambion (Cambridgeshire, UK), Amersham Biosciences 
(Buckinghamshire, UK), Anachem (Bedfordshire, UK), Applied Biosystems 
(Cheshire, UK), Beckman Coulter (Buckinghamshire, UK), Bibby Sterilin 
(Staffordshire, UK), Bioquote (Yorkshire, UK), Biorad (Hertfordshire, UK), 
Coming CoStar (The Netherlands), Difco Laboratories Ltd (Surrey, UK), DuPont 
Instruments (Hertfordshire, UK), Eppendorf, (Cambridgeshire, UK), Eurogentec 
(Hampshire, UK), Fisher Scientific (Leicestershire, UK), Fluka Biochemika 
(Dorset, UK), IKA (Staufen, Germany), Invitrogen Life Technologies 
(Strathclyde, UK), Jencons-PLS (Bedfordshire, UK), Kendro Laboratory 
Products (Hertfordshire, UK), Labtech International (East Sussex, UK), Leica 
(Wetzlar, Germany), Millipore (Hertfordshire, UK), MJ Research 
(Massachusetts, USA), MRC-Holland (Amsterdam, The Netherlands), MWG- 
Biotech (Buckinghamshire, UK), New England Biolabs (Hertfordshire, UK),
Palm (Germany), PreAnalytiX (Hombrechtikon, Switzerland), Promega 
(Hampshire, UK), Qiagen (West Sussex, UK), Roche Biochemicals (East 
Sussex, UK), Sarstedt (Germany), Sartorius (Epsom, UK), Sigma Ltd (Dorset, 
UK), StarLab (Milton Keynes, UK) and Thermo Electron Corporation 
(Hampshire, UK).
2.2 Materials
2.2.1 Chemicals
General chemicals were supplied from Sigma Ltd unless otherwise stated.
2.2.2 Nucleic acid extraction and purification
QIAamp DNA Micro and QIAprep Miniprep kits were supplied by Qiagen. 
PAXgene Blood RNA tubes and PAXgene Blood RNA kit were from 
PreAnalytiX. TURBO DNA-free kit, RNaseZap, DNAZap and DEPC-treated 
water were obtained from Ambion.
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2.2.3 First strand synthesis
Superscript III First-Strand Synthesis System for RT-PCR was supplied by 
Invitrogen Life Technologies.
2.2.4 PCR
AmpliTaq Gold DNA polymerase and GeneAmp PCR buffer were from Applied 
Biosystems. Individual deoxynucleotidetriphosphates (dNTPs) were purchased 
from Amersham Biosciences. HPSF purified oligonucleotide primers were 
supplied by MWG-Biotech or Eurogentec. Dimethyl Sulfoxide (DMSO) was 
obtained from Sigma Ltd.
2.2.5 PCR purification
Exonuclease I and Shrimp alkaline phosphatase were purchased from New 
England Biolabs and Amersham Biosciences respectively. QIAquick PCR 
purification kit was supplied by Qiagen
2.2.6 Multiplex ligation-dependent probe amplification (MLPA)
SALSA P043 APC MLPA kit was supplied by MRC-Holland.
2.2.7 Electrophoresis
Multipurpose agarose was obtained from Roche. New England Biolabs and 
Invitrogen Life Technologies supplied the 100bp DNA ladder and 1kb DNA 
ladder respectively. Ethidium bromide was supplied by Fluka Biochemika.
2.2.8 Sequencing and fluorescent product sizing
BigDye Terminator Cycle Sequencing Kit (Version 1.1 or 3.1), POP6  polymer, 
HiDi formamide and Genescan 500-ROX size standard were purchased from 
Applied Biosystems. Millipore supplied Montage SEQ96 sequencing reaction 
clean up kits and Sigma provided capillary electrophoresis running buffer.
2.2.9 Restriction enzymes
All restriction endonucleases were supplied, with the appropriate buffer and 
BSA, if required, by New England Biolabs.
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2.2.10 Cloning
pGEM-T Easy vector system I was purchased from Promega and subcloning 
efficiency DH5a chemically competent E.coli cells were obtained from Invitrogen 
Life Technologies. Tryptone, yeast extract and agar were supplied by Difco 
Laboratories Ltd. Ampicillin, X-gal (5-bromo-4-chloro-3-indoyl-D-galactoside) 
and IPTG (isopropyl-p-D-thio-galactopyranoside) were obtained from Sigma 
Ltd.
2.2.11 Clinical Material
All tissue and blood samples were obtained with patient consent and ethical 
approval for research.
2.3 Equipment
2.3.1 Plastics and glassware
Sterile tips for Gilson pipettes were supplied by Bioquote or StarLab. RNase- 
and DNase-free sterile barrier tips were obtained from Promega. Distritips and 
sterile tips for multi-channel pipettes were bought from Anachem. Sterile 25ml 
stripettes were obtained from Corning CoStar. 0.65ml, 1.5ml and 2.0ml plastic 
eppendorfs were purchased from Bioquote and 1.5ml microcentrifuge tubes 
were supplied by Fisher Scientific. Thermo Electron Corporation provided 96 
well Thermo-fast PCR reaction plates. Adhesive PCR sealing sheets, 0.2ml 
Thermo-strip tubes and 96 well Thermo-fast skirted detection plates were 
purchased from ABgene. Sterile universals and petri dishes were obtained from 
Bibby Sterilin and Sarstedt respectively. Glass flasks and beakers were 
provided by Jencons-PLS or Fisher Scientific.
2.3.2 Thermocycling
Thermocycling was carried out using a MJ Research DNA Engine Tetrad PTC- 
225 or an Applied Biosystems GeneAmp 9700.
2.3.3 Electrophoresis
Electrophoresis was carried out using 96 well gel apparatus from ABgene or the 
Horizon 11.14 gel tank from Invitrogen Life Technologies. Power packs were
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purchased from BioRad. Visualisation of ethidium bromide stained gels was 
carried out using a Biorad GelDoc200 or Biorad GelDoc XR transluminator. 
Capillary electrophoresis of fluorescent sequencing or MLPA products was 
carried out using an ABI 3730 DNA Analyser or an ABI 3100 Genetic Analyser.
2.3.4 Other equipment
DuPont Instruments supplied the Sorvall RT6000B refrigerated centrifuge and 
the Sorvall LegendRT centrifuge was provided by Kendro Laboratory Products. 
The minishaker MS2 was purchased from IKA. The Biofuge pico centrifuge and 
the Vortex-Genie 2 were obtained from Jencons-PLS. Sartorius supplied the 
BP1200 top pan balance. The Biomek FX robot was provided by Beckman 
Coulter. Quantitation of DNA and RNA was carried out using the NanoDrop 
ND-1000 spectrophotometer (Labtech International).
2.4 Sequence data
Genbank (http://www.ncbi.nlm.nih.gov/Genbank/) accession numbers for genes 
analysed in this project are as follows:
Genomic mRNA
APC NC_000005 NM_000038
MUTYH NC_000001 NM_012222
MBD4 NC_000003 NM_003925
NUDT1 NC_000007 NM_198952
NUDT5 NC_000010 NM_014142
NTHL1 NC_000016 NM_002528
POLL NC_000010 NM_013274
SMUG1 NC_000012 NM_014311
MPG NC_000016 NM_002434
TDG NC_000012 NM_003211
UNG NC_000012 NM_080911, NM_003362
APE1 NC 000014 NM 001641
2.5 Bioinformatic tools
BLAST searches (http://www.ncbi.nlm.nih.gov/blast/) were carried out against 
DNA sequences from Genbank. Multiple sequence alignments were carried out
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using Clustal W (http://www.ebi.ac.uk/clustalw/). Reported single nucleotide 
polymorphisms and pathogenic mutations were identified from the Human Gene 
Mutation Database (http://www.hgmd.cf.ac.uk/), dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP/) and APC gene database (Soussi.T., 
personal communication). Splice site prediction was carried out using 
NetGene2 (http://www.cbs.dtu.dk/services/NetGene2) or SpliceSiteFinder 
(http://violin.genet.sickkids.on.ca/~ali/splicesitefinder.html) and ESEfinder v3.0 
(http://rulai.cshl.edu/tools/ESE/)was used to predict putative exonic splicing 
enhancers (ESEs). Protein structures were obtained from the RCSB Protein 
Data Bank (http://www.rcsb.org/pdb/) and viewed using RasMol v2.6-P-2 
(http://openrasmol.org/).
2.6 Methods
All solutions were made using MilliQ water and autoclaved at 15lb/sq.in at 
121°C for 40 min where necessary.
2.6.1 General reagents
TAE buffer: 40mM Tris-acetate, 1mM EDTA pH8
2.6.2 Nucleic acid extraction
2.6.2.1 DNA extraction from paraffin-embedded tissue 
DNA was extracted from paraffin-embedded tissue cores using the QIAamp 
DNA Micro kit, according to the manufacturer’s instructions. To 2-5 tissue cores 
(diameter 6mm), 15pl SDS-containing lysis buffer (Buffer ATL; contents trade 
secret [CTS]) and 10pl proteinase K solution were added. The sample was 
mixed by vortexing then incubated at 56°C for 16 hours. To aid efficient lysis, 
the sample was occasionally vortexed during incubation. An additional 10pl 
proteinase K solution was added to the sample which was vortexed then 
incubated at 56°C for a further 3 hours. 25pl buffer ATL and 50pl buffer AL 
(CTS) were added to the sample which was then mixed by pulse-vortexing for 
15 seconds to obtain a homogeneous solution. To this solution 50pl 100% 
ethanol was added, the sample was mixed by pulse-vortexing and then 
incubated at room temperature for 5 minutes. This addition of Buffer AL and
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ethanol allows optimal adsorption of DNA to the silica gel membrane of the 
column. The solution was then applied to the QIAamp MinElute spin column 
and centrifuged at 6000 x g for 1 min to facilitate DNA binding. The column was 
then transferred to a clean collection tube, and washed to remove any residual 
contaminants. 500 pi of the first wash buffer, AW1 (CTS) was added, and the 
column re-centrifuged for 1 min at 6000 x g. The eluate was discarded before a 
second wash step was carried out by adding 500pl buffer AW2 (contains 
ethanol, CTS) then centrifuging for 1 min at 6000 x g. Any residual carryover of 
the ethanol-containing wash buffer would inhibit downstream reactions, so the 
column was centrifuged at 13,000 x g for 3 min to ensure its complete removal. 
DNA was eluted into a clean microcentrifuge tube by applying 30pl distilled 
water to the column, incubating at room temperature for 5 min and centrifuging 
at 13,000 x g for 1 min. Samples were stored at -20°C.
2.6.2.2 RNA extraction
RNA was extracted using the PAXgene Blood RNA system and TURBO DNA- 
free kit, according to the manufacturers’ instructions. All equipment was treated 
with RNaseZap and DNAZap then rinsed with DEPC-treated water. This 
removed any ribonucleases that would degrade the RNA and any DNA that 
would contaminate the sample. Blood (2.5ml) was collected from the patient 
into a PAXgene Blood RNA tube which already contained 6.9ml additive (CTS). 
The additive stabilises the in vivo gene transcription profile of a sample by 
reducing in vitro RNA degradation and minimising gene induction, allowing 
accurate detection and quantification of gene transcripts. The blood and 
additive were mixed by inverting the tube 8-10 times which was then kept 
upright at room temperature for 3.5 hours during transportation. The sample 
was then either frozen at -20°C for later use or incubated at room temperature 
for a further 17 hours before processing. If the sample had been frozen, it was 
left to thaw and incubate at room temperature for 17 hours before processing. 
After incubation the sample was centrifuged at 3000 x g for 10 minutes to pellet 
the nucleic acids. The supernatant was discarded and the pellet washed with 
the addition of 4ml RNase-free water. The sample was vortexed to dissipate 
the pellet then centrifuged again at 3000 x g for 10 minutes. The supernatant
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was discarded and 350pl resuspension buffer (CTS) added to the pellet. The 
sample was vortexed until the pellet was visibly dissolved then transferred to a 
1.5ml microcentrifuge tube. 300pl binding buffer (contains guanidine 
thiocyanate, CTS) and 40pl proteinase K were added to the sample which was 
vortexed for 5 seconds then incubated for 10 minutes at 55°C in a shaker- 
incubator at 450rpm. This resulted in digestion of the protein present. The 
solution was then applied to a PAXgene Shredder spin column and centrifuged 
for 3 minutes at 13,000 x g to homogenize the cell lysate and remove residual 
cell debris. The supernatant of the flow-through fraction was transferred to a 
clean 1.5ml microcentrifuge tube without disturbing the pellet in the processing 
tube. To this solution 350pl 100% ethanol was added to adjust the binding 
conditions and the sample was mixed by vortexing. 700pl of the solution was 
applied to a PAXgene RNA spin column and centrifuged for 1 minute at 13,000 
x g to facilitate total RNA binding. The eluate was discarded and the column 
transferred to a clean collection tube. The remainder of the sample was applied 
to the column and centrifuged for 1 minute at 13,000 x g. The column was then 
transferred to a clean collection tube and washed to remove any residual 
contaminants. 350pl wash buffer 1 (contains ethanol and guanidine 
thiocyanate, CTS) was added and the column centrifuged for 1 minute at 
13,000 x g. DNase I treatment of the column was carried out between wash 
steps to remove trace amounts of bound DNA. 10pl DNase I stock solution 
(contains bovine DNase I, 2.7 U/pl, CTS) was mixed with 70pl DNA digestion 
buffer (CTS) by gentle flicking as DNase I is sensitive to physical denaturation. 
This mixture was then applied to the column and incubated at room temperature 
for 15 minutes. The column was washed again with 350pl wash buffer 1 then 
centrifuged at 13,000 x g for 1 minute. The column was transferred to a clean 
collection tube and washed with a second buffer by adding 500pl wash buffer 2 
(contains ethanol, CTS) then centrifuging for 1 minute at 13,000 x g. The 
column was transferred to a clean collection tube and washed again with wash 
buffer 2 (500pl) then centrifuged for 3 minutes at 13,000 x g. Any residual 
carryover of the ethanol-containing wash buffer would inhibit downstream 
reactions, so the column was transferred to a clean collection tube then 
centrifuged at 13,000 x g for 1 min to ensure its complete removal. RNA was
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eluted into a clean 1.5ml microcentrifuge tube by applying 40pl elution buffer 
(CTS) to the column then centrifuging at 13,000 x g for 1 min. This elution step 
was repeated to obtain the maximum RNA yield. The RNA was then denatured 
ready for downstream applications by incubating at 65°C for 5 minutes then 
chilling immediately on ice.
Chai, V. et al found the on-column DNase I treatment insufficient to remove low 
levels of DNA contamination so in order to remove any DNA still remaining in 
the RNA sample, it was treated again using the TURBO DNA-free kit. 4pl 10X 
TURBO DNase buffer (contains Tris, NaCI, CTS) and 1pl TURBO DNase (2 
U/pl, CTS) were added to 40pl RNA (1.2pg to 4.5pg). The sample was mixed 
gently then incubated at 37°C for 30 minutes. A further 1pl TURBO DNase was 
added and the sample incubated again for 30 minutes at 37°C. 8pl DNase 
inactivation reagent (CTS) was mixed with the sample and incubated for 2 
minutes at room temperature with occasional vortexing to remove the DNase 
and divalent cations which can catalyze heat-mediated RNA cleavage. The 
sample was centrifuged at 10,000 x g for 1.5 minutes to pellet the DNase 
inactivation reagent. The supernatant (RNA) was transferred to a clean tube 
and stored at -80°C.
2.6.3 Quantification of nucleic acids
The concentration of DNA and RNA samples was determined by UV 
spectrophotometry at wavelengths of 260nm and 280nm to quantify the amount 
of DNA or RNA present and allow protein content to be established. An 
absorbance ratio of 1.8 at 260nm:280nm indicates high sample purity.
2.6.4 First strand synthesis
In order to amplify messenger RNA, which makes up between 1% and 5% of 
total RNA, a complementary DNA strand is required to provide a template for 
PCR. Random 6bp oligonucleotides bind along the RNA and prime the reverse 
transcription reaction. This first strand synthesis was carried out using the 
Superscript III first strand synthesis system for RT-PCR, according to the 
manufacturer’s instructions. A 10jnl reaction containing 0.24pg to 0.58pg total
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RNA, 1 mM dNTPs and 50ng random hexamers was incubated at 65°C for 5 
minutes and then chilled on ice. 10X RT buffer (200mM Tris-HCI, pH 8.4, 
500mM KCI), 5mM MgCfe, 2\i\ 0.1M dithiothreitol, 40U RNaseOUT recombinant 
ribonuclease inhibitor and 200U Superscript III reverse transcriptase were then 
added. The reaction was incubated for 10 minutes at 25°C followed by 50 
minutes at 50°C. The reaction was terminated by denaturation of the enzyme at 
85°C for 5 minutes and then was chilled on ice. To increase the sensitivity of 
cDNA amplification by PCR, the RNA template was removed from the 
cDNA:RNA hybrid molecule by adding 2U E.coli RNase H and incubating at 
37°C for 20 minutes. The cDNA reaction was stored at -20°C.
2.6.5 Primer design
Oligonucleotides were designed using Oligo Version 4 software (Molecular 
Biology Insights Inc., USA). The melting temperatures of the primer pair were 
within 2°C of each other and oligonucleotides were more stable at their 5’ 
regions if possible. Primers were between 18 and 25 nucleotides in length, 
lacked repetitive motifs and had little predicted dimerization or secondary 
structure formation.
2.6.6 Polymerase chain reaction (PCR)
The polymerase chain reaction allows the specific in vitro amplification of 
defined DNA target sequences within a source of DNA. This occurs in an 
exponential manner. Double stranded DNA templates are heat denatured and 
oligonucleotides bind specifically to complementary target sites on each strand. 
Thermostable DNA polymerases extend the primers in the 5' to 3' direction by 
incorporating dNTPs to create a complementary DNA strand. This cycle is 
repeated 20-40 times to produce up to 5pg DNA (Mullis et al, 1986).
For standard PCR, 25ng template DNA, 0.25mM dNTPs, 25pmoles forward 
and reverse primers, 10X GeneAmp PCR buffer (100mM Tris-HCI, pH8.3, 
500mM KCI, 15mM MgCh, 0.01% w/v gelatin), and 0.5U AmpliTaq Gold DNA 
polymerase were used in a total volume of 20pl. Cycling conditions were 95°C 
for 12 minutes, followed by 35 cycles of 95°C for 30 seconds, annealing
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temperature (52°C to 62°C) for 30 seconds, 72°C for 30 seconds, and a final 
elongation step of 72°C for 10min.
A 20pl RT-PCR reaction contained 3pl cDNA, 0.25mM dNTPs, 25 pmoles 
forward and reverse primers, 10X GeneAmp PCR buffer (100mM Tris-HCI, 
pH8.3, 500mM KCI, 15mM MgCI2> 0.01% w/v gelatin), and 0.5U AmpliTaq Gold 
DNA polymerase. Cycling conditions were 95°C for 12 minutes, followed by 35 
cycles of 95°C for 30 seconds, 58°C for 30 seconds, 72°C for 30 seconds, and 
a final elongation step of 72°C for 10min.
2.6.7 Amplification refractory mutation system (ARMS)
ARMS is an allele-specific PCR technique that detects known single nucleotide 
point mutations. The normal and mutant alleles are amplified in separate PCR 
reactions. Allele-specific primers of 19-23bp were designed with the 3’ base 
complementary to either the normal or mutant allele. A mismatched base was 
included at the third to last position of the 3’ end to ensure that both primers had 
an equal binding affinity and a similar yield of PCR products was obtained from 
both reactions. Pyrimidine/pyrimidine and purine/purine mismatches are more 
destabilising than pyrimidine/purine mismatches. If the allele-specific base of 
the primer bonds to its complementary base with 3 hydrogen bonds, a strongly 
destabilising mismatch was inserted (the same base as in the target DNA 
sequence). If the allele-specific base of the primer bonds to its complementary 
base with 2 hydrogen bonds, a weaker destabilising mismatch was inserted (the 
opposite type of base as in the target DNA sequence and that is not the 
complementary one). The common primer was designed as described in 
section 2.6.5. All ARMS reactions also included a pair of control primers to 
prevent false negative results. The annealing temperature and relative 
concentrations of ARMS and control oligonucleotides were optimised to ensure 
specific amplification. Heterozygous samples produce a PCR product in both 
ARMS reactions, whereas samples that are homozygous generate products 
only during the PCR specific for that allele.
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2.6.8 Multiplex ligation-dependent probe amplification (MLPA)
MLPA is a PCR-based method that can be used to detect copy number 
changes of single exons in one reaction. Instead of amplifying sample DNA, 
probe oligonucleotides are hybridized to the target sequences and a ligation 
reaction occurs resulting in a copy of each target sequence present in the 
sample. It is these ligated probes that are then amplified in a single multiplex 
PCR reaction (Figure 2.1). Each probe consists of two oligonucleotides which 
hybridize to adjacent target sequences. Only matching oligonucleotides are 
ligated together to produce a probe and one of the pair contains a non­
hybridizing stuffer sequence. The length of this sequence is different in each 
different probe, allowing amplification products to be separated by capillary 
electrophoresis. Every probe ends with the same PCR primer sequences so 
only one pair of universal primers is needed to amplify all probes in a single 
reaction. Non-ligated probe oligonucleotides cannot be exponentially amplified 
as they do not contain both PCR primer sequences. Once the amplification 
products have been identified and quantified using capillary electrophoresis, 
they are compared to control samples to determine their copy number 
(Schouten, J.P. etal, 2002).
Known point mutations can also be detected by MLPA. For every mutation 
there are two possible probes that could be amplified. Each probe consists of 
two ligated oligonucleotides, one M13 derived oligonucleotide which is common 
to both probes and one allele specific synthetic oligonucleotide. The probes 
end with the same PCR primer sequences so are amplified in one reaction 
using a pair of universal primers. The allele specific oligonucleotides differ at 
their 3’ ends in order to be complementary to either the mutant or wild type 
allele. Their specific target sequences are adjacent to the target sequence of 
the common oligonucleotide so when hybridized to their complementary 
sequence they can be ligated with the common oligonucleotide to form a probe. 
Mismatched oligonucleotides, for example an oligonucleotide complementary to 
the mutant allele mismatched to a wild type target, cannot be ligated and 
therefore exponentially amplified as they lack one of the PCR primer 
sequences. The allele specific oligonucleotides differ in length slightly so the 
probes can be separated and identified using capillary electrophoresis. If the
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(A)
Synthetic oligonucleotide M13 derived oligonucleotide
PCR primer X Target specific Stuffer sequence PCR primer Y
binding site sequences binding site
(B)
Probe 1
Probe 2
1a
2a
1b
2b
Target sequence
I Multiplex hybridization and ligation
\i2b 1b /
Target sequence 
2
PCR with universal 
primers X and Y
Target sequence 
1
No ligation of mismatched 
probe oligonucleotides
Capillary electrophoresis and control sample comparison to 
determine copy number of target sequences 1 and 2.
Figure 2.1. Multiplex ligation-dependent probe amplification (MLPA).
(A) Each probe consists of two oligonucleotides. A non-hybridizing stuffer sequence is 
incorporated into the M13 derived oligonucleotide. All probes have the same PCR  
primer sequences at their ends. (B) Multiple probe oligonucleotides are hybridized to 
sample DNA and bind to their complementary target sequences. Matching 
oligonucleotides are ligated together and the probes produced are amplified by PCR  
using the same pair of universal primers. The amplification products undergo capillary 
electrophoresis and control sample comparison to determine their copy number.
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sample is heterozygous for the mutation two products will be seen. If the 
sample is either wild type or homozygous mutant only one product will be seen 
but the mutant and wild type products will differ in size and so can be identified.
MLPA was performed using the SALSA P043 APC MLPA kit, according to the 
manufacturer’s instructions. 200 ng DNA was denatured by incubation at 98°C 
for 5 minutes. The sample was cooled to 25°C then 1.5pl SALSA probe mix 
(CTS) and 1.5pl MLPA buffer (1.5M NaCI, EDTA, CTS) were added. The 
mixture was incubated for 1 minute at 95°C then 16 hours at 60°C to allow 
hybridization of the probes to their target sequences. 3pl Ligase-65 buffer A 
(contains NAD), 3pl Ligase-65 buffer B (contains MgCI2), 1 pi Ligase-65 and 
25pl sterile water were mixed together then chilled on ice. The hybridized 
sample was cooled to 54°C and the Ligase-65 mix was added. The reaction 
was incubated for 15 minutes at 54°C to allow ligation of probes then heated to 
98°C for 5 minutes to inactivate the ligase. A 40pl PCR mix contained 10X 
SALSA PCR buffer (200mM Tris buffer pH 8.5; 500mM KCI; 16mM MgCI2; non­
ionic detergents), 2pl SALSA PCR primers (contained FAM labelled forward 
primer and dNTPs), 2pl SALSA enzyme dilution buffer (contains buffer, NaCI, 
non-ionic detergents) and 0.5pl SALSA Polymerase (a thermostable 
polymerase). 10pl ligation reaction was added to the PCR mix and the cycling 
conditions were 95°C for 10 seconds, followed by 33 cycles of 95°C for 30 
seconds, 60°C for 30 seconds, 72°C for 1 minute, and a final elongation step of 
72°C for 20min. The fluorescent PCR product was diluted 1 in 4 with sterile 
water and 2pl of this dilution was added to 10pl highly deionised formamide and
0.5pl ROX GS500 size standard and denatured at 95°C for 3 minutes. The 
reaction was cooled rapidly on ice to prevent the formation of heteroduplexes 
before running on the 3100 Genetic Analyzer. Products were visualised and 
quantified using GeneScan software. Genotyper software was then used to 
identify each peak as a particular probe amplification product based on the 
sizes of the expected MPLA products. The peak areas for these products were 
exported to an Excel file and normalised. Dosage quotients for each product 
were calculated by comparing the normalised test sample peak area to the 
average normalised peak area of 5 normal control samples. If the dosage
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quotient is 1.0, there are two copies of the product in test sample i.e. normal. If 
the dosage quotient is 0.5, there is only one copy of the product in test sample
i.e. deleted. If the dosage quotient is 1.5, there are three copies of the product 
in test sample i.e. duplicated. Internal quality control for each sample was 
assessed by examining the variation between control probe amplification 
products in that sample.
2.6.9 Agarose gel electrophoresis
Agarose gels were prepared with 1X TAE buffer to a concentration of 2.0% to 
2.5% w/v. The higher the gel concentration, the better the separation of small 
DNA fragments because of the smaller pore size. 0.05pg/ml ethidium bromide 
was included in the gel as it intercalates DNA, enabling the DNA to be 
visualised under UV light at a wavelength of 300nm. 3pl loading dye (15% w/v 
ficol, 10mM Tris pH8,1mM EDTA, 0.2% orange G) was added to each sample 
before loading and electrophoresis was performed in 1X TAE buffer at 100V. 1 
kb or 100bp DNA ladders were used to allow fragment sizing. DNA was 
visualised on a UV transluminator and photographed using the GelDoc 200 or 
XR system.
2.6.10 Restriction endonuclease digestion
NEBcutter software (http://tools.neb.com/NEBcutter2/index.php) version 2.0 
was used to identify restriction endonuclease recognition sites in DNA 
sequences. A total reaction volume of 20pl contained 17pl PCR product or 1 pi 
plasmid DNA, 10X appropriate buffer, 0.1X bovine serum albumin (BSA) where 
required, and 2.5U restriction endonuclease. The reactions were incubated at 
37°C, 50°C or 60°C for 6 hours and the products analysed using gel 
electrophoresis.
2.6.11 PCR purification
PCR products were purified using an ExoSap method or the QIAquick PCR 
purification kit. For the ExoSap method, 3pl of PCR product was purified by 
adding 10U exonuclease I and 0.5U shrimp alkaline phosphatase. The sample 
was incubated at 37°C for 15min to allow digestion of excess primers and
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removal of phosphate groups from dNTPs before denaturation of the enzymes 
at 80°C for 15min.
Alternatively, the QIAquick PCR purification kit was used according to the 
manufacturer’s instructions. 15pl of PCR product was mixed with 5 volumes of 
buffer PB (contains guanidine hydrochloride and isopropanol, CTS), applied to 
the silica gel membrane of the QIAquick column and centrifuged at 13,000 x g 
for 1 minute to facilitate DNA binding. Buffer PB provides the correct salt 
concentration and pH for adsorption of DNA to the membrane. The eluate was 
discarded and the column was washed with 750pl buffer PE (contains ethanol) 
and centrifuged for 1 minute at 13,000 x g to remove any residual contaminants. 
The flow through was discarded and the column was centrifuged again as any 
residual carryover of the ethanol-containing wash buffer would inhibit 
downstream reactions. The DNA was eluted into a clean microcentrifuge tube 
by applying 30pl buffer EB (10mM Tris.CI, pH 8.5) to the column, incubating at 
room temperature for 5 min and centrifuging at 13,000 x g for 1 min.
2.6.12 Cycle sequencing
Sanger sequencing uses dideoxynucleotide triphosphates (ddNTPs) which lack 
the 3’ hydroxyl group present in deoxyribose sugars. As a result of this, 
ddNTPs can be efficiently incorporated into a nascent strand by DNA 
polymerases but prevent further extension of the growing chain (Sanger et al, 
1977). In automated sequencing the reaction can take place in a single tube 
because each ddNTP is labelled with a different fluorphore. The template DNA 
is denatured and bound by a single specific oligonucleotide. DNA polymerase 
extends this primer by incorporating either an unlabelled dNTP or a chain 
terminating ddNTP at each position. The relative concentrations of dNTPs and 
ddNTPs are such that the labelled products formed differ in size by one 
nucleotide. Capillary electrophoresis is used to separate the single stranded 
DNAs, with smaller fragments migrating fastest through the polymer and 
passing through the laser beam first. The emitted wavelength is detected and 
used to determine the ddNTP incorporated at a particular position. The order of 
nucleotides provides a sequence read of up to 500bp.
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Sequencing reactions were performed using the BigDye Terminator Cycle 
Sequencing kit (Version 3.1 or 1.1) according to the manufacturer’s instructions. 
A total reaction volume of 10pl contained 0.6-1.5pl purified PCR product (~5ng) 
or 1pl plasmid DNA (~250ng), 1pl Terminator Ready Reaction Mix (Labelled A, 
C, G and T dye terminators, dNTPs, AmpliTaq DNA polymerase FS, MgCI2 and 
Tris-HCI buffer, pH 9.0), 1.6pmoles primer and 1.5pl BigDye terminator 
sequencing buffer (CTS). Cycle sequencing conditions were 25 cycles of 96°C 
for 10s, 50°C for 5s and 60°C for 3min 30s.
The Montage SEQ96 Sequencing Reaction Cleanup Kit was used to purify 
sequencing reactions. 20pl injection solution (CTS) was mixed with the 
reaction and transferred to a filter plate. A vacuum of 18 inches Hg was applied 
until the wells were empty, then a further 25pl injection solution was added and 
the vacuum applied again to ensure that all contaminating salts and 
unincorporated dye terminators were filtered out. Purified sequencing products 
were resuspended in 25pl injection solution by shaking for 12 min. Samples 
were run on an ABI 3100 or ABI 3730 Genetic Analyser.
2.6.13 Bacteriological methods
2.6.13.1 Bacteriological media and solutions
LB-Broth: 5g Bactotryptone, 2.5g yeast extract and 2.5g NaCI in 500ml dH2 0  
LB agar: 5g Bactotryptone, 2.5g yeast extract, 2.5g NaCI and 8 g Bactoagar in 
500ml dH20
2.6.13.2 Ligation
Purified PCR products were ligated into the pGEM-T Easy vector which has 
thymidine overhangs to facilitate TA cloning. The reaction consisted of plasmid 
vector and insert at a molar ratio of 1:2, 2X rapid ligation buffer (60mM Tris-HCI, 
pH 7.8, 20mM MgCI2, 20mM DTT, 2mM ATP, 10% PEG), and 3U T4 DNA 
ligase in a total volume of 10pl. The reaction was incubated at 4°C overnight.
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2.6.13.3 Transformation
50jnl E. coli subcloning efficiency DH5a competent cells were thawed on ice and 
4pl ligation product was added. The cells were then incubated at 4°C for 20min 
before being subjected to a heat shock at 42°C for 45 seconds to semi- 
permeabilise the cell membrane and facilitate transfer of the plasmid into the 
cell. 950pl LB medium was added and the cells incubated at 37°C with 
agitation at 150rpm for 1.5 hr. 50pl bacteria were then diluted with an equal 
volume of LB medium and spread onto LB agar plates containing 50pg/ml 
ampicillin, 32pg/ml X-gal (5-bromo-4-chloro-3-indoyl-D-galactoside) and 
32pg/ml IPTG (isopropyl-p-D-thio-galactopyranoside). Plates were incubated 
overnight at 37°C. White colonies are formed when the lacZ gene is 
insertionally inactivated and there is no p-galactosidase produced to convert the 
colourless X-gal substrate into its blue product. These colonies therefore 
contained recombinant plasmids and were streaked out on LB plates containing 
50pg/ml ampicillin and incubated at 37°C overnight.
2.6.13.4 Plasmid preparations
The QIAprep miniprep kit was used to purify plasmids according to the 
manufacturer’s instructions. 5ml of LB medium containing ampicillin (100pg/ml) 
were inoculated with single colonies and cultures grown for 16h at 37°C with 
shaking at 250rpm. Bacterial cells were pelleted by centrifugation at 10,000rpm 
for 3min and resuspended in 250pl Buffer P1 (100pg/ml RnaseA, 50mM Tris- 
HCI, 10mM EDTA). 250pl of the alkaline Buffer P2 (200mM NaOH, 1% SDS) 
was then added to lyse the cells. The sample was gently mixed to avoid 
shearing of chromosomal DNA and then incubated at room temperature for 
5min. 350pl Buffer N3 (3M Potassium acetate) was added to neutralise the 
solution and provide the high salt concentration necessary to precipitate celllular 
debris, chromosomal DNA and proteins. The precipitate was pelleted by 
centrifugation at 13,000rpm for 10min and the supernatant was applied to the 
spin column. The column was then centrifuged at 13,000rpm for 1min to 
facilitate binding of plasmid DNA to the silica membrane. Any salts were 
removed by adding 750pl of the ethanol-based buffer PE (CTS) and centrifuging 
at 13,000rpm for imin. The flow through was discarded and the column re­
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centrifuged to ensure complete removal of the buffer before the DNA was eluted 
in 30pl buffer EB (10mM Tris.CI; pH 8.5). This method typically yields 5-1 Opg 
DNA. Plasmids were digested using a restriction endonuclease, visualised 
using agarose electrophoresis and stored at -20°C.
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Chapter Three
The contribution of germline APC and MUTYH mutations to colorectal
polyposis
3.1 Introduction
Polyposis registers enable the coordination of genetic testing and clinical 
management in families affected by colorectal polyposis (Bulow, S. et al, 1995). 
Results from the Danish Polyposis Register show how such registration can 
help reduce CRC prevalence and improve the prognosis of FAP patients by 
effective use of prophylactic procedures (Bulow, S., 2003). Most UK regional 
polyposis registers cover geographically defined health regions, with the Wales 
Polyposis Register responsible for a population of approximately 3 million.
Cases with more than 100 macroscopic colorectal adenomas have traditionally 
been diagnosed with classical FAP and about a third of patients with 10-100 
adenomas can be accounted for by AFAP (Nielsen, M. etal, 2007a; Friedl, W. 
et al, 2001). The MAP phenotype overlaps with that of FAP (especially AFAP, 
Figure 3.1) as cases typically have tens or hundreds of colorectal adenomas 
(Sampson, J.R. etal, 2003; Sieber, O.M etal, 2003; Nielsen, M. etal, 2005; 
Aretz, S. et al, 2006). The distinction between FAP and MAP would appear 
straightforward as the former is dominantly inherited whereas the latter is a 
recessively inherited disease. However, approximately 25% of cases with 
colorectal adenomatous polyposis occur sporadically or have affected siblings 
but unaffected parents (Bisgaard, M.L. etal, 1994). Such cases could result 
from de novo APC gene mutations or gonadal mosaicism in a clinically 
unaffected parent, but could also represent MAP. In addition, a small number of 
MAP cases have been reported with an apparently dominant family history of 
polyposis and/or CRC and thus could resemble a family affected by FAP 
(Nielsen, M. etal, 2007a; Aretz, S. etal, 2006; Jo, W-S. etal, 2005). One 
family was confirmed to have MAP cases in two generations as the spouse of 
an affected mother was a heterozygous MUTYH mutation carrier and their three 
children were all affected (Nielsen, M. etal, 2007a). An accurate diagnosis is 
important for appropriate genetic counselling and clinical management of
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A) B)
Figure 3.1 Colorectal adenomas in typical colectomy specimens from A) AFAP and B) MAP cases. The phenotypes of these 
diseases overlap making an accurate diagnosis on the basis of symptoms alone more difficult. Arrows indicate examples of 
adenomas.
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affected families. An apparently sporadic case with FAP has a 50% risk to 
offspring and a low risk to siblings whereas MAP poses little risk to offspring but 
a 25% risk to siblings. Decisions regarding surveillance and preventative 
measures such as prophylactic colectomy are influenced by disease type. 
Diagnosis based on phenotype and family history alone can no longer be relied 
on and must be complemented by molecular genetic analysis.
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3.2 Methods
3.2.1 Clinical samples
As of 1st January 2008, 107 apparently unrelated families affected by 
adenomatous colorectal polyposis were registered with the Wales Polyposis 
Register. The criterion for inclusion was one or more affected family members 
with at least ten colorectal adenomas at colonoscopy or colectomy. Blood DNA 
samples from affected members of 92 of the 107 families have been subject to 
a variety of forms of molecular analysis at the APC and MUTYH loci since the 
first identification of these genes in 1991 and 2002. Causative mutations had 
been identified in 57/107 families (Figure I), but in many of the remainder 
comprehensive analysis had not been completed since the progressive 
improvements in diagnostic specificity and sensitivity had been applied only 
sporadically in response to immediate diagnostic demands in specific families.
Prior to this project pathogenic germline APC mutations had been identified in 
43 families, 36 of which were identified by the All Wales Medical Genetics 
Service (AWMGS) or by researchers of the Academic Department of Medical 
Genetics. The remaining seven APC mutations were identified in affected 
relatives living outside Wales. Biallelic germline MUTYH mutations had been 
identified in 14 families, with mutations in 11 of them identified by the AWMGS 
or by researchers of the Academic Department of Medical Genetics. The 
MUTYH mutations in three families were identified in affected relatives living 
outside of Wales. DNA samples were not available from eight families, four of 
whom had members clinically diagnosed with FAP. Three further families had 
members referred to the Wales Polyposis Register as they were at risk because 
of affected family members outside Wales (in whom no mutations had been 
identified) but were themselves found to be clinically unaffected. An index case 
from one family is currently being screened for mutations in APC by the 
AWMGS. Index cases from three families have been screened for mutations in 
APC by the AWMGS but both sequencing analysis and MLPA did not identify 
any pathogenic mutations so these samples are currently being screened for 
mutations in MUTYH ORF by this service. The initial step in this study was to 
complete comprehensive mutation analysis of APC and MUTYH in the 
remaining 35 families (shaded boxes in Figure I, appendix).
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3.2.2 Screening for mutations in APC
Exons 1-15 of APC were PCR amplified as 35 fragments (Table 3.1) and 
screened for mutations using automated sequencing. Large deletions and 
duplications at the APC locus were screened for by MLPA. Two probes 
covered the promoter region, one probe detected changes within the 5’ UTR 
and exons 1-14 were each covered by one probe (Table 3.2). Five probes 
identified changes exon 15, two of which covered the common small deletions 
at mutational hotspots codons 1061 and 1309. Thirteen control probes for other 
genes on different chromosomes were also included to assess the internal 
quality of the sample. If the standard deviation of the mean dosage quotients 
for all the control probes was less than 0.10 this was taken as an acceptable 
level of DNA quality. If the mean dosage quotient for an APC probe in a test 
sample was in the range 0.85-1.20, 0.35-0.65 or greater than 1.35 the region 
covered by the probe was considered to be normal, deleted or duplicated 
respectively. Analysis of MLPA data was performed using an Excel 
spreadsheet created by A. Wallace, National Genetics Reference Laboratory 
Manchester.
3.2.3 Screening for mutations in MUTYH
Cases in which a pathogenic APC mutation was not detected in the present 
study were screened for mutations in MUTYH. Exons 1-16 were PCR amplified 
and screened using automated sequencing as previously described (Al-Tassan, 
N. et al, 2002), with the exception of exon 3 which was PCR amplified using a 
primer set (Table 3.1) designed to cover exon 3 including the additional 33bp of 
coding sequence upstream of the originally described exon 3 (Ohtsubo, T. et al, 
2000).
3.2.4 Assay for MUTYH sequence variant in controls
The putative splice site mutation c. 1509+2 T>C was assayed by ARMS using 
normal (5’- TGGGAGAGGCCTAGGAGACCTA) or mutant 
(5 - TGGGAGAGGCCTAGGAGACATG) allele specific primers with a common 
forward primer (5’-TGAAGTTAAGGGCAGAACACCG). Primers were annealed 
at 58°C and generated a 120bp product. TSC2_Ex26F 
(5-GAGCTTTGGCCCTTGGTGATA) and TSC2_Ex26R
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Gene/Primer
name
Primer sequence (5’—>3’)
Annealing 
temperature (°C)
Product size 
(bp)
I v ' | | g g | j g j ^
APCxlF* AGGTCCAAGGGTAGCCAAGG 55 197
APCxI R* TAAAAATGG ATAAACTAC AATTAAAAG
APCx2F* AAATACAGAATCATGTCTTGAAGT 55 212
APCx2R* ACACCTAAAGATGACAATTTGAG
APCx3F TGCTTAAAGCAATTGTTGTAT 55 286
APCx3R GTACACAAGGCAATGTTTACT
APCx4(2)F TGCAGTCTTTATTAGCATTGTT 58 305
APCx4(2)R CAGGCCTAAAGTTGGGTAA
APCx5F Cl I I I I IGCI I I IACTGA11AACG 55 243
APCx6R TGTAATTCATTTTATTCCTAATAGCIC
APCx6F* GGTAGCCATAGTATGATTATTTCT 55 204
APCx6R* CTACCTATTTTTATACCCACAAAC
APCx7F* AAGAAAGCCTACACCATTTTT GC 57 238
APCx7R* GATCATTCTTAGAACCATCTTGC
APCx8F* ACCTATAGTCTAAATTATACCATC
55 184
APCx8R* GT CAT GGCATTAGT GACCAG
APCx9F AGTCGTAATTTTGTTTCTAAACTC 55 457
APCx9R CTTTGAAACATGCACTACGA
APCxI OF* AAACATCATTGCTCTTCAAATAAC 55 216
APCxlOR* TACCATGATTTAAAAATCCACCAG
APCxlOAF CCTGTATTCCAATGGATTGTAG 55 200
APCxlOAR CTATGTCCCCAGCAGTCAC
APCx11F* GAT GATT GT CTTTTT CC1CTTGC 58 215
APCx11R* CT GAGCTATCTTAAGAAATACAT G
APCx12F AAGCTTGGCTTCAAGTTGTC 55 199
APCx12R CAGAGTGAGACCCTGCCTC
APCx13(2)F TCCCAAAGTGATAGGATTACA 58 440
APCx13(2)R AGGGAATCTCATGGCTAAA
APCx14F* TAGATGACCCATATTCTGTTTC 55 308
APCxI 4R* CAATTAGG1C1 I I  1 T GAGAG1A
APCx16.1F CAAAAGGAGAT GT GG AATACT 55 420
APCx15.1R AGCCAGGAGACATAATATTG
APCx15.2F CAGGAAGCATTATGGGACAT 55 422
APCx15.2R GAGGAGCT GGGTAACACT GTAG
APCxI 5.3F AAGGCAT CT CATCGTAGTAA 55 480
APCx15.3R TTCCGACTTAGTGAAATTGTA
APCx15.4F CTGGGTCTACCACTGAATTAC 55 506
APCx15.4R AGTTGTACTTTGATTCCTTGAT
APCxI 5.5(1 )F CCTAGCCCATAAAATACATAGT 52 522
APCxI 5.5(1 )R ATAGGCTGATCCACATGAC
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APCxI 5.6F AATCAAAATGTAAGCCAGTCT 55 486
APCxI 5.6R AGCTGATGACAAAGATGATAA
APCxI 5.7F CTGCCACTTGCAAAGTTTC 52 502
APCxI 5.7R ATTCCACTGCATGGTTCAC
APCxI 5.8F CAAAAGT GGTGCT C AG AC AC 58 505
APCxI 5.8R TTCCTGAACTGGAGGCATTA
APCxI 5.9F GACCTAAGCAAGCTGCAGTA 55 509
APCxI 5.9R CCCCGGTGTAAAACTAACA
APCxI 5.1 OF CCCAGACTGCTTCAAAATTAC 55 444
APCxI 5.1 OR C ACGGAAAG GCTTGT GACT
APCx15.11F AAAACCTCATCTGTAACCATAC 55 445
APCxI 5.11R TTCCTTCAATAGGCGTGTA
APCx15.12F AATTTAAATGCTGAGAGAGT 55 441
APCx15.12R CCCTCTGTCTGGTATGTCT
APCxI 5.13(1 )F TACCAGCCACACAGAACTAAC 58 527
APCxI 5.13(1 )R CACCCATATTTCTGGGACTAT
APCx15.14(3)F CACAGGGAGAACCAAGTAAAC 58 460
APCx15.14(3)R AATGGTGATCCCAGAGAGAT
APCx15.15F GAAGGTGCAAATTCCATAGTA 55 486
APCx15.15R GGCTGTTTGACCTTCACTAG
APCx15.16F AGGCAGGACAATGATTCATAT 55 487
APCx15.16R GGCATTCTT GGATAAACCT G
APCx15.17F CCCTAGTACTGCTTCAACTAAG 55 517
APCxI 5.17R TGGTCTTCCATCATTATACTCT
APCx15.18F AGACCAGCTTCTCCCACTAG 55 492
APCx15.18R ACCT G AGGAAACGGT CTG A
APCx15.19F ACAAAGTAAAGAAAACCAAGTA 55 486
APCx15.19R GGGGTACGTTCCACTATAG
APCxI 5.20F TCGCCTGAACTCCTTTATTC 55 512
APCxI 5.20R TTCCAGAACAAAAACCCTCTA
M r t w i i w f c M „ ' * " ' ' * *
MUTYHx3(1)F GGCCAGAAACTTAGCCACAG
58 413
MUTYHx3(1)R CAACCCCAGATGAGGAGTTAGG
Table 3.1 Sequences of primers and PCR conditions used to screen APC 
and MUTYH exon 3. ‘ Primers published by Groden, J. etal, 1991.
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DQ control bands* Not ligation dependent 64, 70, 76, 82
Synthetic control probe 2q14 94
Control probe 5q31 130
APC probe Promoter 139
APC probe Promoter 148
Control probe 14q13 157
APC probe 5’ UTR 166
APC probe Exon 1 175
Control probe 4q34 184
APC probe Exon 2 193
APC probe Exon 3 202
Control probe 9q21 211
APC probe Exon 4 220
APC probe Exon 5 229
Control probe 2q14.2 238
APC probe Exon 6 247
APC probe Exon 7 256
Control probe 2p12 265
APC probe Exon 8 274
APC probe Exon 9 283
Control probe 11p12 292
APC probe Exon 10 305
APC probe Exon 11 312
Control probe 8q24 319
APC probe Exon 12 328
APC probe Exon 13 337
Control probe 6q26 346
APC probe Exon 14 355
APC probe Start of exon 15 364
Control probe 14q32 373
APC probe Middle of exon 15 382
APC probe End of exon 15 391
Control probe 15q31 400
APC probe Exon 10A 409
APC probe Codon 1061 hotspot 418
APC probe Codon 1309 hotspot 427
Control probe 16p13 436
Control probe 2p16 445
Table 3.2 APC MLPA probe positions and product sizes. ‘ Indicate the amount of 
sample DNA; prominent peaks from these control bands represent a very small amount 
of sample DNA. Probes designed by A. Nygren at MRC-Holland.
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(5’-CTCGCCCACAGGAGACCTAGA) primers were used as internal controls, 
producing a product of 388bp.
3.2.5 Diagnostic confirmation of mutations
All mutations identified in APC or MUTYH were confirmed by the AWMGS prior 
to application in clinical diagnosis or prediction.
3.2.6 Statistical analysis
Fisher’s exact test was used to compare proportions of colorectal polyposis 
families with biallelic MUTYH mutations in Minitab 14.
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3.3 Results
3.3.1 Contribution of APC mutations to colorectal polyposis in Wales
Of the 92 unrelated index cases screened for APC and/or MUTYH mutations 
(either previously or in the present study), pathogenic germline APC mutations 
were identified in 70 patients (76%). The mutations found in 27 of the 35 
patients screened in the present study are summarized in Table 3.3. Overall, 
nonsense mutations contributed to 37% (26 cases) of APC mutations identified, 
24 cases (34%) carried small deletions, 10% (7 cases) of mutations were 
accounted for by large deletions, small insertions were identified in 7 (10%) 
cases and splice site mutations were found in 3 (4%) cases. The precise 
identities of three (4%) APC mutations were unknown as they were 
characterised in affected relatives outside of Wales and full details were not 
provided (Figure 3.2).
3.3.1.1 Nonsense, splice site, small deletion and insertion mutations in APC 
This category of mutations accounted for 90% of the pathogenic APC mutations 
for which details were available (60/67). All but three of these were located 
within the coding region and just over half were found within the 5’ half of exon 
15 (codons 653-1748) (Figure 3.3). The only pathogenic mutation located 
outside this region but still within exon 15 was c.6030delA which affects codon 
2010. This was the most 3’ pathogenic change identified and was found in one 
case with an AFAP phenotype. This patient presented aged 52 years with 
between 50 and 100 colorectal adenomas in the absence of CRC and also had 
multiple fundic gland polyps (FGPs). There was a dominant family history of 
CRC and colorectal polyps as her father was affected at 58 years. Two 
unrelated cases harboured a mutation at codon 1061 (c.3183_3187delACAAA) 
of which one was identified in the present study (1157; Table 3.3). Neither 
patient had a family history of CRC or polyposis and their phenotypes were very 
similar with both having over a thousand colorectal adenomas diagnosed aged 
29 and 33 years, with the latter also diagnosed with CRC. Codon 1309 was 
mutated (c.3927_3931delAAAGA) in six cases, two of whom were screened in 
the present study (0900, 1208; Table 3.3). The age at diagnosis of patients 
carrying the codon 1309 mutation varied, with two diagnosed in their second 
decades, one in her twenties and two in their thirties. Clinical information was
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Patient Exon / Intron Nucleotide change AA change
Age at 
diagnosis 
(yrs)
Polyp count CRC Extracolonic features Familyhistory Reference
1663 1-15 Promoter_Ex15del / 26 Large numbers N None noted N De Rosa, M. et al, 1999
1222 1-15 Promoter_Ex15del / 40 >100 N DP & FGP D De Rosa, M. et al, 1999
1173 1-2 Promoter Ex2del / 57 Multiple Y(1) None noted D Novel
9712 4-5 Ex4 5del / 24 20 N None noted D Nielsen, M. et al, 2007b
2256 9-10A Ex9 10 Adel / 47 >1000 Y(4) FGP N Novel
1191 5 c.637 O T R213X 32 >1000 N None noted D Miyoshi, Y. et al, 1992
4048 6 c.667 C>T Q223X 40 Numerous(>100) Y(3)
FGP, desmoids & 
osteoma D Novel
0966 6 c.694 O T R232X 50 100s Y (1) SC N Miyoshi, Y. et al, 1992
3318 7 c.739 C>T Q247X 16 Numerous N DP & brain tumour D Moisio, A-L. et al, 2002
7680 7 c.832 O T Q278X 18 10 N None noted D Wallis, Y.L. etal, 1999
1249 9 c.994 O T R332X 34 Multiple N SC & osteoma D Soravia, C. etal, 1998
1346 9 c.1239 1240insA R414fsX418 36 Polyposis N FGP D Novel
2284 IVS9 c. 1312+3 A>G / 35 Polyposis N None noted D Olschwang, S. etal, 1993
1070 IVS13 c.1744-4 O G / 30s Polyposis N None noted D Novel
5449 14 c.1779 G>A W593X 56 100s Y(1) None noted D Nagase, H. etal, 1992a
1042 IVS14 c.1958+1 G>C / 18 -300 N None noted D Novel
1842 15 c.2805 O A Y935X 23 >100 N None noted D Fodde, R. etal, 1992
2857 15 c.2805 O A Y935X 21 100s N None noted N Fodde, R. etal, 1992
1157 15 c.3183 3187delACAAA K1061fsX1062 29 >1000 N None noted N Miyoshi, Y. etal, 1992
0107 15 c.3202 3205delTCAA S1068feX1124 23 Multiple N None noted A Bisgaard, M.L. et al, 2004a
3383 15 c.3202 3205delTCAA S1068feX1124 40 100s N None noted D Bisgaard, M.L. et al, 2004a
1105 15 c.3366 3369delTCAA N1122fsX1124 27 100s N Dermoid cyst D Nagase, H. etal, 1992a
0900 15 c.3927 3931delAAAGA E1309fsX1312 13 100s N None noted D Miyoshi, Y. etal, 1992
1208 15 c.3927 3931delAAAGA E1309feX1312 35 Unknown N None noted D Miyoshi, Y. etal, 1992
1239 15 c.4132 C>T Q1378X 38 >1000 Y(1) GP N Novel
1098 15 c.4393_4394delAG S1465fsX1467 22 Polyposis N SDT D Miyoshi, Y. etal, 1992
1078 15 c.4666delA T1556feX1564 18
Quite a few 
throughout 
colon
N Desmoids, SC & dental abnormalities N Oka, T. et al, 2004
Table 3.3 Pathogenic germline APC mutations identified in 27 unrelated colorectal polyposis patients in the present study. Novel 
mutations are shown in bold and references provided for previously reported identical mutations. AA; amino acid, DP; duodenal polyps, FGP; 
fundic gland polyps, GP; gastric polyps, SC; sebaceous cysts, SDT; subcutaneous dermoid tumours, D; dominant, N; no family history, A; 
adopted.
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Small
insertion
(10%)
Splice site
(4%) Unknown
Nonsense
(37%)
Large
deletion
(10%)
Small deletion
(34%)
Figure 3.2 Class of pathogenic germline APC mutations identified in 70 
apparently unrelated colorectal polyposis patients. The class of APC 
mutation in three families on the Wales Polyposis Register is unknown as these 
mutations were identified in affected relatives outside of Wales and details were 
not available.
75
7wa»</>re<3
OL<
1309
0 4- III L
0 100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300 2400 2500 2600 2700 2800
Codon number
Figure 3.3 Distribution of coding region pathogenic germline APC mutations in 57 colorectal polyposis patients. The most frequently 
mutated codon is 1309.
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not available for one patient. Two cases were described as having hundreds 
and a carpet of colorectal polyps, respectively. A polyp count was not known 
for the other patients but they had been clinically diagnosed with FAP. Four 
cases were not affected by CRC and no extracolonic manifestations had been 
noted in two patients. One case had a scalp cyst, another had learning 
difficulties and one case was diagnosed with fundic gland polyps, sebaceous 
cysts, a lipoma and an osteoma of the skull. Three patients had a dominant 
family history of CRC and/or colorectal polyps, one case was sporadic and 
family history details of two patients were unknown.
Regions other than exon 15 affected by nonsense, splice site, small deletion or 
insertion mutations were exons 4-9,12 and 14, the acceptor splice site in intron 
13 and the donor splice sites in introns 9 and 14. Seventeen of the twenty-nine 
base substitutions (59%) were C to T transversions. One small insertion, two 
nonsense and two splice site mutations identified in the present screen of 35 
unrelated polyposis patients had not been previously unreported and are shown 
in Figure 3.4, with phenotypes described in Table 3.3. The intron 13 splice site 
mutation (c.1744-4 C>G) is predicted to activate a cryptic splice acceptor site in 
intron 13 and the intron 14 splice site mutation (c.1958+1 G>C) is predicted to 
abolish the splice donor site of intron 14 by SpliceSiteFinder 
(http://violin.genet.sickkids.on.ca/~ali/splicesitefinder.html).
3.3.1.2 Large deletions in APC
Seven apparently unrelated cases were found to have a large deletion in the 
APC gene, five of which were identified in the present screen of 35 polyposis 
patients (Figure 3.5, Table 3.3). The two other large deletions had been 
previously identified in patients on the Wales Polyposis Register; one was a 
deletion of exons 11 and 12 and the other covered exons 13,14 and up to at 
least codon 1628 in exon 15. The patient with the former mutation had a family 
history of multiple colorectal polyps and was diagnosed aged 40 years with 
approximately 100 colorectal polyps without CRC. The latter mutation was 
identified in a case with a family history of colorectal polyposis and was 
diagnosed aged 29 years with colorectal and gastric polyps in the absence of 
CRC.
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Figure 3.4 Novel APC mutations identified in a screen of 35 
colorectal polyposis patients. Normal sequences are shown on the 
left and corresponding mutant sequences on the right. N indicates 
position of mutation.
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3.3.1.3 Missense and silent mutations in APC
Five APC missense mutations (R106H, R1450L, M2491T, G2502S and 
S2621C) were each identified as heterozygous changes in single cases in the 
present screen of 35 colorectal polyposis patients. All but one (S2621C c.7862 
C—>G) were detected in patients who also harboured a truncating APC 
mutation. The S2621C variant was identified in case 8163 and although it was 
originally reported as a pathogenic mutation (Miyoshi, Y. et a/, 1992), 
subsequent studies have shown this change does not segregate with the FAP 
phenotype (Walon, C. etal, 1997; Ruiz-Ponte, C. etal, 2001) and it is not 
predicted to affect splicing (Sharp, A. etal, 2004). The G2502S (c.7504 G—>A) 
missense mutation has been previously reported with no evidence that this 
variant affects splicing in vivo and it was not thought to affect protein function 
(rs2229995; Sharp, A. etal, 2004; Miyoshi, Y. etal, 1992). The three novel 
missense mutations R106H (c.317 G—>A), R1450L (c.4349 G—►T) and M2491T 
(c.7472 T->C) were not found in the Human Gene Mutation Database 
(http://www.hgmd.cf.ac.uk/) or the dbSNP database
(http://www.ncbi.nlm.nih.gov/SNP/) but were found in patients with a truncating 
APC mutation so are unlikely to be the disease-causing mutations. The 
previously reported missense variant E1317Q (c.3439 G->C; rs1801166, 
Frayling, I.M. etal, 1998) had been identified in four Wales Polyposis Register 
families by the AWMGS or by researchers of the Academic Department of 
Medical Genetics but only in conjunction with a co-existing APC truncating 
mutation or biallelic MUTYH mutations.
The common APC polymorphisms Y486Y (c.1458 C->T; rs2229992), T1493T 
(c.4479 A—G; rs41115), G1678G (c.5034 A—G; rs42427), S1756S (c.5268 
G—>T; rs866006), D1822V (c.5465 A->T; rs459552) and P1960P (c.5880 A—►G; 
rs465899) were detected along with the previously reported silent variant 
S2307S (rs2229993).
3.3.2 Contribution of biallelic MUTYH mutations to colorectal polyposis in Wales 
Of the 92 unrelated colorectal polyposis cases screened for mutations in APC 
and/or MUTYH (either previously or in the present study), biallelic germline 
MUTYH mutations were identified in 15 families (16%). One MAP case was
80
identified in the present screen. This patient was already known to be a Y176C 
(c.527 A>G) heterozygote but the current screen identified a second germline 
MUTYH mutation; a previously reported intron 15 splice site mutation (c.1509+2 
T>C; Aretz, S. etal, 2006), which was found in the compound heterozygous 
state in this patient but was not found in over 728 control chromosomes. This 
variant is predicted to abolish the splice donor site by the splice site prediction 
program NetGene2 (http://www.cbs.dtu.dk/services/NetGene2). This case 
without a family history of CRC and/or polyps was diagnosed aged 41 years 
with approximately ten colorectal adenomas, metaplastic polyps and a CRC. 
She then had two additional colorectal carcinomas at 65 and 68 years and a 
breast carcinoma aged 71 years. The clinical and molecular genetic details of 
all Wales Polyposis Register patients with biallelic germline MUTYH mutations 
are described in chapter four. The common MUTYH polymorphisms V22M 
(c.64 G—>A; rs3219484) and Q335H (c.1005 C—►G; rs3219489) were detected 
in the present screen.
3.3.3 Colorectal polyposis cases without pathogenic APC or MUTYH mutations 
In seven of the 92 unrelated polyposis cases screened for mutations in APC 
and/or MUTYH (either previously or in the present study), no pathogenic 
germline mutations were detected in APC or MUTYH. All seven patients were 
in the present screen and had the entire APC and MUTYH ORFs screened by 
sequencing. MLPA was performed to detect large deletions at the APC locus in 
all but one of these cases which failed due to poor quality DNA. One of the 
seven patients had an affected sibling but the remaining six were sporadic 
cases. The colorectal phenotype varied (Table 3.4) with polyp counts ranging 
from 14 to hundreds of polyps and the age at diagnosis was between 23 and 56 
years. Five cases developed CRC of which one had two cancers.
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Patient Polyp count CRC Family history
diagnosis
1187 23 50-100 Y (1) Sporadic
0830 24 57 N Sporadic
1137 28 14 N Sporadic
4093 33 100s Y (1) Sporadic
2302 34 100-200 Y (1) Sporadic
1149 42 16 Y (2) Sister CRC aged 35yr
8163 56 -20 Y (1) Sporadic
Table 3.4 Phenotypes of colorectal polyposis patients in whom no 
pathogenic germline APC or MUTYH mutations were identified. All cases 
had their entire APC and MUTYH ORFs screened and MLPA of the APC gene 
performed in the present study.
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3.4 Discussion
3.4.1 Prevalence of germline APC mutations in polyposis patients 
The Wales Polyposis Register includes the families of all patients with at least 
ten colorectal adenomas identified by the All Wales Medical Genetics Service. 
The 107 apparently unrelated families vary in size from one to eleven affected 
family members. Seventy-six percent of families on the Wales Polyposis 
Register that were screened for mutations in APC and/or MUTYH harboured a 
pathogenic germline mutation in the APC gene. This is a higher proportion than 
previously reported in several recent screens of polyposis registers which 
described pathogenic APC mutations in 50-69% of unrelated cases with a 
clinical diagnosis of FAP, AFAP or multiple adenomas (Bisgaard, M.L. et al, 
2004a; Vandrovcova, J. et al, 2004; Aceto, G. etal, 2005; Truta, B. et al, 2005; 
Aretz, S. et al, 2006). Some of the variation could be due to differences in 
techniques used to screen for APC mutations, for example a number of 
previous studies would not have been able to detect single exon, multi-exon or 
whole gene deletions (Bisgaard, M.L. etal, 2004a; Vandrovcova, J. etal, 2004; 
Truta, B. et al, 2005) which were screened for in all families on the Wales 
Polyposis Register in whom no truncating APC or biallelic MUTYH mutations 
were identified. However, this cannot account for all differences as Aceto et al
(2005) and Aretz et al (2006) undertook comprehensive APC screening in their 
polyposis patients but only identified a pathogenic mutation in 52% and 50% of 
unrelated cases, respectively. The variation is unlikely to be a result of 
screening families from different populations as previous studies of UK FAP 
families identified pathogenic APC mutations in just 45% of those in 
Birmingham (Wallis, Y.L etal, 1999) and 54% of families on the Northwest of 
England Regional Polyposis Register (Armstrong, J.G. etal, 1997) of cases.
Cao et al (2006) recently detected pathogenic APC mutations in 94% (50/53) of 
families on the Singapore Polyposis Register but strict selection criteria were 
applied; only cases with more than a hundred colorectal adenomas or those 
diagnosed with CRC and at least twenty adenomas under the age of 50 years 
with a dominant family history were screened. APC analysis was also 
extensive, comprising PTT assay, MLPA and differential expression analysis 
(Cao, X. et al, 2006). Aretz et al (2006) observed that pathogenic APC 
mutations were detected at a higher frequency in unrelated patients with typical
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FAP (83%) than those with an AFAP phenotype (22%) and that neither APC nor 
biallelic MUTYH mutations were identified in 17% and 64% of unrelated 
classical FAP and AFAP cases, respectively. Similarly, recent screens of 
unrelated patients with over a hundred colorectal adenomas identified 
pathogenic APC mutations in 71% (Kim, D-W. etal, 2005), 76% (De Rosa, M. 
et al, 2004) and 88% (De la Fuente, M.K. et al, 2007) of cases and Nielsen et al 
(2007a) described pathogenic APC mutations in 36% of AFAP families. The 
proportions of cases with these phenotypes will therefore affect the number of 
APC mutations detected. All affected members of families on the Wales 
Polyposis Register had at least ten colorectal adenomas but clinical details 
were not available for all cases so exact proportions of patients with a clinical 
diagnosis of classical FAP or AFAP could not be calculated. An additional 15 
families on the Wales Polyposis Register have not been screened to date due 
to lack of DNA from an affected member or are in the process of being 
screened for mutations in APC and/or MUTYH. The proportion of families on 
the Wales Polyposis Register with pathogenic APC mutations may therefore 
alter once these additional families have been screened.
3.4.2 Spectrum and frequency of pathogenic APC mutations
3.4.2.1 APC nonsense, splice site, small deletion and insertion mutations 
Just over half (52%) of the mutations in this category detected in Wales 
Polyposis Register families for which details were available were small deletions 
or insertions. Forty-three percent were nonsense mutations and 5% were 
predicted to affect splicing. Previous APC screens in colorectal polyposis cases 
reported slightly higher proportions of small deletions and insertions (59-70%) 
and lower proportions of nonsense mutations (27-39%) (van der Luijt, R.B. et al, 
1997; Friedl, W. etal, 2001; Bisgaard, M.L. etal, 2004a; Vandrovcova, J. etal, 
2004; Truta, B. et al, 2005; Cao, X. et al, 2006). However, Aceto et al (2005) 
and Stekrova et al (2007) described similar proportions of small deletions and 
insertions (53% and 50%, respectively) and nonsense mutations (40% and 
43%, respectively) as in the present study. Splice site mutations have been 
reported to contribute 0-11% of mutations (van der Luijt, R.B. et al, 1997; Friedl, 
W. et al, 2001; Bisgaard, M.L. etal, 2004a; Truta, B. et al, 2005) in colorectal 
polyposis patients but no more than nine cases have been described in a single
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study (Friedl, W. et al, 2001). Variation in the proportions of nonsense, splice 
site, small deletion and insertion mutations may be due to differences in the 
sensitivity of screening techniques (as discussed above) or sample sizes; Friedl 
etal (2001) reported pathogenic point mutations, small insertions or deletions in 
322 colorectal polyposis cases whereas such mutations were detected in 59 
families on the Wales Polyposis Register.
Consistent with previously reported coding region germline pathogenic APC 
mutations (Figure 1.5, Thierry Soussi APC mutation database, personal 
communication), the majority of such mutations identified in Wales Polyposis 
Register families were found in the 5’ half of the gene (Figure 3.3). No 
mutations were identified before codon 159 but a small number have been 
described within this region (Stekrova, J. et al, 2007; Figure 1.5, Thierry Soussi 
APC mutation database, personal communication). Only one mutation was 
detected downstream of codon 1600 in accordance with the reported rarity of 
mutations 3’ to this codon (Figure 1.5, Thierry Soussi APC mutation database, 
personal communication).
The most frequent APC mutation identified in unrelated cases on the Wales 
Polyposis Register was c.3927_3931delAAAGA, affecting codon 1309. This is 
by far the most commonly identified mutation (Figure 1.5, Thierry Soussi APC 
mutation database, personal communication) with very few reports from 
registries in which this change was not detected in any colorectal polyposis 
cases (Ruiz-Ponte, C. etal, 2001; Scott, R.J. etal, 2001). The high frequency 
of this mutation is not likely to be a result of a founder effect as it has been 
identified in patients from a wide range of ethnic backgrounds (Miyoshi, Y. et al, 
1992; Cao, X. etal, 2006) and there is a high incidence of this deletion among 
de novo cases (Ripa, R. et al, 2002; Aretz, S. et al, 2004a). This suggests that 
the mutation is recurrent, supported by the fact that codon 1309 is part of a 
short repeat sequence which may increase its mutability (Segditsas, S. & 
Tomlinson, I., 2006). Aretz et al (2004a) found significantly fewer 
c.3927_3931delAAAGA mutations in familial FAP cases than in de novo cases 
but of the six unrelated index patients carrying this mutation on the Wales 
Polyposis Register, the family history of two cases was unknown (one through
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lack of index case contact with family), three were familial cases and only one 
had no family history of CRC or polyps. The difference may be because the 
probands screened are offspring of de novo cases who have survived to 
reproduce due to successful treatment. This appears to be the case for two of 
the three unrelated familial cases as both their fathers were the first members of 
their families to be affected. The small numbers of unrelated cases with this 
mutation on the Wales Polyposis Register may also not reflect the frequency of 
the deletion in familial and de novo cases very accurately.
Codon 1061 has been reported as a hotspot for germline APC mutations 
(Figure 1.5, Thierry Soussi APC mutation database, personal communication; 
van der Luijt, R.B. etal, 1997; Friedl, W. et al, 2001) in colorectal polyposis 
patients but mutations at this codon only accounted for two of the mutations 
detected in Wales Polyposis Register families. Similarly, Bisgaard et al 
(2004a), Cao et al (2006) and Stekrova et al (2007) did not find mutations 
affecting this codon at higher frequencies than mutations at several other 
codons. Differences in the frequency of codon 1061 mutations do not appear to 
be the result of population differences as Wallis et al (1999) described 
pathogenic changes at this codon in 10% of cases with APC mutations from the 
Birmingham area. Both of the unrelated Wales Polyposis Register cases with a 
codon 1061 mutation did not have a family history of CRC or polyps and 
mutations affecting this codon have been previously reported in de novo FAP 
cases, although at a much lower frequency than 1309 mutations (Ripa, R. et al, 
2002; Aretz, S. etal, 2004a). Codon 1061 is part of a short repeat sequence 
which may increase its mutability (Segditsas, S. & Tomlinson, I., 2006) and 
sample size may account for the differences between studies. Despite the 
relatively low frequency of mutations at codon 1061 in Wales Polyposis Register 
families, the region of APC between codons 1061 and 1136 (225 bp) harboured 
17% of the nonsense, splice site, small deletion and insertion mutations 
detected in Wales Polyposis Register families for which details were available.
Mutations affecting codons 332, 934 and 1556 were each identified in three 
unrelated cases on the Wales Polyposis Register, with the remaining mutations 
detected in one or two families. The R332X mutation has been previously
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described in a maximum of two unrelated cases in any one study (Thierry 
Soussi APC mutation database, personal communication; Hutter, P. etal, 2001) 
and so is not a frequently reported mutation. The c.2802-2805delTTAC 
mutation affecting codon 934 has been previously reported to account for a 
similar proportion of mutations as in the present study (5-6%) (Gavert, N. et al, 
2002; Bisgaard, M.L. et al, 2004a) which may be due to its proximity to a short 
repeat sequence. The insertion or deletion of a single adenine at codon 1556 
was identified in three unrelated cases on the Wales Polyposis Register and a 
small number of cases have been reported to carry the insertion mutation 
(Thierry Soussi APC mutation database, personal communication) which is 
likely to be because the poly(A)6 tract in which codon 1556 lies increases its 
mutability. All unreported APC mutations were identified in single families on 
the Wales Polyposis Register.
Consistent with previously reported germline pathogenic APC point mutations 
(Thierry Soussi database, personal communication), the majority of base 
substitutions (59%) were C to T transversions which may be the result of 
spontaneous deamination of 5-methylcytosine, a product of intracellular 
metabolism (Olschwang, S. etal, 1993).
3.4.2.2 Large deletions in the APC gene
Of the pathogenic APC mutations detected in Wales Polyposis Register families 
for which details were available, 10% were large deletions (7/67). This is 
consistent with Michils et al (2005) and Cao et al (2006) who reported large 
deletions accounting for 12% (4/34) and 10% (5/50) of APC mutations in 
polyposis patients, respectively. Studies with larger numbers of patients 
described lower proportions of 8% (Nielsen, M. et al, 2007b) and 5% (Aretz, S. 
et al, 2005) of APC mutations accounted for by large deletions, which may be a 
more accurate reflection of the contribution of such mutations. As shown in 
Figure 3.6, whole gene and partial gene deletions affecting a range of exons 
have been identified. Unlike previous reports (Michils et al, 2005; Aretz, S. et 
al, 2005; Cao etal, 2006; Nielsen, M. etal, 2007b), no single exon deletions 
were found in Wales Polyposis Register families; five unrelated patients carried 
deletions of two or three exons and two harboured a whole gene deletion.
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Figure 3.6 Distribution and frequency of large submicroscopic APC deletions in FAP patients. Deletions are shown as blue lines, novel 
mutations identified in the present study are shown in red and the green line represents a novel mutation identified outside of Wales reported 
as a deletion of exons 13, 14 & up to at least codon 1628 of exon 15. Dashed lines represent unknown 5’ and 3’ breakpoints. The most 
frequently reported deletion is that of the whole gene. Adapted from Nielsen et al (2007b) with additional information from Cao et al (2006), 
Stekrova et al (2007) and Cattaneo et al (2007).
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Whole gene deletions are the most frequently reported large deletion (Figure 
3.6; De Rosa, M. etal, 1999; Sieber, O.M. etal, 2002; Michils etal, 2005; Aretz, 
S. etal, 2005; Cao etal, 2006; Nielsen, M. etal, 2007b) and were the most 
common large deletion in the present study. One of the two whole-gene 
deletion cases was familial and the other was a de novo case. The extent of 
the whole gene deletions identified in the present study is not known; they may 
extend significantly outside of the APC gene as has been previously described 
in a few cases (De Rosa, M. et al, 1999; Sieber, O.M. et al, 2002). All novel 
deletions were identified in single families on the Wales Polyposis Register.
3.4.3 APC missense mutations
The previously reported missense mutations I1307K (Laken, S.J. etal, 1997) 
and E1317Q (Frayling, I.M. etal, 1998) have been associated with increased 
CRC susceptibility but only E1317Q was identified in families on the Wales 
Polyposis Register and only in conjunction with an APC truncating mutation (3 
families) or biallelic MUTYH mutations (1 family).
3.4.4 Genotype-phenotype relationships in FAP
3.4.4.1 Severe colorectal polyposis
Mutations between codons 1250 and 1464 have been identified in cases with 
profuse polyposis (more than 5000 colorectal polyps; Nagase, H. etal, 1992b) 
with codon 1309 mutations associated with an early onset of severe polyposis 
(Caspari, R. etal, 1994; Ficari, F. etal, 2000; Friedl, W. etal, 2001). As 
expected, patients harbouring mutations within codons 1250-1464 (including 
codon 1309) develop CRC at an earlier age than cases carrying mutations 
outside this region (Caspari, R. et al, 1994; Friedl, W. et al, 2001). It is thought 
that the selection for somatic LOH in the context of a germline mutation around 
codon 1309 leads to severe polyposis as LOH occurs at a higher spontaneous 
frequency than truncating mutations close to codon 1300, (Lamlum, H. et al, 
1999; Crabtree, M. etal, 2003). Within the six families on the Wales Polyposis 
Register carrying the same codon 1309 mutation, there were a total of twelve 
clinically affected patients but family history information was not available for 
two index patients. The mean age at diagnosis of nine cases who presented 
symptomatically was 25 years (range 6-41 years) and two of these
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had CRC. Exact polyp counts were not available for many patients but they 
were described as having polyposis, hundreds of polyps or in one case a colon 
‘carpeted’ with polyps. Only the youngest patient (6 years) may not have had 
more than a hundred polyps but no description was available. Three cases 
developed symptoms before the age of 20 years and another died from CRC 
aged 26 years, consistent with previous reports of an early disease onset 
associated with mutations at codon 1309 (Nagase, H. etal, 1992b; Caspari, R. 
etal, 1994; Ficari, F. etal, 2000; Friedl, W. etal, 2001). Inter- and intrafamilial 
differences in colorectal polyp density have been described in patients with the 
same codon 1309 mutation (Giardiello, F.M. et al, 1994) and these were also 
observed in families on the Wales Polyposis Register. This suggests that other 
genetic or environmental factors are contributing to the expression of the 
disease. Detailed clinical information on two Wales Polyposis Register patients 
carrying mutations in the region codons 1250 and 1464 (at 1262 and 1415) was 
not available.
3.4.4.2 Attenuated colorectal polyposis
AFAP patients generally carry germline APC mutations at the 5’ or 3’ ends of 
APC (codons <163 and 1596-2644) or between codons 329 and 338 in the 
alternatively spliced region of exon 9 (Galiatsatos, P. & Foulkes, W.D., 2006). 
Unlike classical FAP, mutations in these regions may allow residual tumour 
suppressor activity (Spirio, L.N. etal, 1998; Su, L-K. etal, 2000; Heppner Goss, 
K. et al, 2002) so two somatic APC mutations (one on the mutated allele and 
another on the wild-type allele) may be required for inactivation of the tumour 
suppressor activity. This delays tumour initiation so AFAP cases have fewer 
adenomas at a later age of onset than classical FAP patients. Six Wales 
Polyposis Register families harboured a germline mutation within, or at the 
boundary of, these AFAP-associated regions of APC. Three families carried the 
R332X mutation and had nine clinically affected patients between them. All but 
one had been diagnosed with CRC at a mean age of 50 years (range 44-54 
years) consistent with AFAP, but no colorectal polyp details were available.
90
The case without CRC also had an AFAP phenotype; she was diagnosed with 
multiple polyps aged 34 years. A single family carried a mutation within the 3’ 
region (at codon 2010) and the two affected members displayed AFAP rather 
than classical FAP. The index case was diagnosed with 50-100 polyps at 52 
years and her father had CRC and polyps at 58 years. Consistent with previous 
reports (Soravia, C. etal, 1998; Sieber, O. etal, 2006), the two families with 
mutations at the 5’ end of the gene (Y159X and Q163X) had a phenotype that 
was more severe than the other AFAP patients but remained milder than 
classical FAP. The Q163X mutation was identified in an apparently de novo 
case who presented aged 45 years with CRC in the absence of recognised 
polyposis then later re-presented with hundreds of colorectal polyps. Her 
daughter had approximately ten adenomas in her thirties. The family 
harbouring the Y159X mutation included 11 clinically affected members, six of 
whom died from CRC aged 33-55 years without a diagnosis of FAP having 
been recognised. The index case presented with hundreds of mainly right­
sided polyps and CRC at 45 years but differences in colorectal phenotype 
existed between affected family members. Intrafamilial variability has been 
reported in several pedigrees with mutations affecting the 5’, exon 9 and 3’ 
regions associated with AFAP (Scott, R.J. etal, 1995; Brensinger, J.D. et al, 
1998; Soravia, C. etal, 1998; Rozen, P. etal, 1999). No other Wales Polyposis 
Register families with mutations outside the regions above appeared to have 
AFAP but clinical information was not available for all cases.
3.4.4.3 Extracolonic manifestations
Detailed data on extracolonic manifestations have not been collected 
systematically on the Wales Polyposis Register. Previous studies have shown 
that CHRPE is associated with mutations between codons 311 and 1444 
(Nieuwenhuis, M.H. & Vasen, H.F.A., 2007) and desmoids are mostly found in 
patients with mutations beyond codon 1444 (Caspari, R. etal, 1995; Friedl, W. 
et al, 2001). Mutations 3’ to codon 1400 are also frequently associated with the 
presence of multiple extracolonic manifestations including osteomas (Dobbie, A. 
et al, 1996b). Desmoids were known to be present in four unrelated cases from 
Wales Polyposis Register families with mutations affecting codons 1465, 1468 
and 1556. Three had other affected family members who were not reported to
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have desmoids and one was a sporadic case. Consistent with Fried! et al 
(2001) who identified desmoids in some patients with a mutation 5’ to codon 
1444, a single case carrying the novel Q223X mutation was diagnosed with 
desmoids, but not all affected family members had desmoids. This case and 
her daughter had osteomas, as did five others each carrying a mutation at 
either codon 332,1309,1465,1468 or 1477. Osteomas have been reported in 
patients with mutations at 1309 (Paul, P. etal, 1993; Giardiello, F.M. etal,
1994) and after 1400 (Dobbie, A. etal, 1996b) but were not identified in several 
patients with mutations at codon 332 (Soravia, C. et al, 1998; Hutter, P. et al, 
2001; Cao, X. et al, 2006) which is consistent with the observation that 
extracolonic manifestations (apart from upper Gl polyps) are rare in AFAP 
patients (Knudsen, A.L. et al, 2003). Osteomas are therefore not confined to 
cases with mutations at codons 767-1513 as has been suggested (Bisgaard, 
M.L. & Bulow, S., 2006). A brain tumour was diagnosed in a Q247X carrier, a 
patient with the Q223X mutation had papillary thyroid cancer and two 
hepatoblastoma cases had been identified, including one carrying the 
c.1239_1240insA mutation. Such tumours are only rarely associated with FAP 
(Nieuwenhuis, M.H. & Vasen, H.F.A., 2007) so it is not surprising that no other 
family members were affected by these tumours. Epidermoid cysts have been 
reported to be more frequent in cases with mutations at codons 1395-1493 
(Wallis, Y.L. etal, 1999) but skin lesions were observed in Wales Polyposis 
Register patients with a wider range of mutations. Bertario et al (2003) reported 
an increased risk of duodenal adenomas in cases with mutations between 
codons 976 and 1067 but duodenal and gastric polyps were detected in Wales 
Polyposis Register patients with a range of mutations, in accordance with 
previous studies (Friedl, W. etal, 2001; Nieuwenhuis, M.H. & Vasen, H.F.A., 
2007). Extracolonic manifestations in patients with the same mutation showed 
inter- and intrafamilial variability as previously described (Giardiello, F.M. etal, 
1994; Paul, P. etal, 1993).
3.4.4.4 Phenotypic expression of novel nonsense, splice site and small deletion 
mutations
Five novel mutations were each identified once in the present screen of 35 
unrelated patients from the Wales Polyposis Register. The nonsense mutation
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Q223X was detected in a case with classical colorectal polyposis (well over a 
hundred polyps aged 40 years), as would be predicted by the location of this 
mutation. As for other mutations resulting in classical polyposis, the Q223X 
mutation is predicted to truncate the APC protein before any 20aa repeat 
sequences and somatic APC mutations resulting in a truncated protein with one 
or two 20aa repeats are predicted to be selected for tumour initiation 
(Albuquerque, C. et al, 2002). Unlike mutations resulting in AFAP, no residual 
tumour suppressor activity is predicted to be present in the protein encoded by 
this mutant allele as exon 6 is not alternatively spliced and codon 223 is beyond 
the alternative translational start site in exon 5. This case was diagnosed with 
three synchronous CRCs and Cao et al (2006) reported synchronous CRCs in 
5% (6/122) of APC mutation positive cases. The presence of multiple CRCs in 
this Wales Polyposis Register case may be because of the late age at diagnosis 
as prophylactic surgery was not undertaken. Only tumour initiation is 
accelerated in FAP, not its progression, so the probability of three adenomas 
progressing to CRC at a similar time in a patient who was not described as 
having thousands of polyps would not be expected to be high. Additional 
environmental or genetic factors may be contributing to the expression of the 
disease and evidence for this is the intrafamilial variability; the patient’s mother 
was diagnosed with CRC and polyps in her sixties whereas the patient’s 
daughter had multiple polyps at 16 years. A mutation at codon 223 would not 
be predicted to result in a high risk of extracolonic manifestations (Dobbie, A. et 
al, 1996b) but this patient had desmoids, an osteoma and fundic gland polyps 
(FGPs). Her daughter also had an osteoma, FGPs, epidermoid cysts and a 
papillary thyroid cancer. Although desmoids, osteomas, FGPs and epidermoid 
cysts have been reported in FAP cases with mutations at a wide range of 
codons, Venesio et al (2003a) detected Q222X in a patient with classical FAP 
diagnosed aged 44 years without CRC or extracolonic lesions.
The novel exon 9 small insertion c.1239_1240insA is predicted to result in a 
stop codon at codon 418 and was identified in a case with classical colorectal 
polyposis (polyposis aged 36 years without CRC) and FGPs. This is as 
expected from the mutation location as it does not affect the AFAP-associated 
alternatively spliced region of exon 9. De Rosa et al (2007) recently described
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alternative splicing of the entire of exon 9 resulting in a stop codon in exon 10 
so despite being located in an alternatively spliced exon, the c.1239_1240insA 
mutation is predicted to result in a truncated protein without any residual tumour 
suppressor activity or 20aa repeat sequences. Therefore as for other mutations 
resulting in classical polyposis, a somatic APC mutation resulting in a truncated 
protein with one or two 20aa repeats is predicted to be necessary for tumour 
initiation (Albuquerque, C. et al, 2002). Similarly, other exon 9 mutations not 
located within the AFAP-associated alternatively spliced region have been 
described in classical FAP cases (Hutter, P. etal, 2001; Bisgaard, M.L. etal, 
2004a). Six additional members of this family showed a classical FAP 
phenotype; three were found to have multiple colorectal polyps in their second 
decades, two were diagnosed with polyposis in their early thirties and one had 
CRC aged 42 years. FGPs and subcutaneous cysts were each identified in one 
of the six cases and another family member died aged 7 years from a 
hepatoblastoma. Olschwang e ta l(1993) reported a c.1238_1239insT mutation 
but no phenotypic details were provided.
The novel splice site mutation c. 1744-4 C>G is predicted to activate a cryptic 
acceptor splice site which results in an in-frame 3bp insertion upstream of exon 
14. The 3bp encode a stop codon, truncating the protein at codon 582. This 
mutation was identified in a case diagnosed in his thirties with classical 
colorectal polyposis without CRC. The truncated protein is not predicted to 
have any residual tumour suppressor activity or 20aa repeat sequences. A 
somatic APC mutation resulting in a truncated protein with one or two 20aa 
repeats is predicted to be necessary for tumour initiation (Albuquerque, C. et al,
2002), as is expected for other mutations resulting in classical polyposis. Seven 
other members of this family are thought to be affected; one was diagnosed 
with hundreds of colorectal polyps without CRC at 53 years and another was 
described as having symptoms of FAP and underwent colectomy at 24 years.
A further five family members died from CRC at ages ranging from ~29 years to 
58 years. One of these had two CRCs and multiple adenomas but polyp counts 
were not available for the other affected family members. Van der Luijt et al 
(1997) reported a c. 1744-2 A>G mutation in a single index patient clinically 
described as having FAP but no further phenotypic details were provided.
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The novel donor splice site mutation c. 1958+1 G>C is predicted to skip exon 14 
resulting in a stop codon at position 671 and was identified in a case with 
classical colorectal polyposis (-300 polyps aged 18 years) without CRC. Aretz 
et al (2004b) have previously reported G>T and G>A mutations at this position 
and transcript analysis revealed exon 14 skipping. This mutation is therefore 
predicted to result in a truncated protein without any residual tumour suppressor 
activity or 20aa repeat sequences. A somatic APC mutation resulting in a 
truncated protein with one or two 20aa repeats is predicted to be necessary for 
tumour initiation (Albuquerque, C. et al, 2002), as is expected for other 
mutations resulting in classical polyposis. Three other members of this family 
are thought to be affected, one underwent colectomy aged 14 years but no 
further clinical information about these cases was available. Aretz et al (2004b) 
described two patients with mutations at c. 1958+1; one had hundreds of 
colorectal polyps at 25 years and duodenal adenomas at 32 years and the other 
had over a hundred colorectal polyps at 36 years. Neither case had any 
extracolonic manifestations. Bala et al (1997) reported a mutation at the exon 
14 splice acceptor site resulting in skipping of this exon in a FAP family. Similar 
to the patient in the present study, both affected members had hundreds of 
colorectal adenomas diagnosed at an early age (16 and 27 years) with the latter 
also having CRC at diagnosis.
The novel nonsense mutation Q1378X was identified in an apparently de novo 
case diagnosed with over a thousand colorectal adenomas, CRC and gastric 
polyps at 38 years. The affected codon lies within the region associated with 
severe polyposis and Q1378X is predicted to result in a truncated protein with a 
single 20aa repeat. Somatic selection for LOH mutations would be predicted in 
tumours in this patient. Since this event occurs at a higher spontaneous 
frequency than do truncating mutations close to codon 1300, a severe 
phenotype would be predicted (Lamlum, H. etal, 1999; Crabtree, M. etal,
2003). The patient’s son is also said to be affected but detailed clinical 
information was not available.
The phenotypes observed in the five index cases with previously unreported 
mutations are therefore consistent with previous studies and with the current
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models of tumourigenesis in FAP (Lamlum, H. etal, 1999; Albuquerque, C. et 
al, 2002; Crabtree, M. et al, 2003).
3.4.4.5 Phenotypes associated with large deletions 
Far fewer reports of colorectal polyposis patients with large submicroscopic 
deletions have been published than those with truncating point mutations, small 
insertions and deletions due in part to previous difficulties in detecting such 
gross mutations but some correlation between genotype and phenotype has 
been observed. Whole gene deletions tend to result in classical rather than 
severe polyposis with some cases also exhibiting extracolonic manifestations 
such as CHRPE, upper Gl polyps, desmoids, osteomas and epidermoid cysts 
(Sieber, O.M. etal, 2002; Aretz, S. etal, 2005; Michils, G. etal, 2005; Nielsen, 
M. etal, 2007b; Stekrova, J. et al, 2007). Thyroid, duodenal, ovarian and 
nasopharyngeal cancers have also been reported in single whole-gene deletion 
cases (Michils, G. et al, 2005; Cao, X. et al, 2006). Only one case with a whole- 
gene deletion has been reported to have an AFAP phenotype with less than 70 
polyps and CRC at 65 years (Venesio, T. et al, 2003b). Unlike some cases with 
cytogenetically detectable deletions involving APC (Raedle, J. etal, 2001), 
patients with submicroscopic deletions have not been reported to have any 
mental retardation (Mandl, M. etal, 1996; De Rosa, M. etal, 1999). The 
classical FAP phenotypes of the four affected members of two families with 
whole gene deletions identified in the present study are consistent with previous 
observations. As with other mutations resulting in classical polyposis, a whole 
gene deletion will not result in a protein with any tumour suppressor activity so a 
somatic APC mutation resulting in a truncated protein with one or two 20aa 
repeats is predicted to be necessary for tumour initiation (Albuquerque, C. et al, 
2002).
Most cases with partial APC gene deletions also display a classical FAP 
phenotype with or without extracolonic features but these mutations appear to 
be associated with more inter- and intrafamilial variability, ranging from classical 
FAP to AFAP phenotypes (Aretz, S. et al, 2005; Nielsen, M. et al, 2007b). The 
exon 4-5 deletion identified in the present study was found in a case with only 
20 macroscopic colorectal polyps aged 24 years. Three other family members
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were affected; two died from CRC, one at 55 years and the other at 70 years, 
and another had colorectal polyps in the absence of CRC at 40 years. Nielsen 
et al (2007b) reported the same mutation in a classical FAP patient with over a 
hundred polyps and CRC aged 41 years. This deletion is out-of-frame so would 
not be predicted to produce any functional protein and therefore result in a 
classical FAP phenotype. Modifying factors affecting expression of truncating 
point mutations, small insertions and deletions are also likely to affect the 
expression of large deletions. The out-of-frame deletion of exons 11-12 was 
found in a Wales Polyposis Register family with three members affected by 
multiple colorectal polyps, but they were diagnosed at a later age (33-50 years) 
than a case with the same mutation reported by Aretz et al (2005) who had 
multiple colorectal polyps at 17 years. A deletion of exons 13-15 was initially 
identified outside of Wales and was described as a deletion of exons 13-15J.
No exon 13-15 deletions have been reported to date but deletions of exons 14- 
15 ,14-part of 15 and 11-15 have been described in classical FAP patients, 
consistent with the Wales Polyposis Register patient who also harboured this 
mutation. Detailed clinical information was not available for the other 14 
affected members of this family.
The novel promoter-exon 2 deletion was identified in a single family on the 
Wales Polyposis Register with 15 affected members. Detailed clinical 
information was not available for seven cases but five of the remaining eight 
patients had CRC at a mean age of 47 years (range 25-57 years). Three cases 
were diagnosed with multiple colorectal polyps at 14, 26 and 57 years, one 
patient had numerous polyps in his twenties, another had hundreds aged 50 
years and a single case aged 19 years had fewer than a hundred colorectal 
polyps. Two cases were only known to have died from CRC so no information 
about colorectal polyps was available. Sebaceous cysts, FGPs and duodenal 
polyps were each noted in single cases. This family shows the intrafamilial 
phenotypic variability associated with APC mutations but the predicted 
phenotype would be that of classical polyposis because without the promoter 
this mutation is predicted to be functionally equivalent to a whole gene deletion. 
In accordance with this, only classical FAP patients have been described with
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deletions of promoter-exon 1 and promoter-exon 5 (Aretz, S. et al, 2005; 
Nielsen, M. et al, 2007b).
A novel deletion of exons 9-10A was detected in a single apparently de novo 
case with a severe phenotype of over a thousand colorectal polyps and four 
CRCs aged 47 years. This is the first mutation reported to affect the 
alternatively spliced exon 10A and although exon 9 can also be alternatively 
spliced (Groden, J. etal, 1991; De Rosa, M. etal, 2007), exon 10 is 
constitutively expressed thus all transcripts will be affected and no functional 
protein produced. The predicted phenotype would be that of classical FAP as a 
somatic APC mutation resulting in a truncated protein with one or two 20aa 
repeats is predicted to be necessary for tumour initiation (Albuquerque, C. et al, 
2002). The severity of this patient’s phenotype is likely to be due to his late age 
at diagnosis resulting from the lack of family history of CRC or polyps.
3.4.5 Prevalence of blallellc germline MUTYH mutations in polyposis patients 
Sixteen percent of families on the Wales Polyposis Register that were screened 
for mutations in APC and/or MUTYH harboured biallelic germline mutations in 
the MUTYH gene. This is a significantly higher proportion than reported by 
Aretz et al (2006) in unselected, unrelated cases with a clinical diagnosis of 
FAP or AFAP (15/92 vs 55/660, p=0.016; Fisher’s exact test). Aceto et al
(2005) also reported biallelic MUTYH mutations in just 8% of cases clinically 
diagnosed with FAP or AFAP, but this was not statistically different from the 
present study (15/92 vs 5/60, p=0.12; Fisher’s exact test). Possible 
explanations for variation in the prevalence of biallelic MUTYH mutations 
include differences in ascertainment, population differences in mutant allele 
frequencies or differences in the sensitivity of molecular testing. However, 
since the entire MUTYH ORF was screened in the previous studies (Aceto, G. 
et al, 2005; Aretz, S. et al, 2006) any differences are unlikely to be a result of 
undetected MAP cases in these cohorts. Notably, of the 92 unrelated Wales 
Polyposis Register cases screened for APC and/or MUTYH, only seven (8%) 
were mutation negative. By comparison, Aceto et al (2005) and Aretz et al
(2006) reported an APC or MUTYH mutation in only 62% and 58% of cases, 
respectively. An additional fifteen families on the Wales Polyposis Register
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have not been screened to date due to lack of DNA from an affected member or 
are in the process of being screened for mutations.
As described above, the proportions of patients with classical FAP and AFAP 
phenotypes can affect the APC mutation detection rate and the same is true of 
detecting MUTYH mutations. Aretz et al (2006) did not identify biallelic MUTYH 
mutations in patients with ‘typical’ FAP but did detect such mutations in 64% of 
cases with an AFAP phenotype. The proportions of cases with these 
phenotypes will therefore affect the number of MAP patients detected. All 
families on the Wales Polyposis Register had one or more family member with 
at least ten colorectal adenomas but polyp counts were not available for all 
cases so exact proportions of patients with a clinical diagnosis of classical FAP 
or AFAP could not be calculated.
3.4.6 Colorectal polyposis patients without APC or biallelic MUTYH mutations 
Seven of the 92 unrelated Wales Polyposis Register cases screened for 
mutations in APC and/or MUTYH did not carry pathogenic mutations in either 
gene that could be detected by APC and MUTYH ORF sequence analysis or 
MLPA of APC. These cases may carry an APC mutation not detected by the 
methods used such as intronic mutations or promoter mutation or 
hypermethylation. However, germline hypermethylation of the APC promoter 
has not been identified (Hitchins, M. etal, 2005; Romero-Gimenez, J. etal, 
2007) and is unlikely to be the cause of the colorectal polyposis in our cases. 
Constitutional reduction in expression from one APC allele has been described 
in several FAP patients (Laken, S. etal, 1999; Yan, H. etal, 2002; Renkonen, 
E.T. et al, 2005; Cao, X. et al, 2006) but mutations in the promoter regions or 3’ 
UTR could not be identified in these cases (Yan, H. etal, 2002; Renkonen, E.T. 
et al, 2005) suggesting the mutations responsible are in other noncoding or 
regulation regions. The two unrelated cases with reduced APC expression 
identified by Renkonen et al (2005) were apparently de novo cases with over a 
hundred colorectal polyps in the absence of extracolonic manifestations. 
Recently, Venesio et al (2007) described increased constitutional expression of 
an APC mRNA isoform connecting exon 10 to exon 15 which encoded a stable 
truncated peptide in AFAP cases. This confirms the need to perform
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constitutional APC transcription analysis in cases in which no APC or MUTYH 
mutations are identified by conventional techniques.
Another reason for failure to detect APC mutations in FAP patients is somatic 
mosaicism. Mutant alleles may be present at only low levels in the blood DNA 
of these patients, or even absent in the context of segmental disease. Aretz et 
al (2007) identified mosaicism in 8/75 (11%) of de novo FAP cases who carried 
pathogenic mutations within the region associated with typical or severe FAP. 
However, six of the eight mosaic patients had an AFAP or atypical phenotype. 
Hes, F.J. et al (2007) estimated that 20% of FAP de novo cases are accounted 
for by mosaic APC mutations and described somatic mosaic cases with 
phenotypes ranging from AFAP to florid polyposis with extracolonic 
manifestations. Six of the seven APC and MUTYH-negative cases in the 
present study are sporadic and could be accounted for by somatic mosaic APC 
mutations.
Alternatively, undetected MUTYH mutations such as large deletion/insertions or 
promoter mutation or hypermethylation could be present in the mutation- 
negative cases but no such mutations have been described to date. An AX/A/2 
nonsense mutation has been identified in an APC mutation-negative family with 
dominantly-inherited severe tooth agenesis in association with between 1 and 
68 colorectal polyps (Lammi, L. et al, 2004). However, subsequent AXIN2 
mutational analysis in a total of 30 APC mutation-negative colorectal polyposis 
patients has failed to detect any obviously pathogenic mutations (Renkonen, 
E.T. et al, 2005; Lejeune, S. et al, 2006) suggesting that mutations in AXIN2 
very rarely contribute to colorectal polyposis and that other genetic factors must 
account for a small proportion of colorectal polyposis.
The phenotype of polyposis patients in whom no APC mutation has been 
identified is controversial; Giarola etal (1999), Heinimann et al (2001) and 
Moisio et al (2002) have suggested a milder phenotype but Bisgaard et al 
(2004b) reported a more severe phenotype in mutation-negative families. The 
mean age at diagnosis of mutation-negative index patients in the present study 
was 34 years (range 23-56 years), five cases had CRC at a mean age of 38
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years (range 23-56 years) and the polyp count varied from 14 to hundreds but 
none had severe polyposis.
3.4.7 Management of colorectal polyposis patients
Identification of the genetic cause of colorectal polyposis in families is crucial for 
correct clinical management and counselling. Whereas apparently sporadic 
APC mutation-positive cases have a 50% risk to offspring and a low risk to 
siblings, MAP poses little risk to offspring but a 25% risk to siblings. The 
correlations between APC mutation site and disease severity led Nieuwenhuis 
et al (2007) to suggest that mutational data might inform the type of prophylactic 
surgery needed to prevent CRC. The most difficult patients to diagnose on the 
basis of symptoms and family history are de novo colorectal polyposis patients. 
They could be the result of biallelic MUTYH mutations or an APC mutation. The 
present study highlights the need to screen the entire ORF of both genes and to 
look for large deletions in APC. If these methods fail to detect causative 
mutations other possibilities such as somatic mosaicism and reduced APC 
constitutional expression should be investigated.
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Chapter Four
Clinical and molecular genetic characterization of MUTYH-associated
polyposis (MAP)
4.1 Introduction
MAP was first identified in a single British family with three siblings affected by 
colorectal tumours. Two siblings had approximately fifty adenomas in their 
fifties and the third had CRC with adenomas but a complete assessment of the 
colorectum was not performed. Analysis of the APC gene in these tumours 
revealed a high frequency of somatic G:C to T:A transversions which lead to 
germline screening of the MUTYH gene through which biallelic mutations were 
identified in all three affected siblings (Al-Tassan, N. et al, 2002). Subsequent 
studies carried out MUTYH mutation analysis in multiple colorectal adenoma 
patients and confirmed that biallelic MUTYH mutations predispose to colorectal 
adenoma and carcinoma (Jones, S. etal, 2002; Sieber, O.M. etal, 2003; 
Sampson, J.R. etal, 2003).
Additional studies of MAP patients have now been described, with most cases 
reported to have tens or hundreds of colorectal adenomas typically by the fifth 
or sixth decade (Sieber, O.M. etal, 2003; Venesio, T. etal, 2004; Wang, L. et 
al, 2004; Nielsen, M. etal, 2005; Jo, W-S etal, 2005; Aretz, S. et al, 2006). The 
colorectal phenotype can be very variable however, and in a small number of 
patients polyp number may apparently be as low as zero in mid-life (Croitoru, 
M.E. et al, 2004; Wang, L., et al, 2004) or as high as over a thousand (Isidro,
G., etal, 2004; Kanter-Smoler, G. etal, 2006). The risk of developing CRC is 
not clearly defined at present and although extracolonic manifestations have 
been reported in MAP patients (Nielsen, M. et al, 2005; Aretz, S. et al, 2006), 
many have not been described at significant frequencies making their 
association with MAP unclear.
A better understanding and characterization of the MAP phenotype may allow 
surveillance strategies to be improved with extracolonic screening implemented 
if necessary. Unlike FAP, no genotype-phenotype relationships have been
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described to date as the phenotypes of only a relatively small number of MAP 
patients have been extensively characterised and the true spectrum of MUTYH 
mutations is only now becoming apparent. A collaborative study was therefore 
established to generate a large series of well characterized MAP cases and 
allow a more accurate assessment of the MAP phenotype with consequences 
for patient care and demonstration of any correlations between MUTYH 
genotype and the MAP phenotype.
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4.2 Methods
4.2.1 Clinical samples
A collaborative project was established between The Institute of Medical 
Genetics (IMG), Cardiff, The Institute of Human Genetics, Bonn and The Centre 
of Human and Clinical Genetics, Leiden resulting in a cohort of 237 MAP 
patients with biallelic MUTYH mutations (182 index cases and 55 affected 
relatives).
Fifty-four MAP index cases were identified from 281 apparently unrelated index 
cases referred from various Regional Clinical Genetics Services, Regional 
Polyposis Registers and Gastroenterology departments to the All Wales 
Medical Genetics Service (AWMGS) for MUTYH germline mutation analysis. 
Adequate phenotypic details were not always provided with referrals but most of 
the patients for whom information was provided had multiple colorectal 
adenomas with or without CRC. The AWMGS identified 45 index cases with 
biallelic MUTYH mutations and 17 index cases with apparently monoallelic 
mutations (Figure I, appendix) by screening for the more frequent MUTYH 
mutations (Y176C and G393D in non-Asian cases and additionally Y101X and 
E477X in Asian cases). Biallelic MUTYH mutations were also detected in 16 
affected relatives by the AWMGS (Figure I, appendix).
I screened the MUTYH ORF for germline mutations in 17 index cases found to 
carry one of the more frequent MUTYH mutations (Y176C or G393D) and in five 
index patients who were negative for the common MUTYH mutations and five 
further cases in whom no MUTYH analysis had been undertaken but who had 
characteristics similar to those of previously described MAP cases; less than a 
hundred colorectal adenomas with or without CRC or CRC at a young age, a 
family history of CRC or colorectal adenomas consistent with a recessive 
inheritance or previous negative mutation screening of the APC gene (shaded 
boxes in Figure I, appendix). All mutations identified in MUTYH were confirmed 
by the AWMGS prior to application in clinical diagnosis or prediction.
MAP cases identified through The Institute of Medical Genetics, Cardiff were 
recruited into the ‘Investigating cancer risk in people with MUTYH gene
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changes’ study (MREC for Wales ref. 06/MRE09/19) or the ‘Genes and Multiple 
Colorectal Adenomas- The Polyp Study’ (MREC for Wales ref. 02/9/22).
Medical history details were obtained from Regional Clinical Genetics Services 
and additional information was obtained, if required, from the patients directly 
via questionnaires or phone calls. Consent forms, information letters and 
questionnaires are shown in the appendix. Pathology reports were requested 
from hospital histopathology departments if necessary. An honorary NHS 
contract was obtained for me for the duration of this study to enable these 
clinical elements of the work.
The Institute of Human Genetics, Bonn identified 73 unrelated index MAP cases 
following sequencing of the MUTYH ORF in adenomatous polyposis patients 
referred for APC and/or MUTYH testing. Fourteen affected relatives were also 
identified as biallelic MUTYH mutation carriers and are included in the present 
study. Fifty-eight of these MAP cases (52 index cases and 6 affected relatives) 
have been previously reported (Aretz, S. et al, 2006). The Centre of Human 
and Clinical Genetics, Leiden identified 55 unrelated index MAP cases through 
a combination of denaturing gradient gel electrophoresis (DGGE) analysis and 
sequencing of the MUTYH ORF in colorectal adenoma patients either referred 
to their DNA Diagnostic Laboratory or identified through the Netherlands 
National Polyposis Register, Leiden. Forty of these index biallelic MUTYH 
mutation carriers have been previously reported (Nielsen, M. et al, 2005). 
Twenty-five affected relatives were also identified as biallelic MUTYH mutation 
carriers and are included in the present study. Informed consent was obtained 
and clinical and pathological data were obtained from patient records for the 
German and Dutch cases as for cases identified through the Institute of Medical 
Genetics, Cardiff.
4.2.2 Screening formulations in MUTYH
Exons 1-16 of MUTYH were PCR amplified and screened using automated 
sequencing as described in section 3.2.3. All mutations were confirmed by 
sequencing an independent PCR product.
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4.2.3 Assays for sequence variants in controls
ARMS assays were designed to determine the presence and frequency of rare 
missense or splice site variants in at least 716 control chromosomes (Table 
4.1).
4.2.4 MUTYH transcript analysis
A 439bp region of cDNA from exon 6 to exon 10 was PCR amplified using 
primers MYHx6F_Q216Q (5’-GTGGCCTACACTGCAGGACC) and 
MYHx10R_Q216Q (5-AGGGCACTGGCTGCACAG) at an annealing 
temperature of 58°C to characterize the MUTYH mutation Q227Q (c.681 G—>A). 
The RT-PCR products were cloned then sequenced using the same primers 
(MYHx6F_Q216Q & MYHx10R_Q216Q).
4.2.5 Statistical analysis
The chi-squared test or Fisher’s exact test were used to assess differences in 
proportions. The chi-squared test was used to assess trends in proportions. 
Univariate ANOVA (Analysis of Variance) was used to compare the mean ages 
at presentation and CRC diagnosis between different genotypes. The 
relationship between number of Y176C alleles and ages at presentation and 
CRC diagnosis was assessed using linear regression analysis. A probability (p) 
of <0.05 was considered statistically significant and all tests were carried out 
with either SPSS 12 or Minitab 14.
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Variant Primer name Primer sequence (5’—>3’)
Anneal
temp
(°C)
Product
size
(bp)
G213E 
(c.638 G—A)
MUTYH_G202E_GF CAGCTCCTGCCTGGCGTCGG
60 141MUTYH J3202E_AF CAGCT CCT GCCT GGCGTAG A
MUTYH_G202E_R AGAGGGGCCAAAGAGTTAGC
Q227Q 
(c.681 G—>A)
MUTYH_Q216Q_GF GCCT CTAT CGCCTTT GGCG AG
60 146MUTYH_Q216Q_AF GCCTCTATCGCCTTTGGCTAA
MUTYH_Q216Q_R ACAGCACCCGT GCTACGTT G
N235S 
(c.704 A—»G)
MUTYH_N224S_AF ACCGGT GT GGT GG AT GGTAA
60(A)
58(G)
149MUTYH_N224S_GF ACCGGTGTGGT GGATGGG AG
M UTYH_N224S_R GCAGAGCTCCTTT GC AG AC
R242H 
(c.725 G—A)
MUTYH_R231 H_GF CGTAGCACGGGT GCT GT GGCG 58(G)
60(A)
149MUTYH_R231 H_AF CGTAGCACGGGT GCT GT GT CA
MUTYH_R231 H_R GAAGGGAACACT GCT GT GAAG
L417M 
(c.1249 C—>T)
MUTYH_L406M_(1 )_CF GCAGCTTCAGCGCAAGGGCC
58 141MUTYH_L406M_( 1 )_AF GCAGCTTCAGCGCAAGGTCA
MUTYH_L406M_(1 )_R GCCT GTGG ATATAGCCT CAA
T474M 
(C.1421 C—T)
MUTYH_T463M_CF CCAGGT GCT CGCT GGCT CAC
56 138MUTYH_T463M_TF CCAGGT GCTCGCT GGCTAAT
MUTYH_T463M_R TACACAGTAATATATTCATGTAG
Table 4.1 ARMS primers and conditions used to assay for specific rare 
MUTYH variants in controls. Internal control primers were used to validate 
the assays; TSC2_Ex26F (5’-GAGCTTTGGCCCTTGGTGATA) and 
TSC2_Ex26R (S’-CTCGCCCACAGGAGACCTAGA), product size 388bp.
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4.3 Results & Discussion
4.3.1 Spectrum of biallelic MUTYH mutations
A total of 36 different MUTYH mutations were detected in 182 unrelated MAP 
index cases referred for genetic testing in Cardiff, Bonn and Leiden. Twenty-six 
of these had been reported previously in MAP patients with biallelic MUTYH 
mutations. Two of the remaining ten mutations, R306C and R106W, were 
identified in single Dutch cases in combination with Y176C and G393D 
respectively, and had been previously reported but only as monoallelic MUTYH 
mutations (Sieber, O.M et a/, 2003; Olschwang, S. etal, 2007). The novel 
MUTYH mutations R19X, V212M, R238Q and G247D were identified in Bonn 
and I identified four novel mutations among patients referred to IMG, Cardiff; 
G213E, N235S, c.681 G>Aand c.1092delC.
Although Y176C and G393D were the most frequent mutations in all three 
centres, there were some differences in the nature and frequencies of other 
mutations (Figure 4.1). As the strategy for mutation screening in most UK 
cases included a pre-screen for the common mutations, compound 
heterozygosity or homozygosity for rare mutations may have gone undetected 
in some cases.
To date, 54 different MUTYH mutations have been reported in the literature in 
patients with biallelic mutations. Together with the additional 10 mutations 
described above, their distribution along the MUTYH gene is shown in Figure
4.2. Mutations have been identified along the length of the gene in all exons 
except the extreme 5’ (exon 1) and 3’ (exon 16) ends and also in introns 4-6, 8, 
10, 12, 13, 15. Nearly half are missense changes (30 mutations, 47%), 
nonsense mutations account for a fifth, nine (14%) are predicted to affect 
splicing, nine are small insertions or deletions and three in-frame insertions or 
deletions have been identified. More than one change has been detected at 
codons 242 (R242H, R242C, R242L), 238 (R238W, R238Q) and 179 (R179H, 
R179C), with nucleotide c.1092 affected by both a small insertion and deletion. 
Two splice site mutations have been described at the same nucleotide in intron 
4 (c.380-1 G>A, c.380-1 G>C) but all other mutations affected different codons 
and nucleotides.
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Figure 4.1 Frequency and spectrum of mutant MUTYH alleles in 182 unrelated 
European index cases. A) Mutant MUTYH allele frequencies in 52 cases from the UK 
and Ireland. The most frequently mutated alleles are Y176C and G393D. All E477X 
and Y101X mutant alleles were identified in patients of Indian and Pakistani descent, 
respectively. Biallelic MUTYH mutations were also identified in two cases living outside 
the UK and Ireland so these mutant alleles are not shown. B) Mutant MUTYH allele 
frequencies in 73 patients from Germany. The most frequently mutated alleles are 
Y176C and G393D. All P292L, V212M and R179H mutant alleles were identified in 
patients of Turkish or Arabic descent and the single mutant alleles c.495+19_30del13 
and Q335X were carried by patients of Greek and Russian origin, respectively. C) 
Mutant MUTYH allele frequencies in 55 patients from the Netherlands. The most 
frequently mutated alleles are Y176C, G393D and P402L. All Q388X and 
c.1428_1430delGGA mutant alleles were identified in patients of Turkish descent and 
only a case of Moroccan descent carried c.1219_1220insGG mutation.
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Figure 4.2 Spectrum and distribution of O Missense □ RPA binding site
germline MUTYH mutations. Only mutations o Nonsense □ DNA minor groove reading motif
from patients with biallelic MUTYH mutations are A Small deletion □ Pseudo HhH motif
shown. Novel mutations I identified are shown as A Small deletion (in-frame) □ HhH motif
grey-filled shapes and novel mutations identified V Small insertion □ MSH6 binding site
by the German and Dutch centres are outlined in V Small insertion (in-frame) □ Adenine recognition motif
purple and orange, respectively. References for 
the previously reported mutations are shown in 
appendix Table I.
□ Splice site 
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4.3.2 Mutation frequency in MUTYH
4.3.2.1 Comparison of MUTYH mutation frequencies between populations 
Compound heterozygosity for Y176C/G393D was the most frequent genotype in 
MAP index cases from the UK and Ireland (16/52, 31%) and Germany (17/73, 
23%), but not in cases from the Netherlands (8/55, 15%). The most common 
genotype in MAP index patients from the Netherlands was homozygosity for 
Y176C (18/55, 33%). This was the second most frequent genotype in the UK 
and Ireland (13/52, 25%) and Germany (12/73, 16%). G393D homozygotes 
were found at a lower frequency than Y176C homozygotes and Y176C/G393D 
compound heterozygotes in all three populations, accounting for 8% (4/52),
10% (7/73) and 7% (4/55) of MAP index cases from the UK and Ireland, 
Germany and the Netherlands, respectively.
Y176C was the most frequently mutated allele in MAP index patients from the 
UK and Ireland, Germany and the Netherlands, contributing 47%, 40% and 51% 
of mutant alleles, respectively, while the G393D mutation accounted for 28%, 
25% and 21% of mutant alleles in cases from the UK and Ireland, Germany and 
the Netherlands, respectively (Figure 4.1). Current data suggests that these 
mutations occur at minor allele frequencies (MAFs) of approximately 0.3% 
(Y176C) and 0.7% (G393D) in healthy non-Asians (Croitoru, M.E. etal, 2004; 
Farrington, S.M. etal, 2005; Peterlongo, P. etal, 2006; Tenesa, A. etal, 2006; 
Webb, E.L. et al, 2006) and both have been commonly identified in MAP 
patients from a range of populations (Table 4.2, Figure 4.3). Given the higher 
frequency of G393D in healthy controls, this change would be expected to 
account for more mutant alleles identified in MAP cases than Y176C but the 
inverse was true in the present study. This may be due to an ascertainment 
bias; the vast majority of index cases in the present study were referred from 
colorectal polyposis registers. Y176C may be more likely than G393D to result 
in a polyposis phenotype in MAP patients and G393D mutations may account 
for colorectal phenotypes outside of the inclusion criteria for such registers.
Y176C and G393D mutations are not consistently associated with specific 
alleles at D1S2667 which suggests that there are likely to have been recurrent
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MUTYH Proportions of different mutant alleles In a particular population/ethnic group
Mutation Dutch Swedish British 
& Irish
French Swiss German Italian Spanish Portuguese Australian American Canadian Indian Turkish & 
Arabic
Y176C
57/106
(54%)
5/10
(50%)
68/158
(43%)
15/43
(35%)
6/12
(50%)
61/156
(39%)
33/100
(33%)
6/16
(38%)
20/46
(43%)
18/40
(45%)
56/112
(50%)
9/24
(38%)
/ /
G393D
22/106
(21%)
1/10
(10%)
69/158
(44%)
11/43
(26%)
4/12
(33%)
42/156
(27%)
17/100
(17%)
5/16
(31%)
11/46
(24%)
16/40
(40%)
40/112
(36%)
12/24
(50%)
/ /
1138delC
5/106
(5%)
/
2/158
(1%)
3/43
(7%)
/
12/156
(8%)
9/100
(9%)
1/16
(6%)
1/46
(2%)
/
2/112
(2%)
/ / /
c.924+3 A>C
2/106
(2%)
1/10
(10%)
2/158
(1%)
1/43
(2%)
/
8/156
(5%)
2/100
(2%)
/ /
2/40
(5%)
3/112
(3%)
2/24
(8%)
/ /
P402L
15/106
(14%)
3/10
(30%)
/
1/43
(2%)
/
3/156
(2%)
/ / / / / / / /
E477X / / / / / / / / / /
2/112
(2%)
/
10/10
(100%)
/
Y101X / / / / / /
6/100
(6%)
/ / / /
1/24
(4%)
/ /
c. 1428_1430delGGA / /
1/158
(0.6%)
/ /
7/156
(4%)
15/100
(15%)
/ /
3/40
(8%)
4/112
(4%)
/ /
5/14
(36%)
c.1219_1220insGG / / /
5/43
(12%)
/ /
3/100
(3%)
4/16
(25%)
8/46
(17%)
/ / / / /
P292L 1 / /
1/43
(2%)
/ /
1/100
(1%)
/ / / / / /
5/14
(36%)
Table 4.2 Prevalence of particular MUTYH mutations in MAP cases from different populations. Only mutations identified in unrelated 
MAP patients with biallelic MUTYH mutations and either previously reported or part of the present study are included. Populations with at least 
10 reported mutant alleles are shown. Mutations were selected for a frequency of 5% or more in at least one population which was due to 
more than one mutant allele. Mutations identified in patients who were reported to be descended from one population but living in another were 
counted as their population of descent. Frequencies highlighted in bold show a higher prevalence of the mutation in particular populations. 
References are shown in appendix Table I.
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Figure 4.3 Contributions of particular MUTYH mutations to MAP in different 
geographical populations. Proportions, criteria for mutation selection and 
references are as described in Figure 4.2. Map is not to scale.
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□ Y176C □
□ c.1138delC □
□ P402L □
■ Y101X □
■ P292L □
□ Other mutations
G393D 
c.924+3 A>C 
E477X
c. 1428_1430delGGA 
c.1219_1220insGG
mutational events rather than a single ancestral change (Sieber, O.M. etal,
2003). However, these changes were not detected in any of the index MAP 
patients of Indian, Pakistani, Turkish, Arabic, Moroccan or Greek ethnicity in the 
present study. Similarly, neither of these changes has been identified in MAP 
patients of Japanese (Miyaki, M. et al, 2005) or Iranian (Kanter-Smoler, G. et al, 
2006) descent although only one unrelated MAP case from each of these 
populations has been reported to date.
When the frequencies of Y176C and G393D identified in patients living in the 
UK and Ireland, Germany and the Netherlands are separated into ethnic groups 
and combined with data from previous studies (taking into account any 
mutations in the present study which have been previously reported), the 
mutant allele frequencies remain the same or similar for German and Dutch 
cases but change for British and Irish non-Asian cases (Table 4.2). This is 
partly because very few Dutch and German MAP index cases who are not part 
of the present study have been previously reported whereas several previously 
reported British non-Asian MAP patients were not part of the present study.
Only 5% of Dutch mutant alleles and 6% of German mutant alleles were from 
recent immigrant groups whereas 13% of British mutant alleles were of Asian 
ethnicity. The total proportion of British and Irish non-Asian mutant alleles 
accounted for by Y176C and G393D in the present study (87%) is the same as 
the frequency of these alleles in previously reported British non-Asian MAP 
cases (Croitoru, M.E. etal, 2007; Webb, E.L. etal, 2006; Farrington, S.M. etal, 
2005; Fleischmann, C. etal, 2004; Sieber, O.M. etal, 2003; Halford, S.E.R. et 
al, 2003), although the frequencies of the individual mutations were significantly 
different. Whereas in the present study 54% and 32% of British and Irish non- 
Asian mutant alleles were Y176C and G393D respectively, these mutations 
contributed to 28% (Y176C) and 59% (G393D) of previously reported British 
non-Asian mutant alleles (Y176C; 49/90 vs 19/68, p=0.0007, G393D; 29/90 vs 
40/68, p=0.0007, Fisher’s exact test). This variation is likely to be the result of 
differences in ascertainment; the previously reported mutant alleles included 38 
which were identified in studies of population-based CRC cases or early onset 
CRC cases. Twenty-nine of these 38 mutant alleles (76%) were G393D and 
only 6 (16%) were Y176C (Webb, E.L. etal, 2006; Farrington, S.M. etal, 2005;
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Fleischmann, C. etal, 2004; Halford, S.E.R. etal, 2003). The vast majority of 
index cases in the present study were referred from colorectal polyposis 
registers and included multiple colorectal adenoma patients with and without 
CRC. Y176C may therefore be more likely than G393D to result in a polyposis 
phenotype. Y176C is more frequently mutated than G393D in reported non-UK 
European, Australian and American MAP patients (Table 4.2, Figure 4.3).
Several mutations have been identified previously in more than one population 
but some appear to occur at higher frequencies in certain populations (Table
4.2, Figure 4.3).
4.3.2.2 Overall prevalence of MUTYH mutations 
A total of 766 mutant MUTYH alleles have been reported in apparently 
unrelated MAP index cases to date and together with previously unreported 
mutant alleles in the present study, nearly nine hundred have been described. 
As shown in Figure 4.4, Y176C and G393D are ten and seven times more 
prevalent than any other single mutation, respectively. Together they account 
for 70% (631/896) of reported mutant alleles but as described above there has 
been a reporting bias towards these two mutations. Over twenty reports have 
been published to date in which biallelic MUTYH patients have been identified 
by analysis of the MUTYH ORF without pre-screening and as more of these 
unbiased screens are reported, more accurate frequencies of individual 
mutations among MAP patients will be obtained with implications for molecular 
diagnostic testing for MAP.
The remaining 62 reported MUTYH mutations each contribute less than 5% of 
mutant alleles described in unrelated MAP index cases. The most frequent of 
these less common mutations are c.1138delC and c.1428_1430delGGA which 
each account for 4% of mutant alleles. Thirty-seven MUTYH mutations have 
only been described in a single MAP index case, of which four were identified in 
the homozygous state (Figure 4.4).
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Figure 4.4 Frequency of MUTYH mutations previously reported or identified in MAP cases in the present study. Only mutations 
identified in unrelated MAP patients with biallelic MUTYH mutations are included. Y176C and G393D are ten and seven times more prevalent 
than any other single mutation, respectively. References are shown in appendix Table I.
117
4.3.3 Rare and novel pathogenic MUTYH mutations identified in Cardiff 
Biallelic MUTYH mutations were identified in eight of the 26 unrelated index 
cases I screened (Table 4.3). Y176C and G393D mutations in these cases had 
already been identified through previous screening. A c.1138delC homozygote 
(3718) lived in Canada but was of Italian descent and patient 4891 came from 
New Zealand. All other cases were from the UK or Ireland.
Patient Mutation 1 Mutation 2
0748 Y176C1 (C.527A—G) Q227Q (c.681 G—A)
1232 Y176C1 (C.527A—G) Q227Q (c.681 G—A)
2921 Y176C1 (C.527A—G) c. 1138deiC? (L370fsX404)
3718 c. 1138deiC? (L370fsX404) c. 1138deiC? (L370fsX404)
2058 G393D1 (c.1178 G—A) G213E (c.638 G-»A)
0376 G393D1 (c.1178 G—A) N235S (c.704 A—G)
4021 G393D1 (c.1178 G—A) R242H3 (c.725 G-+A)
4891 G393D1 (c.1178 G—A) 1092delC (P364fsX404)
Table 4.3 Biallelic MUTYH mutations identified in a screen of 26 multiple 
colorectal adenoma patients. Mutations previously reported in other MAP 
patients; 1AI-Tassan, N. etal, 2002,2Sieber, O.M. etal, 2003,3Aceto, G et al, 
2005. Novel variants are shown in bold and rare mutations are in italics.
The infrequent c.1138delC mutation has been previously reported (Sieber, O.M. 
et al, 2003) and leads to a frameshift resulting in a stop codon at position 404. 
The pathogenicity of frameshift mutations is usually assumed as they result in a 
truncated protein which is highly likely to have a detrimental functional effect. 
Analysis of a cell line derived from a c.1138delC/G393D compound 
heterozygote MAP patient showed that these cells have approximately half the 
wild-type level of MUTYH as a result of protein instability caused by the 
c.1138delC mutation (Parker, A.R. etal, 2005).
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The previously reported R242H rare missense mutation (Aceto, G. et al, 2005) 
was not found in 726 control chromosomes and is predicted to abrogate 
putative exonic splicing enhancers (ESEs) responsive to SR proteins SF2/ASF 
and SC35 (ESEfinder version 3.0, http://rulai.cshl.edu/tools/ESE/, Cartegni, L. 
et al, 2003). Functional analysis of other MUTYH mutations that lie adjacent to, 
or within, the MSH6 binding domain of the protein (R238W, R242L and V243F) 
has been undertaken. None of the variants affect the physical interaction of 
MUTYH with MSH6 but these mutant MUTYH proteins exhibit defects in 8- 
oxoG:A binding and adenine glycosylase activities. In addition, none of these 
enzymes can complement MutY deficiency in E. coli(Bai, H. etal, 2005; Bai, H. 
et al, 2007) suggesting that R242H is likely to have an effect on the protein.
G213E is a novel missense mutation (Figure 4.5) and was found in combination 
with G393D in a single patient. This variant is a non-conservative amino acid 
change at an evolutionarily conserved site, is predicted to have a probably 
damaging effect on the protein (PolyPhen;
http://genetics.bwh.harvard.edu/pph/) and was not detected in 724 control 
chromosomes. The glycine residue at codon 213 is conserved through 
evolution (Figure 4.6) and the equivalent amino acid in E. coll MutY (Gly118) 
forms part of a HhH motif, a highly conserved structural element found in the 
catalytic domain of several DNA glycosylases (Guan, Y. et al, 1998). Crystal 
structures of E. coli MutY have shown the protein forms a positively-charged 
DNA binding groove which enables the HhH motif to approach the DNA 
backbone. Gly118 is located within the hairpin turn of this HhH motif (Figure 
4.6) and interacts with DNA phosphates. The pseudo HhH motif also has the 
ability to approach the DNA backbone and together both elements may 
compress the DNA intrastrand phosphate distance either side of the mispaired 
adenine causing the DNA to bend and the target base to flip out of the DNA 
helix, into the active site pocket (Guan, Y et al, 1998). The non-conservative 
substitution of G213E results in a negatively-charged amino acid which would 
repel DNA phosphates and may therefore affect the positioning of adenine into 
the active site.
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A)
Normal
Normal
2058
G213E (c.638 G—>A)
T G G N G C G
4891
1092delC
C C C C A G G G A  C C C N N G G N N
B)
Normal
G C A A C G T 
D)
Normal
C C A G G T G
0376
N235S (C.704 A—>G)
A
G C A N C G T
1232
Q227Q (c.681 G—>A)
C C A N G T G
Figure 4.5 Novel MUTYH mutations identified in multiple colorectal adenoma cases. All mutations were identified in 
combination with either Y176C or G393D. Normal sequences are shown on the left and corresponding mutant sequences on the 
right. N indicates position of mutation.
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Figure 4.6 Crystal structure of the E. coli MutY catalytic domain and evolutionary 
conservation of MUTYH. A) Gly118 of E. coli MutY (left, shown as yellow spacefill) 
corresponds to Gly213 of human MUTYH and lies within the hairpin turn of a HhH 
motif, as indicated by the arrow (below) (RCSB Protein Data Bank www.rcsb.org/pdb/). 
The glycine at residue 213 of MUTYH is highly conserved through evolution, as 
indicated by the arrow (right). B) Asn140 of E. coli MutY (left, shown as green spacefill) 
corresponds to Asn235 of human MUTYH and forms part of an a-helix as indicated by 
the arrow (below) (RCSB Protein Data Bank www.rcsb.org/pdb/) which is thought to 
form part of the enzyme’s active site. The asparagine at residue 235 of MUTYH is 
highly conserved through evolution, as indicated by the arrow, right. PDB file 1MUY 
was used to generate the figures using RasMol v2.6-(3-2 (http://openrasmol.org/) and a- 
helices are shown in red. Alignment of human (NP_036354), mouse (NP_573513), 
Xenopus (NP_001072831), Arabidopsis (NP_193010), fission yeast (AAC36207), E. 
coli (NP_417436) and B. stearothermophilus (1RRQA) MUTYH homologues was 
carried out using ClustalW (right). Amino acids are coloured according to their 
biochemical properties.
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The novel N235S mutation (Figure 4.5) is a semi-conservative amino acid 
change at a site conserved through evolution and is predicted to have a 
possibly damaging effect on the protein (PolyPhen; 
http://genetics.bwh.harvard.edu/pph/). This variant was detected in a single 
patient together with G393D but was not found in 722 control chromosomes. 
N235S occurs at a residue conserved through evolution (Figure 4.6) and the 
equivalent amino acid in E. coli MutY (Asn140) forms part of the enzyme’s 
active site (Guan, Y. et al, 1998). Crystal structures of E. coli MutY suggest that 
the amide group of Asn140 hydrogen-bonds to the sugar residue of the target 
adenine nucleotide (Guan, Y. etal, 1998). The N235S substitution results in a 
change in the amino acid side chain from an amide to a hydroxyl group. The 
serine side chain is still capable of hydrogen bonding but spatial positioning of 
this group may be such that bonding is weaker or may even be disrupted. No 
other MUTYH mutations have been reported to affect this codon but a human 
R238W mutant MUTYH protein shows defective 8-oxoG:A binding and adenine 
glycosylase activities (Bai, H. etal, 2005).
The only novel small deletion identified, 1092delC (Figure 4.5), was found in a 
single patient in combination with G393D. This mutation results in a frameshift 
from codon 364 and creates a stop codon at position 404. The resulting 
truncated protein lacks the functionally important C-terminal domain needed for 
substrate recognition (Noll, D.M. etal, 1999; Fromme, J.C. etal, 2004), the 
PCNA binding motif (Parker, A. et al, 2001) and the NLS (Takao, M. et al,
1999). The 1138delC frameshift mutation also results in a stop codon at 
residue 404 so 1092delC is likely to result in protein instability and reduced 
cellular levels of MUTYH (Parker, A.R. et al, 2005). An insertion mutation of a 
single cytosine at nucleotide 1092 resulting in a stop codon near the C-terminus 
of the protein at residue 529 has been previously reported (Lejeune, S. et al, 
2006). Both mutations occur at a polycytosine (Cfe tract and are likely to be the 
result of replication slippage as repetitive sequences are more prone to this 
error.
The novel splice site mutation c.681 G—>A (Figure 4.5) was found together with 
Y176C in two apparently unrelated cases and was not detected in 722 control
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chromosomes. This mutation affects the last nucleotide of exon 8 so transcript 
analysis was undertaken to determine what effect the variant had on splicing.
In addition to the predicted 439bp fragment, RT-PCR from exons 6 to 10 in 
patient 0748 revealed two smaller mRNA species, one of which appeared to be 
much less abundant (Figure 4.7). Sequencing of the cloned products showed 
that 46% of transcripts underwent normal splicing but harboured the Y176C 
mutation (located in exon 7), 46% of transcripts skipped exon 8 and did not 
carry the Y176C mutation and 8% of transcripts skipped exons 8 and 9 and did 
not carry the Y176C mutation (Figure 4.7). Exon 8 skipping results in an in­
frame deletion of 38 amino acids which, based on crystal structures of E. coli 
MutY, include a region of the six helix barrel domain which contains the HhH 
motif. As described above, the HhH element interacts with the DNA backbone 
and works with the pseudo HhH motif to bend DNA and facilitate flipping of the 
target adenine base into the active site (Guan, Y et al, 1998). If both exons 8 
and 9 are skipped, a frameshift results that leads to a stop codon 65 amino 
acids downstream. The truncated protein would lack most functional elements 
including the entire C-terminal domain which is necessary for substrate 
specificity (Noll, D.M. etal, 1999; Fromme, J.C. etal, 2004). Wooden etal 
suggested that a truncated human MUYTH protein (residues 1-135) may have a 
toxic effect on cells as E. coli expressing this mutant exhibited slowed growth 
(Wooden, S.H. et al, 2003). The 1138delC frameshift mutation leads to a stop 
codon further downstream than that caused by skipping of exons 8 and 9 yet 
has been shown to result in protein instability in human cells (Parker, A.R. et al, 
2005) which may also be the case for c.681 G>A. A splice site mutation 
affecting the splice acceptor site of exon 8 has been reported, c.682-1 G>A, but 
further analysis was not undertaken (Nielsen, M. et al, 2005).
4.3.4 Functional analysis of pathogenic MUTYH mutations 
Only a few MUTYH variants have undergone functional analysis, with the 
common Y176C and G393D mutations most comprehensively characterized. 
Both residues are highly conserved through evolution and are located within 
functionally important domains of the protein (Al-Tassan, N. etal, 2002).
Crystal structures of homologous E. coli and B. stearothermophilus MutY 
proteins show the equivalent tyrosine residue is part of a pseudo HhH motif
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Figure 4.7 Characterization of the effect the MUTYH c.681 A—>G mutation has at the 
mRNA level in patient 0748. A) RT-PCR products with 100bp ladder. Patient samples 0748 
1, 2 and 3 were from different blood collection tubes. E; reverse transcriptase, N; normal 
unaffected sample, C; control reaction using cDNA from total HeLa RNA and control primers. 
The three RT-PCR products detected in patient 0748 are indicated by arrows and (i); 439bp (ii); 
325bp and (iii); 222bp. B), C) and D) show sequence traces of cloned RT-PCR products (i), (ii) 
and (iii), respectively. Exon boundaries are indicated by hashed lines. Exon skipping was found 
exclusively on the allele which did not harbour the Y176C mutation.
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which may promote flipping of the mispaired adenine into the active site and the 
tyrosine itself intercalates into DNA 5’ to 8-oxoG which may be required for 
recognition of this damaged base (Guan, Y etal, 1998; Fromme, J.C. etal,
2004). The mutant E. coli MutY protein carrying a Y82C mutation 
(corresponding to Y176C) shows significantly reduced adenine glycosylase 
activity (Chmiel, N.H. etal, 2003), as does the equivalent mutant MUTYH 
mouse protein (Y150C), compared to their wild-type counterparts (Pope, M.A. et 
al, 2005). The human Y176C MUTYH protein displays no DNA binding activity 
on 8-oxoG:A or G:A containing substrates and lacks adenine glycosylase 
activity in vitro (Wooden, S.H. et al, 2003). The ability to complement E. coli 
mutY is also reduced in the Y176C mutant enzyme compared to the wild-type 
protein (Chmiel, N.H. etal, 2003). Cells derived from a Y176C homozygous 
MAP patient have low MUTYH levels and this enzyme exhibits minimal binding 
and cleavage of 8-oxoG:A and 8-oxoA:G mispairs, even when tested at levels 
similar to those in normal cells (Parker, A.R. etal, 2005). This mutation may 
also alter the effect other DNA repair proteins have on MUTYH; human APE1 
almost completely inhibited the adenine glycosylase activity of mouse Y150C 
MUTYH on 8-oxoG:A mispairs without affecting the wild-type enzyme. This was 
suggested to be a result of competition for DNA binding between the two 
proteins (Pope, M.A. et al, 2005).
G393D is predicted to structurally disrupt a C-terminal turn that hydrogen bonds 
with the damaged DNA strand and is therefore thought to affect 8-oxoG 
recognition (Fromme, J.C. etal, 2004). An 85% reduction in glycosylase activity 
on 8-oxoG:A mispairs was observed with the equivalent E. coli mutant, G253D, 
in vitro and human MUTYH has a reduced ability to complement E. coli mutY 
compared to the wild-type protein (Chmiel, N.H. et al, 2003). Expression of 
G365D mutant mouse MUTYH in MUTYH-null ES cells could not suppress their 
mutator phenotype or produce detectable adenine glycosylase activity (Hirano,
S. et al, 2003). In contrast, E. coli-expressed G365D mutant mouse MUTYH 
has been observed to excise adenine opposite 8-oxoG in vitro at levels similar 
to that of the wild-type protein (Hirano, S. et al, 2003; Tominaga, Y. et al, 2004; 
Pope, M.A. etal, 2005; Ushijima, Y. etal, 2005). This discrepancy between in 
vitro and in vivo activities is thought to be related to differences in
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posttranslational modifications of MUTYH, in particular its phosphorylation 
which may be affected by the G365D mutation (Hirano, S. et al, 2003). The 
human G393D MUTYH protein displays a significantly reduced affinity for 8- 
oxoG:A mispairs and lacks adenine glycosylase activity in vitro (Wooden, S.H. 
et al, 2003). Cells derived from a G393D homozygous MAP patient have wild- 
type levels of MUTYH but the mutant enzyme exhibits significantly reduced 
binding and cleavage of 8-oxoG:A and 8-oxoA:G mispairs (Parker, A.R. etal, 
2005). Mouse G365D MUTYH has a lower affinity for 8-oxoG:A pairs resulting 
in a reduced ability to prevent OGG1 from excising 8-oxoG opposite adenine or 
the generated AP site, leaving an uncorrected adenine to cause a G:C to T:A 
transversion or the loss of informative bases on both strands leading to a 
double strand break, respectively (Tominaga, Y. etal, 2004). Recombinant 
human G393D MUTYH protein shows only 1.5% of the wild-type glycosylase 
activity excising 2-hydroxyadenine opposite guanine which could also lead to 
G:C to T:A transversions (Ushijima, Y. et al, 2005).
Alhopuro et al recently analyzed the missense mutation A470D located in the 
MutT-like domain of MUTYH in human cell lines and found that this variant had 
significantly reduced adenine glycosylase activity on 8-oxoG:A mispairs 
compared to a wild-type cell line (Alhopuro, P. et al, 2005). Characterization of 
two splice site mutations through RNA analysis has been reported to date. The 
intron 12 variant c.1178-2 A>G identified in a patient in combination with G393D 
was confirmed to reside on the opposite allele to the common mutation and 
cDNA analysis using primers in exons 10 and 14 showed only mutant G393D 
transcript (Farrington, S.M. etal, 2005). The intron 10 splice site mutation 
c.924+3 A>C was detected in two patients in the present study and Kanter- 
Smoler et al recently reported that this variant causes skipping of exon 10 
resulting in a frameshift and a stop codon at amino acid 267 (Kanter-Smoler, G. 
et al, 2006).
4.3.5 Other variants in MUTYH
The novel missense variant T474M (c.1401 C—>T) is of uncertain significance 
as it was identified as a heterozygous change in a single patient in association 
with both G393D and 1092delC. It is a semi-conservative substitution at a
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residue not conserved in prokaryotes. This variant was not detected in 724 
control chromosomes and is predicted to have a possibly damaging effect on 
the protein (PolyPhen; http://genetics.bwh.harvard.edu/pph/). T474M is 
predicted to abolish one putative ESE responsive to the SR protein SF2/ASF 
and disrupt another so that it may promote exon inclusion more weakly 
(ESEfinder version 3.0, http://rulai.cshl.edu/tools/ESE/, Cartegni, L. et al, 2003). 
The previously reported rare missense variant L417M (c.1249 C—»A,
Peterlongo, P. et al, 2006) was detected in the heterozygous state in two cases, 
one was also a G393D heterozygote and the other patient carried both G393D 
and 1092delC pathogenic changes. This variant was not identified in 716 
control chromosomes and is predicted to abolish a putative ESE responsive to 
the SR protein SC35 (ESEfinder version 3.0, http://rulai.cshl.edu/tools/ESE/, 
Cartegni, L. et al, 2003) but is a semi-conservative change at a site only 
partially conserved through evolution. The common MUTYH polymorphisms 
V22M (c.64 G— A; rs3219484), Q335H (c.1005 C— G; rs3219489) and S512F 
(c.1535 C—>T; Al-Tassan, N. etal, 2003) were also detected, along with the 
previously reported silent variant S343S (c.1029 G—>A) (Kairupan, C.F. etal,
2005). S343S is predicted to abrogate three putative ESEs responsive to the 
SR protein SF2/ASF but generates a novel enhancer responsive to the same 
protein within three nucleotides of these disrupted ESEs. Similarly, this variant 
also abolishes a putative ESE responsive to the SR protein SRp40 but results in 
a novel enhancer responsive to the same protein four nucleotides downstream 
(ESEfinder version 3.0, http://rulai.cshl.edu/tools/ESE/, Cartegni, L. etal, 2003).
4.3.6 Colorectal adenoma patients without biallelic MUTYH mutations 
Biallelic MUTYH mutations were not identified in eighteen of the 26 unrelated 
index cases in whom I sequenced the entire MUTYH ORF. No potentially 
pathogenic MUTYH mutations were identified in eight patients and ten patients 
were heterozygous for either Y176C (4 cases) or G393D (6 cases) and did not 
appear to harbour a pathogenic mutation of the second allele (Table 4.4). The 
proportions of Y176C and G393D heterozygotes in unrelated index cases 
referred to Cardiff for genetic testing of MUTYH in whom biallelic mutations 
were not identified were not significantly different from those found in healthy 
UK non-Asians (Y176C heterozygotes; 34/5656 vs 4/227, p=0.057, G393D
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9atient Pathogenicmutation Sex Polyp count
CRC
(age) Family history
Previous APC 
screening
1598 Y176C M 10s 2(62) None PTT prom.& exons 3-part 
15, MLPA
3196 Y176C F Polyposis N Unknown Entire ORF sequenced1
1068 Y176C M Unknown Unknown Unknown Unknown
3898 Y176C F Unknown Unknown Unknown Unknown
4120 G393D M Multiple N Sister CRC + polyps, grandmother CRC Unknown
3939 G393D F Polyposis aged 35 N None Entire ORF sequenced1
5161 G393D M Multiple aged 31 N None Entire ORF sequenced1, 
MLPA
2088 G393D F >100 1(58) Unknown Entire ORF sequenced1, 
MLPA1
1997 G393D M None 1(28) Brother CRC + -100 polyps. Consanguineous parents Unknown
2125 G393D M Unknown Unknown Unknown Unknown
4822 / M Multiple 1(47) Brother CRC aged 45. Consanguineous parents Entire ORF sequenced1, 
MLPA
3037* / F 22 N 1 of 4 sibs polyps no CRC
I V I w l  f  \
Unknown
3607 / F 10-15 1(35) None. Consanguineous parents Entire ORF sequenced1
3858 / F £50 N None Entire ORF sequenced1
4147 / M -50 aged 40s N None Entire ORF sequenced1
0652 / M 30-40 aged 39 N Unknown Entire ORF sequenced
4234 / M <100 Unknown Dominant family history PTT prom.& exons 3-part 
15, MLPA
1365 / M Unknown Unknown Unknown APC -ve, no details
Table 4.4 Clinical features of patients referred to the All Wales Medical Genetics Service found to carry one or no pathogenic MUTYH 
mutation. Previous screening of the APC gene is shown in the last column. 1Carried out by me as described in section 3.2.2. *This patient was 
also diagnosed with breast cancer aged 50.
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heterozygotes; 75/5656 vs 6/227, p=0.092, Fisher’s exact test) (Al-Tassan, N. 
etal, 2002; Sieber, O.M. etal, 2003; Fleischmann, C. etal, 2004; Farrington, 
S.M. et al, 2005; Tenesa, A. et al, 2006; Webb, E.L. et al, 2006). These cases 
may carry a MUTYH mutation not detected by ORF sequencing such as a large 
deletion/insertion or promoter mutation or hypermethylation. However, Nielsen 
et al (2005) carried out Southern blot analysis in 95 patients which did not 
identify any gross genomic rearrangements. Similarly, no additional MUTYH 
mutations have been found in patients following long-range PCR or fluorescent 
semi-quantitative multiplex PCR analysis (Eliason, K. etal, 2005; Peterlongo, P. 
et al, 2006). MLPA of exons 2 and 16 of the MUTYH gene also did not detect 
any large deletions or duplications (Kanter-Smoler, G. et al, 2006). AFAP or 
FAP could not be fully excluded in six of the 26 unrelated index cases in whom I 
sequenced the entire MUTYH ORF (Table 4.4).
4.3.7 MAP phenotype
All 237 MAP patients (182 index cases and 55 affected relatives) identified 
between the three centres were included in the study of MAP phenotype, 
regardless of ethnicity. Ninety-nine MAP cases were female (42%) and 58% 
(138 cases) were male. The mean age at presentation of 195 MAP patients 
who came to medical attention for reasons other than screening due to an 
affected relative was 45 years (median 45 years, range 12-68 years), consistent 
with previous reports (Wang, L. etal, 2004; Gismondi, V. etal, 2004; Kairupan, 
C.F. etal, 2005; Aceto, G. etal, 2005; Jo, W-S., etal, 2005; Bouguen, G. etal,
2006). Only a single patient presented symptomatically under the age of 20 
years, with more than a hundred colorectal polyps but no CRC, and just 5% of 
cases presented before the age of 30 years. Three patients presented over the 
age of 65 years of whom two were diagnosed as a result of symptoms and one 
due to population screening. All three cases had more than a hundred 
colorectal polyps and two had CRC. These extremes were therefore very rare 
and the majority of patients (134 cases, 69%) presented symptomatically 
between the ages of 35 and 54 years.
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4.3.7.1 Colorectal adenomas and CRC
Colorectal polyp counts were divided into categories based on number or 
terminology used. The colorectal phenotypes of MAP patients in the present 
study closely resembled AFAP (<100 adenomas) or classical FAP (100-1000 
adenomas) (Table 4.5). Only 7% of MAP patients were described as having 
‘few’ or less than ten colorectal polyps and unlike previous studies (Wang, L. et 
al, 2004; Croitoru, M.E. etal, 2004; Balaguer, F. etal, 2007), no cases with 
CRC in the absence of polyps were identified. This is likely to be because index 
cases in the present study were referred mainly from colorectal polyposis 
registers, clinical genetics or gastroenterology services whereas some previous 
studies screened population-based series of CRC cases (Croitoru, M.E. etal, 
2004; Balaguer, F. et al, 2007) or early-onset CRC patients (Wang, L. et al,
2004). Very few MAP cases with CRC in the absence of polyps have been 
reported, suggesting that this phenotype is uncommon. More MAP cases had 
10-99 than 100-1000 colorectal polyps (Table 4.5) which is consistent with the 
majority of previous reports (Wang, L. et al, 2004; Gismondi, V. et al, 2004;
Polyp count No. of cases Proportion of cases (%)
<10 14 6
10-99 119 50
100-1000 54 23
Few 3 1
Multiple 27 11
Numerous 6 3
Polyposis 11 5
Unknown 3 1
Table 4.5 Colorectal polyp count in 237 MAP patients. Cumulative number of 
colorectal polyps is shown grouped into categories based on number or terminology. 
Counts were derived from pathology and/or colonoscopy reports. A polyp count was 
not available for 3 patients.
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Isidro, G. etal, 2004; Venesio, T. etal, 2004; Kairupan, C.F. etal, 2005; Jo, W- 
S. etal, 2005; Russell, A.M. etal, 2006; Lefevre, J.H. etal, 2006; Lejeune, S. et 
al, 2006; Croitoru, M.E. etal, 2007) and may reflect the mechanism of 
tumourigenesis. Only one somatic APC mutation is needed for adenoma 
initiation in FAP but both APC alleles have to be somatically inactivated in MAP. 
However, a significant proportion (23%) of MAP patients in the present study 
had 100-1000 colorectal polyps and this figure may be an underestimation as 
an additional 8% were described as having polyposis or numerous polyps. Two 
somatic APC mutations also appear to be required for tumourigenesis in AFAP 
but the BER defect in MAP is thought to increase the mutation rate in the APC 
gene making adenoma initiation more likely to occur. Two MAP cases with over 
a thousand colorectal polyps have been reported (Isidro, G. et al, 2004; Kanter- 
Smoler, G. et al, 2006) but none of the 237 patients in the present study had 
this number of polyps indicating the rarity of this phenotype in MAP.
The colorectal polyps in most MAP cases were adenomas but in 9% of patients 
a small number of hyperplastic polyps were identified in addition to adenomas. 
Colonic hyperplastic polyps have been previously reported in less than ten MAP 
patients (Sieber, O.M. etal, 2003; Ponti, G. etal, 2005; Croitoru, M. E. etal, 
2007; Ponti, G. et al, 2007) and may be present in more cases but go 
unreported as adenomas have traditionally been seen as the polyps with 
malignant potential. A link between hyperplastic polyposis syndrome (HPS) and 
CRC through a serrated neoplasia pathway has been suggested more recently 
(Leggett, B.A. etal, 2001). Biallelic MUTYH mutations have been reported in a 
single HPS case with more than 40 adenomas, multiple hyperplastic polyps but 
no CRC (Chow, E. et al, 2006).
Fifty-eight percent (138/237) of MAP patients in the present study had been 
diagnosed with CRC. Previous studies of more than ten MAP patients reported 
CRC in 29% (Kairupan, C.F. etal, 2005), 44% (Wang, L. etal, 2004), 50% 
(Sieber, O.M. etal, 2003), 62% (Isidro, G. etal, 2004) and 75% (Gismondi, V. et 
al, 2004) of MAP cases. This variability may be due to differences in 
ascertainment, the age of MAP patients, the number of cases who had 
undergone prophylactic surgery or the small numbers of cases identified in
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these studies (maximum 21 patients). CRC showed no preference for either 
sex (77/138 males, 61/99 females; p=0.370, chi squared test) and of the cases 
with CRC, 82% (113/138) had CRC at presentation whereas 25 patients 
developed CRC later. The mean age at CRC diagnosis was 48 years which is 
consistent with previous reports (Wang, L. etal, 2004; Gismondi, V. et al, 2004; 
Russell, A.M. etal, 2006; Bouguen, G etal, 2007; Croitoru, M.E. etal, 2007). A 
quarter of MAP patients with CRC were diagnosed at 45-49 years but the age at 
CRC diagnosis ranged from 21 to 70 years (Figure 4.8). The majority (80%) of 
MAP cases with CRC in the present study were diagnosed at an older age than 
classical FAP patients who usually develop CRC between the ages of 35 and 
40 years (Galiatsatos, P. & Foulkes, W.D., 2006). HNPCC patients are 
diagnosed with CRC at a mean age of 45 years (Lynch, H.T. etal, 2006) and 
AFAP cases typically develop CRC at a mean age of 50-55 years (Galiatsatos, 
P. & Foulkes, W.D., 2006) although unlike FAP, not all patients affected by 
either disease develop CRC within their lifetimes (Strate, L.L. & Syngal, S.,
2005). Classical FAP patients develop CRC earlier as adenoma initiation is 
quicker so many adenomas arise at an earlier age resulting in a high probability 
of progression to carcinoma, although the rate of progression is not accelerated 
in FAP. HNPCC has accelerated tumour progression but adenoma initiation 
occurs infrequently as this requires somatic mutation of a wild-type MMR allele 
followed by biallelic inactivation of a tumour suppressor. Adenoma initiation in 
MAP and AFAP is not as frequent or early as in classical FAP but it is possible 
that the BER defect in MAP may result in an increased risk of progression 
leading to an earlier onset of CRC than in typical AFAP.
Of the MAP patients diagnosed with CRC in the present study, 36% (49/138 
cases) had at least one synchronous or metachronous CRC. Two, three or four 
synchronous CRCs were identified in 26, 3 and 4 patients, respectively.
Sixteen cases had metachronous CRC, of whom three had two metachronous 
CRC. Several previous reports have also described MAP cases with more than 
one CRC (Lipton, L. etal, 2003; Gismondi, V. etal, 2004; Venesio, T. etal,
2004; Jo, W-S. etal, 2005; Lefevre, J.H. etal, 2006; Croitoru, M.E. etal, 2007). 
HNPCC patients are also at increased risk of synchronous and metachronous 
CRCs (Lynch, H.T. et al, 2006) and Vasen et al (2005) recently reported 18% of
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Figure 4.8 Age at CRC diagnosis of 138 MAP patients with CRC. A quarter of MAP cases with CRC were diagnosed between the ages of 
45 and 49 years. Only 5% of cases were diagnosed before the age of 35 years, the age at diagnosis ranged from 21 to 70 years.
133
cases with CRC had more than one CRC.
The 201 CRCs identified in 138 MAP patients in the present study were 
distributed between the left (42%) and right (51%) side of the colorectum 
(Figure 4.9) where the splenic flexure is counted as left-sided and the 
transverse colon is considered right-sided. This is in contrast to the report of 
Lipton et al (2003) who observed predominantly left-sided CRCs in MAP 
patients, although only 24 CRCs were analyzed. Distal (left-sided) CRCs are 
thought to be more likely to behave aggressively than proximal (right-sided) 
CRCs (Lynch, H.T. & de la Chapelle, A., 2003). Classical FAP CRCs show a 
left-sided predominance (Cao, Y. etal, 2002; Galiatsatos, P. & Foulkes, W.D.,
2006) whereas more AFAP and HNPCC CRCs are right-sided (Cao, Y. et al, 
2002; Strate, L.L. & Syngal, S., 2005; Lynch, H.T. etal, 2006; Mecklin, J-P. et 
al, 2007). Twenty-three percent (47/201) of CRCs in MAP patients in the 
present study were located in the rectum or rectosigmoid. This is a lower 
proportion than previously reported in MAP patients (Lipton, L. et al, 2003; Jo, 
W-S. etal, 2005; Kanter-Smoler, G. etal, 2006; Lefevre, J.H. etal, 2006; 
Croitoru, M.E. etal, 2007). Rectal cancer is also observed in FAP patients 
(Cao, Y. et al, 2002) but is rarely seen in AFAP (Lyster Knudsen, A. et al, 2003) 
or HNPCC cases (Mecklin, J-P. etal, 2007).
Forty-one of the 237 MAP cases were deceased; 26 (63%) died from CRC, two 
died from gastric cancer, one from laryngeal cancer, four died from causes 
other than cancer and the cause of death was unknown in 8 cases.
4.3.7.2 Extracolonic manifestations
Each of the three centres collected retrospective data on extracolonic 
manifestations that had been identified previously in the 237 MAP patients 
(Table 4.6) so the results presented here can only be viewed as preliminary 
data as not all patients had undergone a thorough assessment. As in FAP, 
duodenal and gastric polyps were the most frequently occurring extracolonic 
manifestations (Table 4.6) but had been previously reported in less than ten 
MAP patients (Sieber, O.M etal, 2003; Jo, W-S. etal, 2005; Kanter-Smoler, G. 
etal, 2006; Lejeune, S. etal, 2006; Bouguen, G. etal, 2007; Olschwang, S. et
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A)
Left-sided Unknown Right-sided
B)
Rectum/
Rectosigmoid (23%) Unknown
(7%)
Colon (69%)
Figure 4.9 Location of 201 CRCs identified in 138 MAP cases. A) Proportion 
of left- and right-sided CRCs, B) Proportion of CRCs located in the colon or the 
rectum/rectosigmoid. CRC location data were not available for 15 of the 201 
CRCs.
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Extracolonic manifestation No. of patients
Proportion of 
patients 
(%)
Mean age at 
diagnosis 
(yrs)
M:F
ratio
Gl tract
Appendix carcinoid tumour 2 0.8 46 0:2
Duodenal polyps 25 11 47 10:15
Jejunal polyps 1 0.4 44 0:1
Duodenal cancer 2 0.8 61 2:0
Ileum cancer 2 0.8 53 2:0
Small intestine carcinoid tumour 2 0.8 70 1:1
All gastric polyps 15 6 50 9:6
Gastric adenomas 3 1 38 2:1
Fundic gland polyps 10 4 52 4:6
Gastric polyps with unknown histology 5 2 47 4:1
Gastric cancer 3 1 34 2:1
Skin lesions
Basal cell carcinoma (M) 7 3 55 4:3
Melanoma (M) 2 0.8 31 1:1
Squamous cell carcinoma (M) 2 0.8 64 1:1
Sebaceous gland epithelioma (M) 1 0.4 51 1:0
Sebaceous gland hyperplasia (B) 4 2 41 3:1
Sebaceous gland adenomas (B) 4 2 40 3:1
Steatocystoma (B) 1 0.4 Unknown 1:0
Actinic keratoses (pre-malignant) 2 0.8 46 2:0
Epidermoid cyst (B) 5 2 50 2:3
Follicle cyst formation with branches (B) 1 0.4 38 1:0
Seborrhoeic wart (B) 1 0.4 53 1:0
Lipoma (B) 7 3 41 2:5
Pilar cyst (B) 1 0.4 50 1:0
Dermatofibroma (B) 1 0.4 54 0:1
Naevus naevocellularis pigmentosus (B) 2 0.8 36 1:1
Pigmented spots (B) 1 0.4 Unknown 1:0
Verruca vulgaris (B) 1 0.4 60 1:0
Skin lesions of unknown histology 8 3 40 6:2
Other cancers
Breast cancer 9 4 57 1:8
Bladder cancer 4 2 58 3:1
Laryngeal cancer 1 0.4 57 1:0
Prostate cancer 1 0.4 62 1:0
Teratoma 2 0.8 31 1:1
Testicular cancer 1 0.4 41 1:0
Thyroid cancer 1 0.4 38 0:1
Cervical cancer 1 0.4 39 0:1
Gangliocytoma 1 0.4 52 0:1
Lymphoma 1 0.4 46 1:0
Ovarian cancer 1 0.4 56 0:1
Endometrial cancer 1 0.4 54 0:1
Oesophageal cancer 1 0.4 59 2:0
Soft palate cancer 1 0.4 46 1:0
Table 4.6 Retrospective identification of extracolonic manifestations in 237 MAP 
cases. The most frequent extracolonic manifestations are duodenal and gastric 
polyps. Several cancers other than CRC have been diagnosed in MAP patients. 
Additional benign lesions assumed to be of no clinical importance and patient 
identifiers are shown in appendix Table III. B; benign, M; malignant.
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al, 2007). The small number of MAP patients reported to have upper Gl polyps 
may reflect a lack of routine upper Gl screening or the identification of relatively 
few MAP cases in previous studies. A single patient has been described as 
having jejunal polyps (Lejeune, S. et al, 2006) and one further case was 
identified in the present study. Small intestine carcinoma is rare in the general 
population, accounting for 0.4% of new cancer cases in the U.S in 2005 (Jemal, 
A. et al, 2005) but four cases (two duodenal and two ileal) were identified in the 
present study (Table 4.6) and two have been previously reported (Kumar,
V.K.A. et al, 2007; Olschwang, S. et al, 2007). FAP and HNPCC are associated 
with small bowel cancer (Galiatsatos, P. & Foulkes, W.D., 2006; Vasen, H.F.A.,
2005). Gastric carcinoma has been reported in a single case with biallelic 
MUTYH mutations (Olschwang, S. et al, 2007) and three patients in the present 
study were diagnosed at 48, 38 and 17 years (Table 4.6). However, the 
youngest case also harboured a germline mutation in E-cadherin and mutations 
in this gene have been identified in familial gastric cancer (Guilford, P. et al, 
1998). Two MAP patients in the present study had a small intestine carcinoid 
tumour and two had a carcinoid tumour of the appendix (Table 4.6). Carcinoid 
tumours have not been described before in MAP cases and are rare in the 
general population but are most commonly found in these locations (Cancer 
Research UK). Larger studies are required to investigate the possibility of an 
aetiological association.
Epidermoid cysts, lipomas and fibromas are skin lesions associated with the 
FAP variant Gardner’s syndrome (Galiatsatos, P. & Foulkes, W.D., 2006) but 
they are also common in the general population (Burns, T. et al, 2004) and were 
identified in 5, 7 and 1 MAP patients in the present study, respectively (Table 
4.6). Dermoid and epidermoid cysts have been previously described in one and 
two MAP cases, respectively (Wang, L etal, 2004; Kairupan, C.F. etal, 2005; 
Gismondi, V. et al, 2004). Patients affected by the HNPCC variant Muir Torre 
syndrome have sebaceous adenomas or carcinomas (Lynch, H.T. etal, 2006). 
Four MAP cases with sebaceous adenomas and a single case with sebaceous 
epithelioma were identified in the present study (Table 4.6). Two MAP patients 
have been previously reported to have sebaceous adenomas (Ponti, G. et al, 
2005; Kumar, V.K.A. et al, 2007) and a single case with sebaceous carcinoma
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(Barnetson, R.A. et al, 2007). Both lesions are rare, with sebaceous 
carcinomas accounting for less than 1 % of all skin malignancies (Burns, T. et al, 
2004). Sebaceous gland hyperplasia was identified in four MAP cases in the 
present study (Table 4.6) but occurs in 1% of healthy individuals (Ponti G. et al, 
2007) and is generally considered of no clinical importance (Burns, T. et al, 
2004). However, Ponti et al (2007) recently detected BRAF mutations in 
sebaceous hyperplasias from MAP cases and mutations in this gene are linked 
to tumourigenesis in some skin tumours although the mutation detected was a 
T>A not G>T change. A single case in the present study had been diagnosed 
with steatocystoma which also affects the sebaceous glands. Further studies 
of sebaceous gland tumourigenesis are warranted in MAP. Malignant 
melanoma and squamous cell carcinoma were each identified in two MAP 
cases and basal cell carcinoma (BCC) was found in seven MAP patients in the 
present study (Table 4.6). Melanoma has been previously reported in a single 
MAP case (Enholm, S. et al, 2003) as has BCC (Olschwang, S. et al, 2007) but 
these and squamous cell carcinoma are common cancers and there is 
insufficient information at present to confirm an association with MAP. The only 
other skin lesions reported in MAP cases are pilomatricomas which were 
identified in a single kindred (Baglioni, S. et al, 2005). Two cases in the present 
study had pre-malignant actinic keratoses, seven patients had a range of 
benign skin lesions and eight cases had skin lesions of unknown histology 
(Table 4.6).
A germline defect in the critical BER repair pathway might be expected to give 
rise to tumours in many organs, as is seen in cases with defective MMR in 
HNPCC. Most extracolonic cancers were identified in only one or two MAP 
patients in the present study (Table 4.6) and overall 49 malignant lesions (other 
than CRC) were reported in 237 cases (21%) suggesting that these 
malignancies are not commonly observed in MAP and may just reflect the 1 in 3 
population risk of cancer (Cancer Research UK). However, not all MAP 
patients in the present study have lived through their lifetime cancer risk and 
some may have died from CRC before other cancers had the time to develop. 
The present study of extracolonic manifestations in MAP patients is the largest 
to date as only case reports of extraintestinal cancers have been described
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previously which cannot inform the clinical management of MAP. Single cases 
of cervical cancer (Alhopuro, P. et al, 2005), uterine cancer (Olschwang, S. et 
al, 2007), endometrial cancer (Barnetson, R.A. etal, 2007), thyroid cancer 
(Ponti G. etal, 2005), leukaemia (Croitoru, M.E. etal, 2007), sarcoma 
(Balaguer, F. etal, 2007) and carcinoma of the ampulla of Vater (Croitoru, M.E. 
et al, 2007) have been described in patients with biallelic MUTYH mutations. A 
central nervous system carcinoma was described by Olschwang et al (2007) 
and a schwannoma was reported in a single MAP case (Croitoru, M.E. etal,
2007). Bladder cancer has not been previously reported in MAP cases but 
three urothelial and one squamous cell bladder carcinoma were identified in 
four patients in the present study (Table 4.6). Two of the cases with urothelial 
cancer were siblings so additional genetic factors may have contributed to their 
development. Breast cancer was the most frequent extracolonic cancer in the 
present study, affecting 8% (8/99) of female MAP patients at a mean age of 57 
years and a single male case aged 56 years. This cancer has also been 
previously reported in four MAP cases (Isidro, G. et al, 2004; Jo, W-S. et al, 
2005; Balaguer, F. etal, 2007; Olschwang, S. etal, 2007). One in nine women 
(11%) will develop breast cancer during their lifetime and eight out of ten cases 
are diagnosed aged 50 years or over (Cancer Research UK). The earliest 
diagnosis of breast cancer in the present study was 45 years and 75% (6/8) of 
cases were diagnosed aged 50 years or over so there is no conclusive 
evidence that MAP patients are at increased risk of developing early breast 
cancer as is the case in Muir Torre syndrome (Strate, L.L. & Syngal, S., 2005). 
Unlike HNPCC and FAP, current data does not suggest that MAP confers an 
increased risk of cancer outside the Gl tract.
The phenotypic similarities between MAP and FAP extend beyond the 
colorectum and upper Gl tract in a few cases and may reflect the common 
inactivation of APC during tumourigenesis. A benign bone tumour was 
described in a single patient in the present study and osteomas have been 
reported in two other MAP patients (Gismondi, V. et al, 2004). Four cases in 
the present study had jaw-bone cysts at a mean age of 17 years and dental or 
jaw abnormalities have been described in three other MAP patients (Gismondi, 
V. etal, 2004; Lejeune, S. etal, 2006; Kairupan, C.F. etal, 2006). CHRPE was
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not identified in the present study but has been previously reported in some 
MAP cases (Sieber, O.M. etal, 2003; Gismondi, V. etal, 2004; Jo, W-S. etal, 
2005; Lefevre, J.H. etal, 2006).
4.3.8 Genotype-phenotype relationship
The most frequently mutated alleles in our 237 MAP cases were Y176C and 
G383D. To investigate if these mutations differed in their phenotypic effect, the 
colorectal phenotypes of Y176C homozygotes (55 cases), G393D homozygotes 
(20 cases) and Y176C/G393D compound heterozygotes (59 cases) were 
compared (Table 4.7). The mean age at presentation was inversely correlated 
with the number of Y176C alleles (p=0.003, linear regression) and although the 
proportion of patients with CRC was not significantly different between the three 
genotypes (p=0.087, chi squared test 2 degrees of freedom), the mean age at 
CRC diagnosis was also inversely correlated with the number of Y176C alleles 
(p<0.001, linear regression). Farrington et al (2005) reported CRC in all G393D 
homozygotes, but only by the age of 65 years and biallelic Y176C mutations 
have been previously suggested to have a greater effect on CRC risk than 
biallelic G393D mutations, although the difference was not statistically 
significant (Tenesa, A. etal, 2006). In the present study, the proportion of 
patients with less than ten polyps significantly increased as the number of 
Y176C alleles decreased (p=0.016, chi-squared Test for Trend in proportions, 1 
degree of freedom), but there was little difference in the proportion of cases with 
10-99 or 100-1000 colorectal polyps between the three genotypes and numeric 
counts were not available for all cases. CRC was distributed similarly between 
the left- and right-side of the colorectum in the three genotype groups and 
although no rectal cancer was seen in G393D homozygotes, only ten CRCs had 
been diagnosed in these cases and the same proportion of rectal cancer was 
seen in Y176C homozygotes as compound heterozygotes. Balaguer et al 
(2007) reported Y176C carriers (homozygotes and heterozygotes) were 
diagnosed with CRC at a younger age and had more adenomas and right-sided 
CRCs than CRC patients who did not carry this mutant allele. The differences 
observed between the three genotypes in the present study could be a result of 
the different effects these mutations have on the MUTYH protein. As described 
above, Y176C is thought to have a more detrimental effect on MUTYH
140
Genotype/ 
no. truncating 
alleles
No. MAP 
patients M:F
Mean age at 
presentation 
(yrs) ± SD <10
Polyp count
10-99 100-1000
Proportion 
of cases 
with CRC
Age at CRC 
diagnosis 
(yrs) 
mean ± SD 
(range)
Colon
Location CRC
Rectum sided
Right­
sided
1/55* 27/55 12/55 38/55 47 ± 6** 43/60 17/60 25/60 35/60
Y176C/Y176C 55 33:22 43 ± 8**
(2%) (49%) (22%) (69%) (30-65) (72%) (28%) (42%) (58%)
7/59* 29/59 13/59 31/59 51 ± 10** 31/43 12/43 21/43 22/43Y176C/G393D 59 37:22 48 ± 11**
(12%) (49%) (22%) (53%) (30-67) (72%) (28%) (49%) (51%)
4/20* 10/20 3/20 9/20 58 ± 9** 10/10 3/10 7/10
G393D/G393D 20 12:8 50 ± 12** 0
(20%) (50%) (15%) (45%) (37-70) (100%) (30%) (70%)
14/172 88/172 35/172 102/172 49 ±9 106/142 36/142 64/142 78/142
0 172 102:70 45 ±10
(8%) (51%) (20%) (59%) (29-70) (75%) (25%) (45%) (55%)
22/44 9/44 25/44 46 ±9 25/31 6/31 14/31 17/31
1 44 22:22 43 ±10 0
(50%) (20%) (57%) (21-68) (81%) (19%) (45%) (55%)
9/21 10/21* 11/21 50 ± 11 8/13 5/13 6/13 7/13
2 21 14:7 46 ±9 0
(43%) (48%) (52%) (36-66) (62%) (38%) (46%) (54%)
Table 4.7 Colorectal phenotype of MAP cases according to genotype. Cases homozygous or compound heterozygous for the most 
frequently mutated alleles Y176C and G393D were analyzed for phenotypic differences (top of table). All 237 cases were divided into groups 
determined by the number of truncating alleles they carried; 0,1 or 2 and were analyzed separately (bottom of table). SD, standard deviation. 
*p<0.05, chi squared test; **p<0.005, linear regression.
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glycosylase activity than G393D and whereas mutant G393D MUTYH protein is 
found at wild-type levels in cells derived from a G393D homozygous patient, 
cells derived from a Y176C homozygous patient have lower levels of mutant 
MUTYH protein (Parker, A.R. et al, 2005). This more severe defect in BER 
resulting from Y176C mutations could explain the inverse correlation between 
age at onset of CRC and number of Y176C alleles as the mutation rate in cells 
would be expected to increase with number of Y176C alleles thus increasing 
the chance of mutations needed for tumourigenesis.
A milder disease in G393D homozygotes may explain why this genotype was 
identified much less frequently than homozygosity for Y176C in index cases 
from each of the three centres in the present study, despite the G393D mutant 
allele being approximately twice as frequent as Y176C in healthy individuals 
(Croitoru, M.E. etal, 2004; Farrington, S.M. etal, 2005; Peterlongo, P. etal, 
2006; Tenesa, A. et al, 2006; Webb, E.L. et al, 2006). The vast majority of 
index cases in the present study were referred from colorectal polyposis 
registers and it could be that because G393D homozygotes appear to present 
later and may have fewer colorectal polyps, they are not being referred to such 
registers.
The colorectal phenotype of MAP patients was also analyzed according to how 
many of their biallelic germline MUTYH mutations were predicted to truncate the 
MUTYH protein; none, one or two. Truncating mutations included nonsense, 
frameshift and splice site mutations whereas non-truncating mutations 
comprised missense, in-frame insertion and in-frame deletion mutations. No 
significant differences were observed in mean age at presentation (p=0.485, 
ANOVA) or mean age at CRC diagnosis (p=0.547, ANOVA) between MAP case 
with none, one or two truncating alleles. Only patients with no truncating alleles 
were found to harbour less than ten colorectal polyps whereas similar 
proportions of MAP cases with 10-99 polyps were identified in all three groups. 
Twenty percent of patients carrying either one or no truncating alleles had 100- 
1000 colorectal polyps but a significantly higher proportion of patients with two 
truncating alleles (10/21 vs 44/216, p=0.008 Fisher’s exact test) showed this 
more severe phenotype. However, 26% of MAP cases did not have a
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numerical polyp count and the number of cases with no truncating alleles was 
eight times the number of patients with two truncating alleles. A similar 
proportion of MAP cases developed CRC in the three groups and the proportion 
of rectal cancer was not significantly different in cases with one, two or no 
truncating alleles (p=0.412, chi squared test 2 degrees of freedom). From the 
present study it appears that the number of truncating MUTYH alleles a patient 
carries cannot be correlated with disease severity.
MAP patients with identical MUTYH mutations showed phenotypic variability in 
the present study; one Y176C/G393D compound heterozygote had CRC and 
100-1000 polyps aged 38 years yet another patient with the same genotype 
developed less than ten polyps without cancer aged 52 years. Intrafamilial 
variation was also seen in the present study and has been previously reported 
(Raoof, M. et al, 2007). This suggests that as for other colorectal cancer 
syndromes, additional genetic or environmental factors are modifying the MAP 
phenotype (Crabtree, M.D. etal, 2002).
4.3.9 Management of MAP patients
The present study confirmed that Y176C and G393D are the most frequently 
mutated MUTYH alleles in three European countries. Molecular genetic 
services specifically screen for these mutations but currently not all offer 
comprehensive screening for mutations. Seventeen percent of MAP cases 
identified in the present study did not carry either of these more common 
mutations and would not have been detected unless a full gene screen was 
undertaken. Similarly, 29% of MAP patients only carried Y176C or G393D in 
combination with a less frequent mutation so would have been classed as 
heterozygotes, with implications for surveillance of these patients. The very 
wide spectrum of mutations already identified in cases with MAP suggests that 
sequencing of the entire MUTYH ORF is justified. This will identify mutations of 
uncertain significance and functional analysis will be important in discriminating 
between pathogenic and non-pathogenic changes.
As for FAP, endoscopic surveillance in affected or at-risk individuals could begin 
in their second decade as only a single MAP case presented symptomatically
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before the age of 20 years in the present study but should continue until late in 
life as a patient in the present study was diagnosed with CRC aged 70 years. 
Most CRC was diagnosed at presentation so earlier screening and prophylactic 
surgery should reduce the CRC mortality in MAP patients. Upper Gl screening 
could be worthwhile in MAP cases as several of the patients who had 
undergone such screening in the present study were found to harbour either 
duodenal or gastric polyps and a small number of cases were diagnosed with 
carcinoma of the small intestine or stomach. Also of note were the four cases 
of intestinal carcinoid tumours but larger numbers of cases are needed before 
an association with MAP can be confirmed. MAP patients may also be at 
increased risk of sebaceous adenomas but a thorough assessment of skin 
lesions in more cases is needed to assess this. Although prospective studies 
are indicated, this retrospective study provides reassurance that systematic 
screening outside the Gl tract is unlikely to be needed in MAP.
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Chapter Five
Mortality and cancer risk in monoallelic MUTYH mutation carriers
5.1 Introduction
Since the identification of MAP by Al-Tassan et al in 2002, several studies have 
undertaken germline MUTYH mutation analysis in unrelated colorectal 
polyposis patients. Many have reported monoallelic MUTYH mutations in a 
small number of cases without pathogenic APC mutations (Sieber, O.M. et al, 
2003; Aceto, G. etal, 2005; Nielsen, M. etal, 2005; Aretz, S. etal, 2006; 
Russell, A.M. et al, 2006; chapter four). The clinical significance of carrying a 
single MUTYH mutation is unclear at present as each of the two most common 
MUTYH mutations (Y176C and G393D) are also found as heterozygous 
changes in healthy individuals at a combined minor allele frequency of 
approximately 1% in non-Asians (Croitoru, M.E. etal, 2004; Farrington, S.M. et 
al, 2005; Peterlongo, P. etal, 2006; Tenesa, A. etal, 2006; Webb, E.L. etal,
2006).
Case-control studies in cohorts of CRC patients have described an over­
representation of heterozygous carriers in CRC cases (Croitoru, M.E. etal, 
2004; Fleischmann, C. etal, 2004; Farrington, S.M. etal, 2005; Zhou, X-L. etal, 
2005; Colebatch, A. etal, 2006; Peterlongo, P. etal, 2006; Kury, S. etal, 2007) 
but independent statistical significance was reached in just two studies, and 
then only by considering G393D status in CRC cases and controls over the age 
of 55 years (Farrington, S.M. et al, 2005) or CRC cases from MMR gene 
mutation-negative HNPCC-like families (Peterlongo, P. et al, 2006). Results 
from case-control studies investigating MUTYH heterozygote CRC risk may not 
reach statistical significance because of the large samples size required. Webb 
et al (2006) estimated that 22000 cases and 22000 controls would be required 
to reliably detect a relative risk of 1.2 due to a low penetrance allele with a 
population frequency of less than 2%. In this study I used a kin-cohort 
approach to assess cancer risk and mortality in obligate MUTYH heterozygotes, 
the majority of whom had lived through their lifetime CRC risk. Clarification of 
whether or not monoallelic MUTYH mutation carriers have an increased risk of
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CRC is important for the genetic counselling and clinical management of these 
individuals and their families.
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5.2 Methods
As described in section 4.2.1, a collaborative project was established between 
The Institute of Medical Genetics (IMG), Cardiff, The Institute of Human 
Genetics, Bonn and The Centre of Human and Clinical Genetics, Leiden which 
resulted in a cohort of 182 unrelated MAP index cases. The present study 
aimed to gather all-cause mortality and cancer incidence and mortality data on 
the obligate MUTYH heterozygote parents of these MAP index cases. All of the 
index cases came to medical attention through symptomatic presentation of 
polyposis or CRC or (in 16 cases) through population screening programmes, 
and none because of their family history.
5.2.1 Study approval
As shown in Figure 5.1, several stages of application were necessary for 
approval of the ‘Investigating cancer risk in people with MUTYH gene changes’ 
study in the UK. An honorary NHS contract was obtained for the duration of the 
study as handling identifiable patient data was involved. Cardiff University 
agreed to act as sponsor (ref. SPON CU 237) and the MREC for Wales gave 
ethical approval (ref. 06/MRE09/19). As the study also involved other centres in 
the UK (Birmingham, Manchester and Southampton), once MREC approval had 
been received a site-specific assessment application was made to each of the 
LRECs with the help of the principal investigator (PI) at each centre (Prof. E. 
Maher, Prof. D.G.R. Evans, Prof. D. Eccles). This was followed by applications 
for study approval from the Research and Development (R&D) departments of 
NHS Trusts covering the centres involved with the help of Pis.
Protocols for obtaining informed consent in the Netherlands were approved by 
local ethics review boards and the ethics committee of the University of Bonn 
approved the German part of the study.
5.2.2 Clinical information and samples
Biallelic MUTYH mutations had been identified in 54 apparently unrelated index 
cases referred from Regional Clinical Genetics Services, Regional Polyposis 
Registers and Gastroenterology departments to AWMGS for MUTYH germline 
mutation analysis. These results had been reported back to clinical geneticists
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MREC for Wales approval
Honorary NHS contract 
obtained
Cardiff University agreed 
to act as sponsor
South East 
Wales REC 
approval
Central 
Manchester 
REC approval
South 
Birmingham 
REC approval
Southampton 
and South West 
Hampshire REC 
approval
Cardiff and 
Vale NHS trust 
R&D approval
Birmingham 
Woman’s 
Health Care 
NHS trust R&D 
approval
Southampton 
University 
Hospitals NHS 
trust R&D 
approval
Central 
Manchester & 
Manchester 
Children’s 
University 
Hospital NHS 
trust R&D 
approval
Figure 5.1 Approval of the Investigating cancer risk in people with MUTYH 
gene changes’ study in the UK. Ethics committee and NHS Trust R&D 
approval was obtained for each research site with the aid of the PI at each 
centre.
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at the Regional Genetics Services (RGSs) and discussed with the patients 
concerned. As MAP index cases usually present in the age range 40-70 years 
it was anticipated that the majority of their obligate MUTYH mutation 
heterozygote parents would be deceased. Information about these monoallelic 
carriers was obtained through RGSs, MAP index cases, or the siblings, spouses 
or adult offspring of the MAP index case as shown in Figure 5.2 (forms shown in 
appendix). Medical and family history details for 7 MAP index cases had 
already been obtained for a previous study (Sampson, J.R. et al, 2003) and no 
further details were sought. Informed consent for the release of medical and 
family history details from 41 patients or consenting relatives was obtained 
through recruitment into the ‘Investigating cancer risk in people with MUTYH 
gene changes’ study or the ‘Genes and Multiple Colorectal Adenomas- The 
Polyp Study’ (MREC for Wales ref. 02/9/22). Causes of death were confirmed 
with death certificates and cancer diagnoses were verified with Regional Cancer 
Registries when possible. If a parent had been diagnosed with CRC, pathology 
details along with the date and hospital where any surgery for this cancer took 
place were requested from the Regional Genetics Service. Again, this 
information was not frequently known to the Regional Genetics Service and was 
therefore requested from the MAP index case or consenting relative via a 
questionnaire. These details were then obtained from the relevant hospital 
records. Consent to obtain tissue blocks already stored was obtained from the 
MAP patient or consenting relative then a request was sent to the pathology 
department at the appropriate hospital for their release (Figure 5.2).
The Institute of Human Genetics, Bonn and The Centre of Human and Clinical 
Genetics, Leiden identified 73 and 55 unrelated MAP index cases, respectively. 
These centres obtained clinical information about the monoallelic mutation 
carrier parents of 71 and 55 MAP index cases, respectively, from relatives 
and/or hospital records. Causes of death were confirmed with death certificates 
and cancer diagnoses were verified with hospital records when possible. If a 
parent had been affected by CRC and comprehensive MUTYH mutation 
analysis had not been previously undertaken, a request was sent to the 
pathology department at the appropriate hospital to obtain tissue blocks from 
their CRC surgery. Division of work is shown in Figure I in the appendix.
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CRC Other cancer
Parent deceased Parent alive
No record of 
cancer in parent
Record of cancer 
in parent
Tissue blocks requested
Surgery details 
obtained from RGS
Cause of death 
confirmed with 
death certificate
Consent from MAP 
index case or relative
Clinical information 
obtained from RGS
Consent from MAP 
index case or relative
Confirmation of 
cancer diagnosis 
with Regional 
Cancer Registry
Additional information 
obtained from MAP 
index case or 
consenting relative via 
questionnaire
Additional information 
obtained from MAP 
index case or 
consenting relative via 
questionnaire
Figure 5.2 Protocol for obtaining clinical information about obligate MUTYH 
mutation heterozygote parents and tissue blocks from CRC surgery. RGS, 
Regional Genetics Service.
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5.2.3 Screening for mutations in MUTYH
To exclude the possibility that any of the parents affected by CRC carried 
biallelic MUTYH mutations, I extracted DNA from cores of paraffin-embedded 
non-cancerous tissue taken at surgery for CRC as described in section 2.6.2.1.
I PCR amplified exons 1-16 of MUTYH as 21 fragments (Table 5.1) and 
screened for mutations using automated sequencing (Figure I).
5.2.4 Population data and statistical analysis
Cancer incidence and mortality and overall mortality in monoallelic MUTYH 
mutation carriers were compared with nation, sex, age and date-specific 
population rates (5 year intervals). Table 5.2 shows the periods of time for 
which these population data were available for the different countries. The data 
for England and Wales were obtained by Dr. P. Wark from The Office of 
National Statistics, Dutch data were requested by Dr. F.J. Hes from the 
Eindhoven Cancer Registry and Dr. S. Vogt obtained German data from the 
Saarland Cancer Registry (Figure I). The ICD codes used to select appropriate 
data for CRC and all cancer incidence and mortality rates in the different 
countries are shown in Table 5.3.
Exact standardized mortality ratios (SMRs), exact standardized incidence ratios 
(SIRs) and their exact confidence intervals (CIs) were calculated using Stata 
version 9 (Stata Corporation, USA) and the smri function programmed by P. 
Sasieni. If dates of birth (DOBs), dates of death (DODs) or dates of cancer 
diagnoses of monoallelic MUTYH mutation carriers were incomplete, certain 
assumptions were made so that the data could be used for SMR and SIR 
calculations. If the month and year were available, the day was assumed to be 
the 15th and if only the year was given, the day and month were assumed to be 
the 30th June. If the date of an event was incomplete but the age of the carrier 
at this event was known, the mid-point of the possible time period was used.
The chi-squared test was used to assess the significance of SIRs. Univariate 
ANOVA (Analysis of Variance) was used to compare the mean ages at CRC 
diagnosis between MAP patients (chapter 4) and MUTYH mutation 
heterozygotes. Fisher’s exact test was used to assess the difference in 
proportions of monoallelic mutation carriers excluded for the CRC SIR analysis.
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Primer name Primer sequence (5’—>3’)
Annealing 
temperature (°C)
Product 
size (bp)
MYHxIF* GAAGCTGCGGGAGCTGAAA 60 133MYHxl R* AT CCCCG ACT GCCT GAACC
MYHx2F* CTGCATTTGGCTGGGTCTTT 55 172MYHx2R TGGGCCACAACCTAGTTCC
MYHX3.1F CCAAGACCCT GATGCACAG 58 155MYHx3.1R CCTCGGAAGGCTGTGACTT
MYHX3.2F AGCCGG AAG AGGT GGTATT G 58 216MYHX3.2R CAACCCCAGATGAGGAGTTAGG
MYHx4F* CT CAT CT GGGGTTGC ATT G A 58 167MYHx4R* GGGTT GGCAT G AGGACACT G
MYHx5F* GGGCAGGT CAGCAGT GT C 58 189MYHx5R* TACACCCACCCCAAAGTAGA
MYHx6F* TACTTTGGGGTGGGTGTAGA 58 185MYHx6R* AAGAGAT CACCCGT CAGT CC
MYHx7(1)F CACCCTAGGGTAGGGGAAAT 58 182MYHx7(1)R ACTCCTGGGGTTCCTACCCT
MYHx8F CCAGGAGTCTTGGGTGTCTTAT 58 200MYHx8R CT GGGCACGCACAAAGT G
MYHx9F* AACTCTTTGGCCCCT CT GT G 58 196MYHx9R* GAAGGGAACACT GCT GT GAAG
MYHxl 0.1F AAGGGT GCTT CAGGGGT GT C 58 156MYHxl 0.1R GCGCT GTGGGGTACACACT G
MYHxl 0.2F AGCCCGGCCAGGAGATTT 58 171MYHxl 0.2R AGGGCAGAGTCACTCCTTAGGAC
MYHxl 1(1 )F GAAGGGGCAGTGAGAAGTCC 58 176MYHxl 1(1 )R CTGACTGGGCCAGGAAGGGT
MYHxl 2.1F AGCCCT CTT GGCTT GAGTA 58 188MYHxl 2.1R CCAGGCT GTT CCAG AACAC
MYHxl 2.2(1 )F GGG ACC AG ACCCT GGG AGT G 58 200MYHxl 2.2(1 )R CT GCCG ATT CCCT CCATT CT C
MYHxl 3.1F AGGGCAGT GGCAT GAGTAACA 58 150MYHxl 3.1R TT GCGCT GAAGCTGCTCTG
MYHxl 3.2F T GGCAGGACT GT GGGAGTT 58 177MYHxl 3.2R ATAGCCT CAAAAGCCAACAT C
MYHxl 4.1F T 1GGCTTTTGAGGCTATATCC 58 147MYHxl 4.1R CTGGTGGTACGGTGGTCAC
MYHX14.2F CAGGTT GT CCAC ACCTT CT C 58 128MYHx14.2R CAT GTAGGAAACACAAGGAAGTA
MYHxl 5(1 )F CT CACCT CCCTGT CTT CTT G 58 180MYHxl 5(1 )R CCAGT G AAGCCT GG AGT GG A
MYHxl 6F GGCCT CCCT CCTT CCATTT 58 182MYHxl 6R GGGAATGGGGGCTTTCAGA
Table 5.1 Sequences of primers and PCR conditions used to screen MUTYH.
*Primers published by Al-Tassan, N. et al, 2002. Forty cycles instead of the standard 
35 cycles of PCR were used.
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Rate England & Wales The Netherlands Germany
CRC incidence 1971-2003 1960-2006 1970-2005
All cancer incidence 1971-2003 1960-2006 1970-2005
CRC mortality 1940-2005 1970-2006 1970-2005
All cancer mortality 1940-2005 1970-2006 1970-2005
All cause mortality 1901-2005 1970-2006 1970-2005
Table 5.2 Time periods for which incidence and mortality rates were used in the 
present study. Mortality data were available before 1940 in England and Wales but 
were not used for CRC or all cancer mortality rates as the data were not classified 
clearly enough. Similarly, some earlier mortality and incidence data from Germany was 
provided but was not classified clearly enough and was not sufficiently divided into age 
groups to be used for determination of CRC or all cancer mortality or incidence rates in 
the present study. For all other rates, no earlier data could be provided.
Cancer England & Wales The Netherlands Germany
CRC
ICD5: 46c, 46d 
ICD6:153, 154 
ICD7: 153.0-153.8, 154 
ICD8: 153.0-153.8, 154 
ICD9: 153, 154 
ICD10: C18-C21
ICD8: 153, 154 
ICD9: 153, 154 
ICD10: C18-C20
ICD8: 153, 154 
ICD9: 153, 154 
ICD10: C18-C20
All
cancer
ICD5: 45-55
ICD6: 140-190, 192-205 
ICD7: 140-190, 192-207 
ICD8: 140-172, 173.5, 
174-207
ICD9: 140-172, 174-208 
ICD10: COO-43, C45- 
C85, C88-C94.3, C94.7- 
C97.9, D32.0-D33.9, 
D38, D42.0-43.9
ICD8: 140-208
ICD9: 140-208 
ICD10: all C codes
ICD8: 140-172, 174-203
ICD9: 140-172, 174-203 
ICD10: all C codes
Table 5.3 ICD codes used to select appropriate data for CRC and all cancer 
incidence and mortality rates. ICD codes 5, 6, 7, 8, 9 & 10 cover time periods 1940- 
1949, 1950-1957,1958-1967, 1968-1978, 1979-2000, 2001-present, respectively.
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5.3 Results
5.3.1 Data collection
Mortality and cancer data for the parents of 48, 55 and 71 MAP index patients 
were collected by the Cardiff, Leiden and Bonn centres, respectively. Two 
families from the Netherlands and one family from Germany were already 
known to have two consecutive generations affected by MAP with characterized 
biallelic mutations in both generations and so data for an additional obligate 
MUTYH mutation heterozygote parent were obtained from each of these 
families (parents and spouses of the affected individual in the first generation).
In total, data were collected for 351 apparent monoallelic MUTYH mutation 
carrier parents.
5.3.2 CRC risk in MUTYH mutation heterozygotes
5.3.2.1 Verification of MUTYH mutation status in CRC cases 
Twenty-two parents of MAP index cases had been diagnosed with CRC, of 
whom one was already known to be a MUTYH mutation heterozygote through 
previous molecular genetic analysis. To assess whether other parents with 
CRC were biallelic MUTYH mutation carriers, attempts were made to obtain 
non-cancerous tissue blocks from their CRC surgery (if undertaken). Tissue 
blocks were obtained for all four of the UK CRC cases, four of the eight Dutch 
CRC cases of unknown mutation status and one of the nine German CRC 
patients of unknown mutation status.
MUTYH ORF sequencing of DNA extracted from non-cancerous tissue cores 
revealed biallelic mutations in the single German sample (i.e. 1 of 9 cases with 
tissue identified and 1 of 7 in which at least some molecular analysis was 
possible). This patient was a P154L homozygote and therefore excluded from 
the study, bringing the monoallelic MUTYH mutation carrier total to 350. A 
heterozygous Y176C mutation was identified in four CRC cases, two of which 
were screened for all exons and the other two were screened for all exons 
except exon 4 due to an insufficient quantity of DNA. Two CRC patients 
harboured a heterozygous G393D mutation, of which one was screened for all 
exons and the other was screened for all exons except exons 5, 12 and 14 due 
to an insufficient quantity of DNA. Amplification of DNA extracted from the
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remaining two tissue blocks failed for all MUTYH exons. One of these blocks 
had a very small amount of tissue which was mainly fat cells and the other 
tissue block had been stained which could have interfered with the extraction or 
amplification process.
5.3.2.2 CRC incidence and mortality
Of the 350 obligate monoallelic MUTYH mutation carriers identifed by the three 
centres, 21 (7 male and 14 female) had been diagnosed with CRC (Table 5.4) 
at a mean age of 70 years (median 71 years, range 58-82 years). To assess 
whether or not more monoallelic MUTYH mutation carriers were affected by 
CRC than would have been expected in the relevant general populations, SIRs 
were calculated for the countries separately and together (Table 5.5). A total of 
77 monoallelic MUTYH mutation carriers had to be excluded for this analysis as 
detailed in Table 5.4. Significantly more Dutch monoallelic MUTYH mutation 
carriers were diagnosed with CRC than would have been expected (p<0.05, 
chi-squared test) and the numbers of CRCs were also higher than expected in 
monoallelic mutation carriers from the UK and Ireland and from Germany (Table 
5.5), although the individual data from these countries did not reach significance 
(p>0.05). Combining the data from all three centres revealed a significantly 
increased SIR for CRC of 2.12 (95% CIs 1.30-3.28, p<0.01, chi-squared test) 
among obligate monoallelic carrier parents.
Eight of the 350 monoallelic MUTYH mutation carriers (4 male and 4 female) 
died from CRC (Table 5.4). The cause of death for 23 monoallelic MUTYH 
mutation carriers could not be confirmed or excluded to be CRC. To investigate 
whether or not more monoallelic MUTYH mutation carriers died from CRC than 
would have been expected in the general population, SMRs were calculated for 
the countries separately and together (Table 5.5). A total of 84 monoallelic 
MUTYH mutation carriers had to be excluded for this analysis as detailed in 
Table 5.4. No difference in CRC mortality was observed between monoallelic 
mutation carriers and the general population, even when the data from all three 
centres were combined (Table 5.5).
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UK & Ireland TheNetherlands Germany Total
CRC 4 9 8 21
No CRC 86 103 126 315
CRC unknown
Exclusions for CRC SIR analysis
6 0 8 14
Lived & died outside country 9 0 0 9
No DOB &/or DOD/last contact 10 22 7 39
Death/CRC diagnosis before 
population rate data recorded
5 4 13 22
Remaining unknown CRC status 2 0 5 7
Total excluded 26 26 25 77
Cause of death CRC 1 5 2 8
Cause of death not CRC 87 99 133 319
Cause of death unknown 
Exclusions for CRC SMR analysis
8 8 7 23
Lived & died outside country 9 0 0 9
No DOB &/or DOD/last contact 10 22 7 39
Death before population rate data 
recorded
0 10 13 23
Remaining unknown if CRC 
cause of death
2 7 4 13
Total excluded 21 39 24 84
Table 5.4 CRC incidence and mortality data for 350 monoallelic MUTYH mutation 
carriers. Exclusions for SIR and SMR analysis are shown. Start dates for population 
rate data are shown in Table 5.2.
Country Observed Expected CRC SIR 95% Confidence IntervalsLower Upper
UK & Ireland 4 1.77 2.26 0.62 5.79
The Netherlands 9 3.49 2.58* 1.18 4.90
Germany 7 4.18 1.68 0.67 3.45
All countries 20 9.43 2.12** 1.30 3.28
Country Observed Expected CRC SMR 95% Confidence IntervalsLower Upper
UK & Ireland 1 1.46 0.69 0.02 3.82
The Netherlands 4 3.22 1.24 0.34 3.18
Germany 2 2.20 0.91 0.11 3.28
All countries 7 6.88 1.02 0.41 2.10
Table 5.5 Standardized CRC incidence and mortality ratios. Exact SIRs, SMRs 
and confidence intervals were calculated. Observed refers to the number of MUTYH 
heterozygotes diagnosed with CRC (SIR) or died from CRC (SMR). Exclusions 
required for this analysis are shown in Table 5.4. *p<0.05, **p<0.01
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5.3.3 All cancer risk in MUTYH mutation heterozygotes 
Eighty-four of the 350 monoallelic MUTYH mutation carriers (40 male and 44 
female) had been diagnosed with at least one cancer (Table 5.6). No data were 
available on the cancer status of 20 monoallelic mutation carriers. To assess 
whether or not more monoallelic MUTYH mutation carriers were diagnosed with 
cancer than would have been expected in the general population, SIRs were 
calculated for the countries separately and together (Table 5.7). A total of 83 
monoallelic MUTYH mutation carriers had to be excluded for this analysis as 
detailed in Table 5.6. No significant difference in overall cancer incidence was 
observed between monoallelic mutation carriers and the relevant general 
populations (Table 5.7). The types of malignant cancer identified in monoallelic 
MUTYH mutation carriers are shown in Table 5.8. Other than CRC, lung cancer 
was the most frequently observed cancer, with 15 cases reported. Seven 
obligate monoallelic mutation carriers had been diagnosed with more than one 
type of cancer. Two cases had CRC and breast cancer aged 82 and 90 years 
and 75 and 55 years, respectively. A single monoallelic mutation carrier had 
CRC and lung cancer aged 63 and 74 years, respectively, and another was 
diagnosed with lymphoma (aged 67 years), lung cancer (aged 68 years) and 
CRC (aged 75 years). One case had laryngeal cancer and astrocytoma aged 
57 and 64 years, respectively, and another case was diagnosed with prostate 
and bladder cancer aged 59 years. A single case had gastric cancer aged 59 
years and uterine cancer at an unknown age.
Sixty-two of the 350 monoallelic MUTYH mutation carriers (32 male and 30 
female) died from cancer (Table 5.6). The cause of death for 14 obligate 
monoallelic mutation carriers could not be confirmed or excluded to be cancer. 
To investigate whether or not more monoallelic MUTYH mutation carriers died 
from cancer more frequently than those in the general population, SMRs were 
calculated for the countries separately and together (Table 5.7). A total of 74 
monoallelic MUTYH mutation carriers had to be excluded for this analysis as 
detailed in Table 5.6. No significant difference in cancer mortality was observed 
between monoallelic carriers and the general population (Table 5.7).
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UK & Ireland TheNetherlands Germany Total
Any cancer 20 29 35 84
No cancer 64 81 101 246
Unknown if had cancer 12 2 6 20
Exclusions for all cancer SIR 
analysis
Lived & died outside country 9 0 0 9
No DOB &/or DOD/last contact 10 22 7 39
Death/cancer diagnosis before 6 4 13 23
population rate data recorded 
No date of diagnosis 0 1 5 6
Remaining unknown cancer 1 0 5 6
status
Total excluded 26 27 30 83
Cause of death cancer 14 25 23 62
Cause of death not cancer 75 84 115 274
Cause of death unknown 7 3 4 14
Exclusions for all cancer SMR 
analysis
Lived & died outside country 9 0 0 9
No DOB &/or DOD/last contact 10 22 7 39
Death before population rate data 0 10 13 23
recorded
Remaining unknown if cancer 1 1 1 3
cause of death 
Total excluded 20 33 21 74
Table 5.6 All cancer incidence and mortality data for 350 monoallelic MUTYH mutation 
carriers. Exclusions for SIR and SMR analysis are shown. Start dates for population rate data 
are shown in Table 5.2.
Country Observed Expected Cancer SIR 95% Confidence IntervalsLower Upper
UK & Ireland 14 12.02 1.17 0.64 1.95
The Netherlands 23 28.27 0.81 0.52 1.22
Germany 23 25.01 0.92 0.58 1.38
All countries 60 65.31 0.92 0.70 1.18
Country Observed Expected Cancer SMR 95% Confidence IntervalsLower Upper
UK & Ireland 12 12.65 0.95 0.49 1.66
The Netherlands 18 15.73 1.14 0.68 1.81
Germany 20 16.18 1.24 0.76 1.91
All countries 50 44.56 1.12 0.83 1.48
Table 5.7 Standardized all cancer incidence and mortality ratios. Exact SIRs, SMRs and 
confidence intervals were calculated. Observed refers to the number of MUTYH heterozygotes 
diagnosed with any cancer (SIR) or died from cancer (SMR).
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Cancer No. of cases Mean age at diagnosis (yrs) (range)
CRC 21 70 (58-82)
Lung 16 70 (57-85)
Breast 6 60 (45-90)
Gastric 6 67 (54-78)
Prostate 6 72 (59-80)
Leukaemia 5 64 (52-93)
Lymphoma 3 61 (55-67)
Bladder 3 66 (59-77)
Uterine 2 47
Laryngeal 2 57
Osteosarcoma 2 78 (72-83)
Ovarian 1 72
Cervical 1 >70
Testicular 1 Unknown
Duodenal 1 55
Pancreatic 1 67
Liver 1 59
Plasmocytoma 1 60
Fibrosarcoma 1 68
Glioblastoma 1 65
Astrocytoma 1 64
Thyroid 1 Unknown
Cancer, primary unknown 9 60 (33-79)
Table 5.8 Cancers identified in 84 monoallelic MUTYH mutation carriers. Other 
than CRC, lung cancer was the most frequently identified cancer. Seven monoallelic 
mutation carriers had more than one type of cancer.
5.3.4 Overall mortality in MUTYH mutation heterozygotes 
Of the 350 obligate monoallelic MUTYH mutation carriers, 240 (134 male and 
106 female) were deceased (Table 5.9). It was unknown whether four were 
alive or deceased. To investigate the mortality of monoallelic MUTYH mutation 
carriers, SMRs were calculated for the countries separately and together (Table 
5.10). A total of 71 monoallelic MUTYH mutation carriers had to be excluded 
for this analysis as detailed in Table 5.9. No difference in overall mortality was 
observed between monoallelic carriers and the general population (Table 5.10). 
The mean age at death (among the 240 who had died) was 74 years (range 26- 
106 years) for females and 68 years (range 29-94) for males. The mean age at 
last contact for living monoallelic MUTYH mutation carriers was 72 years (range 
47-92 years) for females and 73 years (range 54-98 years) for males.
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UK & Ireland TheNetherlands Germany Total
Deceased 62 83 95 240
Alive at last contact 32 27 47 106
Unknown if deceased 2 2 0 4
Exclusions for all cause SMR 
analysis
Lived & died outside country 9 0 0 9
No DOB &/or DOD/last contact 10 22 7 39
Death before population rate 0 10 13 23
data was recorded 
Total excluded 19 32 20 71
Table 5.9 All cause mortality data for 350 monoallelic MUTYH mutation carriers.
Exclusions for SMR analysis are shown. Start dates for population rate data are shown 
in Table 5.2.
Country Observed Expected All cause SMR
95% Confidence 
Intervals
Lower Upper
UK & Ireland 48 61.67 0.78 0.57 1.03
The
Netherlands
57 63.13 0.90 0.68 1.17
Germany 75 67.37 1.11 0.88 1.40
All countries 180 192.17 0.94 0.80 1.08
Table 5.10 Standardized all cause mortality ratios. Exact SMRs and confidence 
intervals were calculated. Observed refers to the number of MUTYH heterozygotes 
deceased.
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5.4 Discussion
5.4.1 Monoallelic MUTYH mutation carriers and CRC risk
The SIR analysis performed on 273 obligate monoallelic mutation carriers from 
UK and Ireland, the Netherlands and Germany indicated that these individuals 
had a two-fold increase in CRC risk. As expected, the mean age at CRC 
diagnosis in monoallelic mutation carriers was significantly higher than that in 
biallelic mutation carriers (70 years [range 58-82 years] vs. 48 years [range 21- 
70 years; chapter four], p<0.001; ANOVA).
5.4.1.1 Mechanism underlying increased CRC risk
One possible mechanism which may explain the observed increase in CRC risk 
in monoallelic MUTYH mutation carriers is analogous to that in HNPCC, 
requiring somatic mutation of the wild-type allele. Once both MUTYH alleles 
are mutated, the mutation rate in the compromised cell would be expected to 
increase leading to increased biallelic inactivation of ARC and tumour initiation. 
The later age at CRC diagnosis in monoallelic MUTYH mutation carriers 
compared with MAP patients is consistent with the need for an additional 
somatic MUTYH mutation before ARC mutations accumulate and 
tumourigenesis is initiated. Consistent with such a mechanism, LOH of the 
MUTYH locus on the short arm of chromosome 1 has been reported to be more 
frequent in CRCs from germline monoallelic mutation carriers than in CRCs 
from wild-type individuals but only small numbers of tumours were described 
(Croitoru, M.E. etal, 2004; Kambara, T. etal, 2004) and this loss occurs 
relatively frequently in sporadic CRC (Shih, l-M. et al, 2001; Goel, A. et at,
2003)
Another mechanism which could explain the increased CRC risk in monoallelic 
mutation carriers is that the mutant MUTYH allele may lead the heterozygous 
cell to have a slightly reduced repair activity so that the mutation rate would 
increase, eventually resulting in the biallelic inactivation of APC and tumour 
initiation. Each of the two somatic APC mutations would take longer to arise 
than in MAP, thus delaying the onset of tumourigenesis. However, any 
increase in mutation rate in monoallelic mutation carriers might be expected to
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lead to earlier biallelic inactivation of APC (and thus tumour initiation) than in 
wild-type individuals.
Given the genotype-phenotype correlations observed in MAP cases in chapter 
four, certain MUTYH mutations may result in an earlier onset of CRC in 
monoallelic carriers. Five of the seven monoallelic mutation carriers with CRC 
screened for MUTYH mutations in the present study were Y176C heterozygotes 
and two were G393D heterozygotes. From the MUTYH genotypes of their 
MAP-affected offspring, an additional 12 monoallelic mutation carriers with CRC 
could potentially be Y176C heterozygotes and only two definitely do not carry 
this mutation. Y176C is thought to have a more detrimental effect on MUTYH 
glycosylase activity than G393D. Wild-type levels of mutant MUTYH protein are 
found in cells derived from a MAP patient with homozygous G393D mutations 
whereas cells derived from a MAP patient with homozygous Y176C mutations 
have lower levels of mutant MUTYH protein (Parker, A.R. etal, 2005).
Therefore if a MUTYH heterozygote carries the Y176C mutation, not only is the 
mutant protein produced less active but there may also be less of it. An 
increase in mutation rate may be greater and biallelic inactivation of APC more 
likely in Y176C than G393D heterozygotes.
5A .1.2 Previous kin-cohort studies
There are few kin-cohort studies of CRC risk in monoallelic mutation carriers 
reported in the literature to date. Jenkins et al (2006) recently reported a 
statistically significant (p=0.02) 3-fold increased CRC risk in monoallelic carriers 
and Webb et al (2006) described a non-significant CRC hazard ratio of 1.74 
(95% Cl: 0.62-3.60) for monoallelic mutation carriers. Croitoru et al (2004) 
showed that monoallelic mutation carrier CRC cases were significantly more 
likely than wild-type CRC cases to have a first or second-degree relative with 
CRC and suggested that this reflected transmission of monoallelic CRC risk as 
an autosomal dominant trait but the findings of Balaguer et al (2007) did not 
confirm this.
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5A .1.3 Previous case-control studies
Several previous case-control studies have reported a trend towards over­
representation of MUTYH heterozygotes in CRC cases and suggested the 
possibility of an increased CRC risk in such individuals (Table 5.11). However, 
statistical significance was only achieved in two studies and under certain 
constraints; Farrington e ta l(2005) described a 1.68-fold (95% Cl: 1.07-2.95) 
increase in CRC risk in monoallelic mutation carriers but only over the age of 55 
years and Peterlongo et al (2006) reported an odds ratio (OR) of 2.79 (95% Cl:
1.07-7.25; p=0.04) for monoallelic mutation carriers but significance was lost 
when this was adjusted for ethnic background, age and gender. The scarcity of 
statistically significant results is likely to reflect a lack of power to detect any 
increase in CRC risk due to the low penetrance and population frequency of 
monoallelic MUTYH mutations. The largest case-control study to date is that of 
Webb et al (2006) which did not find an increased CRC risk in monoallelic 
mutation carriers (Table 5.11). The approach used in the present study allowed 
analysis of a much larger number of monoallelic mutation carriers.
A few case-control studies did not find an increase in CRC risk in monoallelic 
carriers but as in the study of Webb et al (2006), their CIs for CRC risk included 
values over 1.0 (Table 5.11). Differences in CRC risk estimates between case- 
control studies may be influenced by the method of CRC case selection. Even 
meta-analyses of the ORs of CRC risk associated with monoallelic Y176C or 
G383D mutations from several case-control studies have not yielded statistically 
significant results as combined ORs of 1.26 (95% Cl: 0.99-1.60) and 1.11 (95% 
Cl: 0.90-1.37) have been reported (Webb, E.L. etal, 2006; Balaguer, F. etal,
2007). Tenesa et al (2006) used a different method of assessing risk for their 
meta-analysis and found a significant genotype relative risk of 1.27 (95% Cl:
1.01-1.61) for monoallelic Y176C or G383D mutation carriers. The largest 
meta-analysis was that of Balaguer et al (2007), with 191/10582 CRC cases 
and 162/9728 controls carrying monoallelic Y176C or G383D mutations which is 
still fewer carriers than were involved in the present study.
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Reference CRC cases Controls Risk (95% Cl)
Significant
result
Enholm, S. etal(2003) 5/1042 0/424 NC Yes(p<0.025)
Croitoru, M.E. etal(2004) 29/1238 21/1255 OR=1.4
(0.8-2.5)
No
Fleischmann, C. et al, (2004) 6/358 2/354 OR=2.9
(0.6-14.4)
No
Kambara, T. et al, (2004) 20/92 14/53 NC No
Wang, L. etal(2004) 10/444 4/313 OR=1.78
(0.55-5.71)
No
Farrington, S.M. et al, (2005) 45/2239 28/1845 GRR=1.35
(0.92-2.07)
No
>55 years only 31/1345 18/1289 GRR=1.68
(1.07-2.95)
Yes
Peterlongo, P. et al, (2005) 4/555 7/918 OR=0.95
(0.20-3.75)
No
Zhou, X-L. etal, (2005) 6/438 3/469 NC No
Colebatch, A. etal, (2006) 11/872 5/478 NC No
Peterlongo, P. et al, (2006) 
Adjusted
6/137 16/967 OR=2.79 
(1.07-7.25) 
OR=1.99 
(0.70-5.69)
Yes
No
Tenesa, A. etal, (2006) 18/928 20/845 GRR=0.8 
(0.5-1.4)
No
Webb, E.M. etal, (2006) 53/2561 57/2695 OR=0.98
(0.66-1.46)
No
Balaguer, F. et al, (2007) 19/1108 21/934 OR=0.76
(0.40-1.42)
No
Kury, S. etal, (2007) 24/1023 21/1121 OR=1.26
(0.70-2.27)
No
Table 5.11 Results of previous case-control studies investigating CRC risk in 
monoallelic MUTYH mutation carriers. Only two studies showed a significantly 
increased CRC risk in monoallelic mutation carriers but several others indicated an 
over-representation of monoallelic carriers in CRC cases. OR, odds ratio; GRR, 
genotype relative risk; Cl, confidence interval.
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5.4.1.4 Potential causes of inaccurate CRC risk estimation
5.4.1.4.1 Incorrect genotype assumptions
The present study attempted to verify that the parental CRC cases identified 
were monoallelic rather than biallelic mutation carriers by screening their non- 
cancerous tissue DNA for MUTYH mutations. Tissue blocks for nine of the 22 
CRC cases were obtained, seven were successfully screened and in one 
further case blood DNA was available. One of these cases was found to carry 
pathogenic biallelic MUTYH mutations. It is possible that other parental cases 
with CRC for whom no blood or tissue was available may also have carried 
biallelic mutations. However, the parental MAP case had 11-20 colorectal 
adenomas at 74 years and a strong family history of CRC; her father died of 
CRC aged 80 years and her sister had CRC at 80 years. No information could 
be obtained about the presence or lack of consanguinity in this family. None of 
the other parental CRC cases for whom blood or tissue was unavailable were 
described as having a polyposis phenotype or strong family history of CRC.
A large proportion of the relatives included in the kin-cohort studies of Jenkins 
et al (2006) and Webb et al (2006) were not genotyped. Some of the assumed 
monoallelic mutation carriers with CRC could actually have been biallelic MAP 
cases and the CRC risk for monoallelic carriers therefore overestimated in 
these studies. Only one of the case-control studies reported to date screened 
the entire MUTYH ORF in CRC cases and controls (Fleischmann, C. et al,
2004). The other studies assayed for Y176C and G393D (and in some cases a 
small number of other specific changes) which was followed in most studies by 
an ORF screen of any monoallelic mutation carriers identified (Enholm, S. et al, 
2003; Croitoru, M.E. et al, 2004; Kambara, T. et al, 2004; Wang, L. et al, 2004; 
Farrington, S.M. etal, 2005; Peterlongo, P. etal, 2005; Zhou, X-L. etal, 2005; 
Colebatch, A. etal, 2006; Peterlongo, P. etal, 2006; Tenesa, A. etal, 2006; 
Webb, E.M. etal, 2006; Balaguer, F. etal, 2007; Kury, S. etal, 2007). CRC 
cases carrying biallelic mutations other than those specifically screened for 
would have been incorrectly classified as wild-type cases and it could have 
contributed to an underestimation of risk. Kambara et al (2004) reported no 
significant difference in the frequency of monoallelic carriers in CRC cases and 
controls but their classification of a monoallelic carrier included individuals
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harbouring variants such as V22M or S501F that appear to be non-pathogenic 
polymorphisms (Al-Tassan, N. etal, 2002). All monoallelic carriers in the 
present study carried pathogenic mutations that resulted in MAP in their 
offspring.
5.4.1.4.2 Ascertainment bias
To avoid a bias in favour of monoallelic mutation carriers with CRC, the present 
study included obligate heterozygote parents only of those MAP index cases 
who presented symptomatically or were identified as a result of population 
screening, but not those who presented because of a family history of CRC.
The MAP index cases were identified through colorectal polyposis registers for 
which a family history of CRC was not an inclusion criterion.
SIR analysis is the method used by epidemiologists to investigate if there is a 
greater incidence (and therefore risk) of a disease in particular individuals than 
in the general population. In order to control for changing cancer incidence over 
time, for obligate heterozygote parents to be included in this analysis certain 
information (e.g. DOB and DOD) was required otherwise they had to be 
excluded. If a MAP index case had a parent affected by CRC, more effort may 
have been made by the clinical genetics services to obtain details these details 
than for an unaffected parent. This could have led to a bias in favour of 
inclusion of parents with CRC and an overestimation of CRC risk in monoallelic 
mutation carriers. Whereas 5% (1/21) of all the parents with CRC were 
excluded, 23% (76/329) of the remaining parents were excluded (p=0.034, 
Fisher’s exact test). However, if these 76 parents were assumed to be 
unaffected by CRC and, along with the excluded CRC case, were included in 
the SIR analysis (through using randomly selected information from the existing 
cohort) a significantly increased CRC risk is still seen (SIR=1.87, 95% CIs 1.16- 
2.87; p<0.05, chi squared test).
Although many of the MAP patients from UK and Ireland underwent pre­
screening for the two common mutations, 17% of MAP patients identified by the 
three centres (Cardiff, Bonn, Leiden) did not harbour a Y176C or G393D 
mutation and 29% carried Y176C or G393D in combination with a less frequent
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mutation (see chapter 4). As noted in chapter four, the ratio of Y176C 
homozygotes to G393D homozygotes observed in our MAP patient cohort was 
greater than expected from the allele frequencies for these mutations in healthy 
individuals. In addition, G393D homozygotes presented and were diagnosed 
with CRC at an older age than Y176C homozygotes, suggesting that G393D 
homozygotes may be less likely to come to the attention of polyposis registers 
from which our index cases were selected for screening (chapter 4). The SIR 
we found may be an overestimation of CRC risk in monoallelic carriers as a 
whole in the general population. Balaguer et al (2007) observed a larger 
monoallelic effect for Y176C carriers than for G393D carriers but Tenesa et al 
(2006) found similar effects for both mutations. Neither of these observations 
was statistically significant and the 95% Cl range for the analysis by Balaguer et 
al (2007) was large (OR=5.33; 95% Cl: 0.70-38.40).
5.4.2 CRC mortality in monoallelic MUTYH mutation carriers 
The SMR analysis performed on 266 monoallelic mutation carriers from UK and 
Ireland, the Netherlands and Germany indicated that no more of these 
individuals died from CRC than would have been expected in the general 
population. This is the first study to investigate CRC mortality in monoallelic 
mutation carriers and given the significantly increased CRC incidence observed 
above, it might have been expected that CRC mortality would also have been 
increased in these individuals. If the treatment and prognosis of CRCs in 
monoallelic mutation carriers was the same as for CRCs in the general 
population, a similar proportion of CRC cases would be expected to die in both 
groups. The numbers in the present study were small and the SMR 95% Cl 
does not preclude an increase in CRC mortality for monoallelic mutation carriers 
(0.41-2.10). Of the 21 monoallelic mutation carrier CRC cases, only 8 were 
known to have died from CRC and one of these had to be excluded from the 
SMR analysis as they died before the appropriate population rate data was 
collected. Four parents with CRC were still alive at the end of the study, one 
died as a result of an overdose and the cause of death for another was 
unknown. The collection of data for the population CRC mortality rates for the 
Netherlands began ten years later than the CRC incidence rate data from this
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country, leading to the additional exclusion of six monoallelic carriers from the 
study
5.4.3 All cancer incidence and mortality in monoallelic MUTYH mutation carriers 
The SIR and SMR analyses performed on 267 and 276 monoallelic mutation 
carriers, respectively, from UK and Ireland, the Netherlands and Germany 
indicated that these individuals do not have a significantly increased risk of 
being diagnosed with, or dying from, cancer. However, neither analysis could 
exclude an increase as the CIs included values over one (SIR 95% Cl: 0.70- 
1.18; SMR 95% Cl: 0.83-1.48). This is the first large study to investigate all 
cancer incidence and mortality in monoallelic mutation carriers. Although CRC 
risk was found to be significantly increased in monoallelic mutation carriers, the 
all cancers risk was not. The all cancers SIR analysis only used information on 
the first cancer as subsequent cancers could have been the result of treatment 
for the first cancer or misdiagnosed metastases. Monoallelic carriers reported 
to be affected by cancer but for whom no date of diagnosis was known (or could 
be reasonably assumed) had to be excluded from the SIR analysis as the end 
of follow-up date could not be identified and not all monoallelic carriers were old 
enough to have lived through their cancer risk so an increase in risk in later life 
was not fully excluded.
Other than CRC, the most frequently identified cancer in monoallelic mutation 
carriers was lung cancer. Of the 330 carriers for whom cancer status was 
known, 16 (4.8%) had lung cancer which is as expected because this is the 
second most common cancer in the UK (Cancer Research UK). Al-Tassan et al 
(2004) reported only a single germline G393D heterozygote in a cohort of 276 
lung cancer patients which is consistent with the frequency of this mutant allele 
in healthy individuals. The only Gl tract cancer in addition to CRC identified in 
more than one monoallelic mutation carrier in the present study was gastric 
cancer (6 cases, 1.8%). Several Asian gastric cancer cases have been 
screened for mutations in MUTYH. Kim et al (2004) reported biallelic MUTYH 
mutations (one somatic missense mutation and LOH of the wild-type allele) in 
2/95 Korean sporadic gastric cancers and 4/23 cases showed LOH at the 
MUTYH locus. Tao et al (2004) described a homozygous germline splice site
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mutation in 1/148 Japanese gastric cancer patients but the heterozygous 
change was no more frequent in cases than in healthy controls. The frequency 
of a variant haplotype at two MUTYH polymorphisms was reported to be 
associated with an increased risk of familial gastric cancer in a Chinese study 
(Zhang, Y. et al, 2006). Gastric cancer is more prevalent in these Asian 
populations than in Europe and the frequency of this cancer in monoallelic 
mutation carriers in the present study in consistent with the UK population (3% 
of diagnosed cancers). A single Y176C heterozygote has been reported 
previously with prostate cancer (Shin, E.J. etal, 2007) and one Y176C 
heterozygote has been described with acute myeloid leukaemia (Akyerli, C.B. et 
al, 2003). The frequencies of prostate cancer, breast cancer and leukaemia 
identified in the present study are not greater than would be expected in the UK 
with 24% and 3% of all cancers accounted for by prostate cancer and 
leukaemia, respectively and the lifetime risk of breast cancer for women is 11 % 
(Cancer Research UK). All other cancers identified in the present study were 
only diagnosed in less than 1 % of monoallelic carriers. Monoallelic germline 
Y176C or G383D mutations have been identified in hepatocellular carcinoma 
and cholangiocarcinoma patients but at no higher frequency than in cancer-free 
controls (Baudhuin, L.M. etal, 2006) and no pathogenic germline mutations 
were detected in 29 sporadic squamous oral carcinoma patients (Gorgens, H. et 
al, 2007). Given the finding that MAP patients do not appear to be at a 
significant risk of cancers outside the Gl tract (chapter 4), it is not surprising that 
monoallelic carriers also do not appear to have a significantly increased risk of 
such cancers. The present study is underpowered to detect small increases in 
risk for rare cancers.
5.4.4 All cause mortality in monoallelic MUTYH mutation earners 
The SMR analysis performed on 279 monoallelic mutation carriers from UK and 
Ireland, the Netherlands and Germany showed no difference to the general 
population. This is the first study to investigate overall mortality in monoallelic 
MUTYH mutation carriers and the results will be helpful in reassuring relatives 
of MAP cases.
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5.4.5 Clinical implications
The present study identified a statistically significant two-fold increase in CRC 
risk in monoallelic MUTYH mutation carriers which is a clinically relevant 
outcome. However, before genetic counselling and surveillance strategies for 
monoallelic carriers are changed in view of these findings, a study of whether or 
not all monoallelic mutations confer the same CRC risk is indicated. Evidence 
from MAP patients suggests that the Y176C mutant allele is associated with an 
earlier CRC onset than the G393D mutant allele (chapter 4) and it has been 
suggested (although no significant results have been reported) that Y176C 
monoallelic carriers may have a greater CRC risk than G393D monoallelic 
carriers. If this is the case, it may explain why some previous population based 
CRC case-control studies have failed to detect a significantly increased CRC 
risk in monoallelic carriers whereas the present study found a doubling of risk.
A large collaborative study of genotyped heterozygotes would be needed to 
assess if different CRC risks are associated with different MUTYH mutations, 
but even then the CRC risk of rarer mutations will be difficult to determine. If 
different mutations are associated with different levels of CRC risk, this will have 
implications for genetic counselling and surveillance of monoallelic mutation 
carriers. For example, screening could be offered only to those with a higher 
risk mutation thus reducing costs. The present study does not provide evidence 
that monoallelic carriers are at a significantly increased risk of cancers other 
than CRC or of other potentially fatal diseases. Large prospective studies of 
monoallelic carriers are ideally needed to confirm the findings of the present 
study but will take a long time to complete.
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Chapter Six
Mutational analysis of the base excision repair and DNA damage 
protection genes TDG, MPG, SMUG1, MBD4, APE1, POLL and NUDT5 in 
patients with multiple colorectal adenomas
6.1 Introduction
6.1.1 Inherited CRC and BER
Known genetic predisposition syndromes caused by high penetrance mutations 
only account for a small proportion of hereditary CRC cases and incompletely 
penetrant mutations are thought to contribute to most of the remaining familial 
CRC cases (Kemp, Z. et al, 2004; de la Chapelle, A., 2004). The present study 
sought inherited high penetrance pathogenic mutations in candidate genes 
involved in DNA repair in fifty-eight multiple colorectal adenoma cases in whom 
no underlying genetic defect had been identified.
MAP is a recently described autosomal recessive disease resulting from biallelic 
germline mutations in the MUTYH gene (Al-Tassan, N. etal, 2002; Sieber, O.M. 
et al, 2003). MUTYH is a DNA glycosylase which functions in the BER pathway 
to remove adenine misincorporated opposite 8-oxoG as a result of oxidative 
DNA damage (Shinmura, K. et al, 2000). BER is the primary mechanism of 
protection against DNA damage caused by cellular metabolism including 
lesions resulting from ROS, deamination, methylation and hydroxylation 
(Hoeijmakers, J.H.J, 2001). Some base modifications caused by exogenous 
agents can also be repaired by BER (King, R.J.B., 2000). The identification of 
MAP has shown that compromised BER can influence CRC susceptibility and 
thus components of this pathway are good candidates for novel CRC 
predisposition genes.
DNA glycosylases initiate BER by recognising DNA damage and most can be 
grouped into families according to structural and/or functional similarities.
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6.1.2 MutM/Nei glycosylases
Members of this DNA glycosyiase family are characterised by a C-terminal zinc 
finger and a helix-two turn-helix motif which are involved in DNA binding. The 
human enzymes NEIL1, NEIL2 and NEIL3 are part of this family (Zharkov, D.O. 
etal, 2003).
6.1.2.1 NEIL1, NEIL2 & NEIL3
The NEIL1 gene is found on chromosome 15q22, consists of nine exons and 
spans 6.1 kb (Bandaru, V. et al, 2002; Morland, I. etal, 2002). The encoded 
protein is expressed in the nuclei of a range of tissues (Morland, I. etal, 2002) 
and is under S phase specific regulation (Hazra, T.K. et al, 2002a). NEIL1 lacks 
a zinc finger, but contains a ‘zincless finger’ instead (Doublie, S. et al, 2004).
The NEIL2 gene is made up of four exons and lies at chromosome 8p23 
(Bandaru, V. et al, 2002). NEIL2 expression is cell cycle independent and 
found at high levels in muscle and testis (Hazra, T.K. et al, 2002b). Both NEIL1 
and NEIL2 are glycosylases with AP lyase activity and unlike other glycosylases 
use a p6-elimination mechanism for catalysis. The resulting 3’ terminal 
phosphate is a poor substrate for mammalian APE1 but is removed by PNK in 
an APE1 -independent BER mechanism (Hazra, T.K. etal, 2007). Both of these 
enzymes are active on substrates within DNA bubble structures suggesting that 
NEIL1 and NEIL2 repair may be associated with replication or coupled to 
transcription, respectively (Dou, H. et al, 2003). ROS-derived pyrimidine lesions 
are substrates for both glycosylases and NEIL1 preferentially excises thymine 
glycol, 5-hydroxyuracil as well as ring-opened purines-formamidopyrimidine 
(Fapy)-adenine and -guanine. The preferred substrates of NEIL2 include 
hydantoins (oxidation products of 8-oxoG), 5-hydroxyuracil and 5- 
hydroxycytosine (Hazra, T.K. et al, 2007). NEIL3 is found at chromosome 4q34 
and consists often exons spanning 55kb (Bandaru, V. etal, 2002; Morland, I. et 
al, 2002). The encoded protein has not been biochemically characterised to 
date.
6.1.3 Endonuclease III glycosylases
Members of this DNA glycosyiase family are characterised by a conserved 
catalytic domain containing an HhH motif followed by a glycine/proline-rich loop
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and a catalytic aspartate residue (HhH-GPD motif). Some HhH glycosylases 
also contain an iron-sulphur cluster (Nash, H.M. etal, 1996). The human 
enzymes MUTYH, OGG1, OGG2, NTHL1 and MBD4 are part of this family.
6.1.3.1 OGG1 &OGG2
The OGG1 gene is located at chromosome 3p26.2 (Arai, K. etal, 1997) and 
consists of nine alternatively spliced exons which encode both nuclear and 
mitochondrial isoforms of the protein (Kohono, T. et al, 1998; Nishioka, K. etal, 
1999). OGG1 is ubiquitously expressed (Arai, K. etal, 1997) and the 
predominant, nuclear isoform has both glycosyiase and AP lyase activities (i.e 
is bifunctional) (Roldan-Arjona, T., et al, 1997). OGG1 substrates include 8- 
oxoG mispaired opposite cytosine, Fapy-G and 7,8-dihydro-8-oxoadenine (8- 
oxoA) (Klungland, A. & Bjelland, S., 2007). OGG2 also excises 8-oxoG, but 
prefers 8-oxoG:A and 8-oxoG:G mispairs. This bifunctional glycosyiase was 
identified in human cell extracts and is likely to act on the daughter strand 
following misincorporation of 8-oxodGTP opposite adenine during DNA 
replication (Hazra, T.K. etal, 1998).
6.1.3.2NTHL1
The NTHL1 gene is found on chromosome 16p13 and contains six exons which 
span 8kb (Imai, K. etal, 1998). NTHL1 is the human homologue of E.coli 
endonuclease III and possesses both glycosyiase and AP lyase activities 
(Aspinwall, R. et al, 1997). Multiple nuclear isoforms of this enzyme exist 
(Ikeda, S. et al, 2002) and NTHL1 expression is ubiquitous and increased 
during S-phase (Imai, K. etal, 1998; Luna, L. etal, 2000). NTHL1 excises a 
range of oxidized pyrimidine lesions including thymine glycol, dihydrouracil, 5- 
hydroxycytosine and urea, (Hazra, T.K. etal, 2007). This glycosyiase also 
recognises AP sites and 8-oxoG when paired opposite guanine (Eide, L. et al, 
2001; Matsumoto, Y. etal, 2001).
6.1.3.3MBD4
MBD4 (also known as MED1) is found on the long arm of chromosome 3, at 
3q21-q22 (Riccio, A. et al, 1999) and is made up of 8 exons (Hendrich, B. et al, 
1999a). Alternatively spliced transcripts, including one which encodes a
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truncated protein, have been identified. MBD4 is expressed in a range of 
human tissues and the encoded protein localizes to the nucleus (Hendrich, B. & 
Bird, A, 1998). This enzyme is a member of the methyl-CpG-binding domain 
(MBD) family of proteins which mediate histone deacetylase-dependent 
transcriptional silencing at symmetrically methylated CpG islands (Ballestar, E.
& Wolffe, A.P., 2001). CpG islands are GC-rich regions of DNA that mostly 
overlap the promoter regions of RNA polymerase ll-transcribed genes (Bird, A.,
2002). Aberrant methylation of CpG islands in the promoters of many cancer- 
related genes results in silencing of their expression (Baylin, S.B. etal, 2001). 
The MBD proteins target corepessor complexes which contain histone 
deacetylase(s) (HDACs) and other transcriptional repressors to methylated 
DNA, thereby silencing expression (Ballestar, E. & Wolffe, A.P., 2001). MBD4 
can bind methylated DNA in vivo (Hendrich, B. & Bird, A, 1998) and binds to the 
hypermethylated promoters of human cancer-related genes CDKN2A and 
MLH1, repressing their transcription in a histone deacetylase-dependent 
manner (Kondo, E. et al, 2005).
Unlike the other MBD proteins, MBD4 is the only one to have an innate DNA 
glycosyiase activity (Hendrich, B. etal, 1999b). MBD4 is a monofunctional 
glycosyiase (lacks AP lyase activity) (Hendrich, B. etal, 1999b; Petronzelli, F. et 
al, 2000a) and binds tightly to AP sites which may protect them from non­
specific processing (Petronzelli, F. et al, 2000a). MBD4 recognises the 
mismatched products of 5-methylcytosine (5meC) and cytosine deamination, 
removing the respective T or U mispaired opposite G (Hendrich, B. etal, 1999b; 
Petronzelli, F. et al, 2000a; Zhu, B. et al, 2000). G:T mispairs are often 
associated with CpG dinucleotides as 70-80% of all CpG dinucleotides (with the 
exception of CpG islands) are methylated in humans (Bird, A., 2002). G:T 
mismatches within CpG or 5meCpG sites are the preferred substrates of this 
enzyme (Petronzelli, F. etal, 2000a; Hendrich, B. etal, 1999b) and mice 
deficient in MBD4 show a 2-3 fold increase in the frequency of C to T transitions 
at CpG sites (Millar, C.B. et al, 2002; Wong, E. et al, 2002). On a cancer- 
susceptible ApcMm,+ background, Mbd4~'' mice have increased numbers of 
intestinal tumours and accelerated tumour progression associated with an 
increase in somatic CpG to TpG mutations in the Ape gene (Millar, C.B. etal,
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2002; Wong, E. et al, 2002). Other MBD4 substrates include 5meC, thymine 
glycol, 5-formyluracil, 5-fluorouracil or S.A^-ethenocytosine paired opposite 
guanine (Zhu, B. etal, 2000; Yoon, J-H., etal, 2003; Liu, P. etal, 2003; 
Petronzelli, F. et al, 2000a; Petronzelli, F. et al, 2000b). This glycosyiase can 
also remove thymine from 0 6-methylguanine (0 6-meG):T mismatches 
(Cortellino, S. et al, 2003).
MBD4 interacts with Fas-associated death domain protein (FADD), an adaptor 
protein implicated in multiple apoptotic responses (Screaton, R.A. etal, 2003) 
and deficiency of MBD4 reduces intestinal apoptosis in response to a variety of 
DNA damaging agents (Sansom, O.J. et al, 2003). Mbd4~,~ MEFs do not 
undergo G2-M cell cycle arrest and apoptosis when treated with antitumour 
DNA damaging agents so DNA damage accumulates (Cortellino, S. et al,
2003).
Frameshift mutations at a poly(A)io tract in MBD4 have been identified in 24- 
43% of MSI colorectal cancers, including sporadic and hereditary cases (Riccio, 
A. et al, 1999; Bader, S. et al, 1999). Most commonly one MBD4 allele is 
mutated at the poly(A)i0 tract and the other remains wild-type, but biallelic 
inactivation of MBD4 through LOH or frameshift mutation of the second allele 
has been found in a small number of cases (Riccio, A. et al, 1999; Bader, S. et 
al, 2000).
6.1.4 Uracil DNA glycosylases
Members of the uracil DNA glycosyiase (UDG) superfamily are characterized by 
the presence of two conserved active site motifs and an aromatic residue which 
forms part of the substrate binding pocket (Pearl, L.H., 2000). These enzymes 
are monofunctional (lack AP lyase activity) and share a common a/p-fold 
structure (Aravind, L. & Koonin, E.V., 2000). The superfamily can be divided 
into four families of glycosylases based on their specificity and mechanism of 
substrate recognition (Pearl, L.H., 2000). The human enzymes TDG, SMUG1 
and UNG are members of different families within the UDG superfamily
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6.1.4.1 UNG
The UNG gene is found at chromosome 12q23-q24.1 (Haug, T. etal, 1996) and 
is made up of seven exons (Nilsen, H. et al, 1997). Alternative splicing and the 
use of its two promoters result in nuclear (UNG2) and mitochondrial (UNG1) 
isoforms (Nilsen, H. etal, 1997). Detectable levels of UNG2 expression are 
found only in proliferating tissues which include the colon, small intestine, 
thymus, placenta and testis (Haug, T. etal, 1998). UNG2 expression is cell 
cycle dependent and peaks early in S phase, accumulating in replication foci 
then is degraded during late S phase (Otterlei, M. etal, 1999; Hardeland, U. et 
al, 2005; Kavli, B. etal, 2002; Fischer, J.A. etal, 2004). UNG2 repairs 
deaminated cytosine lesions (U:G) and is the enzyme mainly responsible for 
excision of uracil misincorporated into nascent DNA during replication (U:A)
(An, Q. et al, 2005; Kavli, B. et al, 2002). Other UNG2 substrates include 5- 
hydroxyuracil, isodialuric acid and alloxan (Dizdaroglu, M. et al, 1996). This 
glycosyiase can also remove uracil from single-stranded DNA (Kavli, B. et al, 
2002) and is involved in immunoglobulin class-switch recombination and 
somatic hypermutation (Kavli, B. et al, 2005).
6.1.4.2SMUG1
The SMUG1 gene is located on the long arm of chromosome 12 (Haushalter, 
K.A. etal, 1999), spans approximately 7.5 kb and consists of two coding exons. 
The encoded protein is nuclear (Haushalter, K.A. etal, 1999) and accumulates 
in nucleoli but not in replication foci (Kavli, B. et al, 2002). SMUG1 excises 
uracil and its derivatives from double-stranded and single-stranded DNA 
(Haushalter, K.A. etal, 1999; Masaoka, A. etal, 2003). The modified uracil 
bases recognised by SMUG1 include 5-hydroxyuracil, 5-hydroxymethyluracil 
and 5-formyluracil (Masaoka, A. etal, 2003). SMUG1 binds tightly to AP sites 
and is important in the repair of deaminated cytosine (U:G) in non-replicating 
chromatin (Pettersen, H.S. et al, 2007). Two deaminated derivatives of oxidized 
cytosine, isodialuric acid and alloxan, are also SMUG1 substrates (An, Q. et al, 
2005). Silencing of SMUG1 in MEFs produces a mutator phenotype which 
moderately increases the frequency of C:G to T:A transitions (An, Q. et al,
2005).
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6.1.4.3 TDG
The TDG gene is found at chromosome 12q24.1 (Sard, L. etal, 1997), spans 
approximately 23 kb and is made up of ten exons. The encoded protein is 
expressed at a similar level in a range of tissues (Sard, L. et al, 1997). TDG is 
a nuclear glycosyiase under cell cycle regulation, it is eliminated by cells 
entering S-phase and deficiency is maintained until G2 (Hardeland, U. etal,
2005). TDG excises uracil and thymine when mispaired opposite guanine. 
These mismatches result from the spontaneous deamination of cytosine and 5- 
methylcytosine, respectively, and if left unrepaired lead to C to T transitions 
(Neddermann, P. & Jiricny, J., 1994). TDG shows a preference for G:T 
mismatches in a CpG sequence context (Neddermann, P. et al, 1996). A 
chicken homologue of TDG possesses 5-methylcytosine DNA glycosyiase 
activity and its overexpression results in demethylation of the promoter of a 
hormone-regulated reporter gene (Zhu, B. et al, 2001). Other TDG substrates 
include 3,N4-ethenocytosine, a highly mutagenic adduct, and derivatives of 
uracil such as 5-hydroxyuracil and 5-hydroxymethyluracil (Cortazar, D. et al, 
2007). Most TDG substrates are mispaired opposite guanine which may reflect 
the enzyme’s substrate recognition mechanism. It is likely that interactions with 
the nucleotide opposite the aberrant base are important for substrate 
recognition by TDG (Cortazar, D. et al, 2007). Similar to MUTYH, TDG can 
interact with the 9-1-1 DNA damage sensor complex, stimulating its glycosyiase 
activity. TDG may act as an adaptor for sensor checkpoint proteins by 
recognizing DNA damage then recruiting the 9-1-1 complex to stimulate BER 
and initiate signal transduction pathways (Guan, X. et al, 2007). TDG binds 
with high affinity to AP sites but is displaced by APE1 (Waters, T.R. et al, 1999). 
TDG can be modified by SUMOs (Small Ubiquitin-like Modifiers) which induce a 
conformational change involving the N-terminal domain of TDG that aids 
release of the enzyme from AP sites due to the abrogation of non-specific DNA 
binding (Steinacher, R. & Schar, P, 2005). Thymine excision from G:T mispairs 
is virtually absent in SUMO-conjugated TDG but G:U mismatch processing 
occurs with enhanced efficiency (Hardeland, U. et al, 2002; Steinacher, R. & 
Schar, P, 2005). TDG may also have a role in the regulation of gene 
expression through interactions with transcription factors of the nuclear receptor 
family including RAR (retinoic acid receptor), RXR (retinoid X receptor) and
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oestrogen receptor a (Um, S. etal, 1998; Chen, D. etal, 2003). Transcriptional 
coactivators CBP (CREB binding protein), p300 and SCR1 also interact with 
TDG (Tini, M. etal, 2002; Lucey, M.J. etal, 2005).
6.1.5 MPG
The MPG gene lies within the terminal region of chromosome 16p, consists of 5 
exons and is expressed in a range of tissues (Vickers, M.A. etal, 1993). Two 
MPG isoforms with the same DNA glycosyiase activities result from alternative 
splicing of this gene (Pendlebury, A. etal, 1994; O’Connor, T.R., 1993). MPG is 
a monofunctional glycosyiase found mainly at the periphery of the nucleus and 
around nucleoli (Campalans, A. et al, 2005). Expression of MPG is cell cycle 
dependent, increasing early in G1 then remaining constant until after mitosis 
(Bouziane, M. et al, 2000). MPG excises a range of damaged bases including 
adenine and guanine alkylation adducts, hypoxanthine, 1,N6-ethenoadenine, 8- 
oxoguanine and its oxidation product, cyanuric acid (Chakravarti, D. etal, 1991; 
O’Connor, T.R., 1993; Saparbaev, M. & Laval, J., 1994; Dosanjh, M.K. etal, 
1994; Bessho, T. etal, 1993; Dherin, C. etal, 2004). MBD1 and MPG have 
been shown to interact, linking transcriptional repression with DNA repair in 
chromatin (Watanabe, S. et al, 2003).
6.1.6 Additional enzymes involved in BER and DNA damage protection 
Several enzymes function downstream of DNA glycosylases in the BER 
pathway, including APE1 and pol A. Other enzymes such as NUDT1 and 
NUDT5 act to prevent the incorporation of aberrant nucleotides into nascent 
DNA.
6.1.6.1 Apurinic/apyrimidinic endonuclease 1 (APE1)
The APE1 gene is found at chromosome 14q11.2-q12 and spans 2.64 kb. It 
consists of five exons (the first of which is untranslated) and is ubiquitously 
expressed (Akiyama, K. etal, 1994; Harrison, L. etal, 1992). APE1 is a nuclear 
protein which possesses AP endonuclease, 3’->5’ exonuclease, 3’-repair 
diesterase and 3’ phosphatase activities (Demple, B. etal, 1991; Seki, S. etal, 
1991; Chou, K-M. & Cheng, Y-C., 2002). This is the major human AP 
endonuclease (Chen, D.S. etal, 1991) which hydrolytically cleaves the DNA
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phosphodiester backbone 5’ to an AP site, generating a terminal 3’ hydroxyl 
group ready for repair synthesis (Levin, J.D. & Demple, B., 1990). DNA 
glycosylases produce AP sites which are recognised by APE1 and some, such 
as OGG1, UNG, TDG and MPG, are specifically stimulated by the 
endonuclease (Vidal, A.E. etal, 2001; Parikh, S.S. etal, 1998; Waters, T.R. et 
al, 1999; Xia, L. etal, 2005). APE1 can also stimulate the activities of enzymes 
downstream in the BER pathway; it facilitates binding of Pol p to DNA and 
stimulates the dRP lyase activity of this polymerase (Bennett, R.A. et al, 1997). 
The enzymatic activities of FEN1 and DNA ligase I (which are involved in long- 
patch BER) are stimulated by this endonuclease and APE1 blocks re-ligation of 
a damaged site and prevents a futile cleavage and ligation cycle (Ranalli, T.A. 
etal, 2002). APE1 has DNA exonuclease activity on mismatched nucleotides at 
3’ termini of nicked or gapped DNA and may increase the fidelity of BER (Chou, 
K-M. & Cheng, Y-C., 2002). Suppression of APE1 in colon cancer cells causes 
inhibition of cell proliferation and activation of apoptosis. The steady-state level 
of endogenous AP DNA damage is up to 10 times greater in APE 1-suppressed 
cells than in control cells (Fung, H. et al, 2005). APE1 also has a second 
function, mediated by its Ref1 domain, regulating the DNA binding activity of 
proteins such as Fos, Jun and p53 through posttranslational reduction 
(Xanthoudakis, S. etal, 1992; Jayaraman, L. etal, 1997). Another AP 
endonuclease is present in humans, APE2. This enzyme has only weak AP 
endonuclease activity but shows strong 3’—>5’ exonuclease and 3’ 
phosphodiesterase activities and may have a role in processing 3’-blocking 
termini or 3’ mismatched nucleotides in nascent DNA (Burkovics, P. et al,
2006).
6.1.6.2 DNA polymerase lambda (pol A)
The POLL gene spans approximately 9kb on chromosome 10q24.3-q25.1 and 
consists of 8 exons. The major 2.7kb transcript is most highly expressed in 
testis, ovary and foetal liver but is also weakly expressed in many other tissues. 
Minor splice variants have been identified but are considered to be non­
functional (Aoufouchi, S. etal, 2000; Nagasawa, K-l. etal, 2000).
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Pol A is part of the X family of DNA polymerases which also includes Pol p and 
all members contain a pol-X core domain which mediates the addition of dNTPs 
to the 3’ end of the growing DNA chain (Ramadan, K. et al, 2004a). Pol A is a 
DNA repair, not replicative, polymerase and exhibits both template-dependent 
(DNA polymerase) (Garcfa-Dfaz, M. et al, 2002) and template independent 
(terminal transferase) (Ramadan, K. et al, 2003) activities, but lacks a 3’—>5' 
exonuclease proofreading activity (Garcfa-Dfaz, M. etal, 2002). Short gaps 
containing a 5’ phosphate group are the preferred substrates of this enzyme in 
human cells and it may be able to function under low cellular levels of dNTPs 
(Garcfa-Dfaz, M. et al, 2002). Similar to pol p, pol A possesses dRPIyase 
activity, a function required in short-patch BER, and pol A can coordinate the 
gap-filling DNA synthesis and dRP excision steps in a reconstituted BER 
reaction (Garcfa-Dfaz, M. etal, 2001). This polymerase has been shown to 
contribute to mammalian BER as pol A null MEF extracts show a deficiency in 
BER compared to the wild-type cells and lack of pol A in Pol p-deficient cell 
extracts reduces in vitro BER (Braithwaite, E.K. et al, 2005a). Pol A mediates 
repair of 5-hydroxymethyluracil in vitro and Pol A deficient MEFs are 
hypersensitive to the incorporation of this lesion into genomic DNA. Pol A 
localises to sites repairing oxidative DNA lesions and can interact with SMUG1 
(Braithwaite, E.K. et al, 2005b). Pol A also has the ability to perform strand 
displacement synthesis on gapped DNA which would be necessary for its 
involvement in long-patch BER (Garcfa-Dfaz, M. etal, 2001). RPA can 
stimulate the polymerase activity of pol A while suppressing its terminal 
transferase activity (Maga, G. et al, 2005) and can selectively prevent the 
generation of mismatches by pol A in vitro, suggesting that pol A could function 
in long-patch BER (Maga, G. et al, 2006). This polymerase can insert dCTP or 
dATP opposite 8-oxo-G (Brown, J.A. etal, 2007; Picher, A.J. & Blanco, L.,
2007), but in the presence of PCNA and RPA it correctly incorporates dCTP 
more than a thousand times more efficiently than dATP (Maga, G. et al, 2007). 
Pol A strongly discriminates against the extension of the mutagenic 8-oxo-G:A 
pair and readily extends the non-mutagenic 8-oxo-G:C pair (Picher, A.J. & 
Blanco, L., 2007). Pol A may function in translesion synthesis (Maga, G. et al, 
2002; Ramadan, K. etal, 2003; Crespan, E. etal, 2007) and non-homologous 
end joining (Bebenek, K. et al, 2003).
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6.1.6.3NUDT1 &NUDT5
NUDT1 (also known as MTH1) is located at chromosome 7p22, spans 
approximately 9 kb and is made up of five exons, the first of which is non-coding 
(Furuichi, M. etal, 1994; Oda, H. etal, 1997). The NUDT1 gene is alternatively 
spliced to produce seven mRNA transcripts and is expressed in a range of 
tissues, with highest expression in the testis and thymus (Oda, H. etal, 1997). 
The NUDT5 gene is found on chromosome 10p13-p14, consists of nine exons 
and spans approximately 18.5 kb (Gasmi, L. etal, 1999; Yang, H. etal, 2000). 
The major mRNA transcript is 1.4kb and expressed in a wide range of tissues, 
with highest expression in liver, kidney, pituitary, placenta and thymus. Minor 
transcripts of 5.0kb and 1.1 kb have also been identified (Gasmi, L. etal, 1999).
NUDT1 and NUDT5 are members of the Nudix (Nucleoside diphosphate-linked 
moiety X ) hydrolase family of pyrophosphohydrolases whose substrates often 
take the form of a nucleoside diphosphate linked to another moiety, X, resulting 
in a nucleoside monophosphate and X-P products. Examples of X include a 
sugar such as ribose or another phosphate group, as in (d)NTPs and their 
oxidized derivatives (McLennan, A.G., 2006). NUDT1 is the mammalian 
homologue of Escherichia coli mutT and preferentially hydrolyzes 8-oxodGTP to 
8-oxodGMP accordingly (Sakumi, K. etal, 1993). NUDT1-deficient mouse cells 
have a mutation frequency approximately double that of the wild-type cells and 
NUDT1-deficient mice develop a greater number of lung, stomach and liver 
tumours (Tsuzuki, T. etal, 2001). Human NUDT1 expression in E. coli mutT 
reduces the spontaneous A:T to C:G mutation frequency (Sakumi, K. et al, 
1993). NUDT5 provides human cells with an additional mechanism for 
preventing incorporation of 8-oxoG into DNA from the nucleotide pool. NUDT5 
specifically hydrolyzes 8-oxodGDP and can also cleave 8-oxodGTP, but only at 
very low levels (Ishibashi, T. et al, 2003). Direct oxidation of dGDP and 
cleavage of 8-oxodGTP by nucleoside triphosphatase (Mo, J.Y. etal, 1992) 
both result in 8-oxodGDP which is readily phosphorylated by nucleoside 
diphosphate kinase to generate 8-oxodGTP (Hayakawa, H. et al, 1995). It is 
therefore important for 8-oxodGDP to be hydrolyzed to the monophosphate as 
this is not a substrate for cellular guanylate kinase and therefore cannot be 
used for DNA synthesis (Hayakawa, H. et al, 1995). Expression of NUDT5 in £.
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coli MutT deficient cells reduced the mutation rate to the wild-type level which 
may be due to the action of nucleoside triphosphatase followed by NUDT5 
(Ishibashi, T. etal, 2003). NUDT5 also promotes the NUDT1 reaction by 
removing its inhibitor, 8-oxodGDP (Bialkowski, K. & Kasprzak, K.S., 1998).
Similar to 8-oxodGTP, 8-oxoGTP can be generated either by direct oxidation of 
GTP or phosphorylation of 8-oxoGDP by nucleoside diphosphate kinase and 
can be incorporated into mammalian cells by RNA polymerase II (Hayakawa, H. 
et al, 1999) but in contrast to DNA, once formed in the RNA it cannot be 
removed (Ishibashi, T. etal, 2005). NUDT1 and NUDT5 function to prevent 
transcriptional errors caused by misincorporation of 8-oxoG-containing 
ribonucleotides by specifically hydrolyzing 8-oxoGDP to 8-oxoGMP (Ishibashi,
T. et al, 2005). The monophosphate is not a substrate for guanylate kinase and 
therefore cannot be reutilized (Hayakawa, H. etal, 1999). NUDT1 can also 
selectively cleave 8-oxoGTP to 8-oxoGMP. Expression of either enzyme in E. 
coli mutT deficient cells reduced the increase in erroneous protein production 
from 28-fold more than the wild-type, to less than 1.5-fold (Ishibashi, T. et al,
2005).
NUDT5 was originally identified as an ADP-sugar pyrophosphatase as it can 
hydrolyze ADP-ribose (and ADP-mannose to a lesser extent) (Gasmi, L. et al, 
1999; Yang, H. etal, 2000). However, NUDT5 hydrolyzes 8-oxodGDP more 
efficiently than ADP-sugars (Ishibashi, T. etal, 2003).
6.1.7 Aims
Our group (Jones, S., Dallosso, A., Dolwani, S., personal communication) have 
previously screened OGG1, NEIL1, NEIL2, NEIL3, NTHL1 and NUDT1 in 
unrelated multiple colorectal adenoma cases and found no evidence to suggest 
that any of these genes possess high penetrance alleles at a significant 
frequency for this phenotype. The present work extended the study to other 
genes involved in BER or DNA damage protection; TDG, MPG, MBD4, SMUG1, 
NUDT5, APE1 and POLL.
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6.2 Methods
6.2.1 Clinical samples
Blood DNA samples from one case from USA and fifty-seven unrelated index 
cases from regional polyposis registers in Cardiff, Manchester, Birmingham, 
Liverpool, Southampton and Cambridge were analysed. All patients had 
between 10 and 100 adenomas recorded at colonoscopy or colectomy, except 
for two who had hundreds of adenomas at colectomy. Eleven cases were 
comprehensively sequenced for germline mutations in the APC and MUTYH 
ORFs with normal results and six of these also underwent APC MLPA with 
normal results. There was no evidence of a germline APC mutation or biallelic 
MUTYH mutations in the remaining forty-seven cases following testing in NHS 
molecular diagnostic laboratories in the referring centres. OGG1, NEIL1,
NEIL2, NEIL3, NTHL1 and NUDT1 had been screened in all fifty-eight cases 
and no clearly pathogenic mutations had been identified. In general, only blood 
DNA samples from the index cases were available and progression to family 
studies and somatic mutation analysis in tumours would only have been 
undertaken were there very strong leads that high penetrance alleles had been 
identified.
6.2.2 Screening for mutations in TDG, MPG, MBD4, SMUG1, NUDT5, APE1 
and POLL
Primers were designed to PCR amplify the coding regions of TDG, MPG, MBD4 
and SMUG1 as 9, 5, 10 and 3 fragments, respectively (Jones, S., Table 6.1). A. 
Dallosso designed PCR primers to amplify the coding region of APE1 as 4 
fragments (Table 6.1). I designed primers to PCR amplify the coding regions of 
NUDT5 and POLL as 8 and 10 fragments, respectively (Table 6.1). I carried out 
PCR optimization for all genes except APE1 which was undertaken by A. 
Dallosso (Table 6.1). The coding regions of all genes were PCR amplified and 
screened for mutations in the 58 cases using automated sequencing. A. 
Dallosso undertook screening of TDG, MPG and APE1, the Wales Gene Park 
Genomic Facility screened SMUG1 and I screened MBD4, NUDT5 and POLL in 
the 58 cases. Division of work is shown in Figure I, appendix, with my 
contribution highlighted in shaded boxes.
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Gene/Primer name Primer sequence (5’->3’)
Annealing temperature 
(°C)
Product size 
(bp)
I; * #
358
TDG_Ex1 F_NEW CAGCCACTGTCTGGGTACTG
62
TDG_Ex1 R_NEW AGAGCAGCCCCGACCT C
TDG_Ex2F CTCTCCTCTGTAATCCACTCTA
59 329
TDG_Ex2R ATCCGATGTTGAACTTTCTAA
TDG_Ex3F AGCT GCTAAAGTTT CTAAGTTAA
59 372
TDG_Ex3R CAAGGACAACTGTTAAGTAAAG
TDG_Ex4F TCCACCACTCCTCCATAGAA
59 360
TDG_Ex4R ACATCCCTCCATTCTCATAGAC
TDG_Ex5F GATCGTGCCACTACACTCTA
62 317
TDG_Ex5R AGCTCAGCTTGAACTAGATACA
TDG_Ex6_7F GCTGTCTGAATTTAGCATATTATA
56 409
TDG_Ex6_7R TCACAATGGATAGGACAAATAA
TDG_Ex8F ACAAATATTCTAATCTCAATGAGT
56 293
TDG_Ex8R TATACACACACAAAATGAATAAA
TDG_Ex9F CGGI I I ITACAGI I Cl IATG
53 406
TDG_Ex9R ATTCCCATTCTTCAATAATTT
TDG_Ex10F CTGCAAAGAGCT GT GATCAT
53 343
TDG_Ex10R AGCAAACT GAGGTT CTACTT GT
.
MPG_Ex1 F TCGAGTGTGTCAGGGTGTT
58 194
MPG_Ex1 R CGTCGGCAAAACTGTAATG
MPG_Ex2F CCTATTCGGATGCTTATTTA
55* 378
MPG_Ex2R GGGTTCAGGGACAACTG
MPG_Ex3F GGGCACT GTTAGGGT GAG
60 357
MPG_Ex3R CCACCTCAGTCCTCCTAG
MPG_Ex4F1new GCTCCACTTCCAAACTGTC
55 242
MPG_Ex4R1 new CCAGCCATACAGCTTCATC
MPG_Ex4F2_NEW CCAGCCGT GT CCTC AAG
60 311
MPG Ex4R2 NEW AAAATCTTGTCTGGGCAGG
SMUG_Ex1 F TGGATCCCTCCTACTCTG
56 420
SMUG_Ex1 R CCAAGCATCCACCTAGAA
SMUG_Ex2F1_NEW1 GGCCTCAGGTCTCCAGTT
56 314
SMUG_Ex2R1_NEW1 GGCAGCTCAGCAGGAGTA
SMUG_Ex2F2 GAGGTCTTCTT CCATCACT GT
58 400
SMUG_Ex2R2 CTTCGAGGTCTTGAATGTGTC
r lm< C* v '' " Ki
ll
ifl
l NR M Wmmi
i
|f|f
f|i
FEX1_2s.APE GAGGCTAAGCGTCTCCGTCAC 58 720
REX1_2s.APE GGTTTGT GAAGAAGTCGCAG
FEX3S.APE GT GT GAAGAAGTCGCAGGAAC 58 383
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REX3a.APE TTCTCCGTTTAGCCTTCAGG
FEX4S.APE GAATATTGTGCTGCTTGACTC
58 420
REX4a.APE CACCT CTT G ATTGCTTT CCC
FEX5S.APE TTGCTAATTCTCTATCTCTG
58 673REX5a.APE CCATTCCTTCTTTAAACACTC
FEX3Rseq AGAAACCTTCACGGGGTGGAG
rtifliimir - .■ ^.
MBD4_Ex1F CTTTCGCAACATTCAGACCTC
58 297
MBD4_Ex1 R ACTGTCCACTCTCCCGATACC
MBD4_Ex2F T GAGTAGGCAGTGGAAGATAA
58 374
MBD4_Ex2R AAGCTAAGATT CCTGCTATGC
MBD4_Ex3F 1 new AATGTGGTCCAGTTCTTTTAA
58 399
MBD4_Ex3R1 new ATCAACACCCT CATCTT CTTT
MBD4_Ex3F2 TT CAAACTGGAACCT CAGG AC
58 361
MBD4_Ex3R2 AGCATCAGAAATGCAGACAGT
MBD4_Ex3F3 GAT GCT GAAAGT GAACCT GTT
58 496
MBD4_Ex3R3 IC I IGGCICI AT I I rCACAIC
MBD4_Ex4F ATTATTTGCATCCCTCAATAT
55 214
MBD4_Ex4R ATAGTGCATCAGAATTGAAAA
MBD4_Ex5F AAT CAG AACAGCAAATT CTAA
58 298
MBD4_Ex5R TGACACACTCAAAATGGACT
MBD4_Ex6F CCACCTGG AGTCTTGTAATCA
58 225
MBD4_Ex6R lATGTTI ITC C n IG G G IG IA
MBD4_Ex7F AT 11 r GGGAGGGTGTCTTTAG
60* 205
MBD4_Ex7R C AG AG ACC AAAT GTGCT G AAT
MBD4_Ex8F CGTCTCTGCCTCTGTATCTTA
58 262
MBD4_Ex8R CATTGGCACACACATTAAGA
NUDT5x1F GCGGCAGTTCCCTCACATAC
58 389
NUDT5x1R CGAGCCCAAAAAAGGGAGTA
NUDT5X2F AAACGTGCCCACAGATTATT
58 389
NUDT5X2R CCCAATTTTATTCAGCAACTAT
NUDT5x3F GGCAAGAGI I rTCGTTGlTA 58 527
NUDT5X3R AGGTGTGGCTTCAAACTATAT
NUDT5x4(1)F CTGTGGAAGGTCAGTGTAGTC
58 557
NUDT5x4(1)R CTCGCTACGAAATGGTTTAG
NUDT5X5F GATTTCCCGCTCCCATCAC 58 313
NUDT5x5R AGGCCCTTCTGGCTCCAG
NUDT5x6F CTACCAAAT GT GAGAACTAGT 58 500
NUDT5x6R GT GGGAATACACTTCATATAG
NUDT5x7/8F GCTCG AGTTT G AC AAT GTAT 58 465
NUDT5x7/8R CTAGGCATTT GACTTTAGT G A
NUDT5X9F AGCATAGGAAGT GACATATA 58 319
185
NUDT5x9R AGCTAATGGCAAATCTAC
1
POLLxlF CTACCCCCAAAGCCTGGTCAG
58 365
POLLxIR AGGCCCTGGACAGGCAGAGT
POLLx2(1)F TTTCAGGGTAGGGGACTGT
61 567
POLLx2(1)R CTCCCACCTAAACCTCTTATAG
POLLx3F GCCTTGATCGTACCACTGTAC
58 492
POLLx3R AGAGCTAAATGGCTTCACAATA
POLLx4.1F GGCCTCACACCCAAGGAGA
58 445
POLU4.1R GCATT GAT GGCCTT G GC ATAG
POLLx4.2F CCAGAAGGCGACCAATCAC
58 329
POLLx4.2R CTCCCAGCTTCAACAACTATCAA
POLLx5F TTACCCAGCCCTCATTCTATC
58 471
POLLx5R CCCAT CAGAGCACAGCATAG
POLLx6F TTCCCAAGTCCTGCTGAGTAC
58 456
POLLx6R GGCCTGGAGCTTCAGTCTTA
POLU7F GCTT GCCTCCT GC AC AGT
58 489
POLLX7R TGCCTCAGGACTGGAACTTC
POLLx8.1F AAGGGCCCAG AGAGGGTAGT
58 474
POLLx8.1R AGGCCTAAGAGCCTGAAGACAT
POLLx8.2F GCCAAAACCAAGGGCAT GAGTCT
58 305
POLLx8.2R GGCCCTGCTCGCTGAGGAA
Table 6.1 Sequences of primers and PCR conditions used to screen TDG, 
MPG, MBD4, SMUG1, NUDT5, APE1 and POLL * 4% DMSO added to PCR 
reaction.
6.2.3 Assays for sequence variants in controls
Specific assays were designed to determine the presence and frequency of 
previously unreported rare missense variants (identified in only one or two 
cases in the present study) in at least 700 control chromosomes (Table 6.2).
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Gene/Variant Primer name Primer sequence (S’->3’)
Anneal.
temp
(°C)
Product 
size (bp)
Assay
Q391K
TDG_Q391 K_CF GACCCAGTCATTTACAGTCC
58(C)
54(A)(c. 1171 C->A) TDG_Q391K_AF
GACCCAGTCATTTACAGGCA 156 ARMS
TDG_Q391K_R AGCAAACTGAGGTTCTACTTGT
1134V TDG_Ex3F AGCTGCTAAAGTTTCTAAGTTAA
59 372
HpyCH4IV digest
(c.400 A—*G) TDG_Ex3R CAAGGACAACTGTTAAGTAAAG Mut allele digested (291 bp + 81 bp)
E240D MPG_E240D_F
CCAGCCGTGTCCTCAAGGA ----------------- 'w ; .................. ................^ .......
(C.240 A—»C) MPG_E240D_TR CACGCTCCAGCCATACAACT
58 126 ARMS
MPG_E240D_GR CACGCTCCAGCCATACACCG
" m m  '
’ ” r. " ’ '.1 , - -:r. 1
N467S MBD4_N467S_F
CCACGACGTAAAGCCTTTAAG
(c.1400 A-»G) MBD4_N467S_AR
TCCCCAAACCTGAGGTCCAAT 58 133 ARMS
MBD4_N467S_GR TCCCCAAACCTGAGGTCCCAC
NUDT5
G165A NUDT5_G165A_F
GCTCGAGTTTGACAATGTAT
54(G) 
56 (C)(c.910 G-»C) NUDT5_G165A_GR
GGAGTTGCAGAACATACCTC 177 ARMS
NUDT5_G165A_CR GGAGTTGCAGAACATACCTG
POLL m m m sam '
P303S
P0LLX5F TTACCCAGCCCTCATTCTATC BsaJI digest
(c.907 C->T) P0LLx5R CCCATCAGAGCACAGCATAG
58 471 Mut allele digested (372bp + 99bp)
WT allele digested (206bp + 165bp + 99bp + 1bp)
Table 6.2 Assays for specific missense variants in TDG, MPG, MBD4, NUDT5 and POLL. Internal control primers were used to validate 
the ARMS assays; TSC2_Ex26F (5’-G AGCTTT GGCCCTT GGT GATA) and TSC2_Ex26R (5’-CT CGCCCACAGGAG ACCTAG A), product size 
388bp.
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6.3 Results
6.3.1 Coding variants identified in TDG
Four missense variants were identified in the TDG gene; 1134V, G199S, V367A 
and Q391K (Table 6.3). No cases were found to have two variants in the TDG 
gene. V367M was found in a heterozygous state in nine cases and in a 
homozygous state in one case, all with between 11 and 100 colorectal 
adenomas. This variant is a semi-conservative amino acid substitution and 
valine is not found at this residue in other species.
The three rare missense variants, G199S, 1134V and Q391K, were identified in 
the heterozygous state only. G199S was found in one patient (CB1) with 
between 11 and 100 colorectal adenomas and is a conservative amino acid 
change at a site partially conserved through evolution. 1134V was detected in 
one case (1137) who presented in the third decade, had 14 colorectal 
adenomas without CRC and no family history of CRC. This case had previously 
been screened (and was negative) for germline mutations in the ORFs of APC 
and MUTYH (see chapter 3). This variant is a conservative amino acid 
substitution at a site partially conserved through evolution but was not found in 
over 700 control chromosomes. Tumour samples were not available to screen 
for somatic inactivation of the wild-type TDG allele and DNA from the previous 
generation was not available to determine whether 1134V was a de novo 
substitution.
Q391K was identified in a single case (M2) with at least 30 colorectal adenomas 
without CRC. This case has a family history of CRC; two of five siblings were 
diagnosed aged 48 and 39 years and their mother died from CRC aged 82.
This variant is an uncharged to a charged amino acid substitution, although 
both amino acids are polar. This site is partially conserved through evolution 
and the change was not detected in over 700 control chromosomes. DNA 
samples were not available to determine if this variant segregated with the 
disease phenotype. Tumour samples were also not available to screen for 
somatic inactivation of the wild-type TDG allele.
188
Gene/ AA Nucleotide Conservation
PolyPhen2 MAF in cases3 Case no.
NCBI dbSNP MAF in
Exon change Change AA Evolution1 (MAF)4 controls
3 1134V c.400 A—>T c Partial Benign 1/116(0.9%) 1137 1 0/724
5 G199S c.595 G-»A c Partial Possibly
damaging
1/116(0.9%) CB1
Rs 4135113 
(18.5%)
ND
10 V367M c.1099 G—>A sc No Benign 11/116(9.5%) B1, B2, C1, C2, CB2, M1, SOI, S02, SY1, 
4822
Rs 2888805 
(22.1%)
ND
10 Q391K c.1171 C—A sc Partial Possibly
damaging
1/116(0.9%) M2 / 0/722
MPG • - i : V \ -
,
4 E240D c.720 A->C
c
No Benign 1/116(0.9%) B3 / 0/716
APE1
3
________
Q51H c.153 G->C sc Partial Benign 2/116(1.7%) 1137, 1187 Rs 1048945 
(3.3%)
ND
5 D148E c.444 T—*-G c No Benign 56/116(48.3%)
B1, B2, S3, B5, B6, B7, 
C1,C2, C3, C4, CB1, 
CB3, CB5, CB6, CB7, 
B4, Lf, M1, M2, M3, M4, 
M5, M6, M7, M8, M9, 
SOI, S02, S03, S06, 
S07, S08, S09, SO10, 
SY1, SY2, 0322, 1187, 
3432, 3607, 3858, 4093, 
4822, 8163
Rs 1130409 
(48.6%)
ND
[ MBD4 I I 1 I | : ■
3 A273T c.817 G-»A sc Partial Benign 12/116(10.3%) C4, CB1.M1 ,M4, S04, S05, SY1, 2302 4093, 
4822, 8163
Rs 10342 
(22.9%)
ND
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3 I358T c.1073 T—>C SC Partial Benign 1/116(0.9%) CB3
Rs 2307298 
(0.6%)
ND
5 N467S c.1400 A—>G SC Partial Benign
2/116(1.7%),
1/218(0.5%)*
M3, S03 /
0/712, 
1/502 (0.2%)*
8 D568H c.1702 G-»C SC Partial Benign 1/116(0.9%) C3
Rs 2307293 
(0.6%)
ND
7 G165A C.910G-C
_________________
C Partial
. '
• ■
Possibly
damaging
1/116(0.9%) M3
:V ■' • ”  
/
■ '
0/706
POLL ' i .......... ' ..... ' ' '
4 T221P c.661 A-*C SC Partial Benign 12/116(10.3%) B2, B4, C2, C5, M3, M5, M6, S01.S06, SY1, 
1137,4093
Rs 3730463 
(11.0%)
ND
5 P303S c.907 C—>T sc Yes Probably
damaging
1/116(0.9%) 5161 / 0/722
7 R438W C.1312 C->T sc Partial Benign 24/116(20.7%)
B5, C6, CB2, CB4, CB5, 
M2, M3, M7, S01.S02, 
S07, SOS, 0322,1149, 
2302, 3432, 3607,4147, 
5161
Rs 3730477 
(17.1%)
ND
Table 6.3 Coding variants identified in TDG, MPG, APE1, MBD4, NUDT5 and POLL ’Alignments of human (NP_003202; NP_002425; 
NP_001632; NP_003916; NP_054861; NP_037406), mouse (NP_766140; NP_034952; NP_033817; NP_034904; NP_058614; NP_064416), 
Xenopus (NP_001084290; NP_001017178; NP_001086779; NP_001037916; NP_001016613; NP_001093716), Drosophila (NP_651925; 
NP_476841, TDG and APE1 only), Arabidopsis (NP_181677; NPJ91862; NP_178524; NP_172522, not TDG or MPG), S. cerevisiae 
(EDN64598; NP_009669, APE1 and NUDT5 only), S. pombe (NP_588515; NP_592977, TDG and Pol A only), C. noyvi (YP_877811, MPG 
only), M. thermautotrophicus (P29588, MBD4 only), P. sfirfzeri (YP_001174562, MBD4 only), P. putida (NP_746917, MPG only), E. coli
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(NP_417540; NP_754044; NP_417856, TDG, APE1 and NUDT5 only) homologues of TDG, MPG, APE1, MBD4, NUDT5 and Pol A were 
carried out using ClustalW. Residues were determined to be conserved, partially conserved or non-conserved through evolution based on the 
number of species with similar amino acids. 2PolyPhen (http://genetics.bwh.harvard.edu/pph/) prediction of effect variant may have on protein. 
3The minor allele frequency (MAF) of each variant in multiple colorectal adenoma patients is shown. Case numbers in normal and italic font 
indicate heterozygotes and homozygotes, respectively. 4NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/) reference numbers and 
MAF are indicated. 5Rare variants (MAF<2% in cases) with no entry in dbSNP were also typed in control samples. *Dutch multiple adenoma 
cases and controls, AA; amino acid, C; conservative substitution, SC; semi-conservative substitution, NC; non-conservative substitution, ND; 
not determined.*Dutch cases and controls.
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6.3.2 Coding variants identified in MPG
One missense variant was identified in the MPG gene, E240D (Table 6.3). This 
rare variant was identified in a heterozygous state in a single case (B3) with 28 
colorectal adenomas and CRC aged 48 but no family history of bowel problems. 
E240D is a conservative amino acid substitution at a site which is not conserved 
through evolution but was not detected in more than 700 control chromosomes. 
No second germline variant in the MPG gene was identified in this case.
Tumour samples were not available to screen for somatic inactivation of the 
wild-type MPG allele and DNA from the previous generation was not available 
to determine whether E240D was a de novo substitution.
6.3.3 Coding variants identified in APE1
Two missense variants were identified in APE1, Q51H and D148E (Table 6.3). 
The MAF of the D148E variant was nearly 50%, with 33 heterozygotes and 4 
homozygotes identified. The phenotype of heterozygous cases ranged from 
between 11 and 100 to hundreds of colorectal adenomas and all homozygotes 
had between 11 and 100 adenomas. This variant is a conservative amino acid 
substitution at a site which is not evolutionarily conserved. Q51H is an 
uncharged to a charged amino acid substitution, although both amino acids are 
polar, and this site is partially conserved through evolution. Q51H was detected 
in the heterozygous state in two cases; one with 50 to 100 colorectal adenomas 
and CRC (1187) and the other had 14 colorectal adenomas in the absence of 
CRC (1137). Neither of these cases had a family history of CRC and both had 
been comprehensively sequenced for germline mutations in the APC and 
MUTYH ORFs with normal results (chapter 3). APC MLPA failed for case 1137 
but a normal result was obtained for patient 1187 (chapter 3). No cases were 
found to have two rare variants in the APE1 gene.
6.3.4 Coding variants identified in MBD4
Four missense variants were identified in MBD4; A273T, I358T, N467S and 
D568H (Table 6.3). A273T was found in the heterozygous state in ten cases, 
eight of whom had between 11 and 100 colorectal adenomas and two had 
hundreds of colorectal adenomas and CRC. One homozygote case (M4) with 
50 colorectal adenomas was identified. This variant is a semi-conservative
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amino acid substitution at a residue which is partially conserved through 
evolution. One case heterozygous for I358T was identified (CB3) and had 
between 11 and 100 colorectal adenomas. This variant is a non-polarto a polar 
amino acid substitution at a site which is partially conserved through evolution. 
D568H was also detected in the heterozygous state in a single case (C3) with 
between 11 and 100 colorectal adenomas. This variant is a negatively-charged 
to a positively-charged amino acid substitution, although both amino acids are 
polar, at a residue that is partially conserved though evolution.
Two N467S heterozygotes were identified, one (M3) had at least 70 colorectal 
adenomas with CRC and had previously been screened (and found to be 
negative) for germline mutations in APC exons 3, 5-15 by PTT and SSCP. This 
case had a family history of CRC, with all three siblings diagnosed in their 
forties or fifties and their father diagnosed aged 72. There was no evidence that 
the father had colorectal adenomas but at least one of the siblings had a 
colorectal polyp in addition to CRC. The other patient (S03) had between 11 
and 100 colorectal adenomas. Both cases were screened for germline 
mutations in APC exons 4 and 9 and the MUTYH ORF by sequencing. No 
mutations were detected. N467S is a semi-conservative amino acid substitution 
at a site which is partially conserved through evolution. This variant was not 
identified in over 700 control chromosomes so a cohort of Dutch multiple 
colorectal adenoma patients and Dutch controls (courtesy of Dr. F.J. Hes) was 
screened (Table 6.3). One out of 109 cases and one of the 251 control 
samples were found to be heterozygous for this variant. No cases were found 
to have two rare variants in the MBD4 gene and tumour samples were not 
available to screen for somatic inactivation of the wild-type MBD4 allele.
6.3.5 Coding variants identified in NUDT5
One missense variant was identified in the NUDT5 gene, G165A (Table 6.3, Fig 
6.1). This variant was identified in a heterozygous state in patient M3 (see 
above for phenotype). G165A is a conservative amino acid substitution at a site 
which is partially conserved through evolution but was not found in over 700 
control chromosomes. No second germline variant in the NUDT5 gene was 
identified in this case and tumour samples were not available to screen for
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A) Normal Patient M3
NUDT5 G165A 
(C.910G— C)
A T G G A G G A T G N A G G
B) Normal Patient 5161
POLL P303S 
(c.1312 C—>T)
A T C C C T G A T C N C T G
Figure 6.1 Rare missense variants in the NUDT5 and POLL genes in 
patients with colorectal adenomas. Patient M3 had at least 70 colorectal 
adenomas and patient 5161 had multiple colorectal adenomas. Both variants 
are novel changes that were not found in controls.
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somatic inactivation of the wild-type allele.
6.3.6 Coding variants identified in POLL
Three missense variants were identified in POLL; T221P, P303S and R438W 
(Table 6.3). Twelve cases were found to be heterozygous for T221P and all but 
one had between 11 and 100 colorectal adenomas, with a single case having 
hundreds of colorectal adenomas. This variant is a polar to a non-polar, cyclic 
amino acid substitution at a residue partially conserved though evolution. 
R438W was found in the heterozygous state in fourteen cases, of which thirteen 
had between 11 and 100 colorectal adenomas and one had hundreds of 
colorectal adenomas with CRC. Five cases with between 11 and 100 colorectal 
adenomas were identified as R428W homozygotes. This variant is a semi­
conservative amino acid substitution at a residue which is partially conserved 
through evolution.
P303S was identified in a single heterozygous case (5161) (Fig 6.1) with 
multiple polyps aged 31 years without a family history of CRC or colorectal 
polyps and both parents had normal colonoscopies in their sixties. This patient 
had been previously screened (and found to be negative) for germline 
mutations in APC by PTT, SSCP, MLPA and sequencing of the entire APC 
coding region. Comprehensive sequencing of the MUTYH ORF was 
undertaken (see chapter 4) and patient 5161 was found to carry only a 
monoallelic G393D mutation. The POLL P303S variant is a non-polar, cyclic to 
a polar amino acid substitution at a residue which is conserved through 
evolution. It was not detected in over 700 control chromosomes. No second 
rare germline variant in the POLL gene was identified in this case and the 
P303S variant was found to be inherited from his unaffected father. Tumour 
samples were not available to screen for somatic inactivation of the wild-type 
POLL allele.
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6.4 Discussion
6.4.1 Mutations in the TDG gene
The missense variants V367M and G199S have been previously reported as 
polymorphisms (rs2888805; rs4135113) but were identified at a lower frequency 
in the present study than in reported normal population samples. This may be 
due to variation in allele frequencies between different populations. V367M is a 
common variant that lies outside of the glycosylase domain (Gallinari, P. & 
Jiricny, J., 1996) within the less conserved C-terminal region of TDG. It is not 
predicted to have a deleterious effect on the protein, has a MAF of 
approximately 20% in dbSNP and has recently been reported in familial CRC 
cases by Broderick et al who identified more than ten heterozygotes in a cohort 
of 94 cases and concluded that V367M is a polymorphism that does not 
contribute significantly to CRC susceptibility (Broderick, P. et al, 2006).
G199S is located in the catalytic core domain of TDG (Baba, D. etal, 2005) but 
is not one of the critical residues of the active site or necessary for substrate 
recognition (Hardeland, U. et al, 2000). It is predicted to have a possibly 
damaging effect on the protein but the substitution of serine for glycine is 
conservative as both are uncharged and small. Despite being classed as non­
polar, the tiny glycine side chain does not really contribute to hydrophobic 
interactions (Nelson, D.L. & Cox, M.M., 2000) so this substitution is unlikely to 
disrupt crucial interactions. G199S has been reported in unaffected individuals 
at a MAF twenty times greater than that observed in cases in the present study 
(18.5% vs 0.9%). Such a large difference in MAF suggests that this allele could 
have a protective effect, decreasing CRC predisposition as has been described 
for homozygous carriers of the MTHFR variant A677V (Houlston, R.S. & 
Tomlinson, I.P.M., 2001). A serine side chain at codon 199 of TDG could 
contribute more to hydrophobic interactions within the catalytic core domain 
than the glycine side chain which could possibly improve substrate recognition 
and/or catalysis.
Two novel coding variants were identified in TDG, Q391K and 1134V. 1134V is 
located in the catalytic core domain of TDG (Baba, D. et al, 2005) but is not 
itself one of the residues crucial for catalysis or substrate recognition
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r(Hardeland, U. et al, 2000). It forms part of a 0-sheet structure in the core 
domain (Baba, D. et al, 2005) which is unlikely to be affected by the substitution 
as both amino acids are non-polar and aliphatic. Despite being part of the 
sequence motifs that mediate SUMO binding (V/J_-X-V/l-V/l) (Mohan, R.D. etal, 
2007) and oestrogen receptor a interaction (LDM) (Chen, D. etal, 2003), the 
amino acid substitution leaves them functionally unaffected, consistent with the 
prediction of a benign effect on the protein. Although 1134V was not identified in 
control samples, there is little evidence that this change is pathogenic.
Q391K is found in a region of the C-terminal domain not required for 
glycosylase activity but lies within an area (residues 273-421) needed for 
interaction with the CH3 domain of transcriptional coactivator CBP (Tini, M. et 
al, 2002). This variant was predicted to be possibly damaging and was not 
detected in control chromosomes. Both amino acids are hydrophilic but 
whereas glutamine is uncharged, lysine is positively-charged which could affect 
electrostatic interactions. Further work is required to determine whether this 
mutation has a pathogenic effect and any influence on colorectal adenoma 
predisposition.
6.4.2 Mutations in the MPG gene
The only missense change identified in MPG was the novel variant E240D but 
there is little evidence this is pathogenic. E240D is not one of those residues 
critical for glycosylase activity (Lau, A.Y. etal, 1998) but is found within a region 
(residues 233-294) required for interaction with the transcriptional repressor 
MBD1 (Watanabe, S. etal, 2003). E240D was not detected in control samples 
but both amino acids are negatively-charged so the substitution is predicted to 
have little effect on the protein.
6.4.3 Mutations in the APE1 gene
The two non-synonymous variants detected in the APE1 gene, Q51H and 
D148E, have both been identified previously in normal populations at 
frequencies similar to those reported in this study (Hadi, M.Z. et al, 2000; 
rs1048945; rs1130409). D148E is a common polymorphism located within the 
nuclease domain but has no impact on endonuclease or DNA binding activities
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of the protein (Hadi, M.Z. et al, 2000), as predicted. Q51H is found outside of 
the nuclease domain, within the Ref domain of APE1 (Hadi, M.Z. et al, 2000) 
and is predicted to have little effect on the protein. There is therefore no 
evidence to suggest that either of these variants represent pathogenic 
mutations.
6.4.4 Mutations in the MBD4 gene
The MBD4 missense variant A273T has been previously reported as a 
polymorphism found at similar (Bader, S. et al, 1999) or higher frequencies 
(rs10342) than in the present study. This discrepancy may be due to variation 
in allele frequencies between different populations. There is no evidence to 
suggest that this variant represents a pathogenic mutation as it is predicted to 
have little effect on the structure or function of the protein.
Three rare variants were detected in the MBD4 gene in the present study.
I358T and D568H have been identified previously (rs2307298; rs2307293) and 
are predicted to have little effect on the MBD4 protein. The I358T residue is not 
required for glycosylase activity and lies outside the methyl-binding domain 
(Wu, P. et al, 2003). Despite being located within the glycosylase domain in a 
region that forms the top of the cleft, D568H is predicted to have a benign effect 
on the protein as both amino acids are hydrophilic and it is the hydrophobic 
residues within this region that are important for cleft formation (Wu, P. et al, 
2003). N467S is a novel rare variant that lies within a loop in the glycosylase 
domain that is important for DNA-binding and base flipping (Wu, P. etal, 2003). 
It was not identified in the initial set of control chromosomes but after analyzing 
a further set of Dutch multiple colorectal adenoma cases and controls, it was 
identified in a single control sample. Both amino acids are polar and uncharged 
so this variant is predicted to have little effect on MBD4. It is therefore unlikely 
that these three variants contribute significantly to multiple colorectal adenoma 
predisposition.
6.4.5 Mutations in the NUDT5 gene
The only missense change identified in NUDT5 was the novel variant G165A. 
This residue is located within the catalytic Nudix domain but is not found in the
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rNudix motif itself (Zha, M. et al, 2006). G165A is predicted to be possibly 
damaging, despite both amino acids being non-polar and aliphatic. NUDT5 
forms homodimers and this variant forms part of a loop which is involved in 
stabilizing interactions between the two subunits and is important for 
dimerization (Fig 6.2) (Zha, M. etal, 2006). G165A was not detected in control 
samples so further work is required to determine whether this mutation has a 
pathogenic effect and any influence on colorectal adenoma predisposition.
6.4.6 Mutations In the POLL gene
The non-synonymous variants T221P and R438W found in POLL have 
previously been reported as polymorphisms (rs3730463; rs3730477). The 
R438W variant was identified at a higher frequency in the present study which 
may to be due to variation in allele frequencies between different populations. 
T221P is located in the serine-proline-rich domain which is dispensable for 
enzymatic activity (Delarue, M. et al, 2002). This variant is not predicted to 
have an effect on the protein as both amino acids are polar and uncharged and 
the substituted proline lies within a proline-rich domain. The common variant 
R438W is found in the palm subdomain of the Pol A polymerization domain but 
is not one of the critical catalytic residues (Garcia-Diaz, M. etal, 2004) and is 
not predicted to have a deleterious effect on the protein. Therefore there is little 
evidence that T221P or R438W are pathogenic changes.
The novel, rare POLL missense change P303S is located in the 8kDa domain of 
Pol A and forms part of a helix-hairpin-helix (HhH) motif which binds 
downstream primer DNA and contains the catalytic residue for dRP lyase 
activity (Fig 6.2) (Garcia-Diaz, M. et al, 2004). Proline reduces the structural 
flexibility of polypeptide regions containing this amino acid (Nelson, D.L. & Cox, 
M.M., 2000) and is therefore important in maintaining the HhH motif structure. 
Substitution of serine for this proline is likely to disrupt the protein structure and 
is predicted to have a deleterious effect on Pol A. P303S was not detected in 
control samples but was identified in the patient’s unaffected father so further 
work is required to determine whether this mutation has an incompletely 
penetrant pathogenic effect and any influence on colorectal adenoma 
predisposition. This patient also harbours a monoallelic germline MUTYH
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Figure 6.2 (A) Crystal structure and structural features of the human NUDT5 
protein. Two NUDT5 monomers (blue and pink ribbons) form a homodimer that is 
stabilized by interactions between the subunits at an interface which includes residue 
165 (shown as yellow spacefill). This residue lies within a hydrogen-bonded turn 
(yellow loop) as indicated by the arrow (below) (RCSB Protein Data Bank 
www.rcsb.org/pdb/). (B) Crystal structure, structural features and evolutionary 
conservation of the human Pol A protein. The Pol A 8kDa domain (purple ribbon) 
bound to a two nucleotide gap. The template strand and primers are shown in green 
and red sticks respectively. This domain interacts with the downstream primer in a
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!region which includes residue 303 (shown as yellow spacefill). This residue lies within a 
hydrogen-bonded turn (yellow loop) of a HhH motif, as indicated by the arrow (below) 
(RCSB Protein Data Bank www.rcsb.org/pdb/). Alignment of human (NP_037406), 
mouse (NP_064416), Xenopus (NP_001093716), Arabidopsis (NP_172522) and yeast 
(NP_592977) Pol A homologues, along with human Polf3, Polp and TdT (terminal 
deoxynucleotidyltransferase), was carried out using ClustalW (right). Amino acids are 
coloured according to their biochemical properties. The highly conserved proline at 
residue 303 is indicated by the arrow. Chains A and B of PDB file 2dsb (NUDT5) and 
chain A of PDB file 1 rzt (Pol A) were used to generate the figures using RasMol v2.6-p- 
2 (http://openrasmol.org/).
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mutation (G393D) which was inherited from his unaffected mother. Neither 
variant may significantly predispose to colorectal adenomas alone (chapter 5), 
but in combination may affect BER sufficiently to produce a phenotypic 
consequence. Rare germline missense variants in NUDT1 (R31Q) and OGG1 
(R197W) have been found individually in combination with a heterozygous 
MUTYH mutation (either Y176C or G393D) in multiple polyposis cases 
(Farrington, S.M. etal, 2005). Alternatively, the presence of a heterozygous 
G393D mutation in combination with P303S may just be coincidental as this 
MUTYH mutant allele is found at a MAF of 1 % (G393D) in healthy Caucasians 
(Croitoru, M.E. etal, 2004; Farrington, S.M. etal, 2005; Webb, E.L. etal, 2006).
6.4.7 No evidence for significant contribution of highly penetrant germline 
mutations in the TDG, SMUG1, MPG, APE1, MBD4, NUDT5 or POLL genes to 
colorectal adenoma predisposition
In contrast to MUTYH, no clearly pathogenic mutations were identified in the 
BER and DNA damage protection genes analyzed in the present study. Similar 
negative results have been reported after screening NTHL1, NEIL1, NEIL2, 
NEIL3, NUDT1, OGG1, UNG, MPG, TDG and SMUG1 in patients with multiple 
colorectal adenomas (Al-Tassan, N. etal, 2002; Sieber, O.M. etal, 2003; 
Broderick, P. et al, 2006; S. Jones, A. Dallosso and S. Dolwani, personal 
communication). There are several possibilities which may explain these 
results.
6.4.7.1 Functional redundancy
Protection against DNA damage is crucial for maintaining genomic integrity so 
organisms have evolved a system with a high degree of functional redundancy. 
DNA glycosylases have partially overlapping substrate specificities and can, to 
a certain extent, functionally compensate for each other in vivo. Mice deficient 
in OGG1, UNG or MBD4 do not display phenotypic abnormalities and exhibit 
only a small (1.4- to 3-fold) increase in mutation rate (Minowa, O. et al, 2000; 
Nilsen, H. etal, 2000; Miller, C.B. etal, 2002; Wong, E. etal, 2002). Nthll 
knock-out mice retain glycosylase activity and are phenotypically normal 
(Takao, M. etal, 2002), as are Mpg'~ mice which show limited glycosylase 
activity (Engelward, B.P. etal, 1997). BER proteins APE1 and Pol A have
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?catalytic activities which are also exhibited by APE2 and Pol p respectively 
(Burkovics, P. etal, 2006; Braithwaite, E.K. etal, 2005). Chicken DT40cells 
lacking Pol A and Pol p showed hypersensitivity to oxidative DNA damage and 
lower BER capacity, but lack of either polymerase alone resulted in only a 
modest effect on sensitivity to oxidative DNA damage and no effect on BER 
capacity compared with wild-type cells (Tano, K. etal, 2007). NUDT1 and 
NUDT5 overlap functionally in preventing incorporation of 8-oxoG into nascent 
DNA or RNA. NUDT1 deficient cells show only a 2-fold increase in mutation 
frequency and both enzymes can reduce the mutation rate in E. coli mutT cells 
(Tsuzuki, T. etal, 2001; Sakumi, K. et al, 1993; Ishibashi, T. etal, 2003).
6.4.7.2 Embryonic lethality
Some of the core components of BER are essential for embryonic development 
as demonstrated by the embryonic lethality of mice lacking Ape1, Pol p, DNA 
ligase I orXRCCI (Xanthoudakis, S. etal, 1996; Friedberg, E.C. & Meira, L.B.,
2003). Ape+I~ mice are phenotypically normal but are haploinsufficient and the 
observed changes in BER activity may be related to the redox regulatory activity 
of APE1 (Raffoul, J.J. etal, 2004). Unlike other DNAglycosylases, TDG 
deficiency is embryonic lethal in mice so this enzyme must have a non- 
redundant function necessary for development which may relate to BER but is 
not simply the excision of damaged bases (Cortazar, D. et al, 2007). Biallelic 
germline mutations in these genes which result in a lack of functional protein 
may therefore not be viable in humans but mutations that produce either 
functionally compromised protein or a reduced amount of functional protein may 
be sufficient for survival and could result in defective BER.
6.4.7.3 Tissue specificity
Inactivation of genes involved in protection against DNA damage other than 
MUTYH may not predispose to colorectal adenomas, but have a different 
phenotypic effect. NUDT1-deficient mice develop more lung, liver and stomach 
tumours than their wild-type counterparts (Tsuzuki, Y. etal, 2001) and there is 
variable expression of some enzymes including Pol A and NUDT5 (Aoufouchi,
S. etal, 2000; Nagasawa, K-l. etal, 2000; Gasmi, L. etal, 1999) between 
tissues. Somatic mutations in the MBD4 gene have been reported in sporadic
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and hereditary MSI colorectal tumours (Riccio, A. etal, 1999; Bader, S. etal, 
1999). Similar to Mutyh'1' mice on a ApcMml+ background (Sieber, O.M. et al,
2004), Mbd4'l~ mice on the same background have increased numbers of 
intestinal tumours and accelerated tumour progression (Millar, C.B. et al, 2002; 
Wong, E. et al, 2002) suggesting that MBD4 function may be important in the 
colorectum. However, MBD4 mutations have only been found at hypermutable 
polyadenine tracts, are not detected in MSS colorectal tumours (Riccio, A. et al, 
1999; Bader, S. et al, 1999) and MBD4 deficiency or heterozygosity provides no 
selective advantage on MMR-deficient tumourigenesis in mice (Sansom, O.J. et 
al, 2004). These data suggest that mutations in MBD4 may just be a 
consequence of MMR deficiency and this glycosylase may not have a critical 
role in the colorectum. Consistent with this, no pathogenic germline MBD4 
mutations were identified in patients with hyperplastic polyposis syndrome 
(Chow, E. et al, 2006). The MBD4 polymorphism E346K may be associated 
with oesophageal squamous cell carcinoma susceptibility (Hao, B. et al, 2004) 
and there is conflicting evidence as to whether this polymorphism is associated 
with lung cancer risk (Shin, M.C. et al, 2006; Sakiyama, T. et al, 2005).
Different glycosylases preferentially act at certain DNA sequences, cell cycle 
stages or when a particular base is paired opposite the damaged site 
(Petronzelli, F. etal, 2000a; Hendrich, B. etal, 1999b; Hardeland, U. etal,
2005; Neddermann, P. etal, 1996; Bouziane, M. etal, 2000; Cortazar, D. etal, 
2007). Different tissues are exposed to different carcinogens and have distinct 
gatekeeper genes which are susceptible to particular types of mutation.
Defects in different DNA glycosylases may therefore result in different, tissue- 
specific phenotypes. APE1 also exhibits tissue-specific variation in activity as 
shown by the haploinsufficient Ape+I~ mice. These mice show different 
alterations in Pol P-dependent BER activity in different tissues. Activity was 
decreased in the liver, increased in the testes and remained the same in the 
brain (Raffoul, J.J. et al, 2004).
6.4.7.4 Low frequency of mutations
Due to the small sample size of the present study, mutations in TDG, MPG, 
SMUG1, MBD4, NUDT5, APE1 and POLL could predispose to colorectal 
adenomas but remain undetected if they are found at a lower frequency than
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MUTYH mutations. This situation occurs in HNPCC, with only a very small 
proportion of cases accounted for by mutations in the PMS2 gene (Peltomaki,
P., 2005). The patient set analyzed in the present study consisted 
predominantly of cases with between 11 and 100 adenomas without evidence 
of vertical transmission of polyposis and included few cases with more than 100 
adenomas and none with early onset CRC in the absence of polyposis. 
Mutations resulting in a slightly different phenotype from that of MAP would 
therefore not have been detected. Patients in whom one potentially pathogenic 
germline variant was identified could also possess a germline mutation on the 
other allele that remained undetected such as a large deletion, a promoter 
mutation or an epimutation, as recently reported in the MSH2 gene in a family 
affected by HNPCC (Chan, T.L. etal, 2006).
6.4.7.5 Reduced penetrance and multifactorial inherited susceptibility 
A substantial proportion of inherited CRC susceptibility is thought to be the 
result of incompletely penetrant, relatively rare variants in different genes.
These might individually confer only a very modest increase in relative risk of 
CRC but act in an additive or multiplicative manner (Fearnhead, N.S. et al,
2005). A significant association between the combined effects of missense 
variants in the APC, AXIN, CTNNB1, MLH1 and MSH2 genes and colorectal 
adenomas has been reported (Fearnhead, N.S et al, 2004). Rare variants 
identified in the present study may be good candidates for multifactorial 
inherited CRC susceptibility as defects in repair could increase genetic 
instability which plays a key role in tumourigenesis. In addition to MLH1 and 
MSH2 variants, a rare variant in the BLM gene may also be involved in CRC 
predisposition (Fearnhead, N.S etal, 2004; Gruber, S.B. etal, 2002). High 
frequency, low penetrance alleles may also be associated with CRC risk but this 
study did not have the power to detect an association between such alleles and 
the multiple adenoma phenotype. There is good evidence of an increased CRC 
risk associated with polymorphisms in the HRAS1, MTHFR and NAT2 genes 
(Kemp, 2. et al, 2004). Large case-control studies will be needed to determine 
whether variants identified in the present study contribute to the hereditary CRC 
predisposition.
Thirlwell et al recently analyzed the frequencies and spectra of somatic 
mutations in the APC, K-ras and BRAF genes in patients with 5-100 colorectal 
adenomas without evidence of vertical transmission in whom no germline 
mutation in known predisposition genes had been identified. Unlike MAP 
tumours, no mutational signature was detected and the genetic pathway of 
tumourigenesis appeared very similar to the classical pathway in sporadic 
adenomas. It was suggested that germline variation acting after tumour 
initiation to cause accelerated progression from microadenoma to 
macroadenoma may result in the multiple colorectal adenoma phenotype and 
that this variation was unlikely to be a in gatekeeper or caretaker gene, but in 
one which could alter the intra- or extracellular microenvironment of cells 
(Thirlwell, C. et al, 2007).
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Chapter Seven
General Discussion
7.1 Summary of results of the present study
Patients and families are included on the Wales Polyposis Register (WPR) 
when at least ten colorectal adenomas with or without CRC are present. A high 
proportion (85/92, 92%) of families on the WPR were confirmed by molecular 
analysis to have either FAP (70/92, 76%) or MAP (15/92, 16%). The seven 
index patients in whom no pathogenic APC or MUTYH mutations were identified 
did not have a dominant family history and had tens to hundreds of colorectal 
adenomas with or without CRC. The proportion of patients whose polyposis 
could not be accounted for by known genes was substantially smaller than 
reported from other polyposis registers (Aceto, G. et a/, 2005; Aretz, S. et al,
2006).
Mutational analysis of 182 unrelated MAP index cases identified through a 
European collaborative project extended the MUTYH mutation spectrum by 
identifying eight novel mutations and highlighted the need for ORF sequencing 
as a significant proportion (31/182, 17%) of cases did not carry either of the two 
common non-Asian mutations (Y176C and G393D). Of 138 cases with CRC,
49 (36%) had more than one colorectal cancer. MAP cases were not found to 
be at increased risk of cancers outside the Gl tract. Genotype-phenotype 
analysis of MAP cases with the common non-Asian mutations revealed that the 
mean age at presentation and at CRC diagnosis were inversely correlated with 
the number of Y176C alleles carried.
Analysis of the obligate heterozygote parents of European MAP index patients 
identified a two-fold increased risk of CRC compared with the general 
population. No increase in mortality or other cancer risk was observed.
No clearly pathogenic mutations were identified in the candidate BER or DNA 
damage protection genes (TDG, MPG, SMUG1, MBD4, APE1, POLL and
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NUDT5) that were screened in 58 unrelated multiple colorectal adenoma 
patients in whom APC and MUTYH mutations had not been found.
7.2 Highly penetrant colorectal adenoma and CRC predisposition alleles 
Pathogenic mutations in APC, MUTYH and MMR genes account for some, but 
not all, familial CRC predisposition. Other high penetrance alleles, if they exist, 
remain unidentified. Linkage analysis could be used to map such alleles but 
requires a large family or many smaller families to be successful. Large CRC 
families are rare and obtaining samples from a large number of affected 
members is not always possible. Even highly penetrant alleles may not achieve 
complete penetrance even by old age and interpretation of results can be 
complicated by the presence of unaffected carriers or individuals who appear to 
be affected but do not carry the disease-associated allele (phenocopies). In 
addition, linkage analysis is difficult if there is locus heterogeneity within the 
group of families studied or if more than one locus is contributing to the disease 
in a family. Consanguineous families are extremely useful for the identification 
of recessive high penetrance alleles. Even if a locus is found to be linked to 
CRC susceptibility through genetic linkage analysis, the disease-associated 
region often remains very large and usually contains many candidate genes. 
Most of the multiple adenoma cases in whom no known genetic defect could be 
identified in the present study occurred as sporadic cases and so were not 
suitable for linkage analysis.
Alternatively, high penetrance alleles could be identified through screening of 
functional candidate genes in early-onset CRC and/or colorectal adenoma 
patients. Such alleles will be rare in the general population but should be 
enriched in the patient panel so large cohorts may not be essential. One 
problem with this approach is candidate gene selection. Highly penetrant CRC 
predisposition genes may act in pathways known to be involved in colorectal 
tumourigenesis but could function in pathways not currently known to be related 
to CRC. Recent analysis of somatic mutations in non-familial CRC identified 
changes in genes not previously known to be associated with tumourigenesis 
(Sjoblom, T. etal, 2006; Wood, L.D., etal, 2007), providing new potential 
candidates for germline screening. A second and major problem is the
interpretation of rare and possibly pathogenic mutations in patients since 
proving their pathogenicity is difficult. Bioinformatic tools can only predict the 
effects of these changes on the encoded protein, with functional work 
necessary to confirm such predictions. Identification of mutations in the same 
gene in several patients provides more evidence of an association with CRC 
susceptibility. In this study rare or unique missense variants were identified in 
plausible novel candidates but functional work was not able to be carried out 
and with the exception of a single case, samples were not available from other 
family members to assess the segregation of these changes with the disease. 
Mouse models can sometimes give an indication of whether or not mutation of a 
particular gene is likely to have a phenotypic effect. If a mutation of uncertain 
significance is identified in a candidate gene, a combination of functional, family 
and population studies may be required to clarify its pathogenicity and the 
nature of any association with the disease.
7.3 Low penetrance alleles predisposing to colorectal adenomas and CRC 
The genetic basis of most inherited CRC susceptibility is thought to be due to 
low penetrance alleles and these are now being identified. Genes in which 
highly penetrant CRC susceptibility alleles have been described may also 
harbour incompletely penetrant changes. The APC missense variant I1307K is 
found in approximately 6-8% of healthy Ashkenazi individuals and confers a 
significantly increased risk of colorectal adenomas and CRC in this population, 
probably through the creation of a hypermutable tract which predisposes to 
somatic mutations (Laken, S.J. etal, 1997; Frayling, I.M. etal, 1998). E1317Q 
is a rare APC variant found in less than 1 % of UK controls and has been 
suggested to predispose to colorectal adenomas and CRC with a low and 
variable penetrance (Frayling, I.M. etal, 1998; Lamlum, H. etal, 2000). Others 
have not observed this association (Popat, S. et al, 2000; Gismondi, V. et al, 
2002) and its pathogenicity remains unclear.
Our group, in collaboration with Myriad Genetic Laboratories and Genzyme 
Genetics, recently reported that multiple rare (MAFs <2%) inherited APC 
missense mutations may predispose to colorectal adenomas (Azzopardi, D. et 
al, 2008). A significantly higher proportion of patients without truncating APC
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mutations or biallelic MUTYH mutations (non-FAP non-MAP) carried rare APC 
missense mutations than did FAP or MAP cases. The highest over­
representation of these rare missense mutations was in non-AFAP non-MAP 
patients with 11-99 colorectal adenomas. Compared to healthy controls, 
significantly more non-FAP non-MAP cases carried rare missense variants in 
the p-catenin down-regulating domain of APC and again the highest over- 
representation was in non-FAP non-MAP patients with 11-99 colorectal 
adenomas. Although I1307K and E1317Q contributed to the excess of rare 
missense changes in non-FAP non-MAP cases, when only variants with a MAF 
of <0.5% were considered (thereby excluding I1307K, E1317Q and G2502S), 
there was still an excess of rare APC missense variants in non-FAP non-MAP 
cases. Rare silent variants and common polymorphisms were detected at 
similar frequencies in non-FAP non-MAP patients, FAP or MAP cases and 
healthy controls (all of whom were of similar ethnic backgrounds) so the findings 
are unlikely to be the result of population stratification. Not all missense 
variants would be expected to have a detrimental effect on APC function but in 
silico analysis predicted 39-46% of the variants were likely to be damaging. 
Functional analysis of 16 missense variants found in the p-catenin down- 
regulating domain showed that seven altered p-catenin-regulated transcription 
in vitro. A novel APC missense mutation (N1026S) has recently been reported 
to be associated with AFAP in a single family. The variant co-segregated with 
the disease in the reported family and functional analysis showed that it altered 
p-catenin-regulated transcription (Menendez, M. et al, 2008).
The MLH1 missense variant D132H has been reported to confer susceptibility 
to CRC in the Israeli population through reduced (but not abolished) MMR 
activity. This variant was found at a significantly higher frequency in CRC cases 
than unaffected controls. CRC developed at a later age in D132H carriers than 
in HNPCC patients and the tumours were mostly MSS. Unlike HNPCC cases, 
multiple primary tumours were rare and no metachronous CRC was found in the 
D132H carriers (Lipkin, S.M. etal, 2004).
Hereditary mixed polyposis syndrome (HMPS) reported in Ashkenazi families is 
associated with the highly penetrant CRAC1 locus and is characterized by
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multiple colorectal polyps (which are not classical adenomas) and CRC. An 
association study of UK CRC cases (selected for family history and/or early 
onset) and unaffected controls found that common SNPs within the CRAC1 
locus were strongly associated with an increased CRC risk suggesting that 
common low penetrance alleles at this locus can contribute to CRC 
predisposition in the general population (Jaeger, E. et al, 2008).
To identify low penetrance CRC predisposition alleles at loci not previously 
associated with an inherited CRC syndrome or colorectal tumourigenesis, 
genome-wide association studies can be used. Such studies have recently 
identified a CRC susceptibility locus at 8q24.21 (Tomlinson, I. etal, 2007; 
Zanke, B.W. et al, 2007). Two common SNPs (rs6983267 & rs10505477) in 
linkage disequilibrium were strongly associated with colorectal neoplasia 
(Tomlinson, I. et al, 2007; Zanke, B.W. et al, 2007) and mapped to a haplotype 
block which had been previously associated with prostate cancer risk (Haiman, 
C.A. etal, 2007; Yeager, M. etal, 2007). This locus does not contain any 
known genes but does have two ORFs. One is an uncharacterized gene with 
multiple alternatively spliced transcripts and harbours rs10505477 within an 
intron. The other is a processed pseudogene of POU5F1 (which encodes a 
transcription factor) and is found 20kb telomeric to rs6983267 (Tomlinson, I. et 
al, 2007; Zanke, B.W. et al, 2007). The MYC oncogene lies 116kb telomeric to 
rs6983267 and outside the haplotype block but its function could be influenced 
by the risk variant through genomic instability or long-range regulation of 
expression. The CRC susceptibility locus at 8q24.21 influences the risk of 
colorectal adenomas so may be affecting tumour initiation rather than 
progression (Tomlinson, I. etal, 2007). Three common SMAD7SNPs which 
influence CRC risk have also recently been identified through a genome-wide 
association study. This gene is involved in TGF-p and Wnt signalling and all 
three variants map to the same block of linkage disequilibrium located in intron 
3 of this gene. Similar to the 8q24.21 locus, the SMAD7 SNPs significantly 
influence the risk of colorectal adenomas so may be affecting tumour initiation 
rather than progression (Broderick, P. et al, 2007).
Individually, common low penetrance alleles may confer only a modest effect on 
CRC risk but could have a substantial effect by acting in an additive or
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multiplicative manner. As more of these alleles are identified, different 
combinations may be associated with varying degrees of risk and some could 
generate a CRC risk which justifies increased tumour surveillance.
7.4 Application of CRC predisposition alleles in clinical practice 
High penetrance CRC predisposition alleles can be readily exploited by medical 
genetics services to improve the counselling and surveillance of families at high 
risk. If a patient carries a pathogenic mutation(s), they can undergo colonic 
surveillance and prophylactic surgery if necessary whereas family members 
who do not carry the mutant allele(s) do not require additional surveillance. 
However, genetic counselling and management of patients who carry variants 
of unknown pathogenicity such as missense changes is difficult, with a 
requirement for unequivocal genetic and functional data before the variant can 
be used with confidence in the setting of pre-symptomatic testing.
Testing for low penetrance alleles should not be applied in a clinical setting at 
present but this situation is likely to change as the risks associated with such 
alleles are clarified. In practice, family history is currently used as an indicator 
of risk in families in which no high penetrance genetic defect can be identified.
In the future common SNPs associated with increased CRC risk may well be 
used to identify individuals in the general population for whom additional CRC 
screening is appropriate.
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A ppendix
Chapter 3
I identified 
mutations in 
35 index 
cases
I assayed 
for novel 
MUTYH 
mutation in 
controls
Mutations 
identified in 
47 index 
cases by 
AWMGS
Samples available from 92 
index cases
107 families on Wales 
Polyposis Register
Mutations 
identified in 10 
index cases by 
diagnostic labs 
outside Wales
Chapter 4
I identified 9 
index cases
61 cases 
(45 index & 
16 relatives) 
identified by 
AWMGS
70 cases (54 index & 
16 relatives) identified 
in Cardiff
I collected clinical data for all UK & Irish MAP cases
237(182 index & 55 
relatives) MAP cases 
identified
87 cases (73 index 
& 14 relatives) 
identified in 
Germany & data 
collection by S. Vogt
80 cases (55 index & 
25 relatives) identified 
in the Netherlands & 
data collection by 
M. Nielsen
I assayed for novel MUTYH  mutations 
in controls, undertook transcript 
analysis & generated 3D images to 
highlight mutated residues using 
protein sequence deposited in PDB 
database
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Chapter 5
German population 
rates obtained by S. 
Vogt
Dutch population 
rates obtained by F. 
J. Hes
England & Wales 
population rates 
obtained by P. Wark
Ethical approval, 
data collection & 
tissue requests for 
monoallelic MUTYH 
mutation carriers in 
Germany by S. Vogt
Ethical approval, 
data collection & 
tissue requests for 
monoallelic MUTYH 
mutation carriers in 
the Netherlands by 
M. Nielsen
I carried out all SIR & SMR analysis using STATA
I carried out DNA extraction & screening of the MUTYH  ORF in all tissue samples
I undertook ethical 
approval (with help from 4 
regional Pis), data 
collection & tissue 
requests for monoallelic 
MUTYH mutation carriers 
in UK & Ireland, including 
all letters, consent forms 
& questionnaires
Chapter 6
PCR optimization for 
APE1 by A. Dallosso
I designed primers 
for NUDT5 & POLL
Primers for APE 1 
designed by A. 
Dallosso
PCR amplified and 
sequenced MBD4, 
NUDT5 & POLL in 
cases
PCR amplification 
and sequencing of 
SMUG1 in cases by 
Wales Gene Park
Primers for TDG, 
MPG, SMUG1 & 
MBD4 designed by 
S. Jones
PCR amplification 
and sequencing of 
TDG, MPG & APE1 
in cases by A. 
Dallosso
I optimized PCRs for TDG, MPG, SMUG1, MBD4 
NUDT5 & POLL
I assayed for all novel variants in controls & generated 3D images to highlight 
mutated residues using protein sequence deposited in PDB database
Figure I. Division of work in the present study. AW M G S, All Wales Medical 
Genetics Service.
214
Authors Year Population/ethnic background*
Enholm, S. et al 2003 Finnish
Sieber, O.M. et al 2003 British*/Finnish/Danish
Halford, S.E.R. etal 2003 British*
Croitoru, M E. etal 2004 Canada*
Fleischmann, C. et al 2004 British*
Gismondi, V. et al 2004 Italian*
Isidro, G. et al 2004 Portugeuse*
Kambara, T. et al 2004 Australian*
Vandrovcovd, J et al 2004 Czech
Venesio, T. et al 2004 Italian*
Wang, L. etal 2004 American*
Aceto, G. et al 2005 Italian*
Alhopuro, P. et al 2005 Finnish
Baglioni, S. et al 2005 Italian*
Eliason, K. et al 2005 American*
Farrington, S.M. et al 2005 British*
Jo, W-S. et al 2005 American*
Kairupan, C. etal 2005 Australian*
Miyaki, M. et al 2005 Japanese
Nielsen, M. et al 2005 Dutch*, Turkish, Morroccan
Peterlongo, P. et al 2005 American*
Ponti, G. et al 2005 Italian*
Truta, B. etal 2005 American*
Aretz, S. et al 2006 German*
Bai, H. et al 2006 Italian*
Chow, E. et al 2006 Australian*
Colebatch, A. et al 2006 Australian*
Di Gregorio, C. et al 2006 Italian*
Kanter-Smoler, G. et al 2006 Sweedish*
Lefevre, J.H. et al 2006 French*
Lejeune, S. et al 2006 French*
Peterlongo, P. et al 2006 Italian*, American*
Piccioli, P. et al 2006 Italian*
Russell, A. et al 2006 Swiss*
van Puijenbroek, M. et al 2006 Dutch*
Webb, E.L. etal 2006 British*
Wynter, C.V.A. et al 2006 Australian*
Balaguer, F. et al 2007 Spanish*
Bouguen, G. et al 2007 French*
Croitoru, M.E. et al 2007 Portuguese*, English*, Polish, Italian*
Ponti, G. et al 2007 Italian*
Sulovg, M. et al 2007 Czech
Kury, S. etal 2007 French*
Table I. References used to create Figures 4 .2 ,4 .3 ,4 .4  and Table 4.2.
*Populations with at least 10 reported mutant alleles and are therefore included in 
Table 4.2 and Figure 4.3.
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;amily
no. Patient Sex
Index/
Sib Ethnicity Mutation 1 Mutation 2 Presentation
11 1083 M Index Pakistani Y101X Y101X Symptomatic
20 4773 M Index Pakistani Y101X Y101X Symptomatic
7 0718 M Index British Y176C Y176C Symptomatic
13 1610 M Index British Y176C Y176C Symptomatic
41 2134 M Index British Y176C Y176C Symptomatic
5 2120 F Index British Y176C Y176C Symptomatic
17 1120 F Index British Y176C Y176C Symptomatic
21 27864 F Index British Y176C Y176C Symptomatic
27 2131 F Index British Y176C Y176C Symptomatic
40 2133 M Index British Y176C Y176C Symptomatic
42 1675 M Index British Y176C Y176C Symptomatic
49 2512 F Index British Y176C Y176C Symptomatic
50 2139 F Index Irish Y176C Y176C Symptomatic
51 4312 F Index Irish Y176C Y176C Symptomatic
52 0366 F Index Irish Y176C Y176C Symptomatic
9 2124 F Index British Y176C c.380-1 G>A Symptomatic
44 2135 M Index British Y176C W117R Symptomatic
48 1232 M Index British Y176C c.681 G>A Symptomatic
46 0748 F Index British Y176C c.681 G>A Symptomatic
45 2136 M Index British Y176C 924+3 A>C Screening- due to anaemia
39 2921 M Index British Y176C c.1138delC Symptomatic
18 1949 F Index British Y176C c. 1509+3 C>T Symptomatic
6 0444 M Index British Y176C G393D Symptomatic
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Age at 
diagnosis
Polyp
count
CRC Age at
CRC CRC Location Extracolonic (age)
51
62
41
45
33
36
38
35
45
50
30
43
31 
33
48
56
30
42
47
46 
53
41
47
432 
>100 
156 
10+ small 
no. 
50-100 
10s 
18+ 
multiple 
adenomas 
8+ several 
small 
numerous 
50
>25 + 
multiple
100s
~120
~200
119
11-30
Multiple,
>10
16+ 
'numerous 
tiny polyps'
Y(1)
Y (1) 
N
N
N
Y (1)
Y (3)
Y (1)
Y (1)
Y (1)
Y (1)
Y (2)
88 Y (1)
13 Y (1)
Multiple+
25 further
removed in ' '
2005
14 N
152 N
N
Y(4)
Y (1)
Y (1)
Y (3)
51 Rectum
66 Caecum
/ /
/ /
/ /
51 Caecum
38 (2) Rectum (2)
41(1) Perineum (1)
45 Rectum
45 Caecum
50 Unknown
30 Ascending colon
Transverse colon 
43 Transverse/
Descending colon 
57 Rectum
40 Caecum
49 Caecum
/ /
/ N
48 Caecum (3)
Descending colon (1)
47 Caecum
53 Rectum
41 (1) Transverse colon (1) 
65(1) Sigmoid (1)
68(1) Caecum (1)
/ /
N
N
>10 duodenal 
adenomas (30-49) 
1 gastric adenoma 
(30-49)
N
N
N
Carcinoid appendix (49) 
N
Salivary adenoma (47) 
Sebaceous gland 
hyperplasia (45)
N
Basal cell carcinoma 
(45)
Benign prostatic 
hyperplasia (56)
Breast carcinoma (71)
Family
no.
10
Patient Sex Index/Sib Ethnicity Mutation 1 Mutation 2 Presentation
0964 M index British Y176C
Y176C
Y176C
G393D
G393D
G393D
Symptomatic 
Screening due to 
affected sib 
Screening due to 
affected sib
15 27459 M Index British
26 4481 M Index British
28 4292 M Index British
29 3771 M Index British
31 2127 M index British
43 2132 M Index British
1 0662 M Index British
4 3890 M Index British
14 1016 F Index British
22 1064 F index British
25 2835 M Index British
32 2180 F Index British
36 3215 F Index Irish
47 0034 F Index British
38 4690 F Index Irish
8 2123 M Index British
30 1107 M Index British
37 3776 F Index British
34 2058 M Index British
24 0376 M Index British
Y176C G393D Symptomatic
Y176C G393D Symptomatic
Y176C
Y176C
G393D
G393D
Symptomatic
Symptomatic
Y176C G393D Symptomatic
Y176C
Y176C
G393D
G393D
Symptomatic
Symptomatic
Y176C G393D Symptomatic
Y176C G393D Symptomatic
Y176C G393D Symptomatic
Y176C G393D Screening due t affected sib
Y176C G393D Symptomatic
G393D G393D Symptomatic
G393D G393D Symptomatic
G393D G393D Symptomatic
G393D G393D Symptomatic
G393D G213E Symptomatic
G393D N235S Symptomatic
217
Age at Polyp
count CRC
Age at
CRC Location Extracolonic (age)
46 <100 N /
49 50-100 N /
46 50-75 N /
52 20-30 N /
44 >20 N /
12 >100 N /
49 Multiple N /
31 2 Y (1) 37
47 25-30 Y (2) 47
43 3 Y (1) 43
65 >100 Y (4) 65
65 several/numerous
3 +
Y (3) 65
58 multiple/nu
merous
Y (4) 58
43 19 Y (1) 43
53 15 Y (1) 53
50 123 N /
62 ~70 Y(2) 62
36 4 Y(1) 37
57 10 Y (2) 57
65 22 Y (1) 68
50 5+ multiple 
small 
sessile
Y (1) 50
I
/
Rectum
Sigmoid (2) 
Rectum 
Caecum (1) 
Splenic flexure (1) 
Rectosigmoid junction 
(1)
Rectum (1) 
Rectum (1) 
Transverse colon (2) 
Rectum (1) 
Caecum (1) 
Transverse colon (1) 
Unknown (1)
Descending colon
Rectum (in situ)
/
Unknown 
Caecum 
Sigmoid (2) 
Appendix 
Sigmoid
N
N
N
Small intestine carcinoid 
tumour (62)
Soft palate cancer (46) 
Multiple actinic 
porokeratoses (28) 
Sebaceous adenomas 
(28)
Gastric cancer (17)
N
Sebaceous hyperplasia 
(33)
N
N
N
N
N
N
N
N
Pilar cyst under right 
mandible (50)
polyps
Family
no.
54
2
16
35
53
3
19 
12
23
33
20
20
20
20
42
42
15
26
31
14
15
26
2
53
Patient Sex Index/Sib Ethnicity Mutation 1 Mutation 2 Presentation
4021 F Index British G393D R242H Symptomatic
2121 F Index Irish G393D c.924+3 A>C Screening due to affected sib
2126 M Index British G393D Q335X Screening due to affected sib
4891 M Index NewZealand G393D 1092delC Symptomatic
3718
0958
18831
19173
M
F
M
M
Index
Index
Index
Index
Italian
Indian
Indian
Indian
1138delC
E477X
E477X
E477X
1138delC
E477X
E477X
E477X
Screening due to 
age/programme 
Symptomatic 
Symptomatic 
Symptomatic
17191 M Index Indian E477X E477X Symptomatic
2130 M Index Indian E477X E477X Symptomatic
brotherl M Sib Pakistani Y101X Y101X Symptomatic
Daughter
1 F Offspring Pakistani Y101X Y101X
Screening to due 
affected parent
Daughter
2 F Offspring Pakistani Y101X Y101X
Screening to due 
affected parent
nephewl
brotherl
M
M
Offspring 
of sib
Sib
Pakistani
British
Y101X
Y176C
Y101X
Y176C
Screening to due 
affected parent 
Screening due to 
affected sib
brother2 M Sib British Y176C Y176C Screening due to affected sib
sisteM
sisterl
brotherl
F
F
M
Sib
Sib
Sib
British
British
British
Y176C
Y176C
Y176C
G393D
G393D
G393D
screening due to 
affected sib 
unknown 
screening due to 
affected sib
brother3 M Sib British Y176C G393D Symptomatic
brotherl M Sib British Y176C G393D Symptomatic
brother3
0675
3717
M
F
M
Sib
Sib
Sib
British
Irish
Italian
Y176C
G393D
1138delC
G393D 
c.924+3 A>C
1138delC
symptomatic 
Symptomatic 
Screening due to 
affected sib
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Age at 
diagnosis
Polyp
count CRC
Age at
CRC Location Extracoionic (age)
49 22 
6+ polyps
N
34 throughout 
the colon
N
49 multiple+25+>20 N
36 Multiple Y (1)
51 30-40 Y (1)
51 40-50 N
49 ~200 N
37 >25 Y (1)
65 >100+74 Y (3)
55 40-50 
multiple in
Y (1)
60 resection, 
at least 12
Y (1)
38 >100
No
N
40 assessment
yet
N
46 >100 N
29 Multiple N
28 >100 N
51 77+multiple N
45 >100 N
14 >100 N
53 >100
2
Y (1)
46 adenomas 
in resection
Y (1)
44 76 Y (1)
57 Unknown Y (1)
45 >100 Y (1)
/
/
/
36
51
/
/
37
65 (2) 
69(1)
55
60
6
46
44
57
45
/
/
/
Unknown
Recto-sigmoid
/
/
Rectum 
Transverse colon (1) 
Caecum (1) 
Unknown (1) 
Caecum
Caecum
Rectum
Rectum
Caecum
Unknown
Caecum
Carcinoid appendix (42) 
Benign breast lump (22)
N
3 gastric adenomas (43- 
45)
Skin lesions (55) 
N
N
N
N
N
N
N
N
N
N
N
N
N
Family
no. Patient Sex
Index/
Sib Ethnicity Mutation 1 Mutation 2 Presentation
Age at 
diagnosis
Polyp
count CRC
Age at 
CRC Location Extracolonic (age)
12 sister2 F Sib Indian E477X E477X Screening due to affected sib 44 143 N / / N
12 sisterl F Sib Indian E477X E477X Screening due to affected sib 36 120 V (1) 36 Transverse colon N
Table II. Genotype and phenotype details of 70 MAP cases referred to the All Wales Medical Genetics Service for MUTYH germline 
mutation analysis.
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Extracolonic
manifestation Patient (age at diagnosis in years)
6 / tract
Appendix carcinoid 0366 (49), 4021 (42)
tumour
Duodenal polyps 1675 (30-49), D2031 (68), D2137 (50), D2124 (56), D2121 (67), D123 (57), D203
(52), D16 (43), D194 (65), D128 (36), G26-2 (36-48), G370-1 (41-47), G398-1 (44-
60), G489-1 (49), G526-1 (41-51), G526-2 (25-43), G719-1 (47-54), G787-1 (56-58),
G818-2 (40), G848-1 (60-65), G925-1 (48), G1125-1 (51-60), G1260-1 (48), G1334-
1 (30-31), G872-1 (37-42)
Jejunal polyps G526-2 (44)
Duodenal cancer D2124 (56), D194 (65)
Ileum cancer D2140 (65), D2159 (41)
Small intestine 4292 (62), D193 (77)
carcinoid tumour
All gastric polyps 1675 (30-49), 4891 (43-45), 17191 (65-66), D48 (46), G660-1 (46-54), G719-1 (47-
54), G1175-2 (40-41), G1468-1 (50-78), D2111 (50), D202 (50), D21 (59), D2137
(53), D2121 (67), D196 (65), G1111-1 (44-52)
Gastric adenomas 1675 (30-49), 4891 (43-45), G1175-2 (40-41)
Fundic gland D2111 (50), D202 (50), D48 (46), D21 (59), D2137 (53), D2121 (67), D196 (65),
polyps G1111-1 (44-52), G719-1 (47-54), G1175-2 (40-41)
Gastric polyps with 1675 (30-49), 17191 (65-66), D48 (46), G660-1 (46-54), G1468-1 (50-78)
unknown histology
Gastric cancer 2127 (17), G548-1 (38), G1293-1 (48)
Skin lesions
Melanoma (M) G885-1 (32), D2124 (30)
Basal cell 2136 (45), D6 (41), D54 (44), D123 (58), D2031 (71), D193 (63), G858-1 (62)
carcinoma (M)
Squamous cell G395-1 (60), G561-1 (68)
carcinoma (M)
Sebaceous gland G1180-1 (51)
epithelioma (M)
Sebaceous gland 0662 (33), 1232 (45), D48 (46), D176 (unknown)
hyperplasia (B)
Sebaceous gland 3771 (28), G925-1 (15), G1222-1 (47), D101 (68, 74)
adenomas (B)
Steatocystoma (B) D176 (unknown)
Actinic keratoses 3771 (28), D180 (63)
(pre-malignant)
Epidermoid cyst G1323-1 (unknown), G489-1 (unknown), D2118 (50), G561-1 (unknown), D176
(B) (unknown)
Follicle cyst D2113 (38)
formation with
branches (B)
Seborrhoeic wart D2111 (53)
(B)
Lipoma (B) G26-1 (unknown), G26-2 (30), G848-1 (65), G1309-1 (33), G1412-1 (unknown),
G489-2 (37), G489-1 (unknown)
Pilar cyst (B) 0376 (50)
Dermatofibroma D2329 (54)
(B)
Naevus G1175-2 (36), D2113 (36)
naevocellularis
pigmentosus
Pigmented spots D84 (unknown)
Verruca vulgaris D123 (60)
Skin lesions of 18831 (55), G1421-1 (25), G1065-1 (36), G774-1 (58), G395-1 (50), D2140
unknown histology (unknown}. D128 (unknown}. G370-1 (15}
Other cancers
Breast cancer 1949 (71), G787-1 (56), G1358-1 (49), G561-1 (60, 68), G1293-1 (45), D39 (50),
D193 (76, 78), D190 (55), D112 (50)
Bladder cancer G526-1 (45), G858-1 (62), D176 (unknown), D178 (67)
Larynx cancer D178 (57)
Prostate cancer D180 (62)
Teratoma G1451-1 (28), G26-2 (33)
Testicular cancer G914-1 (41)
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Thyroid cancer 
Cervical cancer 
Gangliocytoma 
Lymphoma 
Ovarian cancer 
Endometrial cancer 
Oesophageal 
cancer
Soft palate cancer
G1293-1 (38)
G1434-1 (39)
1114-1 (52)
G1087-1 (46)
G489-1 (56)
G1323-1 (54)
D80 (59), G676-1 (unknown) 
4292 (46)________________
Other benign 
abnormalities
Benign breast lump 
Mammary cyst 
Endometrial polyp 
Endometrial 
hyperplasia/ 
tubulaire 
metaplasia 
Cervical plaveisel 
Uterine myomas 
Uterine 
polyps/cysts 
Ovarian cysts 
Uterine leiomyoma 
Prostatic 
hyperplasia 
Fibrous 
histiocytoma 
Renal cyst 
Hepatic cysts 
Salivary adenoma 
Jaw-bone cysts 
Bone tumour 
Capillary 
hemangioma 
(unknown)
Leg exostosis 
Carpall tunnel 
syndrome 
Graves disease 
Basedows disease
2121 (22), D196 (unknown) G1125-1 (59), G641-1 (31) 
G641-1 (32)
1451-2(48)
D52 (unknown)
D122 (27)
D54 (unknown)
G1065-1 (48, 50), G641-1 (32)
G826-1 (unknown), G1371-1 (unknown)
G641-1 (32), G826-1 (unknown), G370-1 (unknown) 
2921 (56), D101 (unknown), D178 (67)
D178 (60)
G1229-1 (64)
G719-1 (47), G1077-2 (70), G1229-1 (64), G489-2 (48) 
1232 (47)
G526-2 (10), G757-1 (14), G370-1 (21), G641-1 (23)
G1222-1 (48)
D176 (unknown)
G26-2 (33)
D11 (unknown)
D52 (unknown) 
G826-1 (unknown)
Table III. Extracolonic manifestations of 237 MAP patients. D or G in patient 
identifier represents cases from the Dutch or German centres, respectively. All other 
patients were referred to The All Wales Medical Genetics Service.
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Covering letter for MAP patients version 2 06/06/06 To be put on RGS-headed paper 
Date Tel no.
Address o f MAP patient.............................
Dear... MAP patient...............
You are invited to participate in a research project as you have been affected by bowel polyps and/or bowel cancer. 
Recently developed gene tests requested by your doctor have shown that in your case the bowel problem is caused by 
changes in the MUTYH gene (also called the MYH gene). This causes an inherited predisposition to bowel polyps and 
bowel cancer that is now called MAP (MUTYH-associated polyposis).
Prof. Julian Sampson’s group at the Institute of Medical Genetics, Cardiff was the first to define the disease MUTYH- 
associated polyposis (MAP), the condition that has affected you. Prof. Sampson’s team are continuing to undertake 
research into this disease and have asked if you would be willing to take part in their study of families with MAP entitled 
“INVESTIGATING CANCER RISK IN PEOPLE WITH MUTYH GENE CHANGES’ as there is still much that is not 
known about the disorder. This would involve relevant details on your medical and family history being passed from us 
to the researchers at Cardiff. If either of your parents were affected by bowel cancer in the past, the researchers would 
also like permission for any tissues stored at the hospital to be made available for analysis.
Please read the enclosed information sheet and complete and return the enclosed consent form. A stamped addressed 
envelope is also enclosed.
Please do not hestitate to contact me on the above number if you have any questions or if I can be of any further help.
If you have any questions for Prof. Julian Sampson you can contact him on 02920 746412.
Yours sincerely
Information sheet for MAP patients version 2 (06/06/06) -to  be put on IMG-headed paper.
Date Direct line: 02920 746412
Dear ...Name o f MAP patient.......
I am part of a team undertaking research into MUTYH-associated polyposis (MAP), a disease that causes an inherited 
predisposition to bowel po Ivps and bowel cancer.
You are being invited to take part in a research study. Before you decide whether to participate it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the following information 
carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is anything that is not clear or if 
you would like more information. Take time to decide whether or not you wish to take part.
Consumers for Ethics in Research (CERES) publish a leaflet entitled ’Medical Research and You’. This leaflet gives 
more information about medical research and looks at some questions you may want to ask. A copy may be obtained 
from CERES, PO Box 1365, London N16 0BW.
Thank you for reading this.
WHY HAVE YOU BEEN CHOSEN?
You are invited to participate in this research project as you have been affected by bowel polyps and/or bowel cancer. 
Recently developed gene tests requested by your doctor have shown that in your case the bowel problem is caused by 
changes in the MUTYH gene (also called the MYH gene). This causes an inherited predisposition to bowel polyps and 
bowel cancer that is now called MAP (MUTYH-Associated Polyposis).
We are conducting a study of families with MAP entitled “INVESTIGATING CANCER RISK IN PEOPLE WITH MUTYH 
GENE CHANGES’. The genetic cause of MAP was only identified in 2002 and there is still much that is not known 
about the disorder. We can only improve our knowledge of the disorder and how best to manage affected families with 
the help of those who are affected. I am therefore writing to ask if you would be willing to take part in our study.
WHAT WOULD THIS RESEARCH INVOLVE FOR YOU?
We would like your permission for your Regional Genetics Service to pass on details of your medical history and family 
history to us and we may ask you for further details if required. Current data indicates that in a very small proportion of 
families a parent of the patient (or patients) with MAP has been affected by bowel cancer. If you agree to the study and
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one (or both) of your parents had bowel cancer but is no longer alive, we would also like to perform genetic analysis on 
any bowel cancer tissue that was removed at surgery and stored in the hospital. We may wish to confirm details about 
this surgery with you if this information is not already known to your Regional Genetics Service. If required we will post 
a questionnaire to you about this along with a stamped, addressed envelope to be returned to us after completion. All 
this information will remain strictly confidential.
DOES THIS AFFECT YOUR FUTURE MEDICAL CARE?
You are under no obligation either to enter this study in the first instance or to continue with it if you change your mind at 
any point. This study will not in any way affect your on-going treatment or care or your legal rights. Participation in this 
study is unlikely to have direct benefits for you but we hope it will be of benefit to others in the future.
ARE THERE ANY IMPLICATIONS FOR INSURANCE?
We will not disclose any clinical or genetic information about you to any third party such as insurance companies and 
strict confidentiality about all information pertaining to you will be maintained at all times.
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH?
The results of the study will be published in a medical journal. You will not be identified in any reports or publications. If 
you would like a copy of the published results you could contact us and we will supply you with these.
If you would like to help with the study please complete the enclosed consent form and return it in the pre-paid 
envelope.
If you do not wish to take part in the study I would be grateful if you could indicate this on the enclosed form and return it 
in the pre-paid envelope. Once the form has been received stating that you do not wish to take part you will not be 
contacted again.
If you have any questions or would like further information before agreeing to help, please do not hesitate to contact me 
at the above address or telephone number.
Many thanks indeed for your help.
Yours sincerely,
Prof. J.R. Sampson 
Professor of Medical Genetics 
THE NEXT STEP IS:-
PLEASE SIGN THE ENCLOSED CONSENT FORM AND POST IT BACK TO US IN THE ENVELOPE PROVIDED. 
THANK YOU
INVESTIGATING CANCER RISK IN PEOPLE WITH MUTYH GENE CHANGES.
CONSENT FOR PARTICIPATION IN STUDY (Consent form 1) VERSION 2 (06.06.2006)
RE: Name o f MAP patient
I have read and understood the nature of the above clinical study as explained in the information sent to me by 
Professor Sampson (letter version 2 06/06/06). I confirm that I have had the opportunity to ask questions.
I understand that as part of the study: (Please put your initials in the boxes, circle either Yes or No & sign at the 
bottom of the letter where indicated)
I agree to take part in this study and hereby give consent for my medical history and family history to be 
reviewed by the researchers involved in the study for the specific purposes of this research.
Yes No
I agree to provide additional information on my medical and family history if required.
Yes No
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I understand that any information about me and my family history will remain confidential and that at any point 
I am free to withdraw from the study without giving any reason and without this affecting my future treatment 
or standard of care or my legal rights.
Yes No
[ Z Z ]  □
SIGNED--------------------------------------- (Patient)
DATE OF BIRTH:
NAME:
DATE:
ADDRESS:
SIGNED----------------------------------------- (Researcher)
NAME: DATE:
Please post this back to us in the envelope provided.
INVESTIGATING CANCER RISK IN PEOPLE WITH MUTYH GENE CHANGES.
CONSENT FOR OBTAINING PREVIOUSLY STORED TISSUE BLOCKS (Consent form 2) VERSION 2 (06.6.2006) 
RE: Name o f affected parent
I have read and understood the nature of the above clinical study as explained in the information sent to me by 
Professor Sampson (letter version 2 06/06/06). I confirm that I have had the opportunity to ask questions.
I understand that as part of the study: (Please put your initials in the boxes, circle either Yes or No & sign at the 
bottom of the letter where indicated)
I consent to research investigations being carried out using tumour tissues that have previously been
removed from my late parent.............................................. at surgery.
Yes No
IZZ I IZZI
I am happy to be contacted again to provide further information on my late parent and their bowel 
problem if required for the research .
Yes No
I understand that any information about me or my family will remain confidential and that at any point I am 
free to withdraw from the study without giving any reason and without this affecting my future treatment 
or standard of care or my legal rights.
Yes No
IZZI
SIGNED-
DATE OF BIRTH:
NAME:
DATE:
ADDRESS:
SIGNED----------------------------------------- (Researcher)
NAME: DATE:
Please post this back to us in the envelope provided.
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INVESTIGATING CANCER RISK IN PEOPLE WITH MUTYH GENE CHANGES. 
Questionnaire 1 version 2 (8/5/06)
Name of MAP index case: To be completed by IMG Your ref no....................
Address: ...Usually Completed by IMG  D.O.B Completed by IMG
1. Is the MAP index case deceased □ (please tick)
alive □ 
unknown ? □
If deceased, please give the D.O.D........................
2. Please provide the following information about the MAP index case;
a. Date of presentation.........................................................................................
b. Mode of presentation: symptomatic presentation □ (please tick)
screening when asymptomatic for (i) family history □
(ii) other a 
(please specify)
unknown □ 
other □
If other, please specify...........................................................................................
• Colorectal cancer at presentation? Yes/No/Unknown (delete as appropriate)
• Subsequent colorectal cancer? Yes/No/Unknown (delete as appropriate)
If yes, please give the date of diagnosis for this cancer......................................
•  Please give details (diagnosis, age at diagnosis) of any other cancer.
3. Please give the following information about the parents of the MAP index case. 
Mother: Name.........................................................  D.O.B.......................
Or age if alive........................
Or age at last Regional Genetics Service contact with family 
Or age at death if DOB and DOD not known........................
Father: Name.......................................................  D.O.B.........................
Or age if alive.......................
Or age at last Regional Genetics Service contact with family 
Or age at death if DOB and DOD not known........................
D.O.D
D.O.D
4. If deceased, what was the cause of death and how was this information obtained?
Mother deceased Father deceased
Cause of death: ..............................  .............................
Info obtained from: relatives □ relatives □
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death certificate □ 
hospital records □ 
other □
death certificate □ 
hospital records □ 
other □
If other, please specify......................................................................................
5. Is there a record of colorectal cancer in mother? Yes/No/Unknown
or father? Yes/No/Unknown
6. Please give details of any other cancer in either parent.
Mother Father
INVESTIGATING CANCER RISK IN PEOPLE WITH MUTYH GENE CHANGES. 
Questionnaire 2 version 1 (09/03/06)
Name of MAP index case: To be completed by IMG Your ref no....................
Address: ... Usually Completed by IMG   D.O.B... Completed by IMG
Name of parent affected by colorectal cancer (CRC) Completed by IMG.
D.O.B............................
Please provide the following clinical information about this parent;
•  Date of CRC operation................................
• Hospital(s) where operation(s) took place
• A copy of the pathology report.
INVESTIGATING CANCER RISK IN PEOPLE WITH MUTYH GENE CHANGES.
Questionnaire 3 for MAP patients version 1 (09/03/06)
Your parent, Completed by IMG   was affected by bowel cancer.
Would you please complete the following questions about Completed by IMG................. to help us to carry out
research investigations using any tumour tissues that were removed from your late parent at surgery and stored at the 
hospital.
1. Affected parent’s date of birth..........................
2. Date of surgery for bowel cancer...............................
(approximate if not known precisely)
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3. Hospital(s) where surgery(s) took place
4. Date of death..........................
If we have difficulty tracking down the records from the hospitals where your affected parent was treated we may want 
to contact you for further details. Please could you provide us with your telephone number and times that would be 
convenient to call you.
Tel no:................................................
Please call between........................... and................................
Thank you for your help.
INVESTIGATING CANCER RISK IN PEOPLE WITH MUTYH GENE CHANGES.
Questionnaire 4 version 1 (01/12/06)
Name of MAP index case: To be completed by IMG Your ref no. To be completed 
D.O.B Completed by IMG
1. If the MAP index case is deceased, please give the cause of death:
• Info obtained from: relatives □
death certificate □ 
hospital records □ 
other □
If other, please specify..............................................................................
Colorectal adenomas
• Age at first colonoscopy.............
•  No. of polyps at first colonoscopy..............
•  Histologic type of colorectal polyps (adenomas, hyperplastic etc.)
• Age at last colonoscopy.............
• Cumulative no. of polyps (approx.).........................
Colorectal Cancer
• Colorectal cancer? Yes/No/Unknown (delete as appropriate)
If yes, date of presentation.......................
• In which part of the colon was the cancer located?............................................
(rectum, sigmoid, descending colon, splenic flexure, transverse colon, c.ascendens, caecum, hepatic flexure, if not 
exactly known; right-sided, left-sided or unknown)
•  Duke’s stage of colorectal cancer...........................................
(A, B1-3, C1-3, D) Carcinoma in situ will not be considered as carcinoma and not included in survival analysis.
• Treatment of colorectal carcinoma (surgery, radiotherapy, chemotherapy)
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• Synchronous colorectal cancer? Yes/No/Unknown (delete as appropriate)
If yes, please give location(s)..............................
• Subsequent (metachronous) colorectal cancer? Yes/No/Unknown
(delete as appropriate)
If yes, please give; date of diagnosis for this cancer.................................................
location of this cancer................................................................
Duke’s stage of this subsequent colorectal cancer.................
treatment of this colorectal carcinoma (if known) (surgery, radiotherapy, chemotherapy)
Gastroduodenal Tumours
• Gastroduodenoscopy? Yes/No/Unknown (delete as appropriate)
• Symptomatic? Yes/No (delete as appropriate)
•  Age/date at gastroduodenoscopy..........................
• Cumulative no. of duodenal polyps.........................
• Histologic type of duodenal polyps (adenomas, hyperplastic etc.)
• Cumulative no. of gastric polyps.........................
• Histologic type of gastric polyps (adenomas, hyperplastic etc.)
• Duodenal or gastric cancer? Yes/No/Unknown (delete as appropriate)
If yes, please give details below.
Extraintestinal Tumours
Please give details of any other tumour/cancer in this patient
Type
Diagnosis was 
verified by the 
following 
examination
Histological
result Location
Age at 
diagnosis
Mode of diagnois
(symptomatic, 
screening, by 
chance)
• Please give details of any other significant health problem.
• Does the MAP index patient have other family members affected by MAP? 
Yes/No/Unknown (delete as appropriate)
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